

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

for (125)
cited in 892
p. 1-4, 82, 83
87, 88

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
30 August 2001 (30.08.2001)

PCT

(10) International Publication Number
WO 01/62928 A2

(51) International Patent Classification⁷: C12N 15/12, 15/54, C07K 14/47, 14/81, C12N 9/12, C07K 16/18, 16/40, C12Q 1/68, G01N 33/53, 33/68, A61K 38/17, 48/00

(21) International Application Number: PCT/US01/06151

(22) International Filing Date: 26 February 2001 (26.02.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/184,951	25 February 2000 (25.02.2000)	US
60/185,548	28 February 2000 (28.02.2000)	US
60/185,967	1 March 2000 (01.03.2000)	US
60/197,723	18 April 2000 (18.04.2000)	US
60/199,957	27 April 2000 (27.04.2000)	US
09/789,390	23 February 2001 (23.02.2001)	US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications:

US	60/184,951 (CIP)
Filed on	25 February 2000 (25.02.2000)
US	60/185,548 (CIP)
Filed on	28 February 2000 (28.02.2000)
US	60/185,967 (CIP)
Filed on	1 March 2000 (01.03.2000)
US	60/197,723 (CIP)
Filed on	18 April 2000 (18.04.2000)
US	60/199,957 (CIP)
Filed on	27 April 2000 (27.04.2000)
US	09/789,390 (CIP)
Filed on	23 February 2001 (23.02.2001)

(71) Applicant (for all designated States except US): CURA-GEN CORPORATION [US/US]; 555 Long Wharf Drive, 11th Floor, New Haven, CT 06511 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): VERNET, Corine, A., M. [FR/US]; 4830 NW 43rd Street P#253, Gainesville, FL 32060 (US). FERNANDES, Elma [IN/US]; 77 Florence Road, #2, Branford, CT 06405 (US). SHIMKETS, Richard, A. [US/US]; 191 Leete Street, West Haven, CT 06516 (US). MACDOUGALL, John [US/US]; 117 Rusell Street, Hamden, CT 06517 (US). SPADERNA, Steven, K. [US/US]; 261 Deerfield Drive, Berlin, CT 06037 (US).

(74) Agent: ELRIFI, Ivor, R.; Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, P.C., One Financial Center, Boston, MA 02111 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/62928 A2

(54) Title: NOVEL POLYPEPTIDES AND NUCLEIC ACIDS ENCODING SAME

(57) Abstract: The present invention provides novel isolated NOVX polynucleotides and polypeptides encoded by the NOVX polynucleotides. Also provided are the antibodies that immunospecifically bind to a NOVX polypeptide or any derivative, variant, mutant or fragment of the NOVX polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the NOVX polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states, as well as to other uses.

NOVEL POLYPEPTIDES AND NUCLEIC ACIDS ENCODING SAME

BACKGROUND OF THE INVENTION

The invention relates generally to nucleic acids and polypeptides.

5

SUMMARY OF THE INVENTION

The present invention is based, in part, upon the discovery of novel human nucleic acid sequences encoding polypeptides. The NOV-X nucleic acids, polynucleotides, proteins, and polypeptides or fragments thereof described herein collectively include NOV-1, NOV-2a, and
10 NOV-2b, which are novel KIAA1233-like polypeptides; NOV-3a, NOV-3b, NOV-3c, and NOV-3d, which are novel STE20-like polypeptides; NOV-4a, NOV-4b, NOV-4c, NOV-4d,
and NOV-4e, which are novel trypsin inhibitor-like polypeptides.

In one aspect, the invention includes an isolated NOV-X nucleic acid molecule which includes a nucleotide sequence encoding a polypeptide that includes the amino acid sequence
15 of SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23. For example, in various embodiments, the nucleic acid can include a nucleotide sequence that includes SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57. Alternatively, the encoded NOV-X polypeptide may have a variant amino acid sequence, e.g., have an identity or similarity less than 100% to the disclosed amino acid sequences, as described herein.

20 The invention also includes an isolated polypeptide that includes the amino acid sequence of SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23, or a fragment having at least 6 amino acids of these amino acid sequences. Also included is a naturally occurring polypeptide variant of a NOV-X polypeptide, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes under stringent conditions to a nucleic acid molecule
25 consisting of a NOV-X nucleic acid molecule.

Also included in the invention is an antibody that selectively binds to a NOV-X polypeptide. The antibody is preferably a monoclonal antibody, and most preferably is a human antibody. Such antibodies are useful, for example, in the treatment of a pathological state in a subject wherein the treatment includes administering the antibody to the subject.

The invention further includes a method for producing a NOV-X polypeptide by culturing a host cell expressing one of the herein described NOV-X nucleic acids under conditions in which the nucleic acid molecule is expressed.

The invention also includes methods for detecting the presence of a NOV-X

5 polypeptide or nucleic acid in a sample from a mammal, e.g., a human, by contacting a sample from the mammal with an antibody which selectively binds to one of the herein described polypeptides, and detecting the formation of reaction complexes including the antibody and the polypeptide in the sample. Detecting the formation of complexes in the sample indicates the presence of the polypeptide in the sample.

10 The invention further includes a method for detecting or diagnosing the presence of a disease, e.g., a pathological condition, associated with altered levels of a polypeptide having an amino acid sequence at least 80% identical to a NOV-X polypeptide in a sample. The method includes measuring the level of the polypeptide in a biological sample from the mammalian subject, e.g., a human, and comparing the level detected to a level of the
15 polypeptide present in normal subjects, or in the same subject at a different time, e.g., prior to onset of a condition. An increase or decrease in the level of the polypeptide as compared to normal levels indicates a disease condition.

Also included in the invention is a method of detecting the presence of a NOV-X nucleic acid molecule in a sample from a mammal, e.g., a human. The method includes
20 contacting the sample with a nucleic acid probe or primer which selectively hybridizes to the nucleic acid molecule and determining whether the nucleic acid probe or primer binds to a nucleic acid molecule in the sample. Binding of the nucleic acid probe or primer indicates the nucleic acid molecule is present in the sample.

25 The invention further includes a method for detecting or diagnosing the presence of a disease associated with altered levels of a NOV-X nucleic acid in a sample from a mammal, e.g., a human. The method includes measuring the level of the nucleic acid in a biological sample from the mammalian subject and comparing the level detected to a level of the nucleic acid present in normal subjects, or in the same subject at a different time. An increase or decrease in the level of the nucleic acid as compared to normal levels indicates a disease
30 condition.

The invention also includes a method of treating a pathological state in a mammal, e.g., a human, by administering to the subject a NOV-X polypeptide to the subject in an amount sufficient to alleviate the pathological condition. The polypeptide has an amino acid sequence at least 80% identical to a NOV-X polypeptide.

5 Alternatively, the mammal may be treated by administering an antibody as herein described in an amount sufficient to alleviate the pathological condition.

Pathological states for which the methods of treatment of the invention are envisioned include hematopoietic, immunological, tumor, cancer, neurodegenerative (e.g. Alzheimer's and Parkinson's disease) and fertility disorders.

10 Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In the case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

15 Other features and advantages of the invention will be apparent from the following detailed description and claims.

20

DETAILED DESCRIPTION OF THE INVENTION

The present invention is based, in part, upon the discovery of novel human nucleic acid sequences and of polypeptides encoded by these nucleic acids. The nucleic acids have been named "NOV 1-4", or collectively, "NOV-X". Representative NOV-X sequences, and 25 representative examples of uses of these sequences, are briefly discussed below.

Table 1 provides a summary of the NOV-X nucleic acids, their encoded polypeptides and homology.

TABLE 1. Sequences and Corresponding SEQ ID Numbers

NOVX Assignment	Internal Identification	SEQ ID NO (nucleic acid)	SEQ ID NO (polypeptide)	Homology
1	10132038.0.67	1	2	KIAA1233 protein
2a	10132038.0.139	3	4	KIAA1233 protein
2b	10132038.0.136	57	5	KIAA1233 protein

3a	18552586_EXT1	6	7	STE20 protein kinase
3b	18552586_EXT2	8	9	STE20 protein kinase
3c	18552586_EXT3	10	11	STE20 protein kinase
3d	18552586_EXT4	12	13	STE20 protein kinase
4a	10093872.0.107	14	15	Trypsin inhibitor
4b	10093872.1	16	17	Trypsin inhibitor
4c	10093872.0.38	18	19	Trypsin inhibitor
4d	10093872.2	20	21	Trypsin inhibitor
4e	10093872.3	22	23	Trypsin inhibitor

NOV-1: A Novel KIAA1233-like Polypeptide

A NOV-1 sequence according to the invention is a nucleotide sequence encoding a polypeptide related to KIAA1233 proteins, which bear sequence similarity to lacunin, thrombospondins, proteinases, semaphorins, ADAM-TS, and properdin family members. This invention maps to Unigene cluster Hs.18705. This cluster has been mapped to Chromosome 15 Marker stSG35204, Interval D15S115-D15S152. By integrating information from the Online Mendelian Inheritance in Man (OMIM), this region is identified as 15q22-qter. Therefore, the chromosomal location of the invention is Chromosome 15 Marker stSG35204, Interval D15S115-D15S152, which corresponds to 15q22-qter.

The nucleic acid of the invention, NOV-1, encoding a KIAA1233-like protein originating from chromosome 15, is shown in TABLE 2. The disclosed nucleic acid (SEQ ID NO: 1) is a full-length clone of 1281 nucleotides and contains an open reading frame (ORF) that begins with an ATG initiation codon at nucleotide 416 and ends with a TAA stop codon at nucleotides 4259. A representative ORF encodes a 1281 amino acid polypeptide (SEQ ID NO: 2). The initiation and stop codons of SEQ ID NO: 1 are shown in bold font. Putative untranslated regions are upstream of the initiation codon and downstream of the stop codon in SEQ ID NO: 1.

20

TABLE 2

TAATAGAGACCTTCAAAGGACAAATTCTGTGAAATAAGTGGTTCTGAAGAGCCTAC
 TAATAGGACAGTGTGTTAATATCACTAATAAGAGAGTAATGATTATAAAAAGGAATAAAT
 TTATTGAAATTGCAAGATACTTTCTCCTTGATTAATATACTGCTAGTTAGTTCTA
 25 CATTTCAAATAGAACTGGGAATTGTGTCGTAGATATTCTGACAACAAAGAGATGG
 TGGCTGAATTGGGATGGTGTAAACACTTGATATTAGTTCCAATTGGAAAGA
 GCTCTGTCTTGGGATGTCATAATTATTCGTCAATTAAATGAATGTGTTAATTATT
 ATAGAAATGATATTCTCACAAATGATTCATTTGAGTGATGGATTAAAGAGATAATGCC
 CTATGACCACCTCCAACCTCTCCTCGCTGGGACATAATCCTGGACTGCATGTC
 30 GTCCTGTGGAGGGAGGGATTCAGAGACGGAGCTTGTGTTAGAGGAATCCATGCATGG
 AGAGATATTGCAAGGTGGAAGAATGGAAGTGCATGTACGCACCCAAACCAAGGTTATGCA

AACTTGTAACTGTTGATTGCCCAAGTGGATTGCCATGGAGTGGTCAGTCAGCAGT
GACTTGTGGCCGAGGGTTACGGTACCGGGTTGTTCTGTGTATTAACCACCGCGGAGAGCA
TGTTGGGGCTGAATCCACAACCTGAAGTTACACATCAAAGAAGAATGTGTCAATTCCCAT
CCCGTGTATAAACCAAAAGAAAAAGTCCAGTGGAAAGCAAAATTGCCTGGCTGAAACAA
5 AGCACAAAGAACTAGAACAGAGACCAGAACATGCAACAGAACAAACGTTCAATTCCAGAAC
CTGGTCAGCCTGCAGTACACAGTGTGGCCGGGTGCAAGTCCGTGAGGTGAAGTGCCTG
TGTGCTCCTCACATTACGCCAGACTGAGACTGAGCTGCCGAGGAAGAGTGTGAAGGCC
CAAGCTGCCACCGAACGCCCTGCCCTGGAAAGCATGTGATGAGAGGCCGGCCCTCCCG
AGAGCTAGACATCCCTCTCCCTGAGGACAGTGAGACGACTTACGACTGGGAGTACGCTGG
10 GTTCACCCCTTGCACAGCAACATGCGTGGGAGGCCATCAAGAACGCCATAGCAGTGTGCTT
ACATATCCAGACCCAGCAGACAGTCATGACAGCAGCTGTGTGATATGGTCACCGTCCTCC
AGCCATGAGCCAGGCCCTGTAACACAGGCCCTGCCCCCCCAGGTGGCATGTGGCTCTTG
GGGCCCTGCTCAGCTACCTGTGGAGTTGAAATTCAAGACCCGAGATGTGTACTGCCTGCA
CCCAGGGAGACCCCTGCCCTGCCCTGAGGAGTGCCAGATGAAAAGCCCCATGCTTACA
15 AGCATGCAATCAGTTGACTGCCCTCTGGCTGGCACATTGAAGAACATGGCAGCAGTGTTC
CAGGACTTGTGGCGGGGGAACTCAGAACAGAACAGTCAACCTGTCGGCAGCTGCTAACGGA
TGGCAGCTTTTGAAATCTCAGATGAATTGTGCCAAGGACCCAAGGCATCGTCTCACAA
GTCCTGTGCCAGGACAGACTGTCCTCACATTAGCTGTGGGAGACTGGTCGAAGTGTTC
TGTCAAGTTGTGGTGTGGAATCCAGAGAACAGCAGGTGTGTCAAAGGCTGGCAGCCAA
20 AGGTCGGCGCATCCCCCTCAGTGAGATGATGTGCAAGGATCTACCAGGGCTCCCTCTGT
AAGATCTTGCCAGATGCCGTGAGTGCAGTAAAATCAAATCAGAGATGAAGAACAAAATTGG
TGAGCAGGGTCCCGAGATCCTCAGTGTCCAGAGAGTCTACATTCAAGACAAGGAAAGAGAA
GCGTATTAACCTGACCATTGGTAGCAGAGCCTATTGCTGCCAACACATCCGTGATTAT
TAAGTGCCAGTGCACGATTCCAGAAATCTCTGATCCAGTGGGAGAAGGATGGCCGTTG
25 CCTGCAGAACTCCAAACGGCTGGCATCACCAGTCAGGCTCACTAAAAATCCACGGTCT
TGCTCCCCCGACATGGCGTGTACGGGTGCATTGCAAGGCTCTGCACAGGAAACAGTTGT
GCTCAAGCTCATTGGTACTGACAACGGCTCATGCCACGCCAGCCCTCAGGGAGCCTAT
GAGGGAAATATCCTGGATGGACCACAGCGAAGCCAATAGTTGGGAGTCACATGGCACAA
AATGAGGCAAATGTGGAATAACAAAATGACCTTATCTGGATGATGACCACATTAGTAA
30 CCAGCCTTCTGAGAGCTGTTAGGCCACTGCAGCAATTCTGCAGGAAGCACCAACTC
CTGGGAGTTGAAAGATAAGCAGTTGAAGCAGCAGTTAAACAAGGAGCATAGCATGGA
TACAGCCCAGTTGATGAGCTGATAAGAAACATGAGTCAGCTCATGGAAACCGGAGAGGT
CAGCGATGATCTGGTCCAGCTGATATATCAGCTGGTGGCCGAATTAGCCAAGGCACA
GCCAACACACATGCAGTGGCGGGCATCCAGGAAGAGACACCTCCTGTCAGCTCAG
35 AGGGAAACAGGGAGTGTGCCCCAAAGCTCGCATGCAAAAAACTCAGGAAGCTGACATT
CAAGCCGAAAGGACCTGTTCTCATGAGGCAAAGCCAACCTCCCTCAATTTCATTAA
AACAAATAAAATTCCAGGATTGGAAATACAGTATACTACATTACAAAAAGGACAGAGGT
TATACTGTGTGACCTTACCCCCAGTGAGGCCACATATACATGGACCAAGGATGGAAAC
CTTGTACAGCCCTCAGTAAAAATAATTGGATGGAACCTGGGAAGATACAGATACAGAA
40 TCCTACAAGGAAAGAACAAAGGCATATATGAATGTTCTGTGAGCTAATCATCTGGTT
TGTGGAAAGTTCTCTGTGCTGTATGCAGAGGCCACTGTCACTTGTCTGTTGAAAGAAA
TATCACCAAAACCGAGAGCACAACCATCTGTCTGTTGGTGGAGGCATCGTGGAGGCAGC

CCTTGGAGCAAACGTGACAATCGATGTCCTGAAAAGGTGCCCTCAGCCTAATATAAC
 TTGGTTGAAGAGAGGAGGATCTCTGAGTGGCAATGTTCCCTGCTTTCAATGGATCCCT
 GTGTTGCAGAAATGTTCCCTGAAAATGAAGGAACCTACGTCTGCATAGCCACCAATGC
 TCTTGGAAAGGCAGTGGCAACATCTGACTCCACTGCTGGAACGAAGATGGCCAGAGAG
 5 TAGAACATCGTATTCGCAAGGACATAAAAAGTACATTCTCCAGGCAACCAACACTAGAAC
 CAACAGCAATGACCCAACAGGAGAACCCCCGCCTCAAGAGCCTTTGGGAGCCTGGTAA
 CTGGTCACATTGTTCTGCCACCTGTGGTCATTTGGGAGCCGCATTAGAGACCCCAGTG
 TGTGATGGCCAATGGGCAGGAAGTGAGTGAGGCCCTGTGATCACCTCCAGAACGCCACT
 GGCTGGGTTTGAGCCCTGTAACATCCGGACTGCCAGCGAGGTGGTCACAAGTGTGTG
 10 GTCACAGTGCTCTGTGCTTGCCTGAAGGATAACCACAGTCGGCAGGTGACGTGCAAGCG
 GACAAAAGCCAATGGAACGTGCAAGGTGGTGTCTCCAAGAGCATGTGCCCCCTAAAGACCG
 GCCCTGGGAAGAAAACATGTTGGTCATCCATGTGTTAGTGGGAACCAGGGAACCG
 GTGTCCTGGACGTTGCATGGCCGTGCTGTGAGGATGCAAGCAGCGTCACACAGCTTGTCA
 ACACAAACAGCTCTGACTCCAAGTGTGATGACAGAAAGAGACCCACCTTAAGAAGGAACGT
 15 CACATCAGGGGCCTGTGATGTTGGCACACAGGCCCTGGAGGCCCTGTACAGCAGC
 CTGTGGCAGGGGTTCCAGTCTCGAAAGTCGACTGTATCCACACAAGGAGTTGCAAACC
 TGTCGCAAGAGACACTGTGTACAGAAAAGAACCAATTCCCTGGCGACTGTCTTGG
 GCCCTCTGTGATAGAGACTGCACAGACACAACACTACTGTATGTTGAAAACATCT
 TAATTGTTGTTCTCTAGACCCGCTACAAACAAAGGTGCTGCCAGTCATGTCAAGAGGGATA
 20 AACCTTTGGAGGGGTCAATGATGCTGCTGTGAAGATAAAAGTAGAAATATAAAAGCTCTTT
 CCCCATGTCGCTGATTCAAAAACATGTATTCTAAAAGACTAGATTCTATGGATCAAAC
 AGAGGTTGATGCAAAACACCACTGTTAAGGTGAAAGTGAATTTCCAATGGTAGTT
 TATATTCCAATTTTAAAATGATGTATTCAAGGATGAACAAAATACTATAGCATGCATG
 CCACTGCACTTGGACCTCATGTCAAGTTGAATCGAGAAATCACCAAGATTATGAGTG
 25 CATCCTCACGTGCTGCCCTTTCTGTGATATGTAGACTAGCACAGAGTGGTACATCCTA
 AAAACTTGGAAACACAGCAACCCATGACTCCCTCTCAAGTTGCAGGTTTCAAC
 AGTTTATAAGGTATTCGATTTAGAAGCTCTGCCAGTAGTTGTTAAGATGTTGGCAT
 TAATGGCATTTCATAGATCCTGGTTAGTCTGTGAAAAAGAACCATCTCTGGATA
 GGCTGTCACACTGACTGACCTAAGGGTTCATGAAAGCATGGCATCTTGTCTTGCTTTA
 30 GAACACCCATGGAAGAAAACACAGAGTAGATATTGCTGTCATTATACAACACAGAAAT
 TTATCTATGACCTAATGAGGCATCTCGGAAGTCAGGAAAGAGGGAAAGTTAACCTTTCT
 ACTGATTCTGTAGTATATTCAAGAGCTTCTTTAAGAGCTGTGAATGAAACTTTCTAA
 GCACATTCTATTGCACACAAACAGAAAACCAAGCCTTATTAGACCTAATTATGCATA
 AAGTAGTATTCCCTGAGAACTTATTGGAAAATTATAAGAAAGTAATCCAATAAGAA
 35 ACACGATAGTTGAAAATAATTCTATAGTAAATAATTGTTGGGCTGATTTTCAGTAA
 ATCCAAAGTGAATTAGGTTAGAAGTTACACTAAGGACCAGGGTTGGAATCAGAATTAG
 TTTAAGATTTGAGGAAAAGGGTAAGGGTTAGTTCTGTGTTAGGATTAGAGCTAGAATTG
 GGTTAGGTGAGAAAAGTTAAGGTTAAGGCTAGAGTTGCTTTAAGGGTTAGGGTTAG
 GACCAGGTTAGGTCAAGGGTGGATTGGGTTAGATTGGGCCAGTGCTGGTGTAGTGT
 40 AGTGTCAAGGATGGAGGTTAGGTTGGAGTAAGCCTGTTGCTGAAGTGAGTTCAAGGCTAG
 CATTAAATTGTAAGTCTGAAGCTGATTTGGTTATGGGTCTTCCCTGTATAACTACCA
 GTTGTGTCTTAGATGGCACACAAGTCCAAATAAGTGGTCATACTTCTTATTCAAGGGTC

TCAGCTGCCTGTACACCTGCTGCCACATCTCTGGCAACAAAGTTACCTGCCACAGGC
 TCTGCTGAGCCTAGTCCTGGTCAGTAATAACTGAACAGTGCATTTGGCTTGGATGTG
 TCTGTGGACAAGCTGCTGAGTTCTACCATATTCTGAGCACACGGCTCTTTGTC
 TAATTCAGCTTCACTGACACTGGGTGAGCACTACTGTATGTGGAGGGTTGGTATTG
 5 GGAATGGATGGGGACAGTGAGGAGGACACACCAGCCCATTAGTTGTTAACATCAATCA
 CATCTGATTGTTGAAGGTTATTAAATTAAAAGAAAGATCATTGTAACATACTCTTGTA
 TATATTATTATATGAAAGGTCAATATTTATTGTCAGTATGTAATAAGACATGG
 GACATATATTTCTTATTAAACAAAATTTCATATTAAATTGCTTCACTTGTTAAG
 10 TAAAAAGTTACTATTTTCAATTGCTATTGACTTTCAATTGTTGTCATTCAATTGACATT
 CCTGTGTACTGTATTTACTACTGTTTATAACATGAGAGTTAATGTTCTGTTCATG
 ATCCTTATGTAATTCAAGAAATAAATTACTTTGATTATTCAAGTGGCATCCTTAT (SEQ ID NO: 1)

MPYDHFQPLPRWEHNPWTACSVSCGGGIQRSSFVCVEESMHGEILQVEEKCMYAPKPKVMQTCNLFDCKWIA
 WSQCTVTCGRGLRYRVVLICINHRGEHVGCGNPQLKLHKEECVIPIPCYKPKEKSPVEAKLPWLKQAQELEETRIA
 15 TEEPTFIPEPWSACSTTCGPVGQVREVKCRVLLFTQTETELPEEECEGPKLPTERPCCLLEACDES
 PEDSETTYDWEYAGFTPCTATCVGGHQEAIAVCLHIQTQQTVNDSLCDMVHRPPAMSQACNT
 CSATCGVGIQTRDVYCLHPGETPAPPEECRDEKPHALQACNQFDCCPGWHIEEWQQCSRT
 TDGSFLNLSDLCQGPKASSHKSCARTDCPPLAVGDWSKCSVSCVGQIQRKQVCQRLAA
 20 KGRRIPLSEMMCRDL PGLPLVRSCQMPECSKIKSEMKTKLGEQGPQILSVQRVYIQTREEKRINLTIGS
 LIQWEKDGRCLQNSKRLGITKSGSLKIHGLAAPDIGVYRCIAGSAQETVV
 DHSEANSILGVTVHKMRQMWNKNNDLYLDDDHISNQPFLALLGHCSNSAG
 QFDELIRNMSQLMETGEVSDDLASQLIYQLVAELAKAQPTHMQWRGIQEET
 TFKPKGPVLMRQSQPPSISFNKTINSRIGHTVYITKRT
 25 EVINILCDLITPSEATYTWTKDGTLLQPSVKII
 KIQIQNPRKEQGIYEC
 VKGVPQPNITWLKGGSLSGNVSLFNGLLQNVSLNEGTYVCIATNALG
 GHKKYILQATNTRNSNDPTGEPPPQEPFWEPGNWSHCATCGHLGARI
 FEPCNIRD
 30 CPARWFTSVWSQCSVSCGEGYHSRQVTCKRTKANGTVQV
 NRCPGRCMGRAVRMQRHTACQHN
 TRSKPVAKRHCVQKKPISWRHCLGPSCDRDCTDTTHYCMFVKHLNLCSLD
 NO: 2) RYKQRCCQSCQEG (SEQ ID

In a search of sequence databases, it was found, for example, that the disclosed NOV-1 nucleotide sequence has 5106 of 5107 bases (99%) identical to a human mRNA for a KIAA1233 protein (SEC1) (GenBank Accession No: ABO33059), as shown in Table 3. In all sequence alignments, identical residues are depicted as “|”. As indicated by the “Expect” value, the probability of this alignment occurring by chance alone is 0.0, the lowest probability.

Furthermore, the encoded amino acid sequence has 1023 of 1023 amino acid residues (100%) identical to, and 1023 of 1023 residues (100 %) positive with, a 1023 amino acid

residue human KIAA1233 protein (GenBank Accession No: BAA86547), as shown in Table 4. As indicated by the “Expect” value, the probability of this alignment occurring by chance alone is 0, the lowest probability.

5 TABLE 3

Score = 1.012e+04 bits (5103), Expect = 0.0
Identities = 5106/5107 (99%)
Strand = Plus / Plus

10 NOV1: 1188 tagcagtgtgcttacatatccagacccaggcagacagtcaatgacagcttgtgtatgg
1247 |||||||
15 SECR : 1 tagcagtgtgcttacatatccagacccaggcagacagtcaatgacagcttgtgtatgg 60

NOV1: 1248 tccaccgtcctccagccatgagccaggcctgtaacacagagccctgtccccccaggtggc
1307 |||||||
20 SECR : 61 tccaccgtcctccagccatgagccaggcctgtaacacagagccctgtccccccaggtggc 120

NOV1: 1308 atgtggcttggggccctgctcagctacctgtggagttggaaattcagacccgagatg
1367 |||||||
25 SECR : 121 atgtggcttggggccctgctcagctacctgtggagttggaaattcagacccgagatg 180

NOV1: 1368 tgtactgcctgcacccagggagacccctgcccctcctgaggagtgccgagatgaaaagc
1427 |||||||
30 SECR : 181 tgtactgcctgcacccagggagacccctgcccctcctgaggagtgccgagatgaaaagc 240

NOV1: 1428 cccatgtttacaaggcatgcaatcagttgactgcctcctggcacattgaagaat
1487 |||||||
35 SECR : 241 cccatgtttacaaggcatgcaatcagttgactgcctcctggcacattgaagaat 300

NOV1: 1488 ggcagcagtgttccaggactgtggcgaaaaactcagaacagaagagtccacgtcgcc
1547 |||||||
40 SECR : 301 ggcagcagtgttccaggactgtggcgaaaaactcagaacagaagagtccacgtcgcc 360

NOV1: 1548 agctgctaacggatggcagctttgaatctctcagatgaatttgccaaaggacccaagg
1607 |||||||
45 SECR : 361 agctgctaacggatggcagctttgaatctctcagatgaatttgccaaaggacccaagg 420

NOV1: 1608 catcgctcacaagtctgtgccaggacagactgtcctccacatttagctgtggagact
1667 |||||||
50 SECR : 421 catcgctcacaagtctgtgccaggacagactgtcctccacatttagctgtggagact 480

NOV1: 1668 ggtcgaagtgttctgtcagttgtggatccagagaagaaaggcagggtgtcaaa
1727 |||||||
SECR : 481 ggtcgaagtgttctgtcagttgtggatccagagaagaaaggcagggtgtcaaa 540
5

NOV1: 1728 ggctggcagccaaaggtcggcgcatccccctcagtgagatgtgcagggatctaccag
1787 |||||||
SECR : 541 ggctggcagccaaaggtcggcgcatccccctcagtgagatgtgcagggatctaccag 600
10

NOV1: 1788 ggctcccttttaagatcttgcagatgcctgagtcagtaaaatcaaattcagagatga
1847 |||||||
SECR : 601 ggctcccttttaagatcttgcagatgcctgagtcagtaaaatcaaattcagagatga 660
15

NOV1: 1848 agacaaaacttggtgagcagggtcccgagatcctcagtgtccagagagtctacattcaga
1907 |||||||
SECR : 661 agacaaaacttggtgagcagggtcccgagatcctcagtgtccagagagtctacattcaga 720
20

NOV1: 1908 caagggaaagagaagcgtattaacctgaccattggtagcagagcctattgtgtccccaaaa
1967 |||||||
SECR : 721 caagggaaagagaagcgtattaacctgaccattggtagcagagcctattgtgtccccaaaa 780
25

NOV1: 1968 catccgtgattattaagtgccagtgcgacgattccagaaatctctgatccagtggaga
2027 |||||||
SECR : 781 catccgtgattattaagtgcccggtgcgacgattccagaaatctctgatccagtggaga 840
30

NOV1: 2028 aggatggccgtgcctgcagaactccaaacggcttgcaccaagtcaaggctcactaa
2087 |||||||
SECR : 841 aggatggccgtgcctgcagaactccaaacggcttgcaccaagtcaaggctcactaa 900
35

NOV1: 2088 aaatccacggtcttgcgtcccccgacatggcgttaccgggtcattgcaggctctgcac
2147 |||||||
SECR : 901 aaatccacggtcttgcgtcccccgacatggcgttaccgggtcattgcaggctctgcac 960
40

NOV1: 2148 agggaaacagttgtgctcaagctcattggtaactgacaacccggctcatcgcacgccc
2207 |||||||
SECR : 961 agggaaacagttgtgctcaagctcattggtaactgacaacccggctcatcgcacgccc
1020 |||||||
45

NOV1: 2208 tcagggagcctatgagggaatatcctggatggaccacagcgaagccaatagttggag
2267 |||||||
SECR : 1021 tcagggagcctatgagggaatatcctggatggaccacagcgaagccaatagttggag
1080 |||||||
50

55

60

NOV1: 2268 tcacatggcacaaaatgaggcaaatgtggataacaaaatgaccttatctggatgatg
2327 |||||||

5 SECR : 1081 tcacatggcacaaaatgaggcaaatgtggataacaaaatgaccttatctggatgatg
1140 |||||||

NOV1: 2328 accacattagtaaccagctttctttagagactctgttaggcactgcagcaattctgcag
2387 |||||||

10 SECR : 1141 accacattagtaaccagctttctttagagactctgttaggcactgcagcaattctgcag
1200 |||||||

15 NOV1: 2388 gaagcaccaactcctggagttgaagaataagcagttgaagcagcagttaaacaaggag
2447 |||||||

20 SECR : 1201 gaagcaccaactcctggagttgaagaataagcagttgaagcagcagttaaacaaggag
1260 |||||||

NOV1: 2448 catatagcatggatacagcccagttgatgagctgataagaaacatgagtcagctcatgg
2507 |||||||

25 SECR : 1261 catatagcatggatacagcccagttgatgagctgataagaaacatgagtcagctcatgg
1320 |||||||

30 NOV1: 2508 aaaccggagaggtcagcgatgatcttgcgtccagctgatatatcagctggtgccgaat
2567 |||||||

SECR : 1321 aaaccggagaggtcagcgatgatcttgcgtccagctgatatatcagctggtgccgaat
1380 |||||||

35 NOV1: 2568 tagccaaggcacagccaaacacacatgcagtggcgaaaaatccaggaagagacacccctcg
2627 |||||||

40 SECR : 1381 tagccaaggcacagccaaacacacatgcagtggcgaaaaatccaggaagagacacccctcg
1440 |||||||

NOV1: 2628 ctgctcagctcagagggaaacaggagttgtgtccaaagctcgcatgaaaaaaaaactcag
2687 |||||||

45 SECR : 1441 ctgctcagctcagagggaaacaggagttgtgtccaaagctcgcatgaaaaaaaaactcag
1500 |||||||

50 NOV1: 2688 gcaagctgacattcaagccaaaggacctgttctcatgaggaaagccaacccctcccaa
2747 |||||||

SECR : 1501 gcaagctgacattcaagccaaaggacctgttctcatgaggaaagccaacccctcccaa
1560 |||||||

55 NOV1: 2748 tttcatttataaaaacaataaaattccaggattggaaatacagtatacattacaaaaagga
2807 |||||||

60 SECR : 1561 tttcatttataaaaacaataaaattccaggattggaaatacagtatacattacaaaaagga
1620 |||||||

NOV1: 2808 cagaggcatcaatactgtgtgaccttattaccccccagtgaggccacatatacatgg
2867 |||||||
SECR : 1621 cagaggcatcaataactgtgtgaccttattaccccccagtgaggccacatatacatgg
1680 |||||||

NOV1: 2868 ccaaggatggaaccttggacagccctcagtaaaaataatttggatgaaactggaaaga
2927 |||||||
SECR : 1681 ccaaggatggaaccttggacagccctcagtaaaaataatttggatgaaactggaaaga
1740 |||||||

NOV1: 2928 tacagatacagaatcctacaaggaaagaacaaggcatatatgaatgttctgttagctaatc
2987 |||||||
SECR : 1741 tacagatacagaatcctacaaggaaagaacaaggcatatatgaatgttctgttagctaatc
1800 |||||||

NOV1: 2988 atcttggttcagatgtggaaagttttctgtgttatgcagaggcacctgtcatcttgc
3047 |||||||
SECR : 1801 atcttggttcagatgtggaaagttttctgtgttatgcagaggcacctgtcatcttgc
1860 |||||||

NOV1: 3048 ctgttggaaagaaatatcaccaaaccagagcacaaccatctgtctgttggttggaggca
3107 |||||||
SECR : 1861 ctgttggaaagaaatatcaccaaaccagagcacaaccatctgtctgttggttggaggca
1920 |||||||

NOV1: 3108 tcgtggaggcagcccttggagcaaacgtgacaatccgatgtcctgtaaaagggtgtccctc
3167 |||||||
SECR : 1921 tcgtggaggcagcccttggagcaaacgtgacaatccgatgtcctgtaaaagggtgtccctc
1980 |||||||

NOV1: 3168 agcctaataacttgggtgaagagaggaggatctctgagtggaatgtttccttgc
3227 |||||||
SECR : 1981 agcctaataacttgggtgaagagaggaggatctctgagtggaatgtttccttgc
2040 |||||||

NOV1: 3228 tcaatggatccctgttggcagaatgttcccttggaaaatgaaggAACCTACGTCTGCA
3287 |||||||
SECR : 2041 tcaatggatccctgttggcagaatgttcccttggaaaatgaaggAACCTACGTCTGCA
2100 |||||||

NOV1: 3288 tagccaccaatgtcttggaaaggcagtggaacatctgtactccacttgc
3347 |||||||
SECR : 2101 tagccaccaatgtcttggaaaggcagtggaacatctgtactccacttgc
2160 |||||||

NOV1: 3348 gatggccagagagtagaatcgtatttctgcaaggacataaaaaagtacattctccaggcaa
3407 |||||||
SECR : 2161 gatggccagagagtagaatcgtatttctgcaaggacataaaaaagtacattctccaggcaa
2220 |||||||

5

NOV1: 3408 ccaacactagaaccaacagcaatgacccaacaggagaaccccccgcctaagagcctttt
3467 |||||||
SECR : 2221 ccaacactagaaccaacagcaatgacccaacaggagaaccccccgcctaagagcctttt
2280 |||||||

10

NOV1: 3468 gggagcctggtaactggcacattgttctgccacctgtggcatttggagccgcattc
3527 |||||||
SECR : 2281 gggagcctggtaactggcacattgttctgccacctgtggcatttggagccgcattc
2340 |||||||

20

NOV1: 3528 agagaccccagtgtgtatggcaatggcaggaagtgagtgaggccctgtgtatcacc
3587 |||||||
SECR : 2341 agagaccccagtgtgtatggcaatggcaggaaagtgagtgaggccctgtgtatcacc
2400 |||||||

25

NOV1: 3588 tccagaagccactggctgggttgagccctgtaacatccggactgccagcgaggtgg
3647 |||||||
SECR : 2401 tccagaagccactggctgggttgagccctgtaacatccggactgccagcgaggtgg
2460 |||||||

30

NOV1: 3648 tcacaagtgtggtcacagtgtctgtcttgcggtaaggataccacagtccggagg
3707 |||||||
SECR : 2461 tcacaagtgtggtcacagtgtctgtcttgcggtaaggataccacagtccggagg
2520 |||||||

35

NOV1: 3708 tgacgtgcaagcggacaaaagccaatggaaactgtgcaggtggtgtctccaagagcatgt
3767 |||||||
SECR : 2521 tgacgtgcaagcggacaaaagccaatggaaactgtgcaggtggtgtctccaagagcatgt
2580 |||||||

40

NOV1: 3768 cccctaaagaccggctctggaaagaaaaccatgtttggcatccatgtgttcagtg
3827 |||||||
SECR : 2581 cccctaaagaccggctctggaaagaaaaccatgtttggcatccatgtgttcagtg
2640 |||||||

45

NOV1: 3828 aaccaggaaaccgggtgtctggacgtgcattggccgtgtgaggatgcagcagcgtc
3887 |||||||
SECR : 2641 aaccaggaaaccgggtgtctggacgtgcattggccgtgtgaggatgcagcagcgtc
2700 |||||||

50

55

60

NOV1: 3888 acacagcttgtcaacacaacagctctgactccaactgtgatgacagaaaagagacccacct
3947 |||||||

5 SECR : 2701 acacagcttgtcaacacaacagctctgactccaactgtgatgacagaaaagagacccacct
2760 |||||||

NOV1: 3948 taagaaggaaactgcacatcagggcctgtgatgtgttggcacacaggcccttggaaagc
4007 |||||||

10 SECR : 2761 taagaaggaaactgcacatcagggcctgtgatgtgttggcacacaggcccttggaaagc
2820 |||||||

15 NOV1: 4008 cctgtacagcagcctgtggcagggtttccagtctcgaaaagtcgactgtatccacacaa
4067 |||||||

20 SECR : 2821 cctgtacagcagcctgtggcagggtttccagtctcgaaaagtcgactgtatccacacaa
2880 |||||||

NOV1: 4068 ggagttgcaaaccctgtggccaagagacactgtgtacagaaaaagaaaaccaatttctggc
4127 |||||||

25 SECR : 2881 ggagttgcaaaccctgtggccaagagacactgtgtacagaaaaagaaaaccaatttctggc
2940 |||||||

30 NOV1: 4128 ggcaactgtcttggccctcctgtgatagagactgcacagacacaactcactactgtatgt
4187 |||||||

SECR : 2941 ggcaactgtcttggccctcctgtgatagagactgcacagacacaactcactactgtatgt
3000 |||||||

35 NOV1: 4188 ttgtaaaacatcttaatttgtgttcttagaccgctacaaacaaaaggtgtgccagtc
4247 |||||||

40 SECR : 3001 ttgtaaaacatcttaatttgtgttcttagaccgctacaaacaaaaggtgtgccagtc
3060 |||||||

NOV1: 4248 gtcaagagggataaacctttggaggggtcatgatgtgtgaagataaaagtagaata
4307 |||||||

45 SECR : 3061 gtcaagagggataaacctttggaggggtcatgatgtgtgaagataaaagtagaata
3120 |||||||

50 NOV1: 4308 taaaagctttccccatgtcgctgattcaaaaacatgtatttcttaaaagactagatt
4367 |||||||

SECR : 3121 taaaagctttccccatgtcgctgattcaaaaacatgtatttcttaaaagactagatt
3180 |||||||

55 NOV1: 4368 ctatggatcaaacagaggttcatgcaaaaacaccactgttaaggtgtaaagtgaaatttt
4427 |||||||

60 SECR : 3181 ctatggatcaaacagaggttcatgcaaaaacaccactgttaaggtgtaaagtgaaatttt
3240 |||||||

NOV1: 4428 ccaatggtagtttatattccaattttaaaatgatgtattcaaggatgaacaaaatac
4487 |||||||
SECR : 3241 ccaatggtagtttatattccaattttaaaatgatgtattcaaggatgaacaaaatac
5 3300 |||||||

NOV1: 4488 tatagcatgcactgcacccacttggacctcatcatgtcagttgaatcgagaaatcacc
4547 |||||||
SECR : 3301 tatagcatgcactgcacccacttggacctcatcatgtcagttgaatcgagaaatcacc
10 3360 |||||||

NOV1: 4548 aagattatgagtgcacgtcacgtgcctcttcctgtgatatgttagactgcacaga
4607 |||||||
SECR : 3361 aagattatgagtgcacgtcacgtgcctcttcctgtgatatgttagactgcacaga
20 3420 |||||||

NOV1: 4608 gtggtacatccaaaaacttggaaacacagcaacccatgacttcctttctcaagtt
4667 |||||||
SECR : 3421 gtggtacatccaaaaacttggaaacacagcaacccatgacttcctttctcaagtt
25 3480 |||||||

NOV1: 4668 gcagggtttcaacagtttataaggtagttgcattttagaagctctggccagtagtttt
4727 |||||||
SECR : 3481 gcagggtttcaacagtttataaggtagttgcattttagaagctctggccagtagtttt
30 3540 |||||||

NOV1: 4728 aagatgttggcattaatggcattttcatagatccttggtttagtctgtaaaaagaaacc
4787 |||||||
SECR : 3541 aagatgttggcattaatggcattttcatagatccttggtttagtctgtaaaaagaaacc
40 3600 |||||||

NOV1: 4788 atctctctggataggctgcacactgactgacctaagggttcatggaagcatggcattt
4847 |||||||
SECR : 3601 atctctctggataggctgcacactgactgacctaagggttcatggaagcatggcattt
45 3660 |||||||

NOV1: 4848 gtccttgcttttagaacacccatggaagaaaacacagagtagatattgtgtcattata
4907 |||||||
SECR : 3661 gtccttgcttttagaacacccatggaagaaaacacagagtagatattgtgtcattata
50 3720 |||||||

NOV1: 4908 caactacagaaatttatctatgacctaattgaggcatctcgaaagtcaaagaagagggaaa
4967 |||||||
SECR : 3721 caactacagaaatttatctatgacctaattgaggcatctcgaaagtcaaagaagagggaaa
55 3780 |||||||

NOV1: 4968 gttaaccctttctactgattcgtatattcagagcttctttaaagagctgtgaatg
5027 |||||||
SECR : 3781 gttaaccctttctactgattcgtatattcagagcttctttaaagagctgtgaatg
5 3840 |||||||

NOV1: 5028 aaacttttctaaggactattctattgcacacaaaacagaaaaaccaaaggcatttagacc
10 5087 |||||||
SECR : 3841 aaacttttctaaggactattctattgcacacaaaacagaaaaaccaaaggcatttagacc
3900 |||||||

15 NOV1: 5088 taatttatgcataaagttagtattcctgagaacttattttggaaaatttataagaagta
5147 |||||||
SECR : 3901 taatttatgcataaagttagtattcctgagaacttattttggaaaatttataagaagta
20 3960 |||||||

NOV1: 5148 atccaaataagaaaacacgatagttgaaaataattttatagtaataattgtttggct
5207 |||||||
25 SECR : 3961 atccaaataagaaaacacgatagttgaaaataattttatagtaataattgtttggct
4020 |||||||

30 NOV1: 5208 gatTTTcagtaaatccaaagtgacttagtttagaagttacactaaggaccagggttgg
5267 |||||||
SECR : 4021 gatTTTcagtaaatccaaagtgacttagtttagaagttacactaaggaccagggttgg
4080 |||||||

35 NOV1: 5268 aatcagaatttagttaaagatttgaggaaaaggtaaggtagttcagtttaggatt
5327 |||||||
SECR : 4081 aatcagaatttagttaaagatttgaggaaaaggtaaggtagttcagtttaggatt
40 4140 |||||||

45 NOV1: 5328 agagctagaattgggttaggtgagaaaagaaagttaaggtaaggctagagttgtcttaa
5387 |||||||
SECR : 4141 agagctagaattgggttaggtgagaaaagaaagttaaggtaaggctagagttgtcttaa
4200 |||||||

50 NOV1: 5388 gggttagggtaggaccaggtaggtcagggttggattgggttagattggggccagtgc
5447 |||||||
SECR : 4201 gggttagggtaggaccaggtaggtcagggttggattgggttagattggggccagtgc
55 4260 |||||||

55 NOV1: 5448 tggtgttagtgcaggatggaggtaggtttggagtaagcggttgcgtgaagt
5507 |||||||
60 SECR : 4261 tggtgttagtgcaggatggaggtaggtttggagtaagcggttgcgtgaagt
4320 |||||||

NOV1: 5508 gagttcaggctagcattaaattgttaagttctgaagctgattggatatgggtcttccc
5567 |||||||

5 SECR : 4321 gagttcaggctagcattaaattgttaagttctgaagctgattggatatgggtcttccc
4380 |||||||

NOV1: 5568 ctgtatactaccagtgtgtcttagatggcacacaagtccaaataagtggtcataactc
5627 .|||

10 SECR : 4381 ctgtatactaccagtgtgtcttagatggcacacaagtccaaataagtggtcataactc
4440 .|||

15 NOV1: 5628 tttattcagggtctcagctgcctgtacacctgctgcctacatcttcttggcaacaaagtt
5687 .|||

20 SECR : 4441 tttattcagggtctcagctgcctgtacacctgctgcctacatcttcttggcaacaaagtt
4500 .|||

NOV1: 5688 acctgccacaggctctgctgagcctagttcctggtcagtaataactgaacagtgcatttt
5747 .|||

25 SECR : 4501 acctgccacaggctctgctgagcctagttcctggtcagtaataactgaacagtgcatttt
4560 .|||

30 NOV1: 5748 ggctttggatgtgtctgtggacaagcttgcgtgagttcttaccatattctgagcacacg
5807 .|||

SECR : 4561 ggctttggatgtgtctgtggacaagcttgcgtgagttcttaccatattctgagcacacg
4620 .|||

35 NOV1: 5808 gtctctttgttctaatttcagcttcaactgacactgggttgagcactactgtatgtggag
5867 .|||

40 SECR : 4621 gtctctttgttctaatttcagcttcaactgacactgggttgagcactactgtatgtggag
4680 .|||

45 NOV1: 5868 ggtttggatggaaatggatggatggggacagtgaggaggacacaccagcccatttgt
5927 .|||

SECR : 4681 ggtttggatggaaatggatggatggggacagtgaggaggacacaccagcccatttgt
4740 .|||

50 NOV1: 5928 taatcatcaatcacatctgattgttgaaggttattaaattaaaagaaagatcatttgtaa
5987 .|||

SECR : 4741 taatcatcaatcacatctgattgttgaaggttattaaattaaaagaaagatcatttgtaa
4800 .|||

55 NOV1: 5988 catactcttgtatatatattatatgaaagggtcaatattttatgtacagtatgt
6047 .|||

60 SECR : 4801 catactcttgtatatatattatatgaaagggtcaatattttatgtacagtatgt
4860 .|||

NOV1: 6048 aataaagacatggacatatattttcttattaacaaaatttcataattgcac
6107 |||||||

5 SECR : 4861 aataaagacatggacatatattttcttattaacaaaatttcataattgcac
4920 |||||||

NOV1: 6108 tttgtatTTaaagttaaaagttactatTTTcattgtctattgtactttcattgttgc
6167 |||||||

10 SECR : 4921 tttgtatTTaaagttaaaagttactatTTTcattgtctattgtactttcattgttgc
4980 |||||||

15 NOV1: 6168 ttcaattgacattcctgtgtactgtatTTTactactgttttataacatgagagttaatg
6227 |||||||

20 SECR : 4981 ttcaattgacattcctgtgtactgtatTTTactactgttttataacatgagagttaatg
5040 |||||||

NOV1: 6228 ttctgtttcatgatccttatgtattcagaataaaatttactttgattattcagtggca
6287 |||||||

25 SECR : 5041 ttctgtttcatgatccttatgtattcagaataaaatttactttgattattcagtggca
5100 |||||||

30 NOV1: 6288 tccttat 6294 (SEQ ID NO: 58)
|||
SECR : 5101 tccttat 5107 (SEQ ID NO: 24)

Table 4

35

Score = 2027 bits (5253), Expect = 0.0
Identities = 1023/1023 (100%), Positives = 1023/1023 (100%)

40 NOV1: 259 AVCLHIQTQQTVNDSLCDMVHRPPAMSQACNTEPCPPRWHVGSWGPCSATCGVGIQTRDV 318
AVCLHIQTQQTVNDSLCDMVHRPPAMSQACNTEPCPPRWHVGSWGPCSATCGVGIQTRDV

SECR : 1 AVCLHIQTQQTVNDSLCDMVHRPPAMSQACNTEPCPPRWHVGSWGPCSATCGVGIQTRDV 60

45 NOV1: 319 YCLHPGETPAPPEECRDEKPHALQACNQFDCPPGWHIEWQOCRTCGGGTQNRRVTCRQ 378
YCLHPGETPAPPEECRDEKPHALQACNQFDCPPGWHIEWQOCRTCGGGTQNRRVTCRQ

SECR : 61 YCLHPGETPAPPEECRDEKPHALQACNQFDCPPGWHIEWQOCRTCGGGTQNRRVTCRQ 120

50 NOV1: 379 LLTDGSFLNLSDELCQGPKASSHKSCARTDCPPHLAVGDWSKCSVSCGVGIQRRKQVCQR 438
LLTDGSFLNLSDELCQGPKASSHKSCARTDCPPHLAVGDWSKCSVSCGVGIQRRKQVCQR

SECR : 121 LLTDGSFLNLSDELCQGPKASSHKSCARTDCPPHLAVGDWSKCSVSCGVGIQRRKQVCQR 180

55 NOV1: 439 LAAKGRRIPLEMCMRDLGPLPLVRSCQMPECSKIKSEMKTKLGEQGPQILSVQRVIQT 498
LAAKGRRIPLEMCMRDLGPLPLVRSCQMPECSKIKSEMKTKLGEQGPQILSVQRVIQT

SECR : 181 LAAKGRRIPLEMCMRDLGPLPLVRSCQMPECSKIKSEMKTKLGEQGPQILSVQRVIQT 240

60 NOV1: 499 REEKRINLTIGSRAYLLPNTSVIICKPVRRFQKS LIQWEKDGRCLQNSKRLGITKSGSLK 558
REEKRINLTIGSRAYLLPNTSVIICKPVRRFQKS LIQWEKDGRCLQNSKRLGITKSGSLK

SECR : 241 REEKRINLTIGSRAYLLPNTSVIICKPVRRFQKS LIQWEKDGRCLQNSKRLGITKSGSLK 300

NOV1: 559 IHGLAAPDIGVYRCIAGSAQETVVLKLIGTDNRLIARPALREPMREYPGMDHSEANSLGV 618
IHGLAAPDIGVYRCIAGSAQETVVLKLIGTDNRLIARPALREPMREYPGMDHSEANSLGV

SECR : 301 IHGLAAPDIGVYRCIAGSAQETVVLKLIGTDNRLIARPALREPMREYPGMDHSEANSLGV 360

NOV1: 619 TWHKMRQMWNKNDLYLDDDHISNQPFLRALLGHCSNSAGSTNSWELKNQFEAAVKQGA 678
TWHKMRQMWNKNDLYLDDDHISNQPFLRALLGHCSNSAGSTNSWELKNQFEAAVKQGA
SECR : 361 TWHKMRQMWNKNDLYLDDDHISNQPFLRALLGHCSNSAGSTNSWELKNQFEAAVKQGA 420

5 NOV1: 679 YSMDTAQFDELIRNMSQLMETGEVSDDLASQLIYQLVAELAKAOPTHMQWRGIQEETPPA 738
YSMDTAQFDELIRNMSQLMETGEVSDDLASQLIYQLVAELAKAOPTHMQWRGIQEETPPA
SECR : 421 YSMDTAQFDELIRNMSQLMETGEVSDDLASQLIYQLVAELAKAOPTHMQWRGIQEETPPA 480

10 NOV1: 739 AQLRGETGSVSQSSHAKNSGKLTFKPKGPVLMRQSQQPSISFNKTINSRIGHTVYITKRT 798
AQLRGETGSVSQSSHAKNSGKLTFKPKGPVLMRQSQQPSISFNKTINSRIGHTVYITKRT
SECR : 481 AQLRGETGSVSQSSHAKNSGKLTFKPKGPVLMRQSQQPSISFNKTINSRIGHTVYITKRT 540

15 NOV1: 799 EVINILCDLITPSEATYTWTKDGTLLQPSVKIIILDGTGKIQIQNPTRKEQGIYECVANH 858
EVINILCDLITPSEATYTWTKDGTLLQPSVKIIILDGTGKIQIQNPTRKEQGIYECVANH
SECR : 541 EVINILCDLITPSEATYTWTKDGTLLQPSVKIIILDGTGKIQIQNPTRKEQGIYECVANH 600

20 NOV1: 859 LGSDVESSSVLYAEAPVILSVERNITKPEHNHLSVVVGIVEAALGANVTIRCPVKGPQ 918
LGSDVESSSVLYAEAPVILSVERNITKPEHNHLSVVVGIVEAALGANVTIRCPVKGPQ
SECR : 601 LGSDVESSSVLYAEAPVILSVERNITKPEHNHLSVVVGIVEAALGANVTIRCPVKGPQ 660

25 NOV1: 919 PNITWLKRGGSLSGNVSLLFNGSLLLQNVSLNEGETYVCIATNALGKAVATSVLHLLERR 978
PNITWLKRGGSLSGNVSLLFNGSLLLQNVSLNEGETYVCIATNALGKAVATSVLHLLERR
SECR : 661 PNITWLKRGGSLSGNVSLLFNGSLLLQNVSLNEGETYVCIATNALGKAVATSVLHLLERR 720

30 NOV1: 979 WPESRIVFLQGHKKYIILQATNTRTN SNDPTGEPPPQEPFWEPGNWSHCSATCGHLGARIQ
1038 WPESRIVFLQGHKKYIILQATNTRTN SNDPTGEPPPQEPFWEPGNWSHCSATCGHLGARIQ
SECR : 721 WPESRIVFLQGHKKYIILQATNTRTN SNDPTGEPPPQEPFWEPGNWSHCSATCGHLGARIQ 780

35 NOV1: 1039 RPQCMANGQEVS EALCDHLQKPLAGFEP CNIRDCPARWFTSVWSQCSVSCGEGYHSRQV
1098 RPQCMANGQEVS EALCDHLQKPLAGFEP CNIRDCPARWFTSVWSQCSVSCGEGYHSRQV
SECR : 781 RPQCMANGQEVS EALCDHLQKPLAGFEP CNIRDCPARWFTSVWSQCSVSCGEGYHSRQV 840

40 NOV1: 1099 TCKRTKANGTVQVVS PRACAPKDRPLGRKPCFGHPCVQWE PGNRCPGRCMGRAVRMQRH
1158 TCKRTKANGTVQVVS PRACAPKDRPLGRKPCFGHPCVQWE PGNRCPGRCMGRAVRMQRH
SECR : 841 TCKRTKANGTVQVVS PRACAPKDRPLGRKPCFGHPCVQWE PGNRCPGRCMGRAVRMQRH 900

45 NOV1: 1159 TACQHNSSDSNCDDRKRPTLRRNCTSGACDVCWHTGPWKPC TAACGRGFQSRKVDCIHTR
1218 TACQHNSSDSNCDDRKRPTLRRNCTSGACDVCWHTGPWKPC TAACGRGFQSRKVDCIHTR
SECR : 901 TACQHNSSDSNCDDRKRPTLRRNCTSGACDVCWHTGPWKPC TAACGRGFQSRKVDCIHTR 960

50 NOV1: 1219 SCKPVAKRHCVQKKKPISWRHCLGPSCDRDCTDTTHYCMFVKHNLCSLDRYKQRCCQSC
1278 SCKPVAKRHCVQKKKPISWRHCLGPSCDRDCTDTTHYCMFVKHNLCSLDRYKQRCCQSC
SECR : 961 SCKPVAKRHCVQKKKPISWRHCLGPSCDRDCTDTTHYCMFVKHNLCSLDRYKQRCCQSC
1020

NOV1: 1279 QEG 1281 (SEQ ID NO: 59)
QEG
SECR : 1021 QEG 1023 (SEQ ID NO: 25)

55 Based the relatedness of NOV-1 to KIAA1233 sequences, which are related to lacumin, thrombospondins, proteinases, semaphorins, ADAM-TS and properdin family members, nucleic acids and proteins according to the invention likely have similar functions as proteins belonging to these families. Thus, the NOV-1 of the invention is implicated in the following

diseases and processes and has therapeutic uses in these diseases and processes: (i) inflammation, (ii) cancer, (iii) neuronal development and axonal guidance, (iv) angiogenesis and vasculogenesis – in cancer as well as for ischemia, and (v) tissue regeneration *in vivo* and *in vitro*, (vi) and other diseases and disorders.

5 Functional roles attributed to this family of proteins include cell attachment, spreading, motility, and proliferation, cytoskeletal organization, wound healing, and angiogenesis. Moreover, these proteins are expressed in the nervous systems during development and are thought to play roles in neuronal growth and patterning. In particular, the thrombospondin, METH-1 and ADAMTS families of proteins are potent inhibitors of angiogenesis. The
10 ADAMTS proteins have also been implicated in cleavage of proteoglycans and the control of organ shape during development. In addition, the thrombospondins have been implicated in the activation of both transforming growth factor-beta (TGF- β) precursors and TGF- β in a variety of disease states. Furthermore, semaphorin proteins have shown expression in undifferentiated neuroepithelium, suggesting that these proteins are actors in axonal guidance.

15

NOV 2: A Novel KIAA1233-like Protein

The NOV-2 sequences according to the invention include nucleotide sequences encoding a polypeptide related to KIAA1233 proteins, which bear sequence similarity to lacunin, thrombospondins, proteinases, semaphorins, ADAM-TS, and properdin family
20 members.

NOV2a and NOV2b are splice variants. Splice variants are sequences that occur naturally within the cells and tissues of individuals. The physiological activity of splice variant products and the original protein, from which they are varied, may be the same (although perhaps at a different level), opposite, or completely different and unrelated. In addition,
25 variants may have no activity at all. When a variant and the original sequence have the same or opposite activity, they may differ in various properties not directly connected to biological activity, such as stability, clearance rate, tissue and cellular localization, temporal pattern of expression, up or down regulation mechanisms, and responses to agonists or antagonists. The presence or level of specific splice variants may be the cause, and/or indicative of, a disease,
30 disorder, pathological or normal condition.

Because a drug may be effective against one variant but not another, or may cause side effects because it targets all splice variants, an effective drug needs to target the particular splice variant. Because soluble variants with therapeutic or disease-related functions may be naturally occurring in specific tissues, they may be optimal candidates for drug targets or

protein therapeutics. Variants may have no activity at all and may thus serve as dominant negative natural inhibitors. Thus, splice variants useful in generating new drug targets, protein therapeutics and markers for diagnostics.

NOV-2 maps to Unigene cluster Hs.18705. This cluster has been mapped to

5 Chromosome 15 Marker stSG35204, Interval D15S115-D15S152. By integrating information from the Online Mendelian Inheritance in Man (OMIM), this region is identified as 15q22-
qter. Therefore, the chromosomal location of the invention is Chromosome 15 Marker
stSG35204, Interval D15S115-D15S152 which corresponds to 15q22-qter.

10 **NOV-2a**

A NOV-2a nucleic acid of the invention, encoding a KIAA1233-like protein originating from chromosome 15 is shown in TABLE 5. The disclosed nucleic acid (SEQ ID NO: 3) is 7260 nucleotides and contains an open reading frame (ORF) that begins with an ATG initiation codon at nucleotide 136 and ends with a TAA stop codon at nucleotides 5209.
15 The representative ORF encodes a 1691 amino acid polypeptide (SEQ ID NO: 4). The initiation and stop codons of SEQ ID NO: 3 are shown in bold font. The protein has a predicted molecular weight of 188743.8 daltons. Putative untranslated regions are upstream of the initiation codon and downstream of the stop codon in SEQ ID NO: 3.

20 **TABLE 5**

```

CGCACGAGGTGTTGACGGGCGGCTTCTGCCAACTCTCCCCAGCGCGCCGAGCCCGCGCCGGCCGGCTGCACGTC
CCAGATACTCTGCGCGCAAGGCTACAACGTGAGACCCGGAGGAGACTAGACCCCCTGGCTTCTGGACGAGCCCTGGT
GGGTGCTGATAGGGATGGCTTCATGCACTCTCCCTCCCGCAGACCACAGCTGAGAAATCTCTGGAGCTATTCCCTT
CCCGAGTTGCACTTTCTCCTCAGGGAAGTTTCTGGAAGACACAACAGGGGAGCAGTCCCTCACTTATCGCTATGATGA
25 CCAGACCTCAAGAACACTCGTTAGATGAAGACAAAGATGGCAACTGGGATGCTGGGGCGACTGGAGTGACTGCTCCC
GGACCTGTTGGGGAGGAGCATCATATTCTGCGGAGATGTTGACTGGAAGGAATTGTGAAGGGCAGAACATTGGTAC
AAGACATGCAATCATGACTGCCCTCCAGATGCAAGAAGATTTCAGAGCCCGAGCTGCTCAGCCTACAATGATGTCCA
GTATCAGGGCAATTACTATGAATGGCTTCCACGATAATGATCCCTGCTGCCCGTGTGCACTCAAGTGTCAATGCCAAC
GACAAAAACTTGGTGGTGGAGCTGGCACCTAAGGTACTGGGATGGAACACCGGACTCCTGGACATGTGTATC
30 AGTGGCATCTGTCAGGCAGTGGCTGCGATCGCAACTGGGAAGCAATGCCAAGGAGGACAACGTGGAGTCTGTGCCGG
CGATGGCTCCACCTGCGAGGCTTGTACGGGACAATCAAAGTCACGTTCTCCTGAAAAAAAGAGAAGAAAATGTAATTG
CTGTTCTTGGGAAGTCGAAGTGTGAGAATTACAGTGAAGGACCTGCCACCTCTTATTGAATCAAAACACTTCAA
GGAAGCAAAGGAGAACACAGCTTAAACAGCCCCGGCTTTGTGCTAGAAAACACAACAGTGGAAATTCAAGGGGCTC
CGAGAGGCAAACCTTTAAGATTCCAGGACCTGATGGCTGATTTCATCTCAAGACAGGTACACTGCAGCCAAAGACA
35 GCGTGGITCAGITCTTCTTTACAGCCCATCAGTCAGTGGAGACAAACTGACTTCTTCCCTGCACTGTGACGTGT
GGAGGAGGTTATCAGCTCAATTCTGCTGAATGTGTGGATATCCGCTTGAAGAGGGTAGTCTCTGACCAATTATTGTCACTA
CTACCCCTGAAAATGTAAAACCAAAACCAAAACTGAAGGAATGCAGCATGGATCCCTGCCCATCAAGTGTGATGGATTTAAAG
AGATAATGCCCTATGACCACTTCCAACCTCTCCTCGCTGGAACATAATCCTGGACTGCATGTTCCGTGTCCGTGGA

```

GGAGGGATTCAAGAGACGGAGCTTGTGTGAGAGGAATCCATGCATGGAGAGATAATTGCAGGTGGAAGAATGGAAGTG
CATGTACGCACCCAAACCCAAGGTTATGCAAACCTGTAACTCTGTTGATTGCCCATGGAGTCGGTCTC
AGTGACAGTGACTTGTGCCGGGGTTACGGTACCGGTTGTGTATTAAACCACCGCGGAGAGCATGTTGGGGC
TGCAATCCACAACACTGAAGTTACACATCAAAGAAGAATGTGTCACTCCCATCCGTGTTAAAACAAAAGAAAAAGTCC
5 AGTGGAAAGCAAATTGCTTGGCTGAAACAAGCACAAGAACTAGAAGAGACCAGAACAGAACGAAACGTTCA
TTCAGAACCTGGTCAGGCTGCACTACACGTGTTGGCGGGGTGCAAGGTCAGGTGAAAGGCCCCAAGCTGCCACCGAACGCCCTGCCCTC
ACATTACGCACTGAGACTGAGCTGAGCTGCCCAGGAAGAGTGTGAAGGCCCCAAGCTGCCACCGAACGCCCTGCCCTC
GGAAAGCATGTGATGAGAGCCGGCTCCCGAGAGCTAGACATCCCTCCCTGAGGACAGTGAGACGACTACGACTGGG
AGTACGCTGGGTTCACCCCTGGCACAGAACATGCGTGGGAGGGCATCAAGAAGCCATAGCAGTGTGTTACATATCCAG
10 ACCCAGCAGACAGTCATGACAGCTTGTGTGATATGGTCCACCGCCTCCAGGCATGAGCCAGGGCTGTAACACAGAGCC
CTGTCCCCCCAGGTGGCATGTGGCTCTGGGGCCCTGCTCAGCTACCTGTGGAGTTGAAATTCAAGACCCGAGATGTG
ACTGCTGACCCAGGGAGACCCCTGCCCTGAGGAGTGGCAGATGAAAAGCCCATGCTTTAACAGCATGCAAT
CAGTTGACTGCCCTCCTGGCTGGCACATTGAAAGAATGGCAGCAGTGTCCAGGACTTGTGGGGGGAACTCAGAACAG
15 AAGAGTCACCTGTCGGCAGCTGCTAACGGATGGCAGCTTTTGAAATCTCTCAGATGAATTGTGCCAAGGACCCAAAGGCAT
CGTCTCACAAGTCTGTGCCAGGACAGACTGTCCTCCACATTAGTGTGGAGACTGGTCAAGTGTCTGTCAGTGT
GGTGTGGAATCCAGAGAAAGAACAGGTGTCAAAGGCTGGCAGCCAAAGGTGGCGCATCCCCCTCAGTGAGATGAT
GTGCAGGGATCTACCAGGGTTCCCTTGTAAAGATCTGCCAGTGCTGAGTAAAGTCAAATCAGAGATGAGA
20 CAAAACTTGGTAGCAGGGCTTGTGCTGCCAACACATCCGTGATTATTAAAGTGCCCGTGGCAGCATTCCAGAAATC
CTGACCATTGGTAGCAGAGCCTATTGCTGCCAACACATCCGTGATTATTAAAGTGCCCGTGGCAGCATTCCAGAAATC
TCTGATCCAGTGGAGAAGGATGGCCCTGCTGAGAACCTCAAACGGCTTGGCATCACCAGTCAGGCTCACTAAAAA
TCCACGGTCTGCTGCCCGACATGGCTGTACCGGTGCACTGCAGGCTCTGCACAGGAAACAGTTGTGCTCAAGCTC
ATTGGTACTGACAACCGGCTATGCCACGCCAGCCCTCAGGGAGCTATGAGGGAAATATCTGGGATGGACCACAGCGA
25 AGCCAAATAGTTGGGAGTCACATGGCACAAATGAGGAAATGTGAAATAACAAAATGACCTTATCTGGATGATGACC
ACATTAGTAACCAGCCTTCTTGAGAGCTGTGAGGCACTGCAATTGCAAGGAAAGCACCACCTGGAGTTG
AAGAATAAGCAGTTGAAGCAGCAGTTAACAAAGGAGCATATAGCATGGATACAGCCCAGTTGATGAGCTGATAAGAAA
30 CATGAGTCAGCTATGGAAACCGGAGAGGTCAAGCGATGATCTTGCTCCAGCTGATATATCAGCTGGGGCGAATTAG
CCAAGGCACAGCCAACACACATGCACTGGGGGCACTCCAGGAAGAGACACCTCCGTGCTCAGCTCAGAGGGAAACA
GGGAGTGTGCCCCAAAGCTCGCATGCAAAACTCAGGCAAGCTGACATTCAAGCGAAAGGACCTGTTCTCATGAGGCA
AAGCCAACCTCCCTCAATTCAATTAAACAAATTCAGGATTGAAATACAGTATACATTACAAAAGGACAG
35 AGGTCAATATACTGTGTGACCTTATTACCCCCAGTGAGGCCACATATACTGACCAAGGATGGAACCTGTGTTACAG
CCCTCAGTAAAATAATTGGATGGAACCTGGGAGAGACAGATAACAGAATCCCTACAAGGAAAGAACAGCATATATGA
ATGTTCTGTAGCTAATCATCTTGGTCAAGATGTGAAAGTTCTCTGTGTGTTGCACTGAGGACACCTGTCATCTGTCTG
TTGAAAGAAATATCACCACAGGACACAACCATCTGCTGTTGAGGCACTGAGGAGGCCCTGGAGCA
40 AACGTGACAATCCGATGCTCTGTAAAGGTGCTCCCTCAGCTTAAATATAACTTGGTGAAGAGAGGAGGATCTGTGAGTGG
CAATGTTCTGCTTCAATGGATCCCTGTTGCAAGATGTTCCCTGAAAATGAAGGAACCTACGTCTGCATAG
CCACCAATGCTCTGGAAAGGCACTGGCAACATCTGATTCCACCTGCAAGGAAAGATGGCAGAGAGTAGAATCGTA
TTCTGCAAGGACATAAAAAGTACATTCTCCAGGCAACCAACACTAGAACCAACAGCAATGACCCAAACAGGAGAACCCCC
GCCTCAAGAGCCTTTGGAGGCTGTAACCTGGGAGGCACTGGTACATTGTCACATTGCTGCCACCTGTTGCAATTGGGAGGCCGATTCA
GACCCCCAGTGTGATGGCAATGGGAGGCAACTGGTACAGTGAGTGGGAGGCCCTGTGTGATCACCTCCAGAACGCCACTGGCTGGGTT
GAGCCCTGTAACATCCGGACTGCCAGCGAGGTGTTCAACAGTGTGTTCAACTGCTCTGTGTTGCGGTGAAGG
ATACCACAGTCGGCAGGTGACGTGCAAGCGAACAAAGCCAATGGAACCTGTGCAAGGGTGTCTCAAGAGCATGTC
CTAAAGACCGGCTCTGGGAAGAAAACATGTTGGTCACTCCATGTGTTCACTGGGAAACCAAGGGAACCGGTGCTCTGG
CGTTGCACTGGGCGTGTGAGGATGCACTGGCAGCGTACACAGCTGTCAACACAAAGCTCTGACTCCAACACTGTGATGA
CAGAAAAGAGACCCACCTTAAAGAAGGAACCTGCAACATCAAGGGGCTGTGATGTTGGCAGCACAGGCCCTGGAAAGGCC

GTACAGCAGCCGTGGCAGGGTTCCAGTCTCGAAAGTCGACTGTATCCACACAAGGAGTTGCAAACCTGTGCCAAG
 AGACACTGTGTACAGAAAAAGAACCAATTCCITGGCGGACTGTCTGGCCCTCTGTGATAGAGACTGCACAGACAC
 AACTCACTACTGTATGTTGAAAACATCTTAATTGTGTTCTAGACCCCTACAAACAAAGGTGCTGCCAGTCATGTC
 5 AAGAGGGATAAACCTTGAGGGTCATGATGCTGTGAAAGATAAAAAGTAGAAATATAAAAGCTCTTPTCCCCATGTC
 CTGATTCAAAAACATGTATTCCTAAAGACTAGATTCTATGGATCAAACAGAGGTTGATGCAAAAACACCACTGTTAAG
 GTGTAAGTGAATTTCATGGTAGTTATATTCAATTAAATGATGTTCAAGGATGAACAAAATACAT
 AGCATGCATGCCACTGCACTGGGACCTCATCATGTCAGTTGAATCGAGAAATCACCAAGATTATGAGTCATCCTCACG
 TGCTGCCCTTCTGTGATATGTAGACTAGCACAGAGTGGTACATCTAAAGCTGGAAACACAGCAACCCATGACT
 TCCTCTCTCAAGTGCAGGTTCAACAGTTATAAGGTATTTGCAAGGCTCTGGATAGGCTGTCACA
 10 ATGTTGGCATTATGGCATTTCATAGATCCTGGTTAGTCTGTGAAAAAGAAACCATCTCTGGATAGGCTGTCACA
 CTGACTGACCTAAGGGTCATGGAAGCAGGGCATCTGCTTGCTTTAGAACACCCATGGAAGAAAACACAGAGTAGA
 TATTGCTGTCATTATAACACTACAGAAATTATCTATGACCTAATGAGGCATCTCGGAAGTCAAAGAAGAGGAAAGTT
 AACCTTTCTACTGATTCGTAGTATATTCAAGGCTCTTAAAGCTGAAACTTTCTAAGCATTCT
 ATTGACACAAACAGAAACCAAAGCTTATTAGACCTAATTATGATAAAAGTAGTATTCTGAGAACCTTATTGGA
 15 AAATTATAAGAAAGTAATCAAATAAGAAACACGATAGTTGAAATTAATTGATAGTAATAAAATTGTTGGCTGAT
 TTTCAAGTAAATCAAAGTGACTTAGGTTAGAAGTTACACTAAGGACCAGGGTTGGAATCAGAAATTAGTTAAGGTTAAG
 GAGGAAAAGGTAAGGGTAGTTCAAGGTTAGGATTAGAGCTAGAAATTGGTTAGGTGAGAAAGAAAGTTAAGGTTAAG
 GCTAGAGTTGTCTTAAAGGGTAGGGTTAGGACAGGTTAGGTCAAGGTTGGATTGGTTAGATTGGGCCAGTGGCTGG
 TGTTAGTGAAGTGTCAAGGATGGAGGTTAGGTTGGAGTAAGCGTTGGCTGAAGTGAGTCAGGCTAGCATTAATTG
 20 TAAGTTCTGAAGCTGATTGGTATGGGTCTTCCCTGTATACTACCAGTTGTCTTAGATGGCACACAAGTCAA
 ATAAGTGGTCATACTTCTTATTCAAGGGTCTCAGCTGCCTGTACACCTGCTGCCACATCTCTGGCAACAAAGTTACC
 TGCCACAGGCTCTGCTGAGCCTAGTCCCTGGTCACTAAACTGAACAGTGCATTGGCTTGGATGTTCTGTGGACA
 AGCTTGTGAGTTCTACCATATTCTGAGCACACGGTCTCTTGTCTAACTCAGCTTCACTGACACTGGTTGAG
 CACTACTGTATGTGGAGGGTTGGTGAATTGGATGGGACAGTGAGGAGGACACACCAGCCATTAGTTGTTAA
 25 TCATCAATCACATCTGATTGTTGAAGGTTATTAAATTAAAGAAAGATCATTTGTAACATACTCTTGTATATTATT
 ATATGAAAGGTGAATATTGATGACAGTATGAAATAAGACATGGACATATATTCTTATTAAACAAAATTTC
 ATATTAAATTGCTTCACTTGTATTAAAGTTAAAGTTACTATTCTTCACTTGTATTGACTTTCAATTGTTGTCATT
 AATTGACATTCTGTGACTGTATTACTGTTTATAACATGAGAGTTAATGTTCTGTTCACTGATCCTATGTT
 AATTCAAGAAATAATTACTTTGATTATTCACTGGCATCCTTATAAAAAAAAAAAAAA (SEQ ID NO: 3)

30

MASWTSPWWVLIGMVFMSPLPQTTAEKSPGAYFLPEFALSPQGSFLEDTTGEQFLTYRYDDQTSRNTRSDEDKDG
 NWDAWDWSDCSRTCGGGASYSLRRCLTGRNCEGQNIRYKTCNSHDCPPDAEDFRAQQCSAYNDVQYQGHYYEWLP
 RYNDPAAPCALKCHAQGQNLVVELAPKVLDGTRCNDSLDMCISGICQAVGCDRQLGSNAKEEDNCGVCA
 GDGSTCR
 35 LVRGQSKSHSPEKREENVIAVPLGSRSVRITVKGP AHLFIESKTLQGSKGEHSFNSPGVVVENTTVEFQRGSER
 QTFKIPGPLMADFIFKTRYTAAKDSVVQFFYQPI SHQWRQTDFFPCTVTCGGYQLNSAECVDIRLKRVVPDHYC
 HYPENVKPKPKLKECSMDPCPSSDGFKEIMPYDHFQPLPRWEHN PWTACSVSCGGIQRRSFVCVEESMHGEILQ
 VEEWKCMYAPKP KVMQTCNLFDCKWIAMEWSQCTVTCRGLRYRVVLCINHRGEHVGCGNPQLKLHKEECV
 IPI
 PCYKPKEKSPV EAKLPWLKQAQELEETRIATEEPTFIPEPWSACSTCGPGVQVREVKCRVLLFTQTETELPEEE
 40 CEGPKLPTERPCCLLEACDES P ASRELDIPLPEDSETTYDWEYAGFTPCTATCVGGHQEAIAVCLHIQTQQTVNDSL
 CDMVHRPPAMSQACNTEPCPPRWHVGSGWPCSATCGVGIQTRDVYCLHPGETPAPPEECRDEKPHALQACNQFDCP
 PGWHIEWQOC SRTCGGGTQNRRVT CRQLLTDGSFLNLSDEL CQGPKASSHKSCARTDCP PHLAVGDWSKCSVSCG

VGIQRRKQVCQRLLAAKGRRIPSEMMCRDLPGFPLVRSCQMPECSKIKSEMKTKLGEQGPQILSVQRVYIQTREEKRINLTIGSRAYLLPNTSVIICKPVRRFQKSЛИQWEKDGRCLQNSKRLGITSGSLKTHGLAAPDIGVYRCIAGSAQETVVLKLIGTDNRLIARPALREPMREYPGMHDSEANSLGVTWHKMRQMWNKNNDLYLDDDHISNQPFLALLGHCSNSAGSTNSWELKNKQFEAAVKQGAYSMDTAQFDELIRNMSQLMETGEVSDDLASQLIYQLVAELAKAOPTHMQWRG
 5 IQEETPPAAQLRGETGSVSQSSHAKNSGKLTFKPKGPVLMRQSOPPSISFNKTINSRIGNTVYITKRTEVINILCDLITPSEATYTWTKDGTLLQPSVKIIDGTGKIQIQNPTRKEQGIYECVANHLGSDVESSSVLYAEAPVILSVERNITKPEHNHLSVVVGIGEEAALGANVTIRCPVKGPQPNITWLKRGGSLSGNVSILLFNGSLLLQNVSLENEGTYCIATNALGKAVATSVFHLLERRWPESRIVFLQGHKKYIILQATNTRNSNDPTGEPPPQEFPWEPGNWSHCSATCGHLGARIQRQCVMANGQEVESEALCDHLLQKPLAGFEPNCIRDCPARWFTSVWSQCSVSCGEGYHSRQVTCKRTKANGTVQ
 10 VVSPRACAPKDRPLGRKPCFGHPCVQWEPGNRCPGRCMGRAVRMQRHTACQHNSSDSNCDDRKRPTLRRNCTSGACDVCWHTGPWKPCTAACGRGFQSRKVDCIHTRSCKPVAKRHCVQKKPISWRHCLGPSCDRDCTDTTHYCMFKVHLNLCSLDRYKQRCCQSCQEG (SEQ ID NO: 4)

In a search of sequence databases, it was found, for example, that the disclosed NOV-
 15 2a nucleotide sequence has 5104 of 5107 bases (99%) identical to a human mRNA for a KIAA1233 protein (GenBank Accession No: ABO33059), as shown in Table 6. In all sequence alignments, identical residues are depicted as "|". As indicated by the "Expect" value, the probability of this alignment occurring by chance alone is 0.0, the lowest probability.

20 Furthermore, the encoded amino acid sequence has 1023 of 1023 amino acid residues (100%) identical to, and 1021 of 1023 residues (100 %) positive with, a 1023 amino acid residue human KIAA1233 protein (GenBank Accession No: BAA86547), as shown in Table 7. As indicated by the "Expect" value, the probability of this alignment occurring by chance alone is 0.0, the lowest probability.

25

TABLE 6

Score = 1.010e+04 bits (5095), Expect = 0.0
 Identities = 5104/5107 (99%)
 Strand = Plus / Plus

30

NOV2a : 2138 tagcagtgtgcttacatatccagaccaggcagacagtcaatgacagcttgtgtatgg
 2197 |||||||

35

SECR : 1 tagcagtgtgcttacatatccagaccaggcagacagtcaatgacagcttgtgtatgg 60
 |||||||

40

NOV2a : 2198 tccaccgtcctccagccatgagccaggcctgttaacacagagccctgtccccccaggtggc
 2257 |||||||

SECR : 61 tccaccgtcctccagccatgagccaggcctgttaacacagagccctgtccccccaggtggc
 120 |||||||

NOV2a : 2258 atgtggcttggggccctgctcagctacctgtggagttggattcagacccgagatg
2317 |||||||

5 SECR : 121 atgtggcttggggccctgctcagctacctgtggagttggattcagacccgagatg
180 |||||||

NOV2a : 2318 tttactgcctgcacccaggagaccctgcccctcctgaggagtgccgagatgaaaagc
2377 |||||||

10 SECR : 181 tttactgcctgcacccaggagaccctgcccctcctgaggagtgccgagatgaaaagc
240 |||||||

15 NOV2a : 2378 cccatgtttacaaggcatgcaatcagtttactgcctcctggctggcacattgaagaat
2437 |||||||

SECR : 241 cccatgtttacaaggcatgcaatcagtttactgcctcctggctggcacattgaagaat
300 |||||||

20 NOV2a : 2438 ggcagcagtgttccaggacttgtggcgaaaaactcagaacagaagagtcacctgtcgcc
2497 |||||||

25 SECR : 301 ggcagcagtgttccaggacttgtggcgaaaaactcagaacagaagagtcacctgtcgcc
360 |||||||

30 NOV2a : 2498 agctgctaacggatggcagcttttaatctctcagatgaatttgccaaggacccaagg
2557 |||||||

SECR : 361 agctgctaacggatggcagcttttaatctctcagatgaatttgccaaggacccaagg
420 |||||||

35 NOV2a : 2558 catcgctcacaaggctgtggcaggacagactgtcctccacattttagctgtggagact
2617 |||||||

40 SECR : 421 catcgctcacaaggctgtggcaggacagactgtcctccacattttagctgtggagact
480 |||||||

45 NOV2a : 2618 ggtcgaagtgttctgtcagttgtgggttggatccagagaagcagggtgtcaaa
2677 |||||||

SECR : 481 ggtcgaagtgttctgtcagttgtgggttggatccagagaagcagggtgtcaaa
540 |||||||

50 NOV2a : 2678 ggctggcagccaaaggctggcgatccccctcagtgagatgtgcagggatctaccag
2737 |||||||

SECR : 541 ggctggcagccaaaggctggcgatccccctcagtgagatgtgcagggatctaccag
600 |||||||

55 NOV2a : 2738 ggccctctttaagatcttgccagatgcctgagtcagtaaatcaaatcagagatga
2797 |||||||

60 SECR : 601 ggccctctttaagatcttgccagatgcctgagtcagtaaatcaaatcagagatga
660 |||||||

NOV2a : 2798 agacaaaacttggtagcgaggccgcagatcctcagtgtccagagatctacattcaga
2857 |||||||
5 SECR : 661 agacaaaacttggtagcgaggccgcagatcctcagtgtccagagatctacattcaga
720 |||||||

NOV2a : 2858 caagggaaagagaagcgtattaacctgaccattggtagcagacgcattttgctgccaaca
2917 |||||||
10 SECR : 721 caagggaaagagaagcgtattaacctgaccattggtagcagacgcattttgctgccaaca
780 |||||||

15 NOV2a : 2918 catccgtgattattaagtgcggcgtgcacgattccagaaatctctgatccagtggaga
2977 |||||||
SECR : 781 catccgtgattattaagtgcggcgtgcacgattccagaaatctctgatccagtggaga
840 |||||||
20

NOV2a : 2978 agatggccgttcctgcagaactccaaacggcttggcatcaccaagtcaggctcactaa
3037 |||||||
25 SECR : 841 agatggccgttcctgcagaactccaaacggcttggcatcaccaagtcaggctcactaa
900 |||||||

NOV2a : 3038 aaatccacggcttgcgtgcggccgacatcggtgttaccggcattgcaggctctgcac
3097 |||||||
30 SECR : 901 aaatccacggcttgcgtgcggccgacatcggtgttaccggcattgcaggctctgcac
960 |||||||

35 NOV2a : 3098 agaaacagttgtgtcaagctcatggtaactgacaaccggctcatcgacgccc
3157 |||||||
40 SECR : 961 agaaacagttgtgtcaagctcatggtaactgacaaccggctcatcgacgccc
1020 |||||||

NOV2a : 3158 tcagggagccatatgaggaatatcctggatggaccacagcgaagccaatagttggag
3217 |||||||
45 SECR : 1021 tcagggagccatatgaggaatatcctggatggaccacagcgaagccaatagttggag
1080 |||||||

50 NOV2a : 3218 tcacatggcacaaaatgaggcaaattgtggataacaacaaaatgaccttatctggatgatg
3277 |||||||
SECR : 1081 tcacatggcacaaaatgaggcaaattgtggataacaacaaaatgaccttatctggatgatg
1140 |||||||
55

NOV2a : 3278 accacatttagtaaccaggcccttcttggagagctctgttaggccactgcagcaattctgcag
3337 |||||||
60 SECR : 1141 accacatttagtaaccaggcccttcttggagagctctgttaggccactgcagcaattctgcag
1200 |||||||

NOV2a : 3338 gaagcaccaactcctggagttgaagaataaggcgttgaagcagcagttaaacaaggag
3397 |||||||
5 SECR : 1201 gaagcaccaactcctggagttgaagaataaggcgttgaagcagcagttaaacaaggag
1260 .

NOV2a : 3398 catatagcatggatacagcccagttgatgagctgataagaaaacatgagtcatgg
3457 |||||||
10 SECR : 1261 catatagcatggatacagcccagttgatgagctgataagaaaacatgagtcatgg
1320 .

15 NOV2a : 3458 aaaccggagaggtcagcgatgtatccgcgtccagctgatataatcagctggtgccgaat
3517 |||||||
SECR : 1321 aaaccggagaggtcagcgatgtatccgcgtccagctgatataatcagctggtgccgaat
1380 .
20

NOV2a : 3518 tagccaaggcacagccaaacacacatgcagttggggcatccaggaagagacacccctg
3577 |||||||
25 SECR : 1381 tagccaaggcacagccaaacacacatgcagttggggcatccaggaagagacacccctg
1440 .

NOV2a : 3578 ctgctcagctcagagggaaacaggagttgtgtccaaagctcgcatgcaaaaactcag
3637 |||||||
30 SECR : 1441 ctgctcagctcagagggaaacaggagttgtgtccaaagctcgcatgcaaaaactcag
1500 .

35 NOV2a : 3638 gcaagctgacattcaagccaaaggacctgttcatgaggcaaagccaaacctccctcaa
3697 |||||||
40 SECR : 1501 gcaagctgacattcaagccaaaggacctgttcatgaggcaaagccaaacctccctcaa
1560 .

NOV2a : 3698 tttcatttaataaaaacaataaatttcaggattggaaatacagtatacattacaaaaagga
3757 |||||||
45 SECR : 1561 tttcatttaataaaaacaataaatttcaggattggaaatacagtatacattacaaaaagga
1620 .

50 NOV2a : 3758 cagaggtcatcaatatactgtgtaccttattaccccaagtgaggccacatatacatgga
3817 |||||||
55 SECR : 1621 cagaggtcatcaatatactgtgtaccttattaccccaagtgaggccacatatacatgga
1680 .

NOV2a : 3818 ccaaggatggaacctttagccctcagtaaaaataatttggatggaactggaaaga
3877 |||||||
60 SECR : 1681 ccaaggatggaacctttagccctcagtaaaaataatttggatggaactggaaaga
1740 .

NOV2a : 3878 tacagatacagaatccatacaggaaacaaggcatatatgaatgttctgttagctaatt
3937 |||||||

5 SECR : 1741 tacagatacagaatccatacaggaaacaaggcatatatgaatgttctgttagctaatt
1800 |||||||

NOV2a : 3938 atcttggttcagatgtggaaagtcttctgtgttatgcagaggcacctgtcatcttgt
3997 |||||||

10 SECR : 1801 atcttggttcagatgtggaaagtcttctgtgttatgcagaggcacctgtcatcttgt
1860 |||||||

15 NOV2a : 3998 ctgttgaagaaaatcaccaaaccagagcacaaccatctgtctgttggttgaggca
4057 |||||||

20 SECR : 1861 ctgttgaagaaaatcaccaaaccagagcacaaccatctgtctgttggttgaggca
1920 |||||||

NOV2a : 4058 tcgtggaggcagcccttggagcaaacgtgacaatccgatgtcctgtaaaagggtgtccctc
4117 |||||||

25 SECR : 1921 tcgtggaggcagcccttggagcaaacgtgacaatccgatgtcctgtaaaagggtgtccctc
1980 |||||||

30 NOV2a : 4118 agcctaataacttggtaagagaggatctctgagttggcaatgtttccttgc
4177 |||||||

SECR : 1981 agcctaataacttggtaagagaggatctctgagttggcaatgtttccttgc
2040 |||||||

35 NOV2a : 4178 tcaatggatccctgttggcagaatgtttcccttggaaaatgaaggAACCTACGTCTGCA
4237 |||||||

40 SECR : 2041 tcaatggatccctgttggcagaatgtttcccttggaaaatgaaggAACCTACGTCTGCA
2100 |||||||

NOV2a : 4238 tagccaccaatgcttggaaaggcagtggcaacatctgtattccacttgc
4297 |||||||

45 SECR : 2101 tagccaccaatgcttggaaaggcagtggcaacatctgtactccacttgc
2160 |||||||

50 NOV2a : 4298 gatggccagagagttagaatcgatattctgc
4357 |||||||

SECR : 2161 gatggccagagagttagaatcgatattctgc
2220 |||||||

55 NOV2a : 4358 ccaacactagaaccaacagcaatgacccaaacaggagaacccccc
4417 |||||||

60 SECR : 2221 ccaacactagaaccaacagcaatgacccaaacaggagaacccccc
2280 |||||||

NOV2a : 4418 gggagcctggttaactggtcacattttctgccacctgtggtcatttggagccgcattc
4477 |||||||

5 SECR : 2281 gggagcctggttaactggtcacattttctgccacctgtggtcatttggagccgcattc
2340 |||||||

NOV2a : 4478 agagaccccagtgtgtatggcaatggcaggaaagttagtgaggccctgtgtgatcacc
4537 |||||||

10 SECR : 2341 agagaccccagtgtgtatggcaatggcaggaaagttagtgaggccctgtgtgatcacc
2400 |||||||

15 NOV2a : 4538 tccagaagccactggctgggtttagccctgttaacatccggactgcccagcgagggtgg
4597 |||||||

20 SECR : 2401 tccagaagccactggctgggtttagccctgttaacatccggactgcccagcgagggtgg
2460 |||||||

NOV2a : 4598 tcacaagtgtgtggtcacagtgtctgtcttgcggtaaggataccacagtcggcagg
4657 |||||||

25 SECR : 2461 tcacaagtgtgtggtcacagtgtctgtcttgcggtaaggataccacagtcggcagg
2520 |||||||

30 NOV2a : 4658 tgacgtgcaagcggacaaaagccaatggaaactgtgcagggtggtgtctccaagagcatgt
4717 |||||||

SECR : 2521 tgacgtgcaagcggacaaaagccaatggaaactgtgcagggtggtgtctccaagagcatgt
2580 |||||||

35 NOV2a : 4718 cccctaaagaccggccttggaaagaaaaccatgtttggcatccatgtgttcagtgg
4777 |||||||

40 SECR : 2581 cccctaaagaccggccttggaaagaaaaccatgtttggcatccatgtgttcagtgg
2640 |||||||

NOV2a : 4778 aaccaggaaaccgggtgtcctggacgttgcattggccgtgtgtgaggatgcagcagcgtc
4837 |||||||

45 SECR : 2641 aaccaggaaaccgggtgtcctggacgttgcattggccgtgtgtgaggatgcagcagcgtc
2700 |||||||

50 NOV2a : 4838 acacagttgtcaacacaacagctctgactccaactgtgtatgacagaaagagacccac
4897 |||||||

55 SECR : 2701 acacagttgtcaacacaacagctctgactccaactgtgtatgacagaaagagacccac
2760 |||||||

NOV2a : 4898 taagaaggaactgcacatcagggccgtgtgtgttgcacacaggcccttggaaagc
4957 |||||||

60 SECR : 2761 taagaaggaactgcacatcagggccgtgtgtgttgcacacaggcccttggaaagc
2820 |||||||

NOV2a : 4958 cctgtacagcagcctgtggcagggttccagtcgaaagtgcactgtatccacacaa
5017 |||||||

5 SECR : 2821 cctgtacagcagcctgtggcagggttccagtcgaaagtgcactgtatccacacaa
2880 |||||||

NOV2a : 5018 ggagttgcaaacctgtggccaagagacactgtgtacagaaaaagaaaaccatccctggc
5077 |||||||

10 SECR : 2881 ggagttgcaaacctgtggccaagagacactgtgtacagaaaaagaaaaccatccctggc
2940 |||||||

15 NOV2a : 5078 ggcactgtctggccctcctgtatagagactgcacagacacaactcactactgtatgt
5137 |||||||

20 SECR : 2941 ggcactgtctggccctcctgtatagagactgcacagacacaactcactactgtatgt
3000 |||||||

NOV2a : 5138 ttgtaaaacatcttaatttgtttcttagaccgctacaaacaaagggtgtgccagtcat
5197 |||||||

25 SECR : 3001 ttgtaaaacatcttaatttgtttcttagaccgctacaaacaaagggtgtgccagtcat
3060 |||||||

30 NOV2a : 5198 gtcaagaggataaacctttggagggtcatgatgctgtgaagataaaagtagaata
5257 |||||||

SECR : 3061 gtcaagaggataaacctttggagggtcatgatgctgtgaagataaaagtagaata
3120 |||||||

35 NOV2a : 5258 taaaagctctttccccatgtcgctgattcaaaaacatgtattcttaaaagactagatt
5317 |||||||

40 SECR : 3121 taaaagctctttccccatgtcgctgattcaaaaacatgtattcttaaaagactagatt
3180 |||||||

NOV2a : 5318 ctatggatcaaacagaggttcatgcacaaacaccactgttaagggtgtaaagtgtaaattt
5377 |||||||

45 SECR : 3181 ctatggatcaaacagaggttcatgcacaaacaccactgttaagggtgtaaagtgtaaattt
3240 |||||||

50 NOV2a : 5378 ccaatggtagtttatattccatttttaaaatgtatgttcaaggatgaacaaaatac
5437 |||||||

SECR : 3241 ccaatggtagtttatattccatttttaaaatgtatgttcaaggatgaacaaaatac
3300 |||||||

55 NOV2a : 5438 tatagcatgcactgcacttggtggacctcatcatgtcagttgaatcgagaaatcacc
5497 |||||||

60 SECR : 3301 tatagcatgcactgcacttggtggacctcatcatgtcagttgaatcgagaaatcacc
3360 |||||||

NOV2a : 5498 aagattatgagtgcacgtgccttcacgtgccttcgtatgttagactgcacaga
5557 |||||||
5 SECR : 3361 aagattatgagtgcacgtgccttcacgtgccttcgtatgttagactgcacaga
3420 |||||||

NOV2a : 5558 gtggtacatcctaaaaacttggaaacacagcaacccatgacttccttcgtcaagtt
5617 |||||||
10 SECR : 3421 gtggtacatcctaaaaacttggaaacacagcaacccatgacttccttcgtcaagtt
3480 |||||||

15 NOV2a : 5618 gcagggtttcaacagtttataaggtaattgcattttagaagctctggccagtagttgtt
5677 |||||||
20 SECR : 3481 gcagggtttcaacagtttataaggtaattgcattttagaagctctggccagtagttgtt
3540 |||||||

NOV2a : 5678 aagatgttggcattaatggcatttcatagatccttggttagtctgtgaaaaagaaaacc
5737 |||||||
25 SECR : 3541 aagatgttggcattaatggcatttcatagatccttggttagtctgtgaaaaagaaaacc
3600 |||||||

30 NOV2a : 5738 atctctctggataggctgtcacactgactgacctaagggttcatggaagcatggcatctt
5797 |||||||
SECR : 3601 atctctctggataggctgtcacactgactgacctaagggttcatggaagcatggcatctt
3660 |||||||

35 NOV2a : 5798 gtccttgctttagaacacccatggaagaaaacacagagttagatattgtgtcatttata
5857 |||||||
40 SECR : 3661 gtccttgctttagaacacccatggaagaaaacacagagttagatattgtgtcatttata
3720 |||||||

NOV2a : 5858 caactacagaaatttatctatgacctaattggcatctcgaaagtcaaagaagagggaaa
5917 |||||||
45 SECR : 3721 caactacagaaatttatctatgacctaattggcatctcgaaagtcaaagaagagggaaa
3780 |||||||

50 NOV2a : 5918 gttaacctttctactgattcgttagtatattcagagcttctttaagagctgtgaatg
5977 |||||||
55 SECR : 3781 gttaacctttctactgattcgttagtatattcagagcttctttaagagctgtgaatg
3840 |||||||

NOV2a : 5978 aaacttttctaagcactattctattgcacacaaaacagaaaacccaaagccttattagacc
6037 |||||||
60 SECR : 3841 aaacttttctaagcactattctattgcacacaaaacagaaaacccaaagccttattagacc
3900 |||||||

NOV2a : 6038 taatttatgcataaaagttagtattcctgagaactttatggaaaattataagaaagta
6097 |||||||

5 SECR : 3901 taatttatgcataaaagttagtattcctgagaactttatggaaaattataagaaagta
3960 |||||||

NOV2a : 6098 atccaaataagaaacacgatagttgaaaataattttatagtaaataattgtttggct
6157 |||||||

10 SECR : 3961 atccaaataagaaacacgatagttgaaaataattttatagtaaataattgtttggct
4020 |||||||

15 NOV2a : 6158 gattttcagtaaatccaaagtgacttagttagaagttacactaaggaccagggttgg
6217 |||||||

20 SECR : 4021 gattttcagtaaatccaaagtgacttagttagaagttacactaaggaccagggttgg
4080 |||||||

NOV2a : 6218 aatcagaatttagttaaagatttggagaaaaggtaagggttagttcagtttaggatt
6277 |||||||

25 SECR : 4081 aatcagaatttagttaaagatttggagaaaaggtaagggttagttcagtttaggatt
4140 |||||||

30 NOV2a : 6278 agagctagaattgggttaggtgagaaagaaaagttaaaggtaaggctagagttgtcttaa
6337 |||||||

SECR : 4141 agagctagaattgggttaggtgagaaagaaaagttaaaggtaaggctagagttgtcttaa
4200 |||||||

35 NOV2a : 6338 gggttagggtaggaccaggtaggtcagggttgattgggttagattggggccagtgc
6397 |||||||

40 SECR : 4201 gggttagggtaggaccaggtaggtcagggttgattgggttagattggggccagtgc
4260 |||||||

NOV2a : 6398 tggtgttagtgcatttcaggatggaggtagttggagtaagcggtttgtcaagt
6457 |||||||

45 SECR : 4261 tggtgttagtgcatttcaggatggaggtagttggagtaagcggtttgtcaagt
4320 |||||||

50 NOV2a : 6458 gagttcaggctagcattaaattgtaaaggctgttttttttttttttttttttttttt
6517 |||||||

SECR : 4321 gagttcaggctagcattaaattgtaaaggctgttttttttttttttttttttttttt
4380 |||||||

55 NOV2a : 6518 ctgtatactaccaggtagttgtcttttagatggcacacaagtccaaataagtggtcataacttc
6577 |||||||

60 SECR : 4381 ctgtatactaccaggtagttgtcttttagatggcacacaagtccaaataagtggtcataacttc
4440 |||||||

NOV2a : 6578 tttattcagggtctcagctgcctgtacacctgctgcctacatcttcttggcaacaaagtt
6637 |||||||
SECR : 4441 tttattcagggtctcagctgcctgtacacctgctgcctacatcttcttggcaacaaagtt
5 4500 |||||||

NOV2a : 6638 acctgccacaggctctgctgagcctagttcctggtcagtaataactgaacagtgcatttt
6697 |||||||
SECR : 4501 acctgccacaggctctgctgagcctagttcctggtcagtaataactgaacagtgcatttt
10 4560 |||||||

NOV2a : 6698 ggctttggatgtgtctgtggacaagcttgctgagttcttaccatattctgagcacacg
6757 |||||||
SECR : 4561 ggctttggatgtgtctgtggacaagcttgctgagttcttaccatattctgagcacacg
20 4620 |||||||

NOV2a : 6758 gtctctttgttctaacttcagcttactgacactgggttagcactactgtatgtggag
6817 |||||||
SECR : 4621 gtctctttgttctaatttcagcttactgacactgggttagcactactgtatgtggag
25 4680 |||||||

NOV2a : 6818 ggtttggtgattggaatggatggatggggacagtgaggaggacacaccagcccatttgt
30 6877 |||||||
SECR : 4681 ggtttggtgattggaatggatggatggggacagtgaggaggacacaccagcccatttgt
4740 |||||||

NOV2a : 6878 taatcatcaatcacatctgattgttgaaggttattaaattaaaagaaagatcatttgtaa
35 6937 |||||||
SECR : 4741 taatcatcaatcacatctgattgttgaaggttattaaattaaaagaaagatcatttgtaa
40 4800 |||||||

NOV2a : 6938 catactcttgtatatatattatattatgaaagggtcaatatttattttgtacagtatgt
45 6997 |||||||
SECR : 4801 catactcttgtatatatattatgaaagggtcaatatttattttgtacagtatgt
4860 |||||||

NOV2a : 6998 aataaaagacatgggacatatattttcttatttaacaaaatttcatattaaattgcttcac
50 7057 |||||||
SECR : 4861 aataaaagacatgggacatatattttcttatttaacaaaatttcatattaaattgcttcac
4920 |||||||

NOV2a : 7058 ttgttatattaaagttaaaagttactattttcatttgtattgtactttcattgttgc
55 7117 |||||||
SECR : 4921 ttgttatattaaagttaaaagttactattttcatttgtattgtactttcattgttgc
4980 |||||||

NOV2a : 7118 ttcaattgacattcctgttactgtatTTTactactgttttataacatgagagttaatg
7177 |||||||

5 SECR : 4981 ttcaattgacattcctgttactgtatTTTactactgttttataacatgagagttaatg
5040 |||||||

NOV2a : 7178 ttctgtttcatgatccttatgttaattcagaataaaatttactttgattattcagtggca
7237 |||||||

10 SECR : 5041 ttctgtttcatgatccttatgttaattcagaataaaatttactttgattattcagtggca
5100 |||||||

15 NOV2a : 7238 tccttat 7244 (SEQ ID NO: 60)

|||||||
SECR : 5101 tccttat 5107 (SEQ ID NO: 26)

TABLE 7

20 Score = 2045 bits (5300), Expect = 0.0
Identities = 1021/1023 (99%), Positives = 1021/1023 (99%)

NOV2A: 669 AVCLHIQTQQTVNDSLCDMVHRPPAMSQACNTEPCPPRWHVGSGWGPCSATCGVGIQTRDV 728
AVCLHIQTQQTVNDSLCDMVHRPPAMSQACNTEPCPPRWHVGSGWGPCSATCGVGIQTRDV

25 SECR : 1 AVCLHIQTQQTVNDSLCDMVHRPPAMSQACNTEPCPPRWHVGSGWGPCSATCGVGIQTRDV 60

NOV2A: 729 YCLHPGETPAPPEECRDEKPHALQACNQFDCPPGWHIEEWQQCSRTCGGGTQNRRVTCRQ 788
YCLHPGETPAPPEECRDEKPHALQACNQFDCPPGWHIEEWQQCSRTCGGGTQNRRVTCRQ

30 SECR : 61 YCLHPGETPAPPEECRDEKPHALQACNQFDCPPGWHIEEWQQCSRTCGGGTQNRRVTCRQ 120

NOV2A: 789 LLTDGSFLNLSDELCQGPKASSHKSCARTDCPPHLAVGDWSKCSVSCGVGIQRRKQVCQR 848
LLTDGSFLNLSDELCQGPKASSHKSCARTDCPPHLAVGDWSKCSVSCGVGIQRRKQVCQR

SECR : 121 LLTDGSFLNLSDELCQGPKASSHKSCARTDCPPHLAVGDWSKCSVSCGVGIQRRKQVCQR 180

35 NOV2A: 849 LAAKGRIPLSEMMCRDLPGFPLVRSCQMPECSKIKSEMKTKLGEQGPQILSVQRVYIQT 908
LAAKGRIPLSEMMCRDLPG PLVRSCQMPECSKIKSEMKTKLGEQGPQILSVQRVYIQT

SECR : 181 LAAKGRIPLSEMMCRDLPGPLPLVRSCQMPECSKIKSEMKTKLGEQGPQILSVQRVYIQT 240

40 NOV2A: 909 REEKRINLTIGSRAYLLPNTSVIICKPVRFFQKSLSIQWEKDGRCLQNSKRLGITKSGSLK 968
REEKRINLTIGSRAYLLPNTSVIICKPVRFFQKSLSIQWEKDGRCLQNSKRLGITKSGSLK

SECR : 241 REEKRINLTIGSRAYLLPNTSVIICKPVRFFQKSLSIQWEKDGRCLQNSKRLGITKSGSLK 300

NOV2A: 969 IHGLAAPDIGVYRCIAGSAQETVVLKLIGTDNRLIARPALREPMREYPGMDHSEANSLGV
1028

45 SECR : 301 IHGLAAPDIGVYRCIAGSAQETVVLKLIGTDNRLIARPALREPMREYPGMDHSEANSLGV 360

NOV2A: 1029 TWHKMRQMWNKNNDLYLDDDHISNQPFLALLGHCSNSAGSTNSWELKNQFEAAVKQGA
1088

50 SECR : 361 TWHKMRQMWNKNNDLYLDDDHISNQPFLALLGHCSNSAGSTNSWELKNQFEAAVKQGA 420

NOV2A: 1089 YSMDTAQFDELIRNMSQLMETGEVSDDLSQLIYQLVAELAKAQPOTHMQWRGIQEETPPA
1148

55 SEC : 421 YSMDTAQFDELIRNMSQLMETGEVSDDLSQLIYQLVAELAKAQPOTHMQWRGIQEETPPA 480

NOV2A: 1149 AQLRGETGSVSQSSHAKNSGKLTFKPKGPVLMRQSOPPSISFNKTINSRIGHTVYITKRT
1208

60 AQLRGETGSVSQSSHAKNSGKLTFKPKGPVLMRQSOPPSISFNKTINSRIGHTVYITKRT

SECR : 481 AQLGETGSVSQSSHAKNSGKLTFKPKGPVLMRQSQPPSISFNKTINSRIGHTVYITKRT 540

NOV2A: 1209 EVINILCDLITPSEATYTWTKDGTLLQPSVKIILDGTGKIQIQNPTRKEQGIYECVANH
1268

5 SECR : 541 EVINILCDLITPSEATYTWTKDGTLLQPSVKIILDGTGKIQIQNPTRKEQGIYECVANH 600

NOV2A: 1269 LGSDVESSSVLYAEAPVILSVERNITKPEHNHLSVVVGIVEAALGANVTIRCPVKGVPQ
1328

10 SECR : 601 LGSDVESSSVLYAEAPVILSVERNITKPEHNHLSVVVGIVEAALGANVTIRCPVKGVPQ 660

NOV2A: 1329 PNITWLKRGGSLSGNVSLFNGSLLLQNVSLNEGTYVCIATNALGKAVATSVFHLLERR
1388

15 SECR : 661 PNITWLKRGGSLSGNVSLFNGSLLLQNVSLNEGTYVCIATNALGKAVATSVLHLLERR 720

NOV2A: 1389 WPESRIVFLQGHKKYILQATNTRNSNDPTGEPPPQEWFEPGNWSHCSATCGHLGARIQ
1448

20 SECR : 721 WPESRIVFLQGHKKYILQATNTRNSNDPTGEPPPQEWFEPGNWSHCSATCGHLGARIQ 780

NOV2A: 1449 RPQCMANGQEVSEALCDHLQKPLAGFEPNCIRDCPARWFTSVWSQCSVSCGEGYHSRQV
1508

25 SECR : 781 RPQCMANGQEVSEALCDHLQKPLAGFEPNCIRDCPARWFTSVWSQCSVSCGEGYHSRQV 840

NOV2A: 1509 TCKRTKANGTVQVVSPRACAPKDRPLGRKPCFGHPCVQWEPGNRCGRCMGRAVRMQRH
1568

30 SECR : 841 TCKRTKANGTVQVVSPRACAPKDRPLGRKPCFGHPCVQWEPGNRCGRCMGRAVRMQRH 900

NOV2A: 1569 TACQHNSSDSNCDDRKRPTLRRNCTSGACDVCWHTGPWKCTAACGRGFQSRKVDCIHTR
1628

35 SECR : 901 TACQHNSSDSNCDDRKRPTLRRNCTSGACDVCWHTGPWKCTAACGRGFQSRKVDCIHTR 960

NOV2A: 1629 SCKPVAKRHCVQKKKPISWRHCLGPSCDRDCTDTTHYCMFKHLNLCSLDYKQRCCQSC
1688

40 SECR : 961 SCKPVAKRHCVQKKKPISWRHCLGPSCDRDCTDTTHYCMFKHLNLCSLDYKQRCCQSC
1020

45 NOV2A: 1689 QEG 1691 (SEQ ID NO: 61)
QEG
SECR : 1021 QEG 1023 (SEQ ID NO: 27)

SignalP and PSORT analysis indicate that NOV-2 may be localized in the endoplasmic reticulum, with likely cleavage sites between positions 26 and 27. Thus, it is likely that NOV-
50 2a protein is available at the appropriate sub-cellular localization for the therapeutic uses described in this application.

Based the relatedness of the disclosed NOV-2a to KIAA1233 sequences, which are related to lacunin, thrombospondins, proteinases, semaphorins, ADAM-TS and properdin family members, the nucleic acids and proteins of the invention can have similar functions as
55 proteins belonging to these families.

Functional roles attributed to this family of proteins include cell attachment, spreading, motility, and proliferation, cytoskeletal organization, wound healing, and angiogenesis. Moreover, these proteins are expressed in the nervous systems during development and are thought to play roles in neuronal growth and patterning. In particular, the thrombospondin, 5 METH-1 and ADAMTS families of proteins are potent inhibitors of angiogenesis. The ADAMTS proteins have also been implicated in cleavage of proteoglycans and the control of organ shape during development. In addition, the thrombospondins have been implicated in the activation of both transforming growth factor- beta (TGF- β) precursors and TGF- β in a variety of disease states. Furthermore, semaphorin proteins have shown expression in 10 undifferentiated neuroepithelium, suggesting that these proteins are actors in axonal guidance. Thus, the NOV-2a sequences of the invention is implicated in the following diseases and processes and has therapeutic uses in these diseases and processes: (i) inflammation, (ii) cancer, (iii) neuronal development and axonal guidance, (iv) angiogenesis and vasculogenesis – in cancer as well as for ischemia, and (v) tissue regeneration *in vivo* and *in vitro*, (vi) and 15 other diseases and disorders.

NOV 2b:

A NOV-2b nucleic acid of the invention, encoding a KIAA1233-like protein, is found within the nucleotide sequence of NOV-2a (SEQ ID NO: 3) in Table 5. The disclosed nucleic 20 acid is 6303 nucleotides in length and contains an open reading frame (ORF) that begins with an ATG initiation codon at nucleotide 425 and ends with a TAA stop codon at nucleotides 4268 (SEQ ID NO: 57). The initiation and stop codons of NOV-2b are shown in bold font in SEQ ID NO: 4. The representative ORF encodes a 406 amino acid polypeptide (SEQ ID NO: 5), which is shown below in Table 8. Putative untranslated regions are upstream of the 25 initiation codon and downstream of the stop codon in SEQ ID NO: 57.

TABLE 8

TATAATTATTAATAGAGACCTTCAAAGGACAAATTCTGTGAAATAAGTGGTTCTGA
 AGAGCCTACTAATAGGACAGTGTGTTAATATCACTAATAAGAGAGTAATGATTATAAAA
 GGAATAAAATTATGAAATTGCAAGATACTTTCTCCTTGATTAATATACTGCTAGTT
 AGTTTCTACATTTCAAATAGAACACTGGGAATTGTGTCGTAGATATTCTTGACAACTA
 AAGAGATGGTGGCTGAATTGGGAATGGTGTGATAACACTTGATATTAGTTCCAA
 TTTGGAAGAGCTCTGCTCTGGGATGTCAAATATTATATCGTCAATTATGAATGTT
 TAATTATGAAATGATATTCTCACAAATGATTTCATTGTAGTGAATGGATTAAAGA
 GATAATGCCCTATGACCACTTCCAACCTCTCCTCGCTGGGAACATAATCCTGGACTGC
 ATGTTCCGTGTCTGGAGGGAGGATTCAAGAGACGGAGCTTGTGTGAGAGGAATC
 CATGCATGGAGAGATATTGCAAGGTGGAAGAATGGAAGTGCATGTACGCACCCAAACCCAA
 GTTATGCAAACCTGTAACTGTTGATTGCCCAAGTGGATTGCCATGGAGTGGCTCA
 GTGCACAGTGACTTGTGGCCGAGGGTTACGGTACCGGTTGTTCTGTGATTAACCACCG
 CGGAGAGCATGTTGGGGCTGCAATCCACAACGAAAGTACACATCAAAGAAGAATGTGT
 CATTCCCATCCCGTGTATAAACCAAAAGAAAAAGTCCAGTGGAGCAGAAATTGCTTG
 GCTGAAACAAGCACAAGAACTAGAAGAGACCAGAAAGCAACAGAAGAACCAACGTTCAT

TCCAGAACCTGGTCAGCCTGCAGTACCACTGTGGGCCGGTGTGCAGGTCCGTGAGGT
 GAAGTGCCTGTCTCACATTACCGCAGACTGAGACTGAGCTGCCGAGGAAGAGTG
 TGAAGGCCAAGCTGCCACCGAACGCCCTGCCCTCCGGAAACCATGTGATGAGAGCC
 5 GGCCTCCGAGAGCTAGACATCCCTCCTGGCACACCATGCGTGGGAGGCCATCAAGAACGCCATAGC
 GTACGCTGGTTCACCCCTGGCACACCATGCGTGGGAGGCCATCAAGAACGCCATAGC
 AGTGTGCTTACATATCCAGACCCAGCAGACAGTCATGACAGCTTGTGATATGGTCCA
 CCGTCCTCCAGCCATGAGCCAGGCCGTGAAACACAGAGGCCGTGCCCCCAGGTGGCATGT
 GGGCTCTGGGGGCCCTGCTCAGCTACCTGTGGAGTTGGAATTAGACACCCAGATGTGTA
 CTGCTGCACCCAGGGAGACCCCTGCCCTCGAGGAGTGCAGGAGATGAAAAGGCCA
 10 TGCTTTACAAGCATGCAATCAGTTGACTGCCCTCCGGCTGCACATTGAAAGAATGGCA
 GCAGTGTCCAGGACTGTGGCGGGGAACTCAGAACAGAACAGTCACCTGCGCAGCT
 GCTAACGGATGGCAGCTTTGAACTCTCAGATGAATTGTCAGCAAGGACCAAGGCATC
 GTCTCACAAAGTCTGTGCCAGGACAGACTGCTCCACATTAGCTGTGGAGACTGGTC
 GAAGTGTCTGTCTAGTTGTGGTGTGAAATCCAGAGAACAGGAGTGTCAAAGGCT
 15 GGCAGCCAAAGGTGCGCGCATCCCCCTCAGTGAGATGATGTCAGGGATCTACCAGGGTT
 CCCCTTGTAAGATCTGTGAGATGCTGAGTGCAGTAAATCAGAGATGAGAAC
 AAAACTTGTGAGCAGGGTCCGAGATCCTCAGTGTCAGAGACTACATTAGACAAAG
 GGAAGAGAACGCTTAAACCTGACCAATTGCTAGCAGAGCCTATTGCTGCCAACACATC
 CGTGATTATAAGTGCCTGTGCAAGTCCAGAAATCTCTGATCCAGTGGGAGAAGGA
 20 TGGCCGTTGCTGAGAACTCCAAACGGCTGGCATCACCAGTCAGGCTCACTAAAAAT
 CCACGGCTTGTGCTGCCCGACATCGCGTGTACCGGTGCACTGCAAGGCCAGCCCTCAG
 AACAGTTGCTCAAGCTCAATTGGTACTGACAACCGGCTCATGSCACGCCAGCCCTCAG
 GGAGCCATGAGGAAATATCTGGATGGACCAACAGCGAACGAAATAGTTGGGAGTCAC
 ATGGCACAATGAGGAAATGTGAAATAACAAAATGACCTTATCTGGATGATGACCA
 25 CATTAGTAACCAGCCTCTTGAGAGCTCTGTAGGCACTGAGCAATTCTGCAAGGAG
 CACCAACTCTGGAGGTTGAAGAATAACGAGCTTGAAGCAGCTTAAACAAAGGAGCATA
 TAGCATGGATACAGCCAGTTTGTGACCTGATAAGAAACATGAGTCAGCTCATGAAAC
 CGGAGAGGTCAGCGATGATCTTGTCCCAGCTGATATATCAGCTGGTGGCGAATTAGC
 CAAGGCACAGCAACACACATGCAGTGGCGGGCATCCAGGAAGAGACACCTCTGTC
 30 TCAGCTCAGAGGGAAACAGGGAGTGTGTCCTAAAGCTCGCATGCAAAAACACTCAGGCAA
 GCTGACATTCAAGCCGAAAGGACCTGTTCTCATGAGGCAAAGCCAACCTCCCTCAATTTC
 ATTAAATAAAACAATAAATTCCAGGATTGAAATACAGTATACTTACAAAAGGACAGA
 GGTGATGAACTTACTGTGACCTTATACCCCACTGAGGCCACATATACATGGACCAA
 GGATGGAACCTTGTACAGCCCTCAGTAAATTAATTGGATGGAACCTGGGAGATACA
 35 GATACAGAACTTACAGGAAACAAAGGCAATATGAATGTTCTGAGCTAATCATCT
 TGGTTCAGATGTGAAAGTTCTGTGATGAGCAGGACCTGTCATCTGTCTGT
 TGAAAGAAATATCACCACCAACAGCAGCACAAACCATCTGTCTGTGTTGGAGGCATCGT
 GGAGGCAGCCCTTGGAGCAAACGTGACAATCCGATGTCCTGTAAGGTTGTCCTCAGCC
 TAATATAACTGGTTGAAGAGAGGAGATCTGAGTGGCAATGTTCTGCTTTCAA
 40 TGGATCCCTGTTGAGAATGTTCCCTGAAAATGAAGGAACTACGCTCTGCATAGC
 CACCAATGCTTGGAAAGGCACTGGCACACATCTGACTCCACTGCTGGAACGAAGATG
 GCCAGAGACTGAAATGTTCTGCAAGGACATAAAAGTACATTCTCCAGGCAACCAA
 CACTAGAACCAACAGCAATGCCAACAGGAGAACCCCCGCTCAAGAGCCTTTGGGA
 GCTGTTAACTGTCACATTGTCACCTGTCAGTGTGTTGTCATTGGAGCCCCATTAGAG
 45 ACCCCAGTGTGATGGCCAATGGCAGGAAGTGGAGTGGCCCTGTGATCACCTCCA
 GAAGCCACTGGCTGGGTTGAGCCCTGTAACATCCGGGACTGCCCCAGCGAGGTGGTTCAC
 AAGTGTGTTGTCACAGTGTCTGTGCTTGGCTGAAGGATACACAGTCGGCAGGTGAC
 GTGCAAGCCGACAAAGCCAATGAACTGTGCAAGGTGGTGTCTCAAGAGCATGTGCC
 TAAAGACCGGCTCTGGAAAGAAAACATGTTGGTCATCCATGTGTTCACTGGGAAAC
 50 AGGGAAACCGGTGCTGGACGTTGACATGGCCGTGCTGTGAGGATGCAAGCGGTGACAC
 AGCTTGTCACACAAACAGCTGACTCCAACGTGATGACAGAAAGAGAACCCACCTTAAG
 AAGGAACATGCACTGGGGCTGTGATGTTGGCACACAGGCCCTTGGAAAGGCCCTG
 TACAGCAGCTGTGGCAGGGGTTTCCAGTCTGGAAAGTCAGTGTATCCACACAAGGAG
 TTGCAAACCTGTGGCAGAGACACTGTGTCAGGAAAGAACCAATTCTGGCGGCA
 55 CTGTCCTGGCCCTCTGTGATAGAGACTGCAACAGACACAACACTCAACTGTATGTTGT
 AAAACATCTTAAATTGTTGTCCTAGACCGCTACAAACAAAGGTGCTGCCAGTCATGTC
 AGAGGGATAAAACCTTGGAGGGGTCATGATGTCGTGTCAGTAAAGTGAATATAAA
 AGCTCTTTCCCCATGTCGCTGATTCAAAACATGTATTCTTAAAGACTAGATTCTAT
 60 GGATCAAACAGAGGTGATGCAAAACACCAACTGTTAAGGTAAAGTGAATTTCCAA
 TGGTAGTTTATATTCCAATTTTAAATGATGTTATTCAACGGATGACAAACAAATACTATA
 GCATGCACTGCCACTGCACTGGGACCTCATGTCAGTTGAACTGAGAACATACCAAGA
 TTATGAGTCATCCTCACGTGCTGCCCTTCCGTGATATGAGACTGACAGAGTGG
 TACATCTTAAACAGTTGGGAAACACAGCAACCCATGACTTCCCTCTCAAGTTGCA
 65 GTTTTCAAGTTTATAAGGTATTGCAATTAGAGCTCTGGCAGTAGTTGTTAAGA
 TGTTGGCATTAATGGCATTTCAGATCCTGGTTAGTCAGTGTGAAAGAAAACCATCT
 CTCTGGATAGGCTGTACACTGACTGACCTAAGGGTTCATGGAAGCATGGCATCTGTC
 TTGCTTTAGAACACCCATGGAAGAAAACACAGAGTAGATATTGCTGTCAATTATAAC
 TACAGAAATTATCTATGACCTAATGAGGCATCTGGAAAGTCAGAACAGAGGGAAAGTTA
 ACCTTTCTACTGATTGCTAGTATATTCAAGAGCTTCTTTAAGAGCTGTGAATGAAAC
 70 TTTTCTAACGCACTATTCTATTGCAACAAACAGAAAACCAAGCCTTATAGACCTAAT

TTATGCATAAAGTAGTATTCTGAGAACCTTATTTGAAAATTATAAGAAAGTAATCC
 AAATAAGAAACAGATAAGTGTAAAATAATTTTATAGATAAAATTGTTGGGCTGATT
 5 TTTCAGTAATCCAAGTGACTTAGGTTAGAAGTTACACTAAGGACCAGGGGTTGGAATC
 AGAATTAGTTAAGATTGAGGAAAGGTAAGGTTAGTTCAAGTTAGGATTAGAG
 CTAGAATTGGGTTAGGTGAGGAAAGGTTAGGTTAAGGCTAGAGTTGTCCTTAAGGGT
 TAGGGTTAGGACAGGTTAGGTAGGTCAGGTTGGATTGGGTTAGATTGGGGCCAGTGCCTGGT
 GTTAGTGTAGTGTCAAGGATGGAGGTAGGTTGGAGTAAGCGTTGTTGCTGAAGTGAGT
 TCAGGCTAGCATTAATTGTAAGTTCTGAAGCTGATTGGTTATGGGGCTTTCCCCCTG
 10 ATACTACAGTTGTGCTTTAGATGGCACACAAGTCAAATAAGTGGTCATACTCTTA
 TTCAGGGTCTCAGCTGCCGTACACCTGCTGCACATCTCTGGCAACAAAGTTACCT
 GCCACAGGCTCTGCTGAGCCTAGTCCTGGTCAGATAACTGAACAGTGCATTTGGCT
 TTGGATGTGCTGTGGACAAGCTTGCTGAGTTCTACCATATTCTGAGCACACGGTCT
 CTTTGTTCTAATTCACTGACACTGGGTGAGCAGTACTGTATGTGGAGGGTT
 TGGTGATTGGGAAATGAGTGGGGACAGTGAGGAGGACACACAGGCCATTAGTTGTTAAT
 15 CATCAATCACATCTGATTGTTGAAGGTTATTAAATTAAAGAAAGATCATTTGTAACATA
 CTCTTGATATATTATATGAAAGGTCAATATTATTTGTCAGTATGTAATA
 AAGACATGGGACATATTTCTATTAAACAAATTTCATATTAAATTGCTTCACTTIG
 TATTTAAAGTTAAAGTACTATTTCATTGCTATTGTCATTGTCATTCA
 20 ATTGACATTCTGTGACTGTATTACTGTTTATAACATGAGAGTTAATGTTCT
 TGTTTCATGATCCTTATGTAATTCAAGAAATAATTACTTGATTATTCACTGTCATCT
 TAT (SEQ ID NO: 57)

MPYDHFQPLPRWEHNPWTACSVSCGGIQRRSFVCVEESMHGEILQVEEWKCMYAPPKPKVMQTCNLFDCKWIA
 WSQCTVTCGRGLRYRVVLCINHRGEHVGCPNQLKLHIKEECVIPICPKPKESPVEAKLPWLQQAQELEETRIA
 25 TEEPTFIPEPWASACSTTCGPVQVREVKCRVLLFTQTETELPEEECEGPKLPTERPCCLLEACDESPASRELDIPL
 PEDSETTYDWEYAGFTPCTATCVGGHQEAIAVCLHIQTOQTVNDSLCDMVHRPPAMSQACNTEPCPPRWHVGSWGP
 CSATCGVGIQTRDVYCLHPGETPAPPEECRDEKPHALQACNQFDCCPPGHIEEWQCSRTCGGGTNQRRVTCRQLL
 TDGSFLNLSDELQGPKASSHKSCARTDCPPHLAVGDWSKCSVSCVGQIQRKQVCQRLAAKGRRIPLEMMCRDL
 PGFPPLVRSCQMPECISKIKSEMKTKLGEQGPQILSVQRVYIQTREEKRNLTIGSRAYLLPNTSVIICKPVRFQKS
 30 LIQWEKDGRCLQNSKRLGITKSGSLKIHGLAAPDIGVYRCIAGSAQETVVLKLIGTDNRLLIARPALREPMREYPGM
 DHSEANSLGVTWHKMRQMWNKNDLYLDHHISNQPFLRALLGHCSNSAGSTNSWELKNQFEAAVKQGAYSMDTA
 QFDELIRNMSQLMETGEVSDDLSQLIYQLVAELAKAQPTHMQWRGIQEETPPAAQLRGETGSVSQSSHAKNSGKL
 TFKPKGPVLMRQSOPPSISFNKTINSRIGNTVYITKRTEVINILCDLITPSEATYTWTKDGTLLQPSVKIIILDGTG
 KIQIQNPTRKEQGIYECVANHIGSDVESSVLYAEAPVILSVERNITKPEHNHLVVVGGIVEALGANVTIRCP
 35 VKGVPQPNITWLKGGSLSGNVSLLFNGSLLLQNVSLNEGTYVCIATNALGKAVATSVLHLLERRWPESRIVFLQ
 GHKKYILQATNTRNSNDPTGEPPPQEPFWEPGNWSHCSATCGHLGARIQRQPCVMANGQEVSALCDHLQKPLAG
 FEPNCIRDCPARWFTSVSQCSVSCGEGYHSRQVTCKRTKANGTVQVVSACAPKDRPLGRKPCFGHPCVQWEPE
 NRCPGRCMGRAVRMQRHTACQHNSDSNDDRKRPTLRRNCTSGACDVCWHTGPWKCTAACGRGFQSRKVDCIH
 TRSCKPVAKRHCVQKKKPISWRHCLGPSCDRDCTTHTYCMFVKHLNLCSLDRYKORCCQSCQEG (SEQ ID
 40 NO: 5)

Table 9 shows a multiple sequence alignment of NOV-1, NOV-2a, and NOV-2b polypeptides with a KIAA1233 protein (GenBank Accession No: BAA86547), that demonstrates the homology between disclosed sequences according to the invention and a known member of the protein family.

TABLE 9

KIAA1233	-----
NOV1	-----
NOV2b	-----
NOV2a	MASWTSPWWVLIGMVFHSPQTTAEKSPGAYFLPEFALSPOGSFLEDTTGEQFLTYRY
5	
KIAA1233	-----
NOV1	-----
NOV2b	-----
NOV2a	DDQTSRNRNTRSDEDKDGNWDAWDWSDCSRTCGGGASYSLRRCLTGRNCEGQNIRYKTCSN
10	
KIAA1233	-----
NOV1	-----
NOV2b	-----
NOV2a	HDCPPDAEDFRAQQCSAYNDVQYQGHYYEWLPRYNDPAAPCALKCHAQGQNLVVELAPKV
15	
KIAA1233	-----
NOV1	-----
NOV2b	-----
NOV2a	LDGTRCNTRSDLDMCISGICQAVGCDRQLGSNAKEEDNCGVCAAGDGSTCRLVRGQSKSHVSP
20	
KIAA1233	-----
NOV1	-----
NOV2b	-----
NOV2a	EKREENVIAVPLGSRSRVITVKGP AHLFIESKTLQGSKGEHSFN SPGVFVVENTTVEFQR
25	
KIAA1233	-----
NOV1	-----
NOV2b	-----
NOV2a	GSERQTFKIPGPLMADFIFKTRYTAAKDSVVQFFFYQPISHQWRQTDFFPCTVTCGGGYQ
30	
KIAA1233	-----
NOV1	-----
NOV2b	-----
NOV2a	LNSAECVDIRLKRVVPDHYCHYYENVKPKPKLKECSMDPCPSSDGFKEIMPYDHFQPLP
35	
KIAA1233	-----
NOV1	RWEHNPWTACSVSCGGGIQRRSFVCVEESMHGEILQVEEKCMYAPKPKVMQTCNLFDGP
NOV2b	RWEHNPWTACSVSCGGGIQRRSFVCVEESMHGEILQVEEKCMYAPKPKVMQTCNLFDGP
NOV2a	RWEHNPWTACSVSCGGGIQRRSFVCVEESMHGEILQVEEKCMYAPKPKVMQTCNLFDGP
40	
KIAA1233	-----
NOV1	KWIAMEWSQCTVTCGRGLRYRVVLCINHRGEHVGCGNPQLKLHIKEECVIPIPCYKPKEK
NOV2b	KWIAMEWSQCTVTCGRGLRYRVVLCINHRGEHVGCGNPQLKLHIKEECVIPIPCYKPKEK
NOV2a	KWIAMEWSQCTVTCGRGLRYRVVLCINHRGEHVGCGNPQLKLHIKEECVIPIPCYKPKEK
45	
KIAA1233	-----
NOV1	SPVEAKLPWLKQAQELEETRIATEEPTFIPEPWSACSTCGPGVQREVKCRVLLTFTQT
NOV2b	SPVEAKLPWLKQAQELEETRIATEEPTFIPEPWSACSTCGPGVQREVKCRVLLTFTQT
NOV2a	SPVEAKLPWLKQAQELEETRIATEEPTFIPEPWSACSTCGPGVQREVKCRVLLTFTQT
50	
KIAA1233	-----
NOV1	ETELPEEECEGPKLPTERPCCLLEACDES P ASRELDIPLPEDSETTYDWEYAGFTPCTATC
NOV2b	ETELPEEECEGPKLPTERPCCLLEACDES P ASRELDIPLPEDSETTYDWEYAGFTPCTATC
NOV2a	ETELPEEECEGPKLPTERPCCLLEACDES P ASRELDIPLPEDSETTYDWEYAGFTPCTATC
55	
KIAA1233	-----
NOV1	-AVCLHIQTQQTVNDSLCDMVHRRPPAMSQACNTEPCPPRWHVG SWG PCSATCG
NOV2b	VGGHQEAIAVCLHIQTQQTVNDSLCDMVHRRPPAMSQACNTEPCPPRWHVG SWG PCSATCG
NOV2a	VGGHQEAIAVCLHIQTQQTVNDSLCDMVHRRPPAMSQACNTEPCPPRWHVG SWG PCSATCG
60	
KIAA1233	*****
NOV1	VGIQTRDVYCLHPGETPAPPEECRDEKPHALQACNQFDCCPPGWHIEWQOC SRTCGGGTQ
NOV2b	VGIQTRDVYCLHPGETPAPPEECRDEKPHALQACNQFDCCPPGWHIEWQOC SRTCGGGTQ

NOV2a VGIQTRDVYCLHPGETPAPPECRDEKPHALQACNQFDCCPPGWHIEWQOCRTCGGGTQ

5 KIAA1233 NRRVTCRQLLTDGSFLNLSDELCQGPKASSHKSCARTDCPPHLAVGDWSKCSVSCGVGIQ
NOV1 NRRVTCRQLLTDGSFLNLSDELCQGPKASSHKSCARTDCPPHLAVGDWSKCSVSCGVGIQ
NOV2b NRRVTCRQLLTDGSFLNLSDELCQGPKASSHKSCARTDCPPHLAVGDWSKCSVSCGVGIQ
NOV2a NRRVTCRQLLTDGSFLNLSDELCQGPKASSHKSCARTDCPPHLAVGDWSKCSVSCGVGIQ

10 KIAA1233 RRKQVCQRLAAKGRRIPLEMCMCRDLPGLPLVRSCQMPECSKIKSEMKTKLGEQGPQILS
NOV1 RRKQVCQRLAAKGRRIPLEMCMCRDLPGLPLVRSCQMPECSKIKSEMKTKLGEQGPQILS
NOV2b RRKQVCQRLAAKGRRIPLEMCMCRDLPGFPLVRSCQMPECSKIKSEMKTKLGEQGPQILS
NOV2a RRKQVCQRLAAKGRRIPLEMCMCRDLPGFPLVRSCQMPECSKIKSEMKTKLGEQGPQILS

15 KIAA1233 VQRVYIQTREEKRINLTIGSRAYLLPNTSVIICKPVRRFQKS LIQWEKDGRCLQNSKRLG
NOV1 VQRVYIQTREEKRINLTIGSRAYLLPNTSVIICKPVRRFQKS LIQWEKDGRCLQNSKRLG
NOV2b VQRVYIQTREEKRINLTIGSRAYLLPNTSVIICKPVRRFQKS LIQWEKDGRCLQNSKRLG
NOV2a VQRVYIQTREEKRINLTIGSRAYLLPNTSVIICKPVRRFQKS LIQWEKDGRCLQNSKRLG

20 KIAA1233 ITKSGSLKIHGLAAPDIGVYRCIAGSAQETVVLKLIGTDNRLIARPALREPMREYPGMDH
NOV1 ITKSGSLKIHGLAAPDIGVYRCIAGSAQETVVLKLIGTDNRLIARPALREPMREYPGMDH
NOV2b ITKSGSLKIHGLAAPDIGVYRCIAGSAQETVVLKLIGTDNRLIARPALREPMREYPGMDH
NOV2a ITKSGSLKIHGLAAPDIGVYRCIAGSAQETVVLKLIGTDNRLIARPALREPMREYPGMDH

25 KIAA1233 SEANSLGVTWHKMRQMWNKNNDLYLDDDHISNQPFLRALLGHCSNSAGSTNSWELKNKQF
NOV1 SEANSLGVTWHKMRQMWNKNNDLYLDDDHISNQPFLRALLGHCSNSAGSTNSWELKNKQF
NOV2b SEANSLGVTWHKMRQMWNKNNDLYLDDDHISNQPFLRALLGHCSNSAGSTNSWELKNKQF
NOV2a SEANSLGVTWHKMRQMWNKNNDLYLDDDHISNQPFLRALLGHCSNSAGSTNSWELKNKQF

30 KIAA1233 EAAVKQGAYSMDTAQFDELIRNMSQLMETGEVSDDLASQLIYQLVAELAKAQPTHMQWRG
NOV1 EAAVKQGAYSMDTAQFDELIRNMSQLMETGEVSDDLASQLIYQLVAELAKAQPTHMQWRG
NOV2b EAAVKQGAYSMDTAQFDELIRNMSQLMETGEVSDDLASQLIYQLVAELAKAQPTHMQWRG
NOV2a EAAVKQGAYSMDTAQFDELIRNMSQLMETGEVSDDLASQLIYQLVAELAKAQPTHMQWRG

35 KIAA1233 IQEETPPAAQLRGETGSVSQSSHAKNSGKLTFKPKGPVLMRQSOPPSISFNKTINSIGN
NOV1 IQEETPPAAQLRGETGSVSQSSHAKNSGKLTFKPKGPVLMRQSOPPSISFNKTINSIGN
NOV2b IQEETPPAAQLRGETGSVSQSSHAKNSGKLTFKPKGPVLMRQSOPPSISFNKTINSIGN
NOV2a IQEETPPAAQLRGETGSVSQSSHAKNSGKLTFKPKGPVLMRQSOPPSISFNKTINSIGN

40 KIAA1233 TVYITKRTEVINILCDLITPSEATYTWTKDGTLLQPSVIIILDGTGKIQIQNPTRKEQGI
NOV1 TVYITKRTEVINILCDLITPSEATYTWTKDGTLLQPSVIIILDGTGKIQIQNPTRKEQGI
NOV2b TVYITKRTEVINILCDLITPSEATYTWTKDGTLLQPSVIIILDGTGKIQIQNPTRKEQGI
NOV2a TVYITKRTEVINILCDLITPSEATYTWTKDGTLLQPSVIIILDGTGKIQIQNPTRKEQGI

45 KIAA1233 YECVANHLDVESSSVLYAEAPVILSVERNITKPEHNHLSVVVGIVEAALGANVTIR
NOV1 YECVANHLDVESSSVLYAEAPVILSVERNITKPEHNHLSVVVGIVEAALGANVTIR
NOV2b YECVANHLDVESSSVLYAEAPVILSVERNITKPEHNHLSVVVGIVEAALGANVTIR
NOV2a YECVANHLDVESSSVLYAEAPVILSVERNITKPEHNHLSVVVGIVEAALGANVTIR

50 KIAA1233 CPVKGPQPNITWLKRGGSLSGNVSLLFNGSLLLQNVSENEGTYVCIATNALGKAVATS
NOV1 CPVKGPQPNITWLKRGGSLSGNVSLLFNGSLLLQNVSENEGTYVCIATNALGKAVATS
NOV2b CPVKGPQPNITWLKRGGSLSGNVSLLFNGSLLLQNVSENEGTYVCIATNALGKAVATS
NOV2a CPVKGPQPNITWLKRGGSLSGNVSLLFNGSLLLQNVSENEGTYVCIATNALGKAVATS

55 KIAA1233 CPVKGPQPNITWLKRGGSLSGNVSLLFNGSLLLQNVSENEGTYVCIATNALGKAVATS
NOV1 CPVKGPQPNITWLKRGGSLSGNVSLLFNGSLLLQNVSENEGTYVCIATNALGKAVATS
NOV2b CPVKGPQPNITWLKRGGSLSGNVSLLFNGSLLLQNVSENEGTYVCIATNALGKAVATS
NOV2a CPVKGPQPNITWLKRGGSLSGNVSLLFNGSLLLQNVSENEGTYVCIATNALGKAVATS

KIAA1233 VLHLLERRWPESRIVFLQGHKKYILQATNTRNSNDPTGEPPPQEFPWEPGNWSHCSATC
 NOV1 VLHLLERRWPESRIVFLQGHKKYILQATNTRNSNDPTGEPPPQEFPWEPGNWSHCSATC
 NOV2b VLHLLERRWPESRIVFLQGHKKYILQATNTRNSNDPTGEPPPQEFPWEPGNWSHCSATC
 NOV2a VFHLLERRWPESRIVFLQGHKKYILQATNTRNSNDPTGEPPPQEFPWEPGNWSHCSATC
 * : ****

5 KIAA1233 GHLGARIQRPOCVMANGQEVSEALCDHLQKPLAGFEPNCNIRDCPARWFTSVWSQCSVSCG
 NOV1 GHLGARIQRPOCVMANGQEVSEALCDHLQKPLAGFEPNCNIRDCPARWFTSVWSQCSVSCG
 NOV2b GHLGARIQRPOCVMANGQEVSEALCDHLQKPLAGFEPNCNIRDCPARWFTSVWSQCSVSCG
 10 NOV2a GHLGARIQRPOCVMANGQEVSEALCDHLQKPLAGFEPNCNIRDCPARWFTSVWSQCSVSCG
 * ****

15 KIAA1233 EGYHSRQVTCKRTKANGTVQVVS PRACAPKDRPLGRKPCFGHPCVQWE PGNRCPGRCMGR
 NOV1 EGYHSRQVTCKRTKANGTVQVVS PRACAPKDRPLGRKPCFGHPCVQWE PGNRCPGRCMGR
 NOV2b EGYHSRQVTCKRTKANGTVQVVS PRACAPKDRPLGRKPCFGHPCVQWE PGNRCPGRCMGR
 NOV2a EGYHSRQVTCKRTKANGTVQVVS PRACAPKDRPLGRKPCFGHPCVQWE PGNRCPGRCMGR
 * ****

20 KIAA1233 AVRMMQRHTACQHNSSDSNCDDRKRPTLRRNCTSGACDVCWHTGPWKCTAACGRGFQSR
 NOV1 AVRMMQRHTACQHNSSDSNCDDRKRPTLRRNCTSGACDVCWHTGPWKCTAACGRGFQSR
 NOV2b AVRMMQRHTACQHNSSDSNCDDRKRPTLRRNCTSGACDVCWHTGPWKCTAACGRGFQSR
 NOV2a AVRMMQRHTACQHNSSDSNCDDRKRPTLRRNCTSGACDVCWHTGPWKCTAACGRGFQSR
 * ****

25 KIAA1233 KVDCIHTRSCKPVAKRHCVQKKKPISWRHCLGPSCDRDCTDTTHYCMFVKHNLICSLDRY
 NOV1 KVDCIHTRSCKPVAKRHCVQKKKPISWRHCLGPSCDRDCTDTTHYCMFVKHNLICSLDRY
 NOV2b KVDCIHTRSCKPVAKRHCVQKKKPISWRHCLGPSCDRDCTDTTHYCMFVKHNLICSLDRY
 NOV2a KVDCIHTRSCKPVAKRHCVQKKKPISWRHCLGPSCDRDCTDTTHYCMFVKHNLICSLDRY
 * ****

30 KIAA1233 KQRCCQSCQEG (SEQ ID NO: 28)
 NOV1 KQRCCQSCQEG (SEQ ID NO: 2)
 NOV2b KQRCCQSCQEG (SEQ ID NO: 5)
 NOV2a KQRCCQSCQEG (SEQ ID NO: 4)
 * ****

35 Consensus key
 * - single, fully conserved residue
 : - conservation of strong groups
 . - conservation of weak groups - no consensus

40 Based the relatedness of the disclosed NOV-2b to the disclosed NOV-1, the disclosed NOV-2a, and KIAA1233 sequences, which as noted are related to lacunin, thrombospondins, proteinases, semaphorins, ADAM-TS and properdin family members, the nucleic acids and proteins of the invention can have similar functions as proteins belonging to these families.

45 Thus, the invention is implicated in the following diseases and processes and has therapeutic uses in these diseases and processes: (i) inflammation, (ii) cancer, (iii) neuronal development and axonal guidance, (iv) angiogenesis and vasculogenesis – in cancer as well as for ischemia, and (v) tissue regeneration *in vivo* and *in vitro*, and (vi) and other diseases and disorders.

Functional roles attributed to this family of proteins include cell attachment, spreading, 50 motility, and proliferation, cytoskeletal organization, wound healing, and angiogenesis. Moreover, these proteins are expressed in the nervous systems during development and are thought to play roles in neuronal growth and patterning. In particular, the thrombospondin,

METH-1 and ADAMTS families of proteins are potent inhibitors of angiogenesis. The ADAMTS proteins have also been implicated in cleavage of proteoglycans and the control of organ shape during development. In addition, the thrombospondins have been implicated in the activation of both transforming growth factor-beta (TGF- β) precursors and TGF- β in a variety of disease states. Furthermore, semaphorin proteins have shown expression in undifferentiated neuroepithelium, suggesting that these proteins are actors in axonal guidance.

The novel nucleic acids of the invention encoding human proteins includes the nucleic acids whose sequences are provided as NOV-1, NOV-2a, and NOV-2b, respectively, or fragments thereof. The invention also includes mutant or variant nucleic acids any of whose bases may be changed from the corresponding bases shown as NOV-1, NOV-2a, and NOV-2b, while still encoding a protein that maintains its human KIAA1233-like protein activities and physiological functions, or a fragment of such nucleic acids. The invention further includes nucleic acids whose sequences are complementary to those just described, including nucleic acid fragments that are complementary to any of the nucleic acids just described. The invention additionally includes nucleic acids or nucleic acid fragments, or complements thereto, whose structures include chemical modifications. Such modifications include, by way of non-limiting example, modified bases, and nucleic acids whose sugar phosphate backbones are modified or derivatized. These modifications are carried out at least in part to enhance the chemical stability of the modified nucleic acid, such that they may be used, for example, as anti-sense binding nucleic acids in therapeutic applications in a subject.

The novel proteins of the invention includes the human KIAA1233-like proteins whose sequences are provided as NOV-1, NOV-2a, and NOV-2b, respectively. The invention also includes a mutant or variant protein any of whose residues may be changed from the corresponding residues shown as NOV-1, NOV-2a, and NOV-2b, while still encoding a protein that maintains its human KIAA1233-like protein activities and physiological functions, or a functional fragment thereof.

The invention further encompasses antibodies and antibody fragments, such as F_{ab} or (F_{ab})₂, that bind immunospecifically to any of the proteins of the invention.

The expression pattern, and protein similarity information for the invention suggest that NOV-1, NOV-2a and NOV-2b may function as human KIAA1233-like proteins. Therefore, the nucleic acid and protein of the invention are useful in potential therapeutic applications implicated, for example but not limited to, (i) inflammation, (ii) cancer, (iii) neuronal development and axonal guidance, (iv) angiogenesis and vasculogenesis – in cancer as well as for ischemia, and (v) tissue regeneration *in vivo* and *in vitro*, (vi) and other diseases

and disorders. The homology to antigenic secreted and membrane proteins also suggests that antibodies directed against the novel genes may be useful in treatment and prevention of (i) inflammation, (ii) cancer, (iii) neuronal development and axonal guidance, (iv) angiogenesis and vasculogenesis – in cancer as well as for ischemia, and (v) tissue regeneration *in vivo* and 5 *in vitro*, and (vi) other diseases and disorders.

Potential therapeutic uses for the invention(s) are, for example but not limited to, the following: (i) protein therapeutic, (ii) small molecule drug target, (iii) antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), (iv) diagnostic and/or prognostic marker, (v) gene therapy (gene delivery/gene ablation), (vi) research tools, and (vii) tissue 10 regeneration *in vitro* and *in vivo* (regeneration for all these tissues and cell types composing these tissues and cell types derived from these tissues).

NOV-3: A Novel STE20 Protein Kinase

The NOV-3 sequences (NOV-3a, NOV-3b, NOV-3c, and NOV-3d) according to the 15 invention are splice variants related to STE20 protein kinases. The differences between the four sequences relate to the four ways of independently combining two deletions arising from two splice variants in the mRNAs.

Splice variants are sequences that occur naturally within the cells and tissues of individuals. The physiological activity of splice variant products and the original protein, from 20 which they are varied, may be the same (although perhaps at a different level), opposite, or completely different and unrelated. In addition, variants may have no activity at all. When a variant and the original sequence have the same or opposite activity, they may differ in various properties not directly connected to biological activity, such as stability, clearance rate, tissue and cellular localization, temporal pattern of expression, up or down regulation mechanisms, 25 and responses to agonists or antagonists. The presence or level of specific splice variants may be the cause, and/or indicative of, a disease, disorder, pathological or normal condition.

Because a drug may be effective against one variant but not another, or may cause side effects because it targets all splice variants, an effective drug needs to target the particular splice variant. Because soluble variants with therapeutic or disease-related functions may be 30 naturally occurring in specific tissues, they may be optimal candidates for drug targets or protein therapeutics. Variants may have no activity at all and may thus serve as dominant negative natural inhibitors. Thus, splice variants useful in generating new drug targets, protein therapeutics and markers for diagnostics.

NOV-3 sequences according to the invention encode polypeptides related to STE20 protein kinases, whose subgroups include GCK, SLK, and PSK proteins. Therefore, the nucleic acids and proteins of the invention can have similar functions as proteins belonging to these subgroups.

5 Functional roles attributed to STE20 proteins include cytoskeletal organization, apoptosis, and signal transduction pathways. Thus, the NOV-3 nucleic acids and polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications in disorders associated with, e.g., metabolic and endocrine disorders, cancer, bone disorders, and tissue/cell growth regulation disorders.

10 NOV-3 sequences were initially identified by searching CuraGen's Human SeqCalling database for DNA sequences that translate into proteins with similarity to the STE20 protein kinase family. The SeqCalling assembly for NOV-3 was analyzed further to identify open reading frame(s) encoding for novel full length protein(s) and novel splice variants of these genes. This was done by extending the SeqCalling assembly using additional SeqCalling assemblies, publicly available EST sequences and public genomic sequence. Public ESTs and additional CuraGen SeqCalling assemblies were identified by the CuraTools program SeqExtend. They were included in the DNA sequence extension for SeqCalling assembly 18552586 when extended overlaps were found.

20 SeqCalling is a differential expression and sequencing procedure that normalizes mRNA species in a sample, and is disclosed in U.S. Ser. No. 09/417,386 filed October 13, 1999, which is incorporated herein by reference in its entirety.

25 A genomic clone of NOV-3 was analyzed by Genscan™ and Grail™ to identify exons and putative coding sequences/open reading frames. The NOV-3 clone was also analyzed by TblastN, BlastX and other homology programs to identify regions translating to proteins with similarity to the original protein/protein family of interest.

30 The results of these analyses were integrated and manually corrected for apparent inconsistencies, thereby obtaining the sequences encoding the full-length proteins. When necessary, the process to identify and analyse cDNAs/ESTs and genomic clones was reiterated to derive the full-length sequence. The full-length DNA sequences as well as their splice forms, and the full-length protein sequences that they encode, are disclosed herein.

NOV-3 was mapped to chromosome 17.

Based on the CuraGen SeqCalling database information, the NOV-3 is expressed in heart tissue. Moreover, based on the expression of STE-20 family members, the following tissues are also likely to express the invention: brain (especially hippocampus and cerebral

cortex), prostate, and blood hematopoietic cell lines. The patterns of expression for this gene and its family members, combined with its similarity to the STE20 kinase family of genes, suggests that the NOV-3 proteins function as kinases in the tissues of expression. Thus, NOV-3 is implicated in disorders involving these tissues. Some of these disorders include:

5 cardiovascular disorders, diabetes, leukemia/lymphoma, cancer, musculoskeletal disorders, muscular generation, reproductive health, metabolic and endocrine disorders, gastrointestinal disorders, immune and autoimmune disorders, respiratory disorders, bone disorders, and tissue/cell growth regulation disorders.

Additional utilities for NOV-3 nucleic acids and polypeptides according to the
10 invention are also disclosed herein.

NOV-3a

A NOV-3a sequence according to the invention is a nucleic acid sequence encoding a polypeptide related to STE20 family of protein kinases. A disclosed NOV-3a nucleic acid and
15 its encoded polypeptide includes the sequences shown in Table 10. The disclosed nucleic acid (SEQ ID NO: 6) is 3999 nucleotides in length and contains an open reading frame (ORF) that begins with an ATG initiation codon at nucleotides 1-3 and ends with a TGA stop codon at nucleotides 3996-3999. The start and stop codons are shown in bold font. The respective ORF encodes a 1332 amino acid polypeptide (SEQ ID NO: 7).

20

TABLE 10

```

ATGGGCGACCCAGCCCCGCCAGCCTGGACGACATCGACCTGTCCGCCCTGCGGGACCCCTGCTGGATCTTGAGCT
TGTGGAGGTGGTCGGCAATGGAACCTACGGACAGGTGTACAAGGGTGGCATGTCAAAGACGGGGAGCTGGCTGCCATCA
AGGTCATGGATGTCACGGAGGACGAGGAGAAGAGATCAAACAGGAGATCAACATGTCAAAAAGTACTCTCACCAACCGC
15 AACATCGCCACCTACTACGGAGCCTTCATCAAGAACAGCCCCCGGGAAACGATGACCAGCTGGCTGGTATGGAGTT
CTGTGGCTGGTCAGTGACTGACCTGGTAAAGAACACAAAAAGGCAACGCCCTGAAGGAGGACTGTATGCCCTATATCT
GCAGGGAGATCCTCAGGGTCTGGCCCATCTCCATGCCACAAGGTGATCCATCGAGACATCAAGGGCAGAACATGTGCTG
CTGACAGAACATGCTGAGGTCAAGCTAGTGGATTGGTGGAGTGTCTAGCTGGACCCGACGGTGGCAGACGGAACAC
20 TTTCATTGGACTCCCTACTGGATGGCTCCAGAGGTCATGCCCTGTGATGAGAACCTGTGATGCCACCTATGATTACAGGA
GTGATATTGGTCTCTAGGAATCACAGCCATCGAGATGGCAGAGGGAGCCCCCTCTGTGTGACATGCACCCATGCGA
GCCCTCTCCTCATCCTCGGAACCCCTCCGCCAGGCTCAAGTCCAAGAACGTTCAAGAACGTTCAATTGACTTCATTGA
CACATGTCTCATCAAGACTTACCTGAGCCGCCCACCCACGGAGCAGCTACTGAAGTTCCCTTCATCCGGGACCAGCCCA
CGGAGCGGCAGGTCCGCATCCAGCTTAAGGACCACATTGACCGATCCGGAAAGAAGCGGGTGAAGAACAGAGGAGACAGAA
TATGAGTACAGCGGCAGCGAGGAGGAAGATGACAGCCATGGAGAGGAAGGAGAGCCAAGCTCCATCATGAACGTGCCCTGG
30 AGAGTCGACTCTACGCCGGAGTTCTCCGGCTCCAGCAGGAAAATAAGAGCAACTCAGAGGTTAAACAGCAGCAGCAGC
AGCTGCAGCAGCAGCAGCGAGACCCGAGGGCACACATCAAAACACCTGCTGCACGCCAGCGCAGCGCGCATAGAGGAG
CAGAAGGAGGAGCGGCAGCGCTGGAGGAGCAACAGCGGGAGCGGGAGCAGCGGAAGCTGCAGGAGAAGGAGCAGCA
CGGGCGGCTGGAGGACATGCAGGCTCTGCCGGGGAGGAGGAGCGGCCAGGCCAGCGAGCGCAGGAATATATTGTC
ACAGGCTAGAGGAGGAGCAGCGACAGCTCGAGATCCTTCAGCAACAGCTGCTCCAGGAACAGGCCCTGCTGCTGGAATAC
35

```

AAGCGGAAGCAGCTGGAGGAGCAGCGGCAGTCAGAACGCTCCAGAGGCAGCTGCAGCAGGAGCATGCCACCTCAAGTC
 CCTGCAGCAGCAGCAACAGCAGCAGCAGCTCAGAAACAGCAGCAGCAGCTCCGTGGGACAGGAAGCCCCCTGT
 ACCATTATGGTCGGGCATGAATCCCCTGACAAACAGCAGCTGGGCCAGAGGTAAGAAGAGAGAACAGGATGAACAAG
 CAGCAGAACTCTCCCTTGGCCAAGAGCAAGCCAGGCAGCACGGGCTGAGCCCCCATCCCCCAGGCCCTCCCCAGGGC
 5 CCCAGGACCCCTTCCCAGACTCCTCTATGCAGAGGCCGGTGGAGCCCCAGGAGGGACCGCACAAGAGCCTGGCAC
 ACCGGGTCCCCTGAAGCCATATGCAGCACCTGTACCCGATCCCAGTCCCTGCAGGACCAGGCCACCCGAAACCTGGCT
 GCCTTCCCAGCCTCCATGACCCGACCCCTGCCATCCCCCAGCCACTGCCACGCCAGTGCCAGGAGCTGTATCCG
 CCAGAATTCAAGACCCACCTCTGAAGGACCTGGCCCAGCCGAATCCCCAGCCTGGTCCGCCAGATAACGAGGCC
 10 CACCCAAAGGTGCCCTCAGAGGACCTCATCTATGCCACTGCCCTAACACCAGTGGGCCGGAGGGTCCGCCAGCCAG
 GCAGTCCGTGCCAGTAACCCGACCTCAGGAGGAGCAGCACCTGGCTGGGAACGCTCGGACAGCGTCCTCCAGCCCTCA
 CGGGCACCTCCCCAGGCTGGCTCACTGGAGCGGAACCGCGTGGAGTCTCCTCAAACCGGACAGCTCCCTGTGCTCT
 CCCCTGGGAATAAAGCAAGCCGACGACCACCGTCACGCCAGGCCAGGCCAGCAGCTATAAGCGAGCAATTGGTGAG
 GACTTTGTGTTGCTGAAAAGAGCGGACTCTGGACGAGGCCCTCGGCCTCCCAAGAAGGCCATGGACTACTCGTCGTCAG
 15 CGAGGAGGTGAAAGCAGTGAGGACGACGAGGAGGAAGGCGAAGGCCAGCAGAGGGAGCAGAGATAACCCCTGGGG
 GCCGCAGCGATGGGGATACAGACAGCGTCAGCACCATGGTGGTCCACGACGTCAGGAGGATCACCGGACCCAGCCCCCA
 TACGGGGCGGCACCATGGTGGTCCAGCGCACCCCTGAAGAGGAGCGGAACCTGCTGCTGACAGCAATGGTACAC
 AAACCTGCCTGACGTGGTCCAGCCACTCACCCACCGAGAACAGCAAAGGCCAAAGGCCACCCCTCGAAGGATGGGA
 GTGGTGAACCTACCGACTCGTGGCTGGTAAAGGCCCTGGCAAGAGCTCGTTACGATGTTGTGGATCTAGGGATCTAC
 20 CAGCCTGGAGGCACTGGGACAGCATTACCCATCACAGCCCTAGTGGGTGGAGAGGCCACTCGGCTCGACCAGCTGCAGTA
 CGACGTGAGGAAGGTTCTGTGGTCAACGTGAATCCCACCAACACCCGGCCACAGTGAGACCCCTGAGATCCGGAAAGT
 ACAAGAAGCGATTCAACTCCGAGATCCTCTGTGCGACCCCTGGGGGTCAACCTGCTGGTGGGACGGAGAACGGGCTG
 ATGTTGCTGGACCGAAGTGGCAGGGCAAGGTGTATGGACTCATGGCGGGCAGCCTCCAGCAGATGGATGTGCTGGA
 GGGGCTCAACCTGCTCATCACCCTCAGGAAAAGGAACAAACTGCGGGTGTATTACCTGCTCTGGCTCCGGAAACAAGA
 TTCTGCACAATGACCCAGAAGTGGAGAAGAACAGGGCTGGACCACCGTGGGGACATGGAGGGCTGGGGCACTACCGT
 25 GTTGTGAAATACGAGCGGATTAAGTCCCTGGTCATGCCCTCAAGAGCTCCGTGGAGGTGTATGCCCTGGGCCCCAAACC
 CTACCACAAATTCACTGGCCTTCAGTCCCTTGCGACCTCCCCACGCCCTCTGCTGGTCGACCTGACAGTAGAGGAGG
 GGCAGCGGCTCAAGGTCTATGGCTCCAGTGGCTCCATGCTGTGGATGTCAGCTGGGAACAGCTATGACATC
 TACATCCCTGTGCACATCCAGAGCCAGATCACGCCCTGCCATCATCTCCCTCCCAACACCGACGGCATGGAGATGCT
 GCTGTGCTACGAGGACGAGGGTGTCTACGTCAACACGTACGGCGCATCTTAAGGATGTTGTGCTGAGTGGGGAGA
 30 TGCCTACTTCTGCGCTACATCTGCTCCAACAGATAATGGCTGGGTGAGAACGCCATTGAGATCCGCTCTGTGGAG
 ACGGGCCACCTCGACGGGTCTCATGCACAAACGAGCTCAGAGGCTCAAGTCCCTGTGAGCGGAATGACAAGGTGTT
 TTTTGCCTCAGTCCGCTCTGGGGCAGCAGCAAGTTACTCATGACTCTGAACCGTAACGCTCATGAACCT
 (SEQ ID NO: 6)

35 MGDPAPARSDDIDLSALRDPAGIFELVEVVGN TYGQVYKGRHVKTGQLAAIKVMDVTEDEEE EIKQEINMLKKYSHHR
 NIATYYGAFTIKKSPPGNDQLWLWMEFCGAGSVTDLVKNTKGNALKEDCIAYICREIIRGLAHLHAKVIHRDIKGQNVL
 LTENAEVKLVDGFVSAQLDRTVGRRNTFIGTPYMAPEVIACDENPDATYDYRSIDIWSLGITAIMEGAPPLCDMHPMR
 ALFLIPRNPPPRILSKKWSKKFIDFIDTCLIKTYLSRPPTEQLLKFPIRDQPTEROVRIQLKDHDIDRSRKKRGEKEETE
 YEYSGSEEEDDSHGEEGEPSSIMNVPGESTLRLREFRLQKENKSNSEALKQQQQLOQQQQRDPEAHIKHLLHQQRRIEE
 40 QKEERRVVEEQRREREQRKLOKEEQQRRLLEDMQALRREEERRQAEREQBYIRHRLEEEQRQLEILOQQQLQEQALLLEY
 KRKQLEEQRQSERLQRQLQOEHAYLKSLOQQQQQQQLQKQQQQQLLPGDRKPLYHYGRGMNPADKPAWAREVEERTRMNK
 QQNSPLAKSKPGSTGPEPPIPOASPGPPGPLSQTPPMQRPVPEQEGPHKSLVAHRVPLKPYAAPVPRSQS LQDQPTRNLA
 AFPASHDPDPAI PAPTATPSARGAVIRQNSDPTSEGPGPSNPPAWVRPDNEAPPKVQRTSSIATNLNTSGAGGSRPAQ
 AVRASNPDLRRSDPGWERSDSVLPASHGHLPOAGSLERNRVGVSSKPDS PVLS PGNKAKPDDHRSRPGRFASYKRAIGE
 45 DFVLLKERTLDEAPRPPKKAMDYSSSSEEVESSEDDEEEEGEGGPAEGSRDTPGGRSDGDTDSVSTMVHDVEEITGTQPP
 YGGGTMV VQRTPEEERNLLHADNSGYTNLPDVVQPSHSPTE NSKGQSPPSKDGSDYQSRGLVKA PGKSSFTMFVDLGIY

QPGGSGDSIPITALVGGEGRILDQLQYDVRKGSVNVNPTNTRAHSETPEIRKYKRFNSEILCAALWGVNLIVGTENGL
 MLLDRSGQGKVYGLIGRRRFQQMDVLEGTLNLLITISGKRNLRVYYLSLWNKILHNDPEVEKKQGWTTVGDMEGCGHYR
 VVKYERIKFLVIALKSSVEVYAWAPKPYHKFMFKSFDLPHRPLLVDLTVEEGQRLKVIYGSSAGFRAVDVDSGNSYDI
 YIPVHIQSQTTPHAIIFLPNTDGMEMLLCYEDEGVYVNTYGRIIKDVLQWGEMPTSVAYICSNQIMGWGEKATEIRSVE
 5 TGHLGVFMHKRAQRLKFLCERNDKVFASVRSGSSQVYFMTLNRCIMNW (SEQ ID NO: 7)

The disclosed NOV-3a nucleic acid sequence has homology (73% identity) to a mouse mRNA for a NIK protein (NIK) (GenBank Accession No: MMU88984), as shown in Table 11. NIK proteins are a subgroup of the STE20 family of protein kinases. As indicated by the 10 “Expect” value, the probability of this alignment occurring by chance alone is 4.3e-298, which is an incredibly low probability score. Moreover, the disclosed, encoded amino acid sequence has 1095 of 1332 amino acid residues (82%) identical to a human NIK-related protein (GenBank Accession No: BAA90753), as shown in Table 12. As indicated by the “Expect” 15 value, the probability of this alignment occurring by chance alone is 0, the lowest probability score.

TABLE 11

Score = 3892 (584.0 bits), Expect = 4.3e-298, Sum P(2) = 4.3e-298
 Identities = 1224/1657 (73%), Positives = 1224/1657 (73%), Strand = Plus /
 20 Plus

NOV3a:	4	GGCGACCCAGCC-CCCGCCCCGCAGCCTGGACGACATCGACCTGTCCGCCCTGCAGGGACCC	62
		GGCGA C A C CCCGC AGCTGG GACAT GACCTGTC CCCTGCAGGGACCC	
NIK :	3	GGCGAACGACTCTCCCAGGAAGAGCCTGGTGGACATTGACCTGTGTCGCCCTGCAGGGACCC	62
NOV3a:	63	TGCTGGGATCTTGAGCTTGTGGAGGTGGTGGCAATGGAACCTACGGACAGGTGTACAA	
122		TGCTGGGAT TTTGAGCT GTGGA GTGGT GG AATGG ACCTA GGACA GT TA AA	
NIK :	63	TGCTGGGATTTTGAGCTGGTGGAAAGTGGTGGAAATGGCACCTATGGACAAGTCTATAA	
NOV3a:	123	GGGTCGGCATGTCAAGACGGGGCAGCTGGCTGCCATCAAGGTATGGATGTCACGGAGGA	
182		GGGTCG CATGT AA ACGG CA CTG C GCCATCAAGGT ATGGA GTCAC GAGGA	
NIK :	123	GGGTCGACATGTTAAAACGGT-CA-CTGCC-GCCATCAAGGTATGGACGTACCGAGGA	
179			
NOV3a:	183	CGAGGAGGAAGAGATCAAACAGGAGATCAACATGCTGAAAAAGTACTCTCACCACCGCAA	
242		GA GAGGAAGA ATCA AC GGAGAT AA ATGCTGAA AAGTA TCTCA CA CG AA	
NIK :	180	TGAAGAGGAAGAAATCACACTGGAGATAATATGCTGAAGAAGTATTCTCATCATCGAAA	
239			
NOV3a:	243	CATGCCACCTACTACGGAGCCTTCATCAAGAAGAGCCCCCGGGAAACGATGACCAGCT	
302		AT GCCAC TACTA GG GC TTCAT AAGAAGAGCCC CC GGA A GATGACCA CT	
NIK :	240	TATTGCCACGTACTATGGCTTCAAGAAGAGCCCTCCAGGACATGATGACCAACT	
299			

NOV3a: 303 CTGGCTGGTATGGAGTTCTGTGGTCTGGTTCACTGACTGACCTGGTAAAGAACACAAA
362 CTGGCT GT ATGGAGTT TGTGG GCTGG TC T AC GACCT GT AAGAACAC AA

5 NIK : 300 CTGGCTTGTATGGAGTTTGTGGGGCTGGGTCCATCACAGACCTGTGAAGAACACCAA
359

NOV3a: 363 AGGCAACGCCCTGAAGGAGGACTGTATGCCATATCTGCAGGGAGATCCTCAGGGTCT
422 AGG AAC C CT AA GA GACTG AT GC TA ATCT CAGGGA ATCCTCAGGGG T

10 NIK : 360 AGGGAACACTCTCAAAGAAGACTGGATTGCTTACATCTCCAGGGAAATCCTCAGGGGATT
419

NOV3a: 423 GGCCCACATCTCCATGCCACAAAGGTGATCCATCGAGACATCAAGGGCAGAATGTGCTGCT
482 GGC CATCTCCAT CAC A GT AT CA CGAGA ATCAAGGG CA AATGTGCTGCT

15 NIK : 420 GGACATCTCCATATTCAACCACGTTATTCAACCGAGATATCAAGGGC AAAATGTGCTGCT
479

NOV3a: 483 GACAGAGAATGCTGAGGTCAAGCTAGTGGATTTGGGGTGAGTGCTCAGCTGGACCGCAC
542 GAC GAGAATGCTGAGGT AA CT GT GATTTGG GT AG GCTCAGCTGGAC G AC

20 NIK : 480 GACCGAGAATGCTGAGGTGAAACTTGTGATTTGGGTGTAAGCGCTCAGCTGGACAGGAC
539

25 NOV3a: 543 CGTGGG-CAGACGGAACACTTCATTGGACTCCCTACTGGATGGCTCCAGAGGTCACTG
601 GT GG C GA G AA AC TTCAT GG AC CCCTACTGGATGGCTCCAGAGGTCACTG

NIK : 540 GTGGACGGA-GAAATACGTTCATAGGCACACCCACTGGATGGCTCCAGAGGTCACTG
598

30 NOV3a: 602 CCTGTGATGAGAACCCCTGATGCCACCTATGATTACAGGAGTGAATTGGTCTCTA-GGA
660 CCTGTGATGAGAACCC GA GCCAC TA GA TACAG AGTGA T TGGTC CT GG

35 NIK : 599 CCTGTGATGAGAACCCAGACGCCACTACGACTACAGAAGTGACCTCTGGTC-CTGTGGC
657

NOV3a: 661 ATCACAGCCATCGAGATGGCAGAGGGAGCCCCCCTCTGTGACATGCACCCATGCGA
720 ATCACAGCCATCGAGATGGCAGAGGGAGCCCCCCTCTGTGACATGCATCCAATGAGA

40 NIK : 658 ATCACAGCCATCGAGATGGCTGAAGGGGGCCCCCTCTGTGACATGCATCCAATGAGA
717

45 NOV3a: 721 GCCCTCTCCCTCATTCCCTCGAACCCCTCCGCCAGGCTCAAGTCCAAGAAGTGGTCTAAG
780 GC CT TT CTCAT CC G AACCCCTCC CCCAGGCT AAGTC AA AA TGGTC AAG
NIK : 718 GCGCTGTTCTCATCCCCAGAAACCCCTCCAGGCTGAAGTCAAAAAAATGGTCAAAG
777

50 NOV3a: 781 AAGTTCATTGA-CTTCATTGACACATGTCTCATCAAGACTTACCTG-AGCCGCCACCCA
838 AA TT TT A CTT AT GA TGTCT T AAGA TTAC TG AGC GCCC C A
NIK : 778 AAATTT-TTCAGCTTATAGAAGGCTGTCTGGTGAAGAATTACATGCAGCGGCCCTCT-A
835

55 NOV3a: 839 CGGAGCAGCTACTGAAGTTCCCTCATCCGGACCAGCCCCACGGAGCGGCAGGTCCGCA
898 C GAGCA CT T AA CC TTCAT GGGG CAGCCCC GA GGCAGGT CG A

60 NIK : 836 CAGAGCAACTTTAAAACACCCCTTCATAAGGGATCAGCCCCATGAAAGGCAGGTTCGAA
895

NOV3a: 899 TCCAGCTTAAGGACCACATTGACCGATCCCGAAGAAGCGGGGTGAGAAAGAGGAGACAG
958

NIK : 896 TCCAGCTTAAGGA CACAT GACCG CC G AAGAAG G GG GAGAAAGA GAGAC G
955 956 TCCAGCTTAAGGATCACATAGACGGACCAGAAAGAACAGAGGGCAGAAAGATGAGACGG

5 NOV3a: 959 AATATGAGTACAGCGGCAGCGAGGAGGAAGATGAC-A-GC-CATGGAG-AGGAAGGAGAG
1014
NIK : 956 AGTACGAGTACAGCGGGAGCGAGGAGGAGGAGGAAGTGCCTG-AGCAGGAGGGAGAG
1014

10 NOV3a: 1015 CCAAGCTCCATCATGAACGTGCCCTGGAGAGTCAGACTCTACGCCGGAGTTCTCCGGCTC
1074
NIK : 1015 CCAAGTTCCATCGTCAATGTGCCCTGGAGAGTCAGACTCTGCACGTGATTCTGAGACTG
1074

15 NOV3a: 1075 CAGCAGGAAAATAAG-AGCAACTCAGAGGCTTAAACAG-CAGCAGCAGCTGCAGCAGC
1132
NIK : 1075 CAGCAGGAGAACAGGAGCGG-TCTGAGGCTCTGCGG-AGACAGCAGCTCTGCAGGAGC
1132

20 NOV3a: 1133 AGCAGCAGCGAGACCCCAGGCACACATCAAACACCTGCTGCACCAGCGGCAGCGCGCA
1192
NIK : 1133 AGCAGCTCCGGAGCAGGAGGTATAAGAGGCAGCTGCTGGCTGAGAGGCAGAACAGCGGA
1192

25 NOV3a: 1193 TAGAGGAGCAGAAGGAGGAGCGGCGCCGCGTGGAGGAGCAACAGCGGCGGAGCGGGA-G
1251
NIK : 1193 TTGAACAGCAGAAAGAACAGAGGAGGCGCTGGAAGAGCAACAAAGAAGAGAACGGGAAG
1252

30 NOV3a: 1252 CAGCGGAAGCTGCAGGAGAAGGAGCAGCAGCGGC-G--CTGGAGGACATGCAGGC-TCT
1307
NIK : 1253 CCA-GGAGGCAGCAGGAGCGTGGAGCAGCGGCGTGAACAACAGGAGAAG-AGGCGTCT
1310

35 NOV3a: 1308 GCGGCGGGGA-GGAGGAGCGGCGGCAGGCGGAGCGCGAGCAGGAATATATTGTCACAGG
1365
NIK : 1311 -CGA-GGAAGCTGGAAAGGCGCGTAAAGAAGAGGAAGAG-AGGAG-ACGGGCAGAACAGG
1366

40 NOV3a: 1366 CTA-GAGGAG-GAGCAGCGACAGCTCGAGATCCTCAGCAACAGCTGCTCCAGGAACAGG
1423
NIK : 1367 AGAAGAGGAGAGTGGAGAGGGAACAGGAG-TACATCAGG--CGGCAGCTAGAGGAGGAGC
1423

45 NOV3a: 1424 CCCTGCTGCTGGA-ATACA--AGCGGAAGCAGCTGGAGGAGCAGCGGCA-GTCAGAACGT
1479
NIK : 1424 AGCGGCACCTGGAGATCCTGCAGCAGCAGCTGCTCCAGGAGCAG-GCCATGTTACTGCAC
1482

50 NOV3a: 1480 CTCCAGAGGCAGCTGCA-GCAGGAGCATGCCTACCTCAAGTCCCTGCAGCAGCAGCAACA
1538
CCA AGG GC GCA GCA AGCA GC CC C G CCC GCAGCAGCAG A CA

NIK : 1483 GACCACAGGAGGCCGCACGCAC-AGCA-GCAG-CCGCC-GCCCCCGCAGCAGCAGGA-CA
1537

5 NOV3a: 1539 GCAGCAG--C-AGCTT-CA-GAACACAGCAGCAGCAGCTCC-TG-CC-TGGGGACAGG
1590

G AGCA C AGCTT CA G CAG AGC AGC C C TG CC TG GACAG
NIK : 1538 GGAGCAAACCGAGCTTCATGCTCCAG-AGCCCAAGCCTCACTATGACCCCTGCTGACAG-
1595

10 NOV3a: 1591 AAGCCCCGTACCATTATGGTCGGGCATGAATCCCGCT-GA-CAAAC-CAGCCTGGGCC
1647

AGC C G A TGGTC C G ATC C C GA CAA C CC G C
NIK : 1596 -AGCTCGGGAGGTACAGTGGTCCCACCTGGCATCTCTCAAGAACAAATGTCTCCCTGTCT
1654

15 NOV3a: 1648 CGAGA 1652 (SEQ ID NO: 62)
CGAGA
NIK : 1655 CGAGA 1659 (SEQ ID NO: 29)

20

TABLE 12

25 Score = 2104 bits (5451), Expect = 0.0
Identities = 1095/1332 (82%), Positives = 1095/1332 (82%), Gaps = 37/1332
(2%)

30 NOV3a: 1 MGDPAPARSLEDDIDLSALRDPAGIFELVEVVGNNGTYGQVYKGRHVKTGQLAAIKVMDVTX 60
MGDPAPARSLEDDIDLSALRDPAGIFELVEVVGNNGTYGQVYKGRHVKTGQLAAIKVMDVT

NIK : 1 MGDPAPARSLEDDIDLSALRDPAGIFELVEVVGNNGTYGQVYKGRHVKTGQLAAIKVMDVTE 60

NOV3a: 61 XXXXXIKQEINMLKKYSHHRNIATYYGAFIKKSPPGNDDQLWLVMFECGAGSVTDLVKNT 120
IKQEINMLKKYSHHRNIATYYGAFIKKSPPGNDDQLWLVMFECGAGSVTDLVKNT
35 NIK : 61 DEEEEIKQEINMLKKYSHHRNIATYYGAFIKKSPPGNDDQLWLVMFECGAGSVTDLVKNT 120

NOV3a: 121 KGNALKEDCIAYICREILGLAHLHAKVIHRDIKGQNVLLENNAEVKLVDGFVSAQLDR 180
KGNALKEDCIAYICREILGLAHLHAKVIHRDIKGQNVLLENNAEVKLVDGFVSAQLDR
40 NIK : 121 KGNALKEDCIAYICREILGLAHLHAKVIHRDIKGQNVLLENNAEVKLVDGFVSAQLDR 180

NOV3a: 181 TVGRRNTFIGTPYWMAPEVIACDENPDATYDYRSIDIWSLGITAIEMAEGAPPLCDMHPMR 240
TVGRRNTFIGTPYWMAPEVIACDENPDATYDYRSIDIWSLGITAIEMAEGAPPLCDMHPMR
NIK : 181 TVGRRNTFIGTPYWMAPEVIACDENPDATYDYRSIDIWSLGITAIEMAEGAPPLCDMHPMR 240

45 NOV3a: 241 ALFLIPRNPPPRLKSKKWSKKFIDFIDTCLIKTYLSRPPTEQLLKFPFIRDQPTERQVRI 300
ALFLIPRNPPPRLKSKKWSKKFIDFIDTCLIKTYLSRPPTEQLLKFPFIRDQPTERQVRI
NIK : 241 ALFLIPRNPPPRLKSKKWSKKFIDFIDTCLIKTYLSRPPTEQLLKFPFIRDQPTERQVRI 300

50 NOV3a: 301 QLKDHIXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXPSIMNPVGESTLRREFLRLQQ 360
QLKDHI PSSIMNPVGESTLRREFLRLQQ
NIK : 301 QLKDHIDRSRKKRGEKEETEYEYSGSEEEDDSHGEEGEPSSIMNPVGESTLRREFLRLQQ 360

NOV3a: 361 ENKSNSEALKXXXXXXXXXXRDPEAHIKHLLHXXXXXXXXXXXXXXXXXXXX 420
ENKSNSEALK RDPEAHIKHLLH
55 NIK : 361 ENKSNSEALKQOCOOLQOOOQRDPEAHIKHLLHQQRORRIEEQKEERRVEEQRREREORK 420

NOV3a: 421 XXXXXXXXXXXXDMQALXXXXXXXXXXXXYIRHXXXXXXXXXXXXXXXY 480
DMQAL Y
NIK : 421 LQEKEQQRLEDMQAL-----RREEERRQAEREQEY 451

60 NOV3a: 481 KRXXXXXXXXXXXXXXXXXHAYLKSXXXXXXXXXXXXPGDRKPLYHYGRGM 540
KRK HAYLKS PGDRKPLYHYGRGM

NIK : 452 KRKQLEEQRQSERLQRQLQQEHAYLKSLOQQQQQQQLQKQQQQQLPGDRKPLYHYGRGM 511

NOV3a: 541 NPADKPAWAREVEERTRMNKQQNSPLAKSKPGSTXXXXXXXXXXXXXXXXXXXXXMQRP 600
NPADKPAWAREVEERTRMNKQQNSPLAKSKPGST MQRP

5 NIK : 512 NPADKPAWAREVEERTRMNKQQNSPLAKSKPGSTGPEPPIPQASPGPPGPLSQTPPMQRP 571

NOV3a: 601 VEPQEGRPHKSLVAHRVPLKPYAAPVPRSOSLQDQPTRNLAAPFASHXXXXXXXXXXXX 660
VEPQEGRPHKSLVAHRVPLKPYAAPVPRSOSLQDQPTRNLAAPFASH

10 NIK : 572 VEPQEGRPHKSLVAHRVPLKPYAAPVPRSOSLQDQPTRNLAAPFASHDPDAIPAPTATPS 631

NOV3a: 661 XRGAVIRQNSDPTSEGPGPSNPAPPWVLDNEAPPKVPQRTSSIATALNTSGAGGSRPAQ 720
RGAVIRQNSDPTSEGPGPSNPAPPWVLDNEAPPKVPQRTSSIATALNTSGAGGSRPAQ

NIK : 632 ARGAVIRQNSDPTSEGPGPSNPAPPWVLDNEAPPKVPQRTSSIATALNTSGAGGSRPAQ 691

15 NOV3a: 721 AVRASNPDLRRSDPGWERSDSVLPASHGHLPQAGSLERNRVGVSSKPDSPVLSPGNKAK 780
AVRASNPDLRRSDPGWERSDSVLPASHGHLPQAGSLERNRVGVSSKPDSPVLSPGNKAK

NIK : 692 AVRASNPDLRRSDPGWERSDSVLPASHGHLPQAGSLERNRVGVSSKPDSPVLSPGNKAK 751

20 NOV3a: 781 PDDHRSRPGRPASYKRAIGEDFVLLKERTLDEAPRPPKKAMDYXXXXXXXXXXXXXX 840
PDDHRSRPGRP-----DFVLLKERTLDEAPRPPKKAMDY

NIK : 752 PDDHRSRPGRP-----DFVLLKERTLDEAPRPPKKAMDYSSSEEVESSEDDEEEG 803

NOV3a: 841 XXXXXXXXRDTPGGRSDGTDTSVSTMVHDVEEITGTQPPYGGTMVVQRTPEEERNLLH 900
RDTPGGRSDGTDTSVSTMVHDVEEITGTQPPYGGTMVVQRTPEEERNLLH

25 NIK : 804 EGGPAEGSRDTPGGRSDGTDTSVSTMVHDVEEITGTQPPYGGTMVVQRTPEEERNLLH 863

NOV3a: 901 ADSNGYTNLPDVVQPSHSPTEENSKGQSPSKDGSGDYQSRLVKA PGKSSFTMFVDLGIY 960
ADSNGYTNLPDVVQPSHSPTEENSKGQSPSKDGSGDYQSRLVKA PGKSSFTMFVDLGIY

30 NIK : 864 ADSNGYTNLPDVVQPSHSPTEENSKGQSPSKDGSGDYQSRLVKA PGKSSFTMFVDLGIY 923

NOV3a: 961 QPGGSGDSIPIITALVGGEGRDLQDQYDVRKGSVNVNPTNTRAHSETPEIRKYKKRFNS
1020 QPGGSGDSIPIITALVGGEGRDLQDQYDVRKGSVNVNPTNTRAHSETPEIRKYKKRFNS

NIK : 924 QPGGSGDSIPIITALVGGEGRDLQDQYDVRKGSVNVNPTNTRAHSETPEIRKYKKRFNS 983

35 NOV3a: 1021 EILCAALWGVNLLVGTENGLMLDRSGQGKVYGLIGRRRFQQMDVLEGILNLITISGKRN
1080 EILCAALWGVNLLVGTENGLMLDRSGQGKVYGLIGRRRFQQMDVLEGILNLITISGKRN

NIK : 984 EILCAALWGVNLLVGTENGLMLDRSGQGKVYGLIGRRRFQQMDVLEGILNLITISGKRN
40 1043 A

NOV3a: 1081 KLRVYYLSWLRNKILHNDPEVEKKQGWTTVGDMECGHRYRVVKYERIKFLVIALKSSVEV
1140 KLRVYYLSWLRNKILHNDPEVEKKQGWTTVGDMECGHRYRVVKYERIKFLVIALKSSVEV

45 NIK : 1044 KLRVYYLSWLRNKILHNDPEVEKKQGWTTVGDMECGHRYRVVKYERIKFLVIALKSSVEV
1103

NOV3a: 1141 YAWAPKPYHKEMAFKSFADLPHRPLLVDLTVEEGQRLKVIYGSSAGFHAVDVDSGN SYDI
1200 YAWAPKPYHKEMAFKSFADLPHRPLLVDLTVEEGQRLKVIYGSSAGFHAVDVDSGN SYDI

NIK : 1104 YAWAPKPYHKEMAFKSFADLPHRPLLVDLTVEEGQRLKVIYGSSAGFHAVDVDSGN SYDI
1163

50 NOV3a: 1201 YIPVHIQSQITPHAIIFLPNTDGMEMLLCYEDEGVVNTYGRIIKDVVLQWGEMPTSVAY
1260 YIPVHIQSQITPHAIIFLPNTDGMEMLLCYEDEGVVNTYGRIIKDVVLQWGEMPTSVAY

NIK : 1164 YIPVHIQSQITPHAIIFLPNTDGMEMLLCYEDEGVVNTYGRIIKDVVLQWGEMPTSVAY
1223

55 NOV3a: 1261 ICSNQIMGWGEKAIEIRSvetGHLDGVFMHKRAQRKFLCERNDKVFFASVRSGGSSQVY
1320 ICSNQIMGWGEKAIEIRSvetGHLDGVFMHKRAQRKFLCERNDKVFFASVRSGGSSQVY

NIK : 1224 ICSNQIMGWGEKAIEIRSVEGHLDGVFMHKRAQRALKFLCERNDKVFFASVRSGGSSQVY
1283

5 NOV3a: 1321 FMTLNRNCIMNW 1332 (SEQ ID NO: 63)
FMTLNRNCIMNW
NIK : 1284 FMTLNRNCIMNW 1295 (SEQ ID NO: 30)

Based on its relatedness to known members of the STE20 family of protein kinases, NOV3a provides new diagnostic and therapeutic compositions useful in the treatment of 10 disorders associated with alterations in the expression of members of the STE20 family of protein kinases. Nucleic acids, polypeptides, antibodies, and other compositions of the present invention are useful in the treatment and diagnosis of a variety of diseases and pathologies, including, by way of nonlimiting example, those involving metabolic and endocrine disorders, cancer, bone disorders, and tissue/cell growth regulation disorders.

15

NOV-3b

A NOV-3b sequence according to the invention is a nucleic acid sequence encoding a polypeptide related to STE20 family of protein kinases. A disclosed NOV-3b nucleic acid and its encoded polypeptide includes the sequences shown in Table 13. The disclosed nucleic acid 20 (SEQ ID NO: 8) is 3912 nucleotides in length and contains an open reading frame (ORF) that begins with an ATG initiation codon at nucleotides 1-3 and ends with a TGA stop codon at nucleotides 3910-3912. The start and stop codons are shown in bold font. The respective ORF encodes a 1303 amino acid polypeptide (SEQ ID NO: 9).

25

TABLE 13

ATGGCGACCCAGCCCCGCCAGCCTGGACGACATCGACCTGTCCGCCCTGCAGGACCCCTGCTGGATCTTGAGCT
TGTGGAGGTGGTCCGCAATGGAACCTACGGACAGGTGTACAAGGGTCGGCATGTCAAGACGGGGCAGCTGGCTGCCATCA
AGGTCATGGATGTACGGAGGACGAGGAGGAAGAGATCAAACAGGAGATCAACATGCTGAAAAAGTACTCTCACCAACCGC
AACATGCCACCTACTACGGAGCCTTCATCAAGAAGAGCCCCGGAAACGATGACCAGCTGGCTGGTATGGAGTT
20 CTGTGGTGTGGTTCACTGACTGACCTGGTAAAGAACACAAAAGGCAACGCCCTGAAGGAGGACTGTATGCCCTATATCT
GCAGGGAGATCCTCAGGGCTGGCCCCTGATCTCCATGCCACAAGGTGATCCATGAGACATCAAGGGCAGAATGTGCTG
CTGACAGAGAATGCTGAGGTCAAGCTAGTGGATTTGGGGTGAGTGCTCAGCTGGACCGCACCCTGGCAGACGGAACAC
TTTCATTGGACTCCCTACTGGATGGCTCCAGGGTCACTCGCTGTGATGAGAACCTGTATGCCACCTATGATTACAGGA
GTGATATTGGTCTCTAGGAATCACAGCCATCGAGATGGCAGAGGGAGCCCCCTCTGTGTGACATGCACCCATGCGA
35 GCCCTTCCCTCATTCCTCGGAACCTCCGCCAGGCTCAAGTCCAAGAAGTGGCTAAGAAGTTCATTGACTTCATTGA
CACATGTCTCATCAAGACTTACCTGAGCCGCCACCCACGGAGCAGCTACTGAAGTTCCCTCATCCGGACAGCCCA
CGGAGCGGCAGGTCCGCATCCAGCTTAAGGACCAATTGACCGATCCCGAAGAACGGGGTGAGAAAGAGGAGACAGAA
TATGAGTACAGCGGCAGCGAGGAGGAAGATGACGCCATGGAGAGGAAGGGAGGCCAAGCTCCATCATGAACGTGCCTGG
40 AGAGTCGACTCTACGCCGGAGTTCTCCGGCTCCAGCAGGAAAATAAGAGCAACTCAGAGGCTTAAACAGCAGCAGCAGC
AGCTGCAGCAGCAGCAGCAGCAGCAGCACACATCAAACACCTGCTGCACCGGGCAGCGGCATAGAGGAG
CAGAAGGAGGAGCGGCCGCGTGGAGGAGCAACAGCGGGGGAGCGGGAGCAGCGGAAGCTGCAGGAGAAGGAGCAGCA

GC GG CG GC GT GG AGG A C AT G C A G G C T C T G C G G C G G G A G G A G G C G G C G G C G A G C A G G A A T A T A T C G C T
A C A G G C T A G A G G A G C A G C G G C A G T C A G A A C G T C T C C A G A G G C A G C T G C A G C A G G A C A G C T A C C T C A G
C A G C A G C A A C G C A G C A G C A G C A G T C A G A A C A G C A G C A G C A G C A G C T C T G C T G G G A C A G G A A G C C C C T G T A C C A T T A
T G G T C G G G C A T G A A T C C C G C T G A C A A A C C A G C C T G G G C C C G A G A G G T A G A A G A G A G A A C A A G G A T G A A C A A G C A G C A G A
5 A C T C T C C C T T G G C C A A G A G C A A G C C A G G C A G C A C G G G C C T G A G C C C C C A T C C C C C A G G C T C C C C A G G G C C C C A G G A
C C C C T T T C C C A G A C T C C T C T A T G C A G A G G C C G T G G A G C C C C A G G A G G G A C C G C A C A A G A G C C T G G T G G C A C A C C G G G T
C C C A C T G A A G C C A T A T G C A G C A C C T G T A C C C G A T C C C A G T C C C T G C A G G A C C A G C C C A C C G A A A C C T G G C T G C C T T C C
C A G C C T C C C A T G A C C C C G A C C C T G C C A T C C C C G A C C C A C T G C C A C G C C C A G T G C C C G A G G A G C T G T C A T C C G C C A G A A T
T C A G A C C C C A C C T G T G A A G G A C T G G G C C C A G G C C G A A T C C C C A G C C T G G G C C C A G A T A A C G A G G C C C C A C C C A
10 G G T G C C T C A G A G G A C C T C A T C T A T G C C A C T G C C T T A A C A C C A G T G G G G C G G A G G G T C C C G G C A G C C C A G G C A G T C C
G T G C C A G T A A C C C C G A C C T C A G G A G G A G C G A C C C T G G G C T G G G A C G C T C G G A C A G C G T C C T T C C A G G C T C T C A C G G G C A C
C T C C C C C A G G C T G G G C T C A C T G G G C G G A A C C G C G T G G G A G T C T C T C C A A A C C G G A C A G C T C C C C T G T G C T C T C C C T G G
G A A T A A A G C C A A G C C C G A C G A C C C G C T C A C G G C C A G G C C G C C G C A A G C T A T A A G C G A G C A A T T G G T G A G G A C T T T G
T G T G C T G A A A G A G C G G A C T C T G G A C G A G G C C C T C G G C C T C C C A A G A A G G C C A T G G A C T A C T C G T C G T C C A G G C A G G A G
15 G T G G A A A G C A G T G A G G A C G A C G A G G A G G A G G C G A A G G C G G C C A G C A G A G G G G A G C A G A G A T A C C C C T G G G G G C C G A G
C G A T G G G G A T A C A G A C A G C G T C A G C A C C A T G G T G G T C C A C G A C G T C G A G G A G A T C A C C G G A C C C A G C C C C C A T A C G G G G
G C G G C A C C A T G G T G G T C C A G G C G C A C C C T G A A G A G G A G G G C G G A A C C T G C T G C A T G C T G A C A G C A A T G G G T A C A C A A C C T G
C C T G A C C T G G T C C A G C C C A G C C A C T C A C C C A C C G A G A A C A G C A A A G G C C A A A G G C C A C C C T C G A A G G A T G G G A T G G T G A
C T A C C A G T C T C G T G G G C T G G T A A A G G C C C T G G C A A G G A G G C T C A G G C T G G G A G A G G G C A C T C G G C T C G A C C A G C T G C A G T A C C A G C T G
20 G A G G C A G T G G G G A C A G C A T C C C C A T C A C G C C T T A G T G G G T G G A G A G G G C A C T C G G C T C G A C C A G C T G C A G T A C C A G C T G
A G G A A G G G T T C T G T G G T C A A C G T G A A T C C C A C C A A C C C C G G C C C A C A G T G A G A C C C T G A G A T C C G G A A G T A C A A G A A
G C G A T T C A A C T C C G A G A T C C T C T G T G C A G C C C T T T G G G G G T C A A C C T G C T G G T G G G C A C G G A A C A G G G C T G A T G T G C
T G G A C C G A A G T G G G C A G G G C A A G G G T G T A T G G A C T C A T T G G G C G G C G A C G C T T C C A G C A G A T G G G A T G T G C T G G A G G G G C T C
A A C T G C T C A T C A C C A T C T C A G G G A A A G G A A C A A A C T G C G G G T G T A T T A C C T G T C T G G C T C C G G A A C A A G A T T C T G C A
25 C A A T G A C C C A G A A G T G G G A G A A G A A G C A G G G C T G G A C C C C G C C T G G G G A C A T G G A G G G C T G C G G G C A C T A C C G T G T G T G A
A A T A C G A G C G G A T T A A G T T C T G G T C A T C G C C C T C A A G G C T C C G T G G A G G G T G T A T G C C T G G G G C C C C A A A C C C T A C C A C
A A A T C A T G G C C T T C A A G T C T T T G C C G A C C T C C C C C A C C G C C C T C T G C T G G T C G A C C T G A C A G T A G A G G A G G G G C A G C G
G C T C A A G G T C A T C T A T G G C T C C A G T G C T G G T C T C C A T G C T G T G G A T G T C G A C T C G G G G A A C A G G C T A T G A C A T C T C A C A T C C
C T G T G C A C A T C C A G A G G C C A G A T C A C G C C C C A T G C C A T C A T C T C C T C C C A A C C C G A C G G C A T G G A G A T G T G C T G C T G T G C
30 T A C G A G G A C G A G G G T G T C A C G T C A A C A C G T A C G G G C C A T C A T T A A G G A T G T G G T G C G A G T G G G G G A C A T G C C T A C
T T C T G T G G C C T A C A T C T G C T C C A A C C A G A T A A T G G G C T G G G G T G A G A A G G C C A T T G A G A T C C G C T C T G T G G A G A C G G G C C
A C C T C G A C G G G G T C T T C A T G C A C A A A C G A G G C T C A G A G G C T C A A G T T C T G T G A G C G G A A T G A C A A G G T G T T T T G C C
T C A G T C C G C T C T G G G G C A G C A G C C A G T T A C T G A C T C T G A C A C G T A C G G G C C A T C A T G A C A C T G A C T C T G A C A C T G A C T
35 N O: 8) (SEQ ID NO: 8)
M G D P A P A R S L D D I D L S A L R D P A G I F E L V E V V G N G T Y G Q V Y K G R H V K T G Q L A A I K V M D V T E D E E E E I K Q E I N M L K K Y S H R
N I A T Y Y G A F I K K S P P G N D D Q I L W L V M E F C G A G S V T D L V K N T K G N A L K E D C I A Y I C R E I I R G L A L H H A K V I H R D I K G Q N V L
L T E N A E V K L V D F G V S A Q L D R T V G R R N T F I G T P Y W M A P E V I A C D E N P D A T Y D Y R S D I W S L G I T A I E M A E G A P P L C D M H P M R
A L F L I P R N P P P R L K S K K W S K K F I D F I D T C L I K T Y L S R P P T E Q L L K F P F I R D Q P T E R Q V R I Q L K D H I D R S R K K R G E K E E T E
Y E Y S G S E E E D D S H G E E G E P S S I M N V P G E S T L R E F L R L Q Q E N K S N S E A L K Q Q Q Q Q L Q Q Q Q Q R D P E A H I K H L L H Q R Q R R I E E
Q K E E R R V E E Q Q R R E E Q R K L Q E K E Q Q R R L E D M Q A L R R E E R R Q A E R E Q E Y I R R L E E Q R Q S E R L Q R Q I Q E H A Y L K S L Q
Q Q Q Q Q Q Q Q L Q Q Q Q Q Q L L P G D R K P L Y H Y G R G M N P A D K P A W A R E V E E R T R M N K Q Q N S P L A K S K P G S T G P E P P I P Q A S P G P P G
P L S Q T P P M Q R P V E P Q E G P H K S L V A H R V P L K P Y A P V P R S Q S L Q D Q P T R N I L A A F P A S H D P D P A I P A P T A T P S A R G A V I R Q N
S D P T S E G P G P S P N P P A V R P D N E A P P K V P Q R T S S I A T A L N T S G A G G S R P A Q A V R A S N P D L R R S D P G W E R S D S V L P A S H G H
40 L P Q A G S L E R N R V G V S S K P D S P V L S P G N K A K P D D H R S R P G R P A S Y K R A I G E D F V L L K E R T L D E A P R P P K K A M D Y S S S E E
V E S S E D D E E E G E G G P A E G S R D T P G G R S D G D T D S V T M V V H D V E E I T G T O P P Y G G G T M V V O R T P E F F E R N I L H A D S N G Y T N I

PDVVQPSHSPTENSKGQSPPSKDGSGDYQSRLVKAPGKSSFTMFVDLGIYQPGGSGDSIPITALVGGEGLDQLQYDV
 RKGSVVNVNPTNTRAHSETPEIRKYKKRFNSEILCAALWGVNLLVGTENGLMLDRSGQGKVYGLIGRRRFQMDVLEGL
 NLLITISGKRNKLRVYYLSWLRNKLHNDPEVEKKQGWTTVGDMEGCCGHYRVVKYERIKFLVIALKSSVEVYAWAPKPYH
 KFMFKSFADLPHRPLLVDLTVEEGQRLKVIYGSSAGFHAVDVDSGNSYDIYIPVHIQSQITPHAIIFLPNTDMEMIILC
 5 YEDEGVYVNTYGRRIKDVLQWGEMLTSVAYICSNQIMGWEKAIEIRSVETGHLDGVFMHKRAQRALKFLCERNDKVFFA
 SVRSGGSSQVYFMTLNRCIMNW (SEQ ID NO: 9)

The disclosed NOV-3b nucleic acid sequence has homology (75% identity) to a mouse mRNA for a NIK protein (NIK) (GenBank Accession No: MMU88984), as shown in Table 10 14. NIK proteins are a subgroup of the STE20 family of protein kinases. As indicated by the “Expect” value, the probability of this alignment occurring by chance alone is 3.3e-295, which is an incredibly low probability score. Moreover, the disclosed, encoded amino acid sequence has 1093 of 1303 amino acid residues (83%) identical to a human NIK-related protein (GenBank Accession No: BAA90753), as shown in Table 15. As indicated by the “Expect” 15 value, the probability of this alignment occurring by chance alone is 0.0, the lowest probability score.

TABLE 14

Score = 3828 (574.4 bits), Expect = 3.3e-295, Sum P(2) = 3.3e-295
 20 Identities = 1128/1488 (75%), Positives = 1128/1488 (75%), Strand = Plus /
 Plus

NOV3b:	4	GGCGACCCAGCC-CCCGCCCGCAGCCTGGACGACATCGACCTGTCCGCCCTGCAGGGACCC	62
	GGCGA C A C CCCGC	AGCCTGG GACAT GACCTGTC CCCTGCAGGGACCC	
25 NIK :	3	GGCGAACGACTCTCCCGCGAAGAGCCTGGTGGACATTGACCTGTGTCGTCCCTGCAGGGACCC	62
NOV3b:	63	TGCTGGGATTTGAGCTTGAGCTTGAGGGTGGTGGCAATGGAACCTACGGACAGGTGTACAA	
122		TGCTGGGAT TTGAGCT GTGGA GTGGT GG AATGG ACCTA GGACA GT TA AA	
30 NIK :	63	TGCTGGGATTTGAGCTGGAGGGTGGTGGAAATGGCACCTATGGACAAGTCTATAA	
122			
NOV3b:	123	GGGTCGGCATGTCAAGACGGGGCAGCTGGCTGCCATCAAGGTATGGATGTCACGGAGGA	
182		GGGTGCG CATGT AA ACGG CA CTG C GCCATCAAGGT ATGGA GTCAC GAGGA	
35 NIK :	123	GGGTCGACATGTTAAAACGGT-CA-CTGCC-GCCATCAAGGTATGGACGTACCGAGGA	
NOV3b:	183	CGAGGAGGAAGAGATCAAACAGGAGATCAACATGCTAAAAAGTACTCTCACCAACCGCAA	
40 242		GA GAGGAAGA ATCA AC GGAGAT AA ATGCTGAA AAGTA TCTCA CA CG AA	
NIK :	180	TGAAGAGGAAGAAATCACACTGGAGATAATATGCTGAAGAAGTATTCTCATCATCGAAA	
239			
45 NOV3b:	243	CATGCCACCTACTACGGAGCCTCATCAAGAAGAGCCCCGGAAACGATGACCAGCT	
302		AT GCCAC TACTA GG GC TTCAT AAGAAGAGCCC CC GGA A GATGACCA CT	
NIK :	240	TATTGCCACGTACTATGGTGTTCATTAAGAAGAGCCCTCCAGGACATGATGACCAACT	
299			

50

NOV3b: 303 CTGGCTGGTGTGGAGTTCTGTGGTGCTGGTCAGTGACTGACCTGGTAAAGAACACAAA
 362
 CTGGCT GT ATGGAGTT TGTGG GCTGG TC T AC GACCT GT AAGAACAC AA
 NIK : 300 CTGGCTTGTATGGAGTTGTGGGCTGGTCCATCACAGACCTTGTGAAGAACACCAA
 5 359
 NOV3b: 363 AGGCAACGCCCTGAAGGAGGACTGTATGCCATATCTGCAGGGAGATCCTCAGGGTCT
 422
 AGG AAC C CT AA GA GACTG AT GC TA ATCT CAGGGA ATCCTCAGGGG T
 10 NIK : 360 AGGAAACACTCTCAAAGAAGACTGGATTGCTTACATCTCCAGGGAAATCCTCAGGGATT
 419
 NOV3b: 423 GGCCCACATCTCCATGCCACAAGGTGATCCATCGAGACATCAAGGGGCAGAATGTGCTGCT
 482
 GGC CATCTCCAT CAC A GT AT CA CGAGA ATCAAGGG CA AATGTGCTGCT
 15 NIK : 420 GGCACATCTCCATATTCAACCACGTTATTCAACCGAGATATCAAGGGCAGAATGTGCTGCT
 479
 NOV3b: 483 GACAGAGAATGCTGAGGTCAAGCTAGTGGATTTGGGTGAGTGCTCAGCTGGACCGCAC
 20 542
 GAC GAGAATGCTGAGGT AA CT GT GATTTGG GT AG GCTCAGCTGGAC G AC
 NIK : 480 GACCGAGAATGCTGAGGTGAAACTTGTGATTTGGTGTAGCGCTCAGCTGGACAGGAC
 539
 NOV3b: 543 CGTGGG-CAGACGGAACACTTCATTGGACTCCCTACTGGATGGCTCCAGAGGTCATCG
 25 601
 GT GG C GA G AA AC TTCAT GG AC CCCTACTGGATGGCTCCAGAGGTCATCG
 NIK : 540 GGTTGGACGGA-GAAATACGTTCATAGGCACACCCACTGGATGGCTCCAGAGGTCATCG
 30 598
 NOV3b: 602 CCTGTGATGAGAACCCGTATGCCACCTATGATTACAGGAGTGATATGGTCTCTA-GGA
 660
 CCTGTGATGAGAACCC GA GCCAC TA GA TACAG AGTGA T TGGTC CT GG
 35 NIK : 599 CCTGTGATGAGAACCCAGACGCCACTACGACTACAGAAGTGACCTCTGGTC-CTGTGGC
 657
 NOV3b: 661 ATCACAGCCATCGAGATGGCAGAGGGAGCCCCCTCTGTGTGACATGCACCCATGCA
 720
 40 ATCACAGCCATCGAGATGGC GA GG G CCCCCCTCT TGTGACATGCA CC ATG GA
 NIK : 658 ATCACAGCCATCGAGATGGCTGAAGGGGGCCCCCTCTGTGTGACATGCATCCAATGAGA
 717
 NOV3b: 721 GCCCTCTCCTCATTCCCGAACCCCTCCGCCAGGCTCAAGTCCAAGAAGTGGTCTAAG
 45 780
 GC CT TT CTCAT CC G AACCCCTCC CCCAGGCT AAGTC AA AA TGGTC AAG
 NIK : 718 GCGCTGTTCTCATCCCCAGAAACCCCTCCAGGCTGAAGTCAGGTCAGGTCAGGTCAGG
 777
 NOV3b: 781 AAGTTCATTGA-CTTCATTGACACATGTCTCATCAAGACTTACCTG-AGCCGCCACCCA
 50 838
 AA TT TT A CTT AT GA TGTCT T AAGA TTAC TG AGC GCCC C A
 NIK : 778 AAATTT-TTCAGCTTATAGAAGGCTGTCTGGTGAAGAATTACATGCAGCGGCCCT-A
 835
 NOV3b: 839 CGGAGCAGCTACTGAAAGTTCCCTCATCCGGACCAGCCCACGGAGCGGCAGGTCCGCA
 55 898
 C GAGCA CT T AA CC TTCAT GGGG CAGCCCA GA GGCAGGT CG A
 NIK : 836 CAGAGCAACTTTAAAACACCCCTTCATAAGGATCAGCCCAATGAAAGGCAGGTTCGAA
 895
 NOV3b: 899 TCCAGCTTAAGGACCACATTGACCGATCCCGAAGAAGCGGGGTGAGAAAGAGGAGACAG
 958

NIK : 896 TCCAGCTTAAGGA CACAT GACCG CC G AAGAAG G GG GAGAAAGA GAGAC G
955 959 AATATGAGTACAGCGGCAGCGAGGAGGAAGATGAC-A-GC-CATGGAG-AGGAAGGGAGAG
1014 A TA GAGTACAGCGG AGCGAGGAGGA GA GA A G C TG AG AGGA GGAGAG
NIK : 956 AGTACGAGTACAGCGGGAGCGAGGAGGAGGAGGAAGTGCCTG-AGCAGGAGGGAGAG
1014
10 NOV3b: 1015 CCAAGCTCCATCATGAACGTGCCTGGAGAGTCGACTCTACGCCGGAGTTCTCCGGCTC
1074 CCAAG TCCATC T AA GTGCCTGGAGAGTC ACTCT CG CG GA TT CT G CT
NIK : 1015 CCAAGTTCCATCGTCAATGTGCCTGGAGAGTCAACTCTGCGACGTGATTTCCTGAGACTG
1074
15 NOV3b: 1075 CAGCAGGAAAATAAG-AGCAAATCAGAGGCTTAAAACAG-CAGCAGCAGCTGCAGCAGC
1132 CAGCAGGA AA AAG AGC TC GAGGCT T AG CAGCAGC CTGCAG AGC
20 NIK : 1075 CAGCAGGAGAACAGGAGCGG-TCTGAGGCTCTGCAGG-AGACAGCAGCTCTGCAGGAGC
1132
NOV3b: 1133 AGCAGCAGCGAGACCCCGAGGCACACATCAAACACCTGCTGCACCAGCGGCAGCGCGCA
1192 AGCAGC CG GA C GAGG A A A CA CTGCTG AG GCCAG GCG A
NIK : 1133 AGCAGCTCCGGAGCAGGAGGAGTATAAGAGGCAGCTGCTGGCTGAGAGGCAGAACCGGA
1192
25 NOV3b: 1193 TAGAGGAGCAGAAGGAGGAGCGGGCGCGTGGAGGAGCAACAGCGGGGGAGCGGGGA-G
1251 T GA ACCAGAA GA AG GG G CG TGGA GAGCAACA G G GA CGGGGA G
NIK : 1193 TTGAACAGCAGAAAGAACAGAGGAGGCGCTGGAAGAGCAACAAAGAAGAGAACCGGAAG
1252
30 NOV3b: 1252 CAGCGGAAGCTGCAGGAGAAGGAGCAGCAGCGCG-G--CTGGAGGACATGCAGGC-TCT
1307 C GGA GC GCAGGAG GAGCAGC CGGGCG G C GAGGA A G AGGC TCT
NIK : 1253 CCA-GGAGGCAGCAGGAGCGTGAAGCAGCGCGCGTGAACAAGAGGAGAAG-AGGCGTCT
1310
35 NOV3b: 1308 GCGGCGGGGA--GGAGGAGCGCGGCAGGCAGCGAGCAGGAATATTCGTACAGG
1365 CG GG A GGA CGGGCG A G GAG GAG AGGA A C A AGG
NIK : 1311 -CGA-GGAACCTGAAAGGCAGCGTAAAGAAGAGGAGAAGAG-AGGAG-ACGGGCAGAACAGGAGG
1366
40 NOV3b: 1366 CTA-GAGGAGCAGCGGC-AGT---CAGAACGT-CTCCAGA-GGCAGCTGCAGCAGGAGCA
1418 A GAGGAG AG GG AG CAG A GT C CAG GGCAGCT AG AGGAGCA
50 NIK : 1367 AGAAGAGGAG-AGTGGAGAGGGAACAGGA-GTACATCAGGCAGCTAGAGGAGGAGCA
1424
NOV3b: 1419 T-GCCTACCTCAAGTCCCTGCAGCAGCAGCAACAGCAGCAGCAGCTTCA-GAAACAGCAG
1476 G C ACCT AG CCTGCAGCAGCAGC C CAG AGCAG CA G AC GCA
NIK : 1425 GCGGC-ACCTGGAGATCCTGCAGCAGCAGCTGCTCCAGGAGCAGGC-CATGTTACTGCAC
1482
55 NOV3b: 1477 CAGCAGCAG 1485 (SEQ ID NO: 64)
A CA CAG
NIK : 1483 GACCA-CAG 1490 (SEQ ID NO: 31)

TABLE 15

Score = 2114 bits (5478), Expect = 0.0
 Identities = 1093/1303 (83%), Positives = 1093/1303 (83%), Gaps = 8/1303 (0%)

5	NOV3b : 1	MGDPA PARSLDD DIDL SALRDP AGIFEL VEVVGN GTYGQV YKGRH VKTGQL AAIKV MDVTX	60
	NIK : 1	MGDPA PARSLDD DIDL SALRDP AGIFEL VEVVGN GTYGQV YKGRH VKTGQL AAIKV MDVTE	60
10	NOV3b : 61	XXXXXIKQEINMLKKYSHHRNIA TYYGAFIK KSPPGN DDQLWL VMEFC GAGSV TDLVKNT	120
	NIK : 61	DEEEEIKQEINMLKKYSHHRNIA TYYGAFIK KSPPGN DDQLWL VMEFC GAGSV TDLVKNT	120
15	NOV3b : 121	KGNALKEDCIAYICREILGLAHL HAKVIHRDI KGQNV LLTENA EVKL VDFGV SAQLDR	180
	NIK : 121	KGNALKEDCIAYICREILGLAHL HAKVIHRDI KGQNV LLTENA EVKL VDFGV SAQLDR	180
	NOV3b : 181	TVGRRNTFIGTPYWM APEVIACDEN PDATYDYRSDI WSL GITAI EAE MAEGAPPL CDMHPMR	240
20	NIK : 181	TVGRRNTFIGTPYWM APEVIACDEN PDATYDYRSDI WSL GITAI EAE MAEGAPPL CDMHPMR	240
	NOV3b : 241	ALFLIPRNPPR LKSKKW SKKFIDF IDTCL IKTYLS SRPPTE QLLK FPFIRD QPTERQ VRI	300
25	NIK : 241	ALFLIPRNPPR LKSKKW SKKFIDF IDTCL IKTYLS SRPPTE QLLK FPFIRD QPTERQ VRI	300
	NOV3b : 301	QLKDHIXXXXXXXXXXXXXX XXXXXXXXXXXX PSSIM NVPGE STLRREF LRLQQ	360
	NIK : 301	QLKDHI DRSKRGE KEETEYE YSGSEE DDSHGEE GEPSSIM NVPGE STLRREF LRLQQ	360
30	NOV3b : 361	ENKSNSE ALKXXXXXXXXX RDPEAH IKHLLH XXXXXXXXXXXX XXXXXXXXXXXX	420
	NIK : 361	ENKSNSE ALKXXXXXXXXX RDPEAH IKHLLH XXXXXXXXXXXX XXXXXXXXXXXX	420
35	NOV3b : 421	XXXXXXXXXXXX DMQAL Y R HAYLKS NIK : 421 LQEKEQQR LEDMQALR REEERRQA EREQEY KRKQLEE QRQSERL QRQLQOE HAYLKS LQ	480
	NOV3b : 481	XXXXXXXXXXXX PGDRK PLYHYG GRGMN PADKP AWARE REVEER TRMN KQQNS PLAKS	540
40	NIK : 481	PGDRK PLYHYG GRGMN PADKP AWARE REVEER TRMN KQQNS PLAKS	540
	NOV3b : 541	KPGSTXXXXXXXXXXXX XMQRP VEPQEG PHKSLV AHRVPL KPYAAP VPRSQ	600
	NIK : 541	KPGST GPEPP IPQAS PGPP GPLSQ TPMQR VPEPQEG PHKSLV AHRVPL KPYAAP VPRSQ	600
45	NOV3b : 601	SLQDQ PTRNL AAFPASH XXXXXXXXXXXX RGAVI RQNSD PTSEGP GPSP PNPPAW VRP	660
	NIK : 601	SLQDQ PTRNL AAFPASH RGAVI RQNSD PTSEGP GPSP PNPPAW VRP	660
50	NOV3b : 661	DNEAPP KVPQRT SSIATA LNTSG AGGS RPAQ AVRAS NPDL RRSD PGWER SDS VLP PASHGH	720
	NIK : 661	DNEAPP KVPQRT SSIATA LNTSG AGGS RPAQ AVRAS NPDL RRSD PGWER SDS VLP PASHGH	720
55	NOV3b : 721	LPQAGSL ERNRV GVSSK PDSSP VLSPGN KAKP DDHRS RPG PASY KRAIG EDF VLL KERT	780
	NIK : 721	LPQAGSL ERNRV GVSSK PDSSP VLSPGN KAKP DDHRS RPG PASY KRAIG EDF VLL KERT	772
	NOV3b : 781	LDEAPR PPKKAM DYXXXX XXXXXX XXXXXX RDT PGGR SDG DTS VSTM VHV	840
60	NIK : 773	LDEAPR PPKKAM DYSS SE VESSED DEEE EGG PAEG SRDT PGGR SDG DTS VSTM VHV	832
	NOV3b : 841	DVEEITGT QPPYGG TMVV QRT PEE ERN LLHAD SNGY TNLP DVV QPS HSPT ENSK GQS P	900

	DVEEITGTQPPYGGGTMVVQRTPEEERNLLHADSGNTNLPDVVQPSHSPTENSKGQSPP
NIK : 833	DVEEITGTQPPYGGGTMVVQRTPEEERNLLHADSGNTNLPDVVQPSHSPTENSKGQSPP 892
5 NOV3b: 901	SKDGSGDYQSRGLVKAPGKSSFTMFVDLGIYQPGGSGDSIPITALVGGEGRLDQLQYDV 960
NIK : 893	SKDGSGDYQSRGLVKAPGKSSFTMFVDLGIYQPGGSGDSIPITALVGGEGRLDQLQYDV 952
10 NOV3b: 961	RKGGSVNVNPNTRAHSETPEIRKYKKRFNSEILCAALWGVNLLVGTENGIMLLDRSGQG 1020
NIK : 953	RKGGSVNVNPNTRAHSETPEIRKYKKRFNSEILCAALWGVNLLVGTENGIMLLDRSGQG 1012
15 NOV3b: 1021	KVYGLIGRRRFQQMDVLEGNLNLLITISGKRNLRVYYLSWLRNKILHNDPEVEKKQGWTT 1080
	KVYGLIGRRRFQQMDVLEGNLNLLITISGKRNLRVYYLSWLRNKILHNDPEVEKKQGWTT
NIK : 1013	KVYGLIGRRRFQQMDVLEGNLNLLITISGKRNLRVYYLSWLRNKILHNDPEVEKKQGWTT 1072
20 NOV3b: 1081	VGDMEGCGHYRVVKYERIKFLVIALKSSVEVYAWAPKPYHKFMAFKSFADLPHRPLLVDL 1140
	VGDMEGCGHYRVVKYERIKFLVIALKSSVEVYAWAPKPYHKFMAFKSFADLPHRPLLVDL
NIK : 1073	VGDMEGCGHYRVVKYERIKFLVIALKSSVEVYAWAPKPYHKFMAFKSFADLPHRPLLVDL 1132
25 NOV3b: 1141	TVEEGQLKVIYGSSAGFHAVDVDSGNSYDIYIPVHIQSQITPHAIIFLPNTDGMEMLLC 1200
	TVEEGQLKVIYGSSAGFHAVDVDSGNSYDIYIPVHIQSQITPHAIIFLPNTDGMEMLLC
NIK : 1133	TVEEGQLKVIYGSSAGFHAVDVDSGNSYDIYIPVHIQSQITPHAIIFLPNTDGMEMLLC 1192
30 NOV3b: 1201	YEDEGVYVNNTYGRRIKDVLQWGEMPTSVAIICSNQIMGWGEKAIEIRSVEVGHLGVFM 1260
	YEDEGVYVNNTYGRRIKDVLQWGEMPTSVAIICSNQIMGWGEKAIEIRSVEVGHLGVFM
NIK : 1193	YEDEGVYVNNTYGRRIKDVLQWGEMPTSVAIICSNQIMGWGEKAIEIRSVEVGHLGVFM 1252
35 NOV3b: 1261	HKRAQRQLKFLCERNDKVFFASVRSGGSSQVFMTLNRCIMNW 1303 (SEQ ID NO: 65)
	HKRAQRQLKFLCERNDKVFFASVRSGGSSQVFMTLNRCIMNW
40 NIK : 1253	HKRAQRQLKFLCERNDKVFFASVRSGGSSQVFMTLNRCIMNW 1295 (SEQ ID NO: 32)

Based on its relatedness to known members of the STE20 family of protein kinases, NOV3b provides new diagnostic and therapeutic compositions useful in the treatment of disorders associated with alterations in the expression of members of the STE20 family of protein kinases. Nucleic acids, polypeptides, antibodies, and other compositions of the present invention are useful in the treatment and diagnosis of a variety of diseases and pathologies, including, by way of nonlimiting example, those involving metabolic and endocrine disorders, cancer, bone disorders, and tissue/cell growth regulation disorders.

50 NOV-3c

A NOV-3c sequence according to the invention is a nucleic acid sequence encoding a polypeptide related to STE20 family of protein kinases. A disclosed NOV-3c nucleic acid and

its encoded polypeptide includes the sequences shown in Table 16. The disclosed nucleic acid (SEQ ID NO: 10) is 3822 nucleotides in length and contains an open reading frame (ORF) that begins with an ATG initiation codon at nucleotides 1-3 and ends with a TGA stop codon at nucleotides 3820-3822. The start and stop codons are shown in bold font. A respective ORF 5 encodes a 1273 amino acid polypeptide (SEQ ID NO: 11).

TABLE 16

ATGGCGACCCAGCCCCCGCCCGAGCCTGGACGACATCGACCTGTCCGCCCTGGGGACCCCTGCTGGGATCTTGAGCT
 10 TGTGGAGGTGGTGGCAATGGAACCTACGGACAGGTGACAAGGGTCGGCATGTCAAGACGGGGCAGCTGGCTGCCATCA
 AGGTCACTGGATGTCACGGAGGACGAGGAGGAAGAGATCAAACAGGAGATCAACATGCTAAAAAGTACTCTCACCAACGC
 AACATGCCACCTACTACGGAGCCTTCATCAAGAAGAGCCCCCGGAAACGATGACCAGCTGGCTGGTATGGAGTT
 CTGTGGTGTGGTCAGTGACTGACCTGGTAAAGAACACAAAAGGCAACGCCCTGAAGGGACTGTATGCCCTATATCT
 GCAGGGAGATCCTCAGGGCTGGCCATCTCCATGCCACAAGGTGATCCATCGAGACATCAAGGGCAGAATGTGCTG
 CTGACAGAGAACATGCTGAGGTCAAGCTAGTGGATTTGGGTGAGTGCTCAGTGGACCCGACCGTGGGAGACCGAACAC
 15 TTTCAATTGGACTCCCTACTGGATGGCTCCAGAGGTATCGCCTGTGATGAGAACCTGTGCCACCTATGATTACAGGA
 GTGATATTGGTCTCTAGGAATCACAGCCATCGAGATGGCAGAGGGAGCCCCCTCTGTGTGACATGCACCCATGCGA
 GCCCTTCCCTATTCTCGAACCCCTCCGCCAGGCTCAAGTCCAAGAAGTGGTCTAAGAACATTGACTTCATTGA
 CACATGTCTCATCAAGACTTACCTGAGCCGCCACCCACGGAGCAGCTACTGAAGTTCCCTCATCGGGACCAAGCCA
 CGGAGCGGCAGGTCCGCATCCAGCTTAAGGACCACATTGACCGATCCCGAAGAACGGGGTGAGAAAGAGGAGACAGAA
 20 TATGAGTACAGCGCAGCGAGGAGGAAGATGACAGCCATGGAGAGGAAGGAGCAGCTCCATCATGAACGTGGCTGG
 AGAGTCGACTCTACGCCGGAGTTCTCCGGCTCCAGCAGGAAAATAAGAGCAACTCAGAGGCTTAAACAGCAGCAGC
 AGCTGCCAGCAGCAGCAGCGAGACCCGAGGCACACATCAAACACCTGCTGCACCAGCGGAGCGGCGCATAGAGGAG
 CAGAAGGAGGAGCGGGCGCGCTGGAGGAGGAGAACAGCGGGAGCAGCGGAAGCTGCAGGAGAACGGAGCAGCA
 CGGGCGGCTGGAGGACATGCAGGCTCTGCGCGGGAGGAGGAGCGGGAGCGCGAGCGAGGAATATATTGTC
 25 ACAGGCTAGAGGAGGAGCAGCGACAGCTCGAGATCCTCAGCAACAGCTGCTCCAGGAACAGGCCCTGCTGGAATAC
 AACCGGAAGCAGCTGGAGGAGCAGCGCAGCTCAGAACAGCAGCAGCAGCTCCAGGAGCATGCCCTACCTCAAGTC
 CCTGCAGCAGCAGCAACAGCAGCAGCAGCTCAGAACAGCAGCAGCAGCTCCAGGAGCATGCCCTGGGACAGGAAGCCCCTGT
 ACCATTATGGTGGGCATGAATCCGCTGACAAACCAGCCTGGGCCAGAGGTAGTGGCACACCGGGTCCCCTGAAG
 CCATATGCAGCACCTGTACCCGATCCCAGTCCCTGAGGACCAAGCCACCCGAAACCTGGCTGCCCTCCAGCCTCCCA
 30 TGACCCCGACCCCTGCCATCCCCGACCCACTGCCACGCCAGTGGCCAGGGACTGTCACTGCCAGAACATTAGACCCCA
 CCTCTGAAGGACCTGGCCCCAGCCGAATCCCCAGCCTGGTCCGCCAGATAACGAGGCCACCCAGGTGCCTCAG
 AGGACCTCATCTATGCCACTGCCCTAACACCAGTGGGCCGGAGGGTCCGCCAGCCAGGAGTCCGTGCCAGTAA
 CCCCACCTCAGGAGGAGCGACCCCTGGCTGGAACGCTCGGACAGCTCCCTCAGGCCCTCTCACGGGACACCTCCCCCAGG
 CTGGCTCACTGGAGCGAACCGCGTGGGAGTCTCCAAACCGGACAGCTCCCTGTGCTCTCCCTGGGAATAAGCC
 35 AAGCCCGACGACCACCGCTCACGCCAGGCCAGGCCAGCAAGCTATAAGCGAGCAATTGGTAGGACTTGTGCTGAA
 AGAGCGGACTCTGGACGAGGCCCTCGGCCCTCCAAGAAGGCCATGGACTACTCGTCGTCAGCGAGGAGGTGAAAGCA
 GTGAGGACGACGAGGAGGAAGCGAAGGCCAGCAGAGGGAGCAGAGGAGATACCCCTGGGGCCAGCGATGGGAT
 ACAGACAGCGTCAGCAGCAGCTGGTCCAGCACGTGAGGAGATCACGGGACCCAGCCCCCATACGGGGCGGCACCAT
 GGTGGTCCAGCGCACCCCTGAAAGAGGAGCGAACCTGCTGCATGCTGACAGCAATGGGTACACAAACCTGCCGTGACGTGG
 40 TCCAGCCAGCCACTCACCCACCGAGAACAGCAAAGGCCAAGGCCACCCCTCGAAGGATGGAGTGGTACTACCAGTCT
 CGTGGGCTGGTAAAGGCCCTGGCAAGAGCTCGTTCAGCATGGTGTGGATCTAGGGATCTACCAGCCTGGAGGCAGTGG
 GGACAGCAGCAGCAGCTAGTGGTGGAGAGGGCACTGGCTCGACCAGCTGCACTGGAGTACAGCAACGGAGAACGGGTT
 CTGTGGTCAACGTGAATCCCACCAACACCCGGCCACAGTGAGACCCCTGAGATCCGGAAAGTACAAGAACGATTCAAC
 TCCGAGATCCTCTGTGCAAGCCCTTGGGGGTCACCTGCTGGTGGGACCGAGAACGGGCTGATGTTGCTGGACCGAAG

TGGGCAGGGCAAGGTGTATGGACTCATTGGCGGCGACGCCCTCCAGCAGATGGATGTGCTGGAGGGCTCAACCTGCTCA
 TCACCATCTCAGGGAAAAGAACAAACTGCGGGTGTATTACCTGTCTGGCTCCGAACAAGATTCTGCACAATGACCCA
 GAAGTGGAGAAGAACGGCAGGGCTGGACCACCGTGGGGACATGGAGGGTGCCTGGGGACTACCGTGTGAAATACGAGCG
 GATTAAGTTCCTGGTCATGCCCTCAAGAGCTCCGTGGAGGTGTATGCCCTGGGCCCCAACCCCTACCACAAATTATGG
 5 CCTPTCAAGTCCTTGCCGACCTCCCCCACCGCCCTCTGCTGGTCGACACTGACAGTAGAGGAGGGCAGCGGCTCAAGGTC
 ATCTATGGCTCCAGTGGCTCCATGCTGTGGATGTCGACTCGGGGAACAGCTGACATCTACATCCCTGTGCACAT
 CCAGAGCCAGATCACGCCCATGCCATCATCTTCCTCCCAACACCGACGGCATGGAGATGCTGCTGTGCTACGAGGACG
 AGGGTGTCTACGTCACACGTACGGCGCATCATAAGGATGTGGTGTGCAGTGGGGGAGATGCCCTACTTCTGTGGCC
 10 TACATCTGCTCCAACCAGATAATGGGCTGGGTGAGAAAGCCATTGAGATCCGCTGTGGAGACGGGCCACCTCGACGG
 GGTCTTCATGCACAAACGAGCTCAGAGGCTCAAGTTCTGTGAGCGGAATGACAAGGTGTTTTGCCCTAGTCGGCT
 CTGGGGGAGCAGCCAAGTTACTCATGACTCTGAACCGTAACGCACTGGTGA (SEQ ID NO: 10)

MGDPAPARSLLDDIDLSALRDPAGIFELVEVVGNGTYGQVYKGRHVKTGQLAAIKVMDVTEDEEEEIKQEINMLKKYSHHR
 NIATYYGAFIKKSPPGNNDQLWLVMFECGAGSVTDLVKNTKGNALKEDCIAYICREILRLAHHLHAKVVIHRDIKGQNVL

15 LTENAEVKLVDGFVSAQLDRTVGRNNTFIGTPYWMAPEVIACDENPDATYDYSRSDIWSLGITAIEMAEGAPPLCDMHPMR

ALFLIPRNPPPRLKSKKWSKKFIDFIDTCLIKTYLSRPPTEQLLKFPFIRDQPTEROVRIQQLKDHDIDRSRKKRGEKEETE

YEYSGSEEEEDSHGEEGEPPSIMNVPGESTIRRERFLRLQQENKSNSEALKQQQOLQQQOORDPEAHIKHLLHQQRRIEE

QKEERRVEEQRREREQRKLOQEKEQQRRLMEDMQALRREEERQAEREQEYTRHRLEEEQRQLEILQQQLLQEALLLEY

KRKOLEEQRQSERLQLQEHAYLKSLOQQQQQQQLOKQQQQOLLPGDRKPPLYHYGRGMNPADKPAWAREVVAVRVPLK

20 PYAAPVPRSQSLQDQPTRNLAAFPASHDPDAIPAPTATPSARGAVIRQNSDPTSEGPGPSPNPPAWVRPDNEAPPKVPQ

RTSSIATALNTSGAGGSRPAQAVRASNPDLLRSDPGWERSDSVLPASHGLPQAGSLERNRVRGVSSKPDSPPVSPGNKA

KPDDHRSRPGRPASYKRAIGEDFVLLKERTLDEAPRPPKKAMDYSSSSEEVESSEDDEEEGEGGPAAEGSRDTPGGRSDGD

TDVSSTMVHDVEITGTQPPYGGTMVVQRTPEEERNLLHADSNGYTNLPDVQPSHSPTENSKGQSPPSKDGSDYQS

RGLVKAPGKSSFTMFVDLGIYQPGGSGDSIPITALVGGEGTRLDQLQYDVRKGSVNVNPTNTRAHSETPEIRKYKKRFN

25 SEILCAALWGVNLLVGTENGLMLLDLRSQGQKVKYGLIGRERRFQQMDVLEGNLNLITISGKRNLRVYYLSWLRNKILHNDP

EVEKKQGWTTVGDMECGCHYRVVKYERIKFLVIALKSVEVYAWAPKPYHKFMFKSFADLPHRPLLVDLTVEEGQRLKV

IYGSSAGFHADVDGSNSYDIYIPVHIQSQTIPHAIIFLPNTDGMEMILLCYEDEGVYVNTYGRIIKDVVLQWGEMPTSVA

YICSNQIMGWGEKALEIRSVEGETGHLDGVFMHKRAQRKLKFLCERNDKVFFASVRSGGSSQVYFMTILNRNCIMNW (SEQ

ID NO: 11)

30

The disclosed NOV-3c nucleic acid sequence has homology (72% identity) to a mouse mRNA for a NIK protein (NIK) (GenBank Accession No: MMU88984), as shown in Table 17. NIK proteins are a subgroup of the STE20 family of protein kinases. As indicated by the “Expect” value, the probability of this alignment occurring by chance alone is 9.1e-299.

35 Moreover, the disclosed, encoded amino acid sequence has 1048 of 1332 amino acid residues (78%) identical to a human NIK-related protein (GenBank Accession No: BAA90753), shown in Table 18. Furthermore, the encoded amino acid sequence also has homology (79% identity) to a human GCK kinase (GenBank Accession No: BAA94838), another subgroup of the STE20 kinase family, as shown in Table 19. As indicated by the “Expect” value, the
 40 probability of these amino acid alignments occurring by chance alone are both 0.0, the lowest probability score.

TABLE 17

Score = 3907 (586.2 bits), Expect = 9.1e-299, Sum P(2) = 9.1e-299
 Identities = 1297/1788 (72%), Positives = 1297/1788 (72%), Strand = Plus /
 5 Plus

NOV3c:	4	GGCGACCCAGCC-CCCGCCCGCAGCCTGGACGACATCGACCTGTCCGCCCTGCAGGGACCC	62
		GGCGA C A C CCCGC AGCCTGG GACAT GACCTGTC CCCTGCAGGGACCC	
NIK :	3	GGCGAACGACTCTCCCGCAAGAGCCTGGTGGACATTGACCTGTCTGCCCTGCAGGGACCC	62
10 NOV3c:	63	TGCTGGGATCTTGAGCTTGTGGAGGTGGTGGCAATGGAACCTACGGACAGGTGTACAA	
	122	TGCTGGGAT TTTGAGCT GTGGA GTGGT GG AATGG ACCTA GGACA GT TA AA	
NIK :	63	TGCTGGGATTTGAGCTGGTGGAAAGTGGTGGAAATGGCACCTATGGACAAGTCTATAA	
15 NOV3c:	123	GGGTCGGCATGTCAAGACGGGGCAGCTGGCTGCCATCAAGGTATGGATGTCACGGAGGA	
	182	GGGTCG CATGT AA ACGG CA CTG C GCCATCAAGGT ATGGA GTCAC GAGGA	
20 NIK :	123	GGGTCGACATGTTAACCGGT-CA-CTGCC-GCCATCAAGGTATGGACGTCACCGAGGA	
	179		
NOV3c:	183	CGAGGAGGAAGAGATCAAACAGGAGATCAACATGCTAAAAAGTACTCTCACCACCGCAA	
	242	GA GAGGAAGA ATCA AC GGAGAT AA ATGCTGAA AAGTA TCTCA CA CG AA	
NIK :	180	TGAAGAGGAAGAAATCACACTGGAGATAATATGCTGAAGAAGTATTCTCATCATCGAAA	
25	239		
NOV3c:	243	CATGCCACCTACTACGGAGCCTTCATCAAGAAGAGCCCCCGGGAAACGATGACCAGCT	
30	302	AT GCCAC TACTA GG GC TTCAT AAGAAGAGCCC CC GGA A GATGACCA CT	
NIK :	240	TATTGCCACGTACTATGGTCTTTCATTAAGAAGAGCCCTCCAGGACATGATGACCAACT	
	299		
35 NOV3c:	303	CTGGCTGGTATGGAGTTCTGTGGTCTGGTCAGTGAATGACCTGGTAAAGAACACAAA	
	362	CTGGCT GT ATGGAGTT TGTGG GCTGG TC T AC GACCT GT AAGAACAC AA	
NIK :	300	CTGGCTTGTATGGAGTTGGTGGGCTGGTCCATCACAGACCTTGTGAAGAACACCAA	
40	359		
NOV3c:	363	AGGCAACGCCCTGAAGGAGGACTGTATGCCCTATATCTGCAGGGAGATCCTCAGGGTCT	
	422	AGG AAC C CT AA GA GACTG AT GC TA ATCT CAGGGA ATCCTCAGGGG T	
NIK :	360	AGGGAACACTCTCAAAGAAGACTGGATTGCTTACATCTCCAGGGAAATCCTCAGGGATT	
45	419		
NOV3c:	423	GGCCCATCTCCATGCCACAGGTGATCCATCGAGACATCAAGGGCAGAATGTGCTGCT	
	482	GGC CATCTCCAT CAC A GT AT CA CGAGA ATCAAGGG CA AATGTGCTGCT	
50 NIK :	420	GGCACATCTCCATATTCAACACGTTATTCAACCGAGATATCAAGGGCCAAATGTGCTGCT	
	479		
NOV3c:	483	GACAGAGAATGCTGAGGTCAAGCTAGTGGATTTGGGTGAGTGCTCAGCTGGACCGCAC	
	542	GAC GAGAATGCTGAGGT AA CT GT GATTTGG GT AG GCTCAGCTGGAC G AC	
55 NIK :	480	GACCGAGAATGCTGAGGTGAAACTTGGTGAAGCGCTCAGCTGGACAGGAC	
	539		
NOV3c:	543	CGTGGG-CAGACGGAACACTTCATTGGACTCCCTACTGGATGGCTCCAGAGGTATCG	
60	601	GT GG C GA G AA AC TTCAT GG AC CCCTACTGGATGGCTCCAGAGGTATCG	

NIK : 540 GGTTGGACGGA-GAAATACGTTCATAGGCACACCCTACTGGATGGCTCCAGAGGTATCG
598

5 NOV3c: 602 CCTGTGATGAGAACCTGATGCCACCTATGATTACAGGAGTGATATTGGTCTCTA-GGA
660 CCTGTGATGAGAACCC GA GCCAC TA GA TACAG AGTGA T TGGTC CT GG
NIK : 599 CCTGTGATGAGAACCCAGACGCCACTACGACTACAGAAGTGACCTCTGGTC-CTGTGGC
657

10 NOV3c: 661 ATCACAGCCATCGAGATGGCAGAGGGAGCCCCCTCTGTGTGACATGCACCCATGCGA
720 ATCACAGCCATCGAGATGGCAGAGGGAGCCCCCTCTGTGTGACATGCACCCATGCGA
NIK : 658 ATCACAGCCATCGAGATGGCTGAAGGGGGCCCCCTCTGTGTGACATGCCAATGAGA
717

15 NOV3c: 721 GCCCTCTCCCTCATCCCTCGAACCCCTCCGCCAGGCTCAAGTCCAAGAAGTGGTCTAAG
780 GC CT TT CTCAT CC G AACCTCC CCCAGGCT AAGTC AA AA TGGTC AAG
NIK : 718 GCGCTGTTCTCATCCCCAGAAACCCCTCCGCCAGGCTGAAGTCAAAGGATGGTCAAAG
777

20 NOV3c: 781 AAGTTCATTGA-CTTCATTGACACATGTCTCATCAAGACTTACCTG-AGCCGCCACCCA
838 AA TT TT A CTT AT GA TGTCT T AAGA TTAC TG AGC GCCC C A
25 NIK : 778 AAATTT-TTCAGCTTTATAGAAGGCTGTCTGGTGAAGAATTACATGCAAGCGGCCCT-A
835

NOV3c: 839 CGGAGCAGCTACTGAAGTTCCCTCATCCGGACCAGCCCACGGAGCGGCCAGGTCCGCA
898

30 NIK : 836 CAGAGCAACTTTAAACACCCCTTCATAAGGGATCAGCCCAATGAAAGGCAGGTTCGAA
895

35 NOV3c: 899 TCCAGCTTAAGGACCACATTGACCGATCCCGGAAGAAGCGGGGTGAGAAAGAGGAGACAG
958 TCCAGCTTAAGGACAT GACCG CC G AAGAAG G GG GAGAAAGA GAGAC G
NIK : 896 TCCAGCTTAAGGATCACATAGACCGGACCAGAAAGAAGAGAGGCGAGAAAGATGAGACGG
955

40 NOV3c: 959 AATATGAGTACAGCGGCAGCGAGGAGGAAGATGAC-A-GC-CATGGAG-AGGAAGGAGAG
1014 A TA GAGTACAGCGG AGCGAGGAGGA GA GA A G C TG AG AGGA GGAGAG
NIK : 956 AGTACGAGTACAGCGGGAGCGAGGAGGAGGAGGAAGTGCCTG-AGCAGGAGGGAGAG
1014

45 NOV3c: 1015 CCAAGCTCCATCATGAACGTGCCTGGAGAGTCAGACTCTACGCCGGAGTTCTCCGGCTC
1074 CCAAG TCCATC T AA GTGCCTGGAGAGTC ACTCT CG CG GA TT CT G CT
NIK : 1015 CCAAGTCCATCGTCAATGTGCCTGGAGAGTCAGACTCTGCACGTGATTCCTGAGACTG
1074

NOV3c: 1075 CAGCAGGAAAATAAG-AGCAACTCAGAGGTTAAACAG-CAGCAGCAGCTGCAGCAGC
1132 CAGCAGGA AA AAG AGC TC GAGGCT T AG CAGCAGC CTGCAG AGC
55 NIK : 1075 CAGCAGGAGAACAGGAGCGG-TCTGAGGCTCTGCAGGAGCAGCTCTGCAGGAGC
1132

NOV3c: 1133 AGCAGCAGCGAGACCCGAGGCACACATCAAACACCTGCTGCACCAGCGGCAGCGCGCA
1192 AGCAGC CG GA C GAGG A A A CA CTGCTG AG GGCAG GCG A
NIK : 1133 AGCAGCTCCGGAGCAGGAGGAGTATAAGAGGCAGCTGCTGGCTGAGAGGCAGAACCGGA
1192

NOV3c: 1193 TAGAGGAGCAGAAGGAGGAGCGGCCGCGTGGAGGAGCAACAGCGCCGGAGCGGGA-G
1251

NIK : 1193 TTGAACAGCAGAAAGAACAGAGGAGGCAGCTGGAAGAGCAACAAAGAAGAGAACGGGAAG
5 1252

NOV3c: 1252 CAGCGGAAGCTGCAGGAGAAGGAGCAGCAGCGC-G--CTGGAGGACATGCAGGC-TCT
1307

NIK : 1253 CCA-GGAGGCAGCAGGAGCGTGGAGCAGCGCAGCGTGAACAAGAGGAGAAG-AGGCAGTCT
10 1310

NOV3c: 1308 GCGGCGGG--GGAGGAGCGGCGGCAGGCGAGCGAGCAGGAATATATTGTCACAGG
1365

NIK : 1311 -CGA-GGAAGTGGAAAGGCAGCTAAAGAAGAGGAAGAG-AGGAG-ACGGGCAGAAGAGG
15 1366

NOV3c: 1366 CTA-GAGGAG-GAGCAGCGACAGCTCGAGATCCTTCAGCAACAGCTGCTCCAGGAACAGG
20 1423

NIK : 1367 AGAAGAGGAGAGTGGAGAGGAACAGGAG-TACATCAGG--CGGCAGCTAGAGGAGGAGC
1423

NOV3c: 1424 CCCTGCTGCTGGA-ATACA--AGCGGAAGCAGCTGGAGGAGCAGCGGCA-GTCAGAACGT
25 1479

NIK : 1424 AGCGGCACCTGGAGATCCTGCAGCAGCTGCTCCAGGAGCAG-GCCATGTTACTGCAC
1482

NOV3c: 1480 CTCCAGAGGCAGCTGCA-GCAGGAGCATGCCTACCTCAAGTCCCTGCAGCAGCAGCAACA
30 1538

NIK : 1483 GACCACAGGAGGCCGCACGCAC-AGCA-GCAG-CCGC-GCCCCCGCAGCAGCAGGA-CA
35 1537

NOV3c: 1539 GCAGCAG--C-AGCTT-CA-GAAACAGCAGCAGCAGCAGCTCC-TG-CC-TGGGGACAGG
1590

NIK : 1538 GGAGCAAACCGAGCTTCATGCTCCAG-AGCCCAAGCCTCACTATGACCCCTGCTGACAG-
1595

NOV3c: 1591 AAGCCCCTGTACCATTATGGTCGGGCATGAATCCCGCT-GA-CAAAC-CAGCCTGGCC
40 1647

NIK : 1596 -AGCTCGGGAGGTACAGTGGTCCCACCTGGCATCTCTCAAGAACAAATGTCTCCCTGTCT
1654

NOV3c: 1648 CGAGAGGTAGTGGCACACCGGGTCCCACTGAAGCCATAT--GCAGCACCTGTACC-CCGA
50 1704

NIK : 1655 CGAGATCCCATTCTT-CAGTGACCT-TCTC-CCAAATTGCA-CACCAACATCTCCGC
1710

NOV3c: 1705 TCCCAGTCCCTGCAGGACCAGCCCACCGAAACCTGGCTGCCTTCCCAGCCTCCATGAC
55 1764

NIK : 1711 TCTCAGGACC--CATGTCCA-CCTTCCCGCAGTGAGGG-GCTCAGTCAGAG-CTC-TGAC
1764

NOV3c: 1765 CCCGACCCCTGCCATCCCCGACCCAC 1790 (SEQ ID NO: 66)

NIK : 1765 TCTAAGTCGGAGGTGCCAGCCCCAC 1790 (SEQ ID NO: 33)

TABLE 18

Score = 1985 bits (5143), Expect = 0.0
Identities = 1048/1332 (78%), Positives = 1051/1332 (78%), Gaps = 96/1332 (7%)

	NOV3c: 1	MGDPAPARSLDDIDL SALRDPAGIFELVEVVGNGTYGQVYKGRHVKTGQLAAIKVMDVTX	60
10	NIK : 1	MGDPAPARSLDDIDL SALRDPAGIFELVEVVGNGTYGQVYKGRHVKTGQLAAIKVMDVT	60
	NOV3c: 61	XXXXXIKQEINMLKKYSHHRNIATYYGAFIKSPPGNDDQLWLVMFECGAGSVTDLVKNT	120
		IKQEINMLKKYSHHRNIATYYGAFIKSPPGNDDQLWLVMFECGAGSVTDLVKNT	120
	NIK : 61	DEEEEIKQEINMLKKYSHHRNIATYYGAFIKSPPGNDDQLWLVMFECGAGSVTDLVKNT	120
15	NOV3c: 121	KGNALKEDCIAYICREILRGLAHLHAKVIHRDIKGQNVLLTENAEVKLVDFGVSAQLDR	180
		KGNALKEDCIAYICREILRGLAHLHAKVIHRDIKGQNVLLTENAEVKLVDFGVSAQLDR	180
	NIK : 121	KGNALKEDCIAYICREILRGLAHLHAKVIHRDIKGQNVLLTENAEVKLVDFGVSAQLDR	180
20	NOV3c: 181	TVGRRNTFIGTPYWMAPEVIACDENPDATYDYRSIDIWSLGITAIEMAEGAPPLCDMHPMR	240
		TVGRRNTFIGTPYWMAPEVIACDENPDATYDYRSIDIWSLGITAIEMAEGAPPLCDMHPMR	240
	NIK : 181	TVGRRNTFIGTPYWMAPEVIACDENPDATYDYRSIDIWSLGITAIEMAEGAPPLCDMHPMR	240
	NOV3c: 241	ALFLIPRNPPPRLKSKKWSKKFIDFIDTCLIKTYLSRPPTEQLLKFPFIRDQPTERQVRI	300
		ALFLIPRNPPPRLKSKKWSKKFIDFIDTCLIKTYLSRPPTEQLLKFPFIRDQPTERQVRI	300
25	NIK : 241	ALFLIPRNPPPRLKSKKWSKKFIDFIDTCLIKTYLSRPPTEQLLKFPFIRDQPTERQVRI	300
	NOV3c: 301	QLKDHIXXXPSSIMNPGESTIRREFLRLQQ	360
		QLKDHIPSSIMNPGESTIRREFLRLQQ	360
	NIK : 301	QLKDHIDRSRKKRGEKEETEYEYSGSEEEEDSHGEEGEPSSIMNPGESTIRREFLRLQQ	360
30	NOV3c: 361	ENKSNSEALKXXXXXXXXXXRDPEAHIKHLLHXXXXXXXXXXXXXXXXXXXXXXXXXXXX	420
		ENKSNSEALKRDPEAHIKHLLH	420
	NIK : 361	ENKSNSEALKQQQOLQQQQORDPEAHIKHLLHQQRRIEEQKEERRVEEQQRREEQRK	420
35	NOV3c: 421	XXXXXXXXXXXXDMQALXXXXXXXXXXXXYIRHRXXXXXXXXXXXXXXXXXXXXY	480
		DMQALY	480
	NIK : 421	LQEKEQQRLEDMQAL-----RREEERRQAEREQEQY	451
40	NOV3c: 481	KRKXXXXXXXXXXXXXHAYLKSXXXXXXXXXXXXPGDRKPLYHYGRGM	540
		KRKHAYLKS PGDRKPLYHYGRGM	540
	NIK : 452	KRKQLEEQRQSERLQROLOQE HAYLKS LQQQQQQQQQLQKQQQQQLLPGDRKPLYHYGRGM	511
	NOV3c: 541	NPADKPAWAREVVAH-----RVP	558
		NPADKPAWAREV + P	558
45	NIK : 512	NPADKPAWAREVEERTRMNKOQNSPLAKSKPGSTGPEPPIPQASPGPPGPLSQTPPMQR	571
	NOV3c: 559	LKPYAAP-----VPRSQSLQDQPTRNLAAPFASHXXXXXXXXXXXX	601
		++P P VPRSQSLQDQPTRNLAAPFASH	601
	NIK : 572	VEPQEGPHKSLVAHRVPLKPYAAPVPRSQSLQDQPTRNLAAPFASHDPDAI PAPTATPS	631
50	NOV3c: 602	XRGAVIRQNSDPTSEGPGPSNPPAWVRPDNEAPPKVPQRTSSIATALNTSGAGGSRPAQ	661
		RGAVIRQNSDPTSEGPGPSNPPAWVRPDNEAPPKVPQRTSSIATALNTSGAGGSRPAQ	661
	NIK : 632	ARGAVIRQNSDPTSEGPGPSNPPAWVRPDNEAPPKVPQRTSSIATALNTSGAGGSRPAQ	691
55	NOV3c: 662	AVRASNPDLRRSDPGWERSDSVLPASHGHLPOAGSLERNRVGVSSKPDSSPVLSPGNKAK	721
		AVRASNPDLRRSDPGWERSDSVLPASHGHLPOAGSLERNRVGVSSKPDSSPVLSPGNKAK	721
	NIK : 692	AVRASNPDLRRSDPGWERSDSVLPASHGHLPOAGSLERNRVGVSSKPDSSPVLSPGNKAK	751
60	NOV3c: 722	PDDHRSRPGPASYKRAIGEDFVLLKERTLDEAPRPPKKAMDYXXXXXXXXXXXX	781
		PDDHRSRPGPRA DFVLLKERTLDEAPRPPKKAMDY	781
	NIK : 752	PDDHRSRPGPRA-----DFVLLKERTLDEAPRPPKKAMDYSSSEEVESSEDDEEEG	803

NOV3c: 782 XXXXXXXXRDTPGGRSDGTDHSVSTMVHDVEEITGTQPPYGGTMVVQRTPEEERNLLH 841
 RDTPGGRSDGTDHSVSTMVHDVEEITGTQPPYGGTMVVQRTPEEERNLLH

5 NIK : 804 EGGPAEGSRDTPGGRSDGTDHSVSTMVHDVEEITGTQPPYGGTMVVQRTPEEERNLLH 863

NOV3c: 842 ADSNGYTNLPDVVQPSHSPTENSKGQSPPSKDGSGDYQSRLVKAPGKSSFTMFVDLGIY 901
 ADSNGYTNLPDVVQPSHSPTENSKGQSPPSKDGSGDYQSRLVKAPGKSSFTMFVDLGIY

NIK : 864 ADSNGYTNLPDVVQPSHSPTENSKGQSPPSKDGSGDYQSRLVKAPGKSSFTMFVDLGIY 923

10 NOV3c: 902 QPGGSGDSIPIITALVGGEGTRLDQLQYDVRKGSVVNPNTRAHSETPEIRKYKKRFNS 961
 QPGGSGDSIPIITALVGGEGTRLDQLQYDVRKGSVVNPNTRAHSETPEIRKYKKRFNS
 NIK : 924 QPGGSGDSIPIITALVGGEGTRLDQLQYDVRKGSVVNPNTRAHSETPEIRKYKKRFNS 983

15 NOV3c: 962 EILCAALWGVNLLVGTEENGLMLDRSGQGKVYGLIGRRRFQQMDVLEGILNLLITISGKRN
 1021 EILCAALWGVNLLVGTEENGLMLDRSGQGKVYGLIGRRRFQQMDVLEGILNLLITISGKRN
 NIK : 984 EILCAALWGVNLLVGTEENGLMLDRSGQGKVYGLIGRRRFQQMDVLEGILNLLITISGKRN
 1043

20 NOV3c: 1022 KLRVYYLSWLRNKILHNDPEVEKKQGWTTVGDMEGCGHYRVVKYERIKELVIALKSSVEV
 1081 KLRVYYLSWLRNKILHNDPEVEKKQGWTTVGDMEGCGHYRVVKYERIKELVIALKSSVEV
 NIK : 1044 KLRVYYLSWLRNKILHNDPEVEKKQGWTTVGDMEGCGHYRVVKYERIKELVIALKSSVEV
 1103

25 NOV3c: 1082 YAWAPKPYHKEMAFKSFADLPHRPLLVDLTVEEGQRLKVIYGSSAGFHAVDVDSGNSYDI
 1141 YAWAPKPYHKEMAFKSFADLPHRPLLVDLTVEEGQRLKVIYGSSAGFHAVDVDSGNSYDI
 NIK : 1104 YAWAPKPYHKEMAFKSFADLPHRPLLVDLTVEEGQRLKVIYGSSAGFHAVDVDSGNSYDI
 1163

30 NOV3c: 1142 YIPVHIQSQITPHAIIFLPNTDGMEMLLCYEDEGVYVNTYGRIIKDVLQWGEMPTSVAY
 1201 YIPVHIQSQITPHAIIFLPNTDGMEMLLCYEDEGVYVNTYGRIIKDVLQWGEMPTSVAY
 NIK : 1164 YIPVHIQSQITPHAIIFLPNTDGMEMLLCYEDEGVYVNTYGRIIKDVLQWGEMPTSVAY
 1223

35 NOV3c: 1202 ICSNQIMGWGEKAIEIRSvetGHLDGVFMHKRAQRALKFLCERNDKVFFASVRSGGSSQVY
 1261 ICSNQIMGWGEKAIEIRSvetGHLDGVFMHKRAQRALKFLCERNDKVFFASVRSGGSSQVY
 NIK : 1224 ICSNQIMGWGEKAIEIRSvetGHLDGVFMHKRAQRALKFLCERNDKVFFASVRSGGSSQVY
 1283

40 NOV3c: 1262 FMTLNRCIMNW 1273 (SEQ ID NO: 67)
 FMTLNRCIMNW
 NIK : 1284 FMTLNRCIMNW 1295 (SEQ IS NO: 34)

45

TABLE 19

Score = 2007 bits (5201), Expect = 0.0
 50 Identities = 1056/1332 (79%), Positives = 1059/1332 (79%), Gaps = 88/1332
 (6%)

NOV3c: 1 MGDPAPARSLDDIDLSALRDPAGIFELVEVVGNNTYQVYKGRHVKTGQLAAIKVMDVTX 60
 MGDPAPARSLDDIDLSALRDPAGIFELVEVVGNNTYQVYKGRHVKTGQLAAIKVMDVT

55 GCK : 1 MGDPAPARSLDDIDLSALRDPAGIFELVEVVGNNTYQVYKGRHVKTGQLAAIKVMDVTE 60

NOV3c: 61 XXXXXIKQEINMLKKYSHHRNIATYYGAFIKKSPPGNDDQLWLVMFECGAGSVTDLVKNT 120
 IKQEINMLKKYSHHRNIATYYGAFIKKSPPGNDDQLWLVMFECGAGSVTDLVKNT

60 GCK : 61 DEEEEIKQEINMLKKYSHHRNIATYYGAFIKKSPPGNDDQLWLVMFECGAGSVTDLVKNT 120

NOV3c: 121 KGNALKEDCIAYICREILRGLAHLHAHKVIHRDIKGQNVLLENAEVKLVDFGVSAQLDR 180

		KGNALKEDCIAYICREILGLAHLHAKVIHRDIKGQNVLLENAEVKLVDGVSACQLDR
GCK : 121		KGNALKEDCIAYICREILGLAHLHAKVIHRDIKGQNVLLENAEVKLVDGVSACQLDR 180
5 NOV3c: 181		TVGRRNTFIGTPYWMAPEVIACDENPDATYDYSRSDIWSLGITAIEMAEGAPPLCDMHPMR 240
GCK : 181		TVGRRNTFIGTPYWMAPEVIACDENPDATYDYSRSDIWSLGITAIEMAEGAPPLCDMHPMR 240
NOV3c: 241		ALFLIPRNPPRPLKSKKWSKKFIDFIDTCLIKTYLSRPPTEQLLKFPFIRDQPTERQVRI 300
10 GCK : 241		ALFLIPRNPPRPLKSKKWSKKFIDFIDTCLIKTYLSRPPTEQLLKFPFIRDQPTERQVRI 300
NOV3c: 301		QLKDHXXXXXXXXXXXXXXXXXXXXXXXXXXXXXPSIMNVPGESTLRREFLRLQQ 360
GCK : 301		QLKDHIDRSRKKRGEKEETEYEYSGSEEEEDSHGEEGEPSSIMNVPGESTLRREFLRLQQ 360
15 NOV3c: 361		ENKSNSEALKXXXXXXXXXXXXRDPEAHIKHLLHXXXXXXXXXXXXXXXXXXXXXX 420
GCK : 361		ENKSNSEALKRDPEAHIKHLLHXXXXXXXXXXXXXXXXXXXXXX 420
20 NOV3c: 421		XXXXXXXXXXXXDMQALXXXXXXXXXXXXYIRHXXXXXXXXXXXXXXXXXXXXXY 480
GCK : 421		DMQAL-----RREEERRQAEREQEY 451 Y
25 NOV3c: 481		KRKXXXXXXXXXXXXXHAYLKSXXXXXXXXXXXXPGDRKPLYHYGRGM 540
GCK : 452		KRK HAYLKS PGDRKPLYHYGRGM
NOV3c: 541		KRKOLEEQRQSERLQRQLQQEHAYLKSLOQQQQQQQLQKQQQQQLLPGDRKPLYHYGRGM 511
30 GCK : 512		NPADKPAWAREVVVAH-----RVP 558
NOV3c: 559		NPADKPAWAREV + P
GCK : 572		NPADKPAWAREVEERTMNKQONSPLAKSKPGSTGPEPIPQASPGPPGPLSQTPPMQR 571
35 NOV3c: 602		LKPYAAP-----VPRSOSLQDQPTRNLAAPFASHXXXXXXXXXXXX 601
GCK : 632		++P P VPRSOSLQDQPTRNLAAPFASH
NOV3c: 662		VEPQEGPHKSLVAHRVPLKPYAAPVPRSOSLQDQPTRNLAAPFASHDPDAIPAPTATPS 631
40 GCK : 692		XRGAVIRQNSDPTSEGPGSPNPPAWVRPDNEAPPKVPQRTSSIATALNTSGAGGSRPAQ 661
NOV3c: 722		RGAVIRQNSDPTSEGPGSPNPPAWVRPDNEAPPKVPQRTSSIATALNTSGAGGSRPAQ
GCK : 752		ARGAVIRQNSDPTSEGPGSPNPPAWVRPDNEAPPKVPQRTSSIATALNTSGAGGSRPAQ 691
45 NOV3c: 782		AVRASNPDLRRSDPGWERSDSVLPASHGHLPOAGSLERNRVGVSSKPDSSPVLSPGNKAK 721
GCK : 812		AVRASNPDLRRSDPGWERSDSVLPASHGHLPOAGSLERNRVGVSSKPDSSPVLSPGNKAK
NOV3c: 842		AVRASNPDLRRSDPGWERSDSVLPASHGHLPOAGSLERNRVGVSSKPDSSPVLSPGNKAK 751
50 GCK : 872		PDDHRSRPGPASYKRAIGEDFVLLKERTLDEAPRPPKKAMDYXXXXXXXXXXXXXX 781
NOV3c: 902		PDDHRSRPGPASYKRAIGEDFVLLKERTLDEAPRPPKKAMDY
GCK : 932		PDDHRSRPGPASYKRAIGEDFVLLKERTLDEAPRPPKKAMDYSSSEVESSEDDEEEG 811
55 NOV3c: 962		NOV3c: 782 XXXXXXXXRDTPGGRSDGTDSTVSTMVHDVEEITGTQPPYGGTMVVQRTPEERNLLH 841
GCK : 1021		RDTPGGRSDGTDSTVSTMVHDVEEITGTQPPYGGTMVVQRTPEERNLLH
NOV3c: 842		EGGPAEGSRDTPGGRSDGTDSTVSTMVHDVEEITGTQPPYGGTMVVQRTPEERNLLH 871
GCK : 872		ADSNGYTNLPDVVQPSHSPTENSKGQSPPSKDGSGDYQSRLVKAPGKSSFTMFVDLGIY 901
NOV3c: 902		ADSNGYTNLPDVVQPSHSPTENSKGQSPPSKDGSGDYQSRLVKAPGKSSFTMFVDLGIY
GCK : 932		ADSNGYTNLPDVVQPSHSPTENSKGQSPPSKDGSGDYQSRLVKAPGKSSFTMFVDLGIY 931
60 NOV3c: 962		QPGGSGDSIPIITALVGGEGRDLQLQYDVRKGSVNNVNPTNTRAHSETPEIRKYKKRFNS 961
GCK : 1021		QPGGSGDSIPIITALVGGEGRDLQLQYDVRKGSVNNVNPTNTRAHSETPEIRKYKKRFNS
		QPGGSGDSIPIITALVGGEGRDLQLQYDVRKGSVNNVNPTNTRAHSETPEIRKYKKRFNS 991
		EILCAALWGVNLLVGTENGLMLDRSGQGKVYGLIGRRRFQQMDVLEGNLNLITISGKRN
		EILCAALWGVNLLVGTENGLMLDRSGQGKVYGLIGRRRFQQMDVLEGNLNLITISGKRN

GCK : 992 EILCAALWGVNLLVGTENGLMLDRSGQGKVYGLIGRRRFQQMDVLEGLNLLITISGKRN
1051

5 NOV3c: 1022 KLRVYYLSWLRNKILHNDPEVEKKQGWTTVGDMEGCGHYRVVKYERIKFLVIALKSSVEV
1081 KLRVYYLSWLRNKILHNDPEVEKKQGWTTVGDMEGCGHYRVVKYERIKFLVIALKSSVEV

GCK : 1052 KLRVYYLSWLRNKILHNDPEVEKKQGWTTVGDMEGCGHYRVVKYERIKFLVIALKSSVEV
1111

10 NOV3c: 1082 YAWAPKPYHKFMFKSFADLPHRPLLVDLTVEEGQRLKVIYGSSAGFHAVDVDSGN SYDI
1141 YAWAPKPYHKFMFKSFADLPHRPLLVDLTVEEGQRLKVIYGSSAGFHAVDVDSGN SYDI

GCK : 1112 YAWAPKPYHKFMFKSFADLPHRPLLVDLTVEEGQRLKVIYGSSAGFHAVDVDSGN SYDI
1171

15 NOV3c: 1142 YIPVHIQSQTIPHAIIFLPNTDGMEMLLCYEDEGVYVNTYGRRIKDVLQWGEMPTSVAY
1201 YIPVHIQSQTIPHAIIFLPNTDGMEMLLCYEDEGVYVNTYGRRIKDVLQWGEMPTSVAY

GCK : 1172 YIPVHIQSQTIPHAIIFLPNTDGMEMLLCYEDEGVYVNTYGRRIKDVLQWGEMPTSVAY
20 1231

NOV3c: 1202 ICSNQIMGWGEKAIEIRSVETGHLDGVFMHKRAQRLKFLCERNDKVFFASVRSGGSSQVY
1261 ICSNQIMGWGEKAIEIRSVETGHLDGVFMHKRAQRLKFLCERNDKVFFASVRSGGSSQVY

25 GCK : 1232 ICSNQIMGWGEKAIEIRSVETGHLDGVFMHKRAQRLKFLCERNDKVFFASVRSGGSSQVY
1291

NOV3c: 1262 FMTLNRCIMNW 1273 (SEQ ID No: 68)
FMTLNRCIMNW

30 GCK : 1292 FMTLNRCIMNW 1303 (SEQ ID NO: 35)

Based on its relatedness to known members of the STE20 family of protein kinases, NOV3b provides new diagnostic and therapeutic compositions useful in the treatment of disorders associated with alterations in the expression of members of the STE20 family of protein kinases. Nucleic acids, polypeptides, antibodies, and other compositions of the present invention are useful in the treatment and diagnosis of a variety of diseases and pathologies, including, by way of nonlimiting example, those involving metabolic and endocrine disorders, cancer, bone disorders, and tissue/cell growth regulation disorders.

40

NOV-3d

A NOV-3d sequence according to the invention is a nucleic acid sequence encoding a polypeptide related to STE20 family of protein kinases. A disclosed NOV-3d nucleic acid and its encoded polypeptide includes the sequences shown in Table 20. The disclosed nucleic acid (SEQ ID NO: 12) is 3735 nucleotides in length and contains an open reading frame (ORF) that begins with an ATG initiation codon at nucleotides 1-3 and ends with a TGA stop codon at nucleotides 3733-3735. The start and stop codons are shown in bold font. The disclosed, respective ORF encodes a 1244 amino acid polypeptide (SEQ ID NO: 13).

TABLE 20

ATGGGCGACCCAGCCCCCGCCAGCCTGGACGACATCGACCTGTCCGCCCTGGGGACCCCTGCTGGGATCTTGAGCT
 TGTGGAGGTGGTCCGCAATGGAACCTACGGACAGGTACAAGGGTCGGCATGTCAAGACACGGGAGCTGGCTGCCATCA
 5 AGGTACATGGATGTCA CGGAGGACGAGGAGGAAGAGATCAACACAGGAGATCAACATGCTGAAAAAGTACTCTCACCA CCGC
 AACATCGCCACCTACTACGGACCTTCATCAAGAAGAGCCCCCGGGAAACGATGACCAGCTCTGGCTGGT GATGGAGTT
 CTGTGGT GCTGGTTCAGT GACTGACCTGGTAAAGAACACAAAAGGCAACGCCCTGAAGGAGGACTGTATGCCCTATATCT
 GCAGGGAGATCCTCAGGGTCTGGCCATCTCCATGCCACAAGGTGATCCATGCCAGACATCAAGGGCAGAATGTGCTG
 10 CTGACAGAGAATGCTGAGGTCAAGCTAGTGGATTTGGGGTAGT GCTCAGCTGGACCGCACC GTGGGAGACCGAACAC
 TTTCATGGGACTCCCTACTGGATGGCTCCAGAGGTACATGCCCTGTGATGAGAACCCGTATGCCACCTATGATTACAGGA
 GTGATATTGGTCTCTAGGAATCACAGCCATCGAGATGGCAGAGGGAGCCCCCTCTGTGTGACATGCACCCATGCCA
 GCCCTCTCCCTCATTCCTCGAACCCCTCCGCCAGGTCAAGTCCAAGAAGTGGTCAAGAACGTTCAATTGACTTCATTGA
 CACATGTCTCATCAAGACTTACCTGAGCCGCCACCCACGGAGCAGCTACTGAAGTTCCCTCATCCGGGACCAGCCA
 15 CGGAGCGGCAGGTCCGATCCAGCTTAAGGACACATTGACCGATCCCGAAGAACGGGGTAGAAGAGGAGACAGAA
 TATGAGTACAGCGGCAGCGAGGAGGAAGATGACAGCCATGGAGAGGAAGGAGAGCCAAGCTCCATCATGAACGGTGCCTGG
 AGAGTCGACTCTACCCCCGGAGTTCTCCGGCTCCAGCAGGAAAATAAGAGCAACTCAGAGGTTTAAACAGCAGCAGC
 AGCTGCAGCAGCAGCAGCAGCAGGAGACCCCGAGGCACACATCAAACACCTGCTGCACCIAGGGCAGGGCAGCAGAGGAG
 CAGAAGGAGGAGGGCGCCGCGTGGAGGAGCAACGGGGAGCAGGGAGCAGGGAGCAGGGAGCAGGGAGCAGCA
 20 GCGGCGGCTGGAGGACATGCAGGCTCTGCGCGGGAGGAGGAGCGGGCGAGGGCGAGCAGGAGAATATATTGCTC
 ACAGGGCTAGAGGAGCAGCGGCAGTCAGAACGTCCTCAGAGGCAGCTGCAGCAGGAGCATGCCAACCTCAAGTCCCTGCAG
 CAGCAGCAACAGCAGCAGCAGCTTCAGAAACAGCAGCAGCAGCAGCTCCTGCCCTGGGACAGGAAGCCCCGTACCATTA
 TGGTCGGGGCATGAATCCCGCTGACAAACCCAGCCTGGGCCAGAGGTAGTGGCACACCGGGTCCC ACTGAAGCCATATG
 CAGCACCTGTACCCGATCCCTGAGGCCAGCCCACCCGAAACCTGGCTGCCCTCCCAGCCTCCCATGACCC
 25 GACCCCTGCCATCCCCCACCCACTGCCACGCCAGTGGCCAGGAGCTGTCACTGCCAGAACGTTCAAGGGCCACCTCTGA
 AGGACCTGGCCCTAGCCCTTAACACCAAGTGGGGCGGAGGGTCCCGCCAGATAACGAGGCCCCACCCAAAGGTGCCTCAGAGGACCT
 CATCTATGCCACTGCCCTTAACACCAAGTGGGGCGGAGGGTCCCGCCAGCCCAGGCAGTCCGTGCCAGTAACCCCGAC
 CTCAGGAGGAGCGACCTGGCTGGAGCAGCTCGACAGCGTCTTCCAGCCTCTCACGGGACACCTCCCCCAGGCTGGCTC
 ACTGGAGCGGAACCCGTGGAGTCTCTCCAAACCCGACAGCTCCCCGTGCTCTCCCTGGGAATAAGCCAAGCCG
 ACGACCACCGCTCACGGCCAGGCCGGCCGCAAGCTATAAGCGAGCAATTGAGGACTTTGTGTTGCTGAAAGAGCGG
 30 ACTCTGGACGAGGCCCTCGGCCCTCCCAAGAACGGCATGGACTACTCGCTGTCAGCGAGGAGGTGGAAAGCAGTGAGGA
 CGACGAGGAGGAAGCGAAGGCCAGCAGGGGAGCAGAGATAACCCCTGGGGCCGAGCGATGGGATACAGACA
 GCGTCAGCACCATGGTGGTCCACGACGTGAGGAGATCACCGGGACCCAGCCCCCATACGGGGCGGCACCATGGTGGTC
 CAGCGCACCCCTGAAGAGGAGCGGAACCTGTCATGCTGACAGCAATGGTACACAAACCTGCCGTACGTGGTCCAGCC
 CAGCCACTCACCCACCGAGAACAGCAAAGGCCAACCCCTCGAAGGATGGAGTGGT GACTACCAGTCTCGTGGG
 35 TGGTAAAGGCCCTGGCAAGAGCTCGTTCAAGATGTTGGATCTAGGATCTACAGCTGGAGGCACTGGGACAGC
 ATCCCCATCACGCCCTAGTGGTGGAGAGGGCACTCGGCTCGACCAGCTGCACTACGACGTGAGGAAGGGTCTGTGGT
 CAACGTGAATCCCAACACCCGGCCACAGTGAGACCCCTGAGATCCGGAGTACAAGAACGATTCAACTCCGAGA
 TCCCTGTGCAAGCCCTTGGGGGTCAACCTGCTGGCAGGAGAACGGCTGATGTTGCTGGACCGAAGTGGCAG
 GGCAAGGTGTATGGACTCATGGCGGCACGCTCCAGCAGATGGATGTGCTGGAGGGCTCAACCTGCTCATCACC
 40 CTCAGGGAAAAGGAACAAACTGCGGGTGTATTACCTGTCCTGGCTCCGAACAAAGATTCTGCACAATGACCCAGAAGTGG
 AGAAGAACGAGCGACCGTGGGACATGGAGGGCTGCGGGCACTACCGTGTGAAATACGAGCGGATTAAG
 TTCCCTGGTCACTGCCCTCAAGAGCTCCGTGGAGGTGATGCCCTGGGCCACACCCCTACCAAAATTCACTGCCCTCAA
 GTCCTTGGCCGACCTCCCCACCGCCCTCTGCTGGTCACGACTAGAGGAGGGCAGCGGCTCAAGGTCACTATG
 GCTCCAGTGCTGGCTCCATGCTGTGGATGTCAGCTGGGAACAGCTATGACATCTACATCCCTGTGCACTCCAGAGC
 45 CAGATCACGCCCATGCCATCATCTCCTCCCCAACACCGACGGCATGGAGATGCTGCTGTGCACTACGAGGACGAGGGTGT
 CTACGTCAACACGTACGGCGCATTAAGGATGTGGTGTGCACTGGGGAGATGCCACTTCTGTGGCTACATCT

GCTCCAACCAGATAATGGGCTGGGTGAGAAAGCCATTGAGATCCGCTCTGTGGAGACGGGCCACCTCGACGGGGTCTTC
ATGCACAAACGAGCTCAGAGGCTCAAGTTCTGTGTGAGCGGAATGACAAGGTGTTTGCCTCAGTCCGCTCTGGGGG
CAGCAGCCAAGTTACTTCATGACTCTGAACCGTAAC TGATCATGAAC TGGTGA (SEQ ID NO: 12)

5 MGDPAPARSLDDIDLSALRDPAGIFELVEVVGNITYGQVYKGRHVKTGQLAAIKVMDVTEDEEEEIKQEINMLKKYSHHR
NIATYYGAFIKKSPPGNDDQLWLWMEFCGAGSVTDLVKNKGNALKECDIAYICRETLRGLAHLHAKVIHRDIKGQNVL
LTENAEVKLVDFGVSAQLDRTVGRNNTFIGTPYMAPEVIACDENPDATYDYSRDIWSLGITAIEMAEGAPPLCDMHPMR
ALFLIPRNPPrLKSKKWSKKFIDFIDTCLIKTYLSRPPTEQLLKFPFIRDQPTERQVRIQLKDHDIDRSRKKRGEKEETE
YEYSGSEEEEDSHGEEGEPPSSIMNVPGESTILRREFLRLQENKSNSEALKQQQQLOQQQOORDPEAHIKHLLHQQRORRIEE
10 QKEERRVEEQRREREQRKLQEKEQQRRLEDQMQLRREEERQAEREQEYIRHLEEQRQSERLQRQLQOEHAYIKSLQ
QQQQQQQQLQKQQQQQLLPGDRKPLYHYGRGMNPADKPAWAREVVAVHRVPLKPYAAPVPRSQSLQDQPTRNLAAFPASHDP
DPAIPAPTATPSARGAVIRQNSDPTSEGPGPSNPAPWVVDNEAPPVVPQRTSSIATALNTSGAGGSRPAQAVRASNPD
LRRSDPGWERSDSVLPASHGHLQAGSLERNRVGSSKPDSVPSPGNKAKPDDHRSRPGRPASYKRAIGEDFVLLKER
TLDEAPRPPKKAMDYSSSSEEVESSEDDEEEGEGGPAGEGSRDTPGGRSDGDTDSVSTMVVHDVEITGTQPPYGGGTMVV
15 QRTPEEERNLLHADSNGYTNLPDVVQPSHSPTENSKGQSPSKDGSGDYQSRLVKA PGKSSFTMFVDLGIYQPGGSGDS
IPITALVGGEGRRLDQLQYDVRKGSSVNVNPTNTRAHSETPEIRKYKKRFNSEILCAALWGVNLLVGTENGMLLDRSGQ
GKVYGLTGRRRFQOMDVLEGLNLITISGKRNKLRVYYILSWLRNKLHNDPEVEKKQGWTTVGDMEGCGHYRVVKYERIK
FLVIALKSSVEVYAWAPKPYHKFMFKSFADLPHRPLLVDLTVEEGQRLKVIYGSSAGFHADVDGNSYDIYIPVHIQS
QITPHAIIFLPNTDGMEMILLCYEDEGVYVNTYGRIIKDVVLQWGEMPTSVAYICSNQIMGWGEKAIEIRSVETGHLDGVF
20 MKRAQLKFLCERNDKVFFASVRSGSSQVYFMTLNRCIMNW (SEQ ID NO: 13)

The disclosed NOV-3d nucleic acid sequence has homology (73% identity) to a mouse mRNA for a NIK protein (NIK) (GenBank Accession No: MMU88984), as shown in Table 21. NIK proteins are a subgroup of the STE20 family of protein kinases. As indicated by the 25 "Expect" value, the probability of this alignment occurring by chance alone is 2.2e-295. Moreover, the disclosed, encoded amino acid sequence has 1046 of 1303 amino acid residues (80%) identical to a human NIK-related protein (GenBank Accession No: BAA90753), shown in Table 22. Furthermore, the disclosed, encoded amino acid sequence also has homology (80% identity) to a human GCK kinase (GenBank Accession No: BAA94838), another 30 subgroup of the STE20 kinase family, as shown in Table 23. As indicated by the "Expect" value, the probability of these amino acid alignments occurring by chance alone are both 0.0, the lowest probability score.

TABLE 21

Score = 3832 (575.0 bits), Expect = 2.2e-295, Sum P(2) = 2.2e-295
 Identities = 1260/1725 (73%), Positives = 1260/1725 (73%), Strand = Plus /
 Plus

5	NOV3d: 4 GCGACCCAGCC-CCCGCCCGCAGCCTGGACGACATCGACCTGTCCGCCCTGCAGGGACCC 62 NIK : 3 GCGAACGACTCTCCCGCGAAGAGCCTGGTGGACATTGACCTGTCGTCCCTGCAGGGACCC 62
10	NOV3d: 63 TGCTGGGATTTGAGCTTGTGGAGGTGGTGGCAATGGAACCTACGGACAGGTGTACAA 122 TGCTGGGAT TTTGAGCT GTGGA GTGGT GG AATGG ACCTA GGACA GT TA AA NIK : 63 TGCTGGGATTTGAGCTGGTGGAAAGTGGTGGAAATGGCACCTATGGACAAGTCTATAA 122
15	NOV3d: 123 GGGTCGGCATGTCAAGACGGGGCAGCTGGCTGCCATCAAGGTATGGATGTCACGGAGGA 182 GGGTCG CATGT AA ACGG CA CTG C GCCATCAAGGT ATGGA GTCAC GAGGA NIK : 123 GGGTCGACATGTTAAAACGGT-CA-CTGCC-GCCATCAAGGTATGGACGTCACCGAGGA 179
20	NOV3d: 183 CGAGGAGGAAGAGATCAAACAGGAGATCAACATGCTGAAAAAGTACTCTCACCAACCGCAA 242 GA GAGGAAGA ATCA AC GGAGAT AA ATGCTGAA AAGTA TCTCA CA CG AA NIK : 180 TGAAGAGGAAGAAATCACACTGGAGATAAATATGCTGAAGAAGTATTCTCATCATCGAA 239
25	NOV3d: 243 CATGCCACCTACTACGGAGCCTTCATCAAGAAGAGCCCCCGGGAAACGATGACCAGCT 302 AT GCCAC TACTA GG GC TTCAT AAGAAGAGCCC CC GGA A GATGACCA CT NIK : 240 TATTGCCACGTACTATGGTCTTCATTAAGAAGAGCCCTCCAGGACATGATGACCAACT 299
30	NOV3d: 303 CTGGCTGGTGTGGAGTTCTGTGGTGTGGTCAGTGACTGACCTGGTAAAGAACACAAA 362 CTGGCT GT ATGGAGTT TGTGG GCTGG TC T AC GACCT GT AAGAACAC AA NIK : 300 CTGGCTTGTATGGAGTTGTGGGCTGGTCCATCACAGACCTGTGAAGAACACCAA 359
35	NOV3d: 363 AGGCAACGCCCTGAAGGAGGACTGTATGCCCTATATCTGCAGGGAGATCCTCAGGGTCT 422 AGG AAC C CT AA GA GACTG AT GC TA ATCT CAGGGAAATCCTCAGGGG T NIK : 360 AGGAAACACTCTCAAAGAAGACTGGATTGCTTACATCTCCAGGGAAATCCTCAGGGGATT 419
40	NOV3d: 423 GGCCATCTCCATGCCACAAGGTGATCCATCGAGACATCAAGGGCAGAATGTGCTGCT 482 GGC CATCTCCAT CAC A GT AT CA CGAGA ATCAAGGG CA AATGTGCTGCT NIK : 420 GGCACATCTCCATATTCAACCACGTTATTCAACCGAGATATCAAGGGCAAAATGTGCTGCT 479
45	NOV3d: 483 GACAGAGAATGCTGAGGTCAAGCTAGGGATTTGGGGTGAGTGCTCAGCTGGACCGC 542 GAC GAGAATGCTGAGGT AA CT GT GATTTGG GT AG GCTCAGCTGGAC G AC NIK : 480 GACCGAGAATGCTGAGGTGAAACTTGTGATTTGGTGTAAAGCGCTCAGCTGGACAGGAC 539
50	NOV3d: 543 CGTGGG-CAGACGGAACACTTCATGGACTCCCTACTGGATGGCTCCAGAGGT 601 GT GG C GA G AA AC TTCAT GG AC CCCTACTGGATGGCTCCAGAGGT NIK : 540 GGTGGACGGA-GAAATACGTTCATAGGCACACCCACTGGATGGCTCCAGAGGT 598

NOV3d: 602 CCTGTGATGAGAACCTGATGCCACCTATGATTACAGGAGTGTATTTGGTCTCTA-GGA
660 CCTGTGATGAGAACCC GA GCCAC TA GA TACAG AGTGA T TGGTC CT GG
5 NIK : 599 CCTGTGATGAGAACCCAGACGCCACTACGACTACAGAAGTGACCTCTGGTC-CTGTGGC
657

NOV3d: 661 ATCACAGCCATCGAGATGGCAGAGGGAGCCCCCTCTGTGTGACATGCACCCATGCGA
720 ATCACAGCCATCGAGATGGC GA GG G CCCCCCTCT TGTGACATGCA CC ATG GA
10 NIK : 658 ATCACAGCCATCGAGATGGCTGAAGGGGGCCCCCTCTGTGTGACATGCATCCAATGAGA
717

NOV3d: 721 GCCCTCTCCTCATTCCTCGAACCCCTCCGCCAGGCTCAAGTCCAAGAAGTGGCTAAG
780 GC CT TT CTCAT CC G AACCTCC CCCAGGCT AAGTC AA AA TGGTC AAG
NIK : 718 GCGCTGTTCTCATCCCCAGAAACCCCTCCAGGCTGAAGTCAAAAAAATGGTCAAAG
777

20 NOV3d: 781 AAGTTCATTGA-CTTCATTGACACATGTCTCATCAAGACTTACCTG-AGCCGCCACCCA
838 AA TT TT A CTT AT GA TGTCT T AAGA TTAC TG AGC GCCC C A
NIK : 778 AAATTT-TTCAGCTTATAGAAGGCTGTCTGGTGAAGAATTACATGCAGCGGCCCT-A
835

25 NOV3d: 839 CGGAGCAGCTACTGAAGTTCCCTCATCCGGACCAGCCCACGGAGCGGCAGGTCCGCA
898 C GAGCA CT T AA CC TTCAT GGGG CAGCCA GA GGCAGGT CG A
NIK : 836 CAGAGCAACTTTAAAACACCCTTCATAAGGGATCAGCCAATGAAAGGCAGGTCGAA
895

30 NOV3d: 899 TCCAGCTTAAGGACCACATTGACCGATCCCGGAAGAAGCGGGTGAGAAAAGAGGAGACAG
958 TCCAGCTTAAGGA CACAT GACCG CC G AAGAAG G GG GAGAAAGA GAGAC G
35 NIK : 896 TCCAGCTTAAGGATCACATAGACCGGACCAGAAAGAAGAGGGCAGAAAGATGAGACGG
955

NOV3d: 959 AATATGAGTACAGCGGCAGCGAGGAGGAAGATGAC-A-GC-CATGGAG-AGGAAGGAGAG
1014 A TA GAGTACAGCGG AGCGAGGAGGA GA GA A G C TG AG AGGA GGAGAG
40 NIK : 956 AGTACGAGTACAGCGGGAGCGAGGAGGAGGAGGAAGTGCCTG-AGCAGGAGGGAGAG
1014

45 NOV3d: 1015 CCAAGCTCCATCATGAACGTGCCTGGAGAGTCGACTCTACGCCGGAGTTCTCCGGCTC
1074 CCAAG TCCATC T AA GTGCCTGGAGAGTC ACTCT CG CG GA TT CT G CT
NIK : 1015 CCAAGTTCCATCGTCAATGTGCCTGGAGAGTCACACTCGCACGTGATTCCTGAGACTG
1074

50 NOV3d: 1075 CAGCAGGAAAATAAG-AGCAACTCAGAGGTTAAAACAG-CAGCAGCAGCTGCAGCAGC
1132 CAGCAGGA AA AAG AGC TC GAGGCT T AG CAGCAGC CTGCAG AGC
NIK : 1075 CAGCAGGAGAACAGGAGCGG-TCTGAGGCTCTGCAGGAGCAGCTCTGCAGGAGC
1132

55 NOV3d: 1133 AGCAGCAGCGAGACCCCGAGGCACACATCAAACACCTGCTGCACCAGCGGCAGCGCGCA
1192 AGCAGC CG GA C GAGG A A A CA CTGCTG AG GGCAG GCG A
NIK : 1133 AGCAGCTCCGGAGCAGGAGGAGTATAAGAGGAGCAGCTGCTGGCTGAGAGGCAGAACAGCGGA
1192

NOV3d: 1193 TAGAGGAGCAGAAGGAGGAGCGGGCGCGTGGAGGAGCAACAGCGGGAGCGGGA-G
1251

NIK : 1193 TGAACAGCAGAAAGAACAGAGGAGGCCTGAAAGAGCAACAAAGAAGAGAACGGAAAG
1252

5 NOV3d: 1252 CAGCGGAAGCTGCAGGAGAAGGAGCAGCAGCGCG-G--CTGGAGGACATGCAGGC-TCT
1307
C GGA GC GCAGGAG GAGCAGC CGGGCG G C GAGGA A G AGGC TCT
NIK : 1253 CCA-GGAGGCAGCAGGAGCGTGAGCAGCGCGGTGAACAAGAGGAGAAG-AGGCGTCT
1310

10 NOV3d: 1308 GCGGCGGG--GGAGGAGCGCGGGCAGGCCGGAGCGCGAGCAGGAATATATTCTCACAGG
1365
CG GG A GGA GCGGCG A G GAG GAG AGGA A C A AGG
NIK : 1311 -CGA-GGAACGGAAAGCGCGTAAAGAAGAGGAAGAG-AGGAG-ACGGGCAGAAGAGG
1366

15 NOV3d: 1366 CTA-GAGGAGCAGCGC-AGT---CAGAACGT-CTCCAGA-GGCAGCTGCAGCAGGAGCA
1418
A GAGGAG AG GG AG CAG A GT C CAG GGCAGCT AG AGGAGCA
20 NIK : 1367 AGAAGAGGAG-AGTGGAGAGGAACAGGA-GTACATCAGGCGCAGCTAGAGGAGGAGCA
1424

25 NOV3d: 1419 T-GCCTACCTCAAGTCCTGCAGCAGCACAGCAGCAGCTTCA-GAAACAGCA-
1475
G C ACCT AG CCTGCAGCAGCAGC C CAG AGCAG CA G AC GCA
NIK : 1425 GCGGC-ACCTGGAGATCCTGCAGCAGCAGCTGCTCCAGGAGCAGGC-CATGTTACTGCAC
1482

30 NOV3d: 1476 G-CAGCAGCAGCTCCTGCCTGGGA-CAGGAAGCCCCGTACCATTATGGTCGGGGCATG
1533
G C CAG AG CC GC G A CAG A GCC C G CC A G C G CA G
NIK : 1483 GACCACAGGAGG-CC-GCACGCACAGCAGCA-GCCGCCGCCCCGCA--G-CAG--CAGG
1534

35 NOV3d: 1534 AATCCCCTGACAAACC-AGCCTGG--GCCGAGAGGTAGTGGCACACCGGGTCCCA-CT
1589
A C G G CAAACC AGC T GC C AGAG G C CAC G CCC CT
NIK : 1535 A--CAGGA-G-CAAACCGAGCTTCATGCTCCAGAGCCCAGCCTCACTATGACCCCTGCT
1590

40 NOV3d: 1590 GA-AGCCATATGCAGC-ACC-TGTACCCGATCCCAGTCCCTGCAGGACCAGCCCACCCG
1646
GA AG T G AG AC TG CCC T CA TC CT AG AC A C CCC
NIK : 1591 GACAGAGCTCGGGAGGTACAGTGGTCCCACCTGGCA-TCTCTCAAGAACATGTCTCCCC
1649

45 NOV3d: 1647 AAACCTG-GCTGCC-TTCC--CAGCCTCCCATGACCCGACCCCTGC-CATCCCCGACCC
1701
C G G T CC TTCC CAG CCC T CCC A C GC CA C CC CC
50 NIK : 1650 TGTCTCGAGATCCCATTCTTCAGTGACCCCTCTCCAAATTC-GCACACCACCATCTCC
1708

NOV3d: 1702 ACTGCCACG-CCCAGTCCCC 1720 (SEQ ID NO: 69)
CT CA G CCCA TG CC

55 NIK : 1709 GCTCTCAGGACCCA-TGTCC 1727 (SEQ ID NO: 36)

TABLE 22

Score = 1995 bits (5170), Expect = 0.0
 Identities = 1046/1303 (80%), Positives = 1049/1303 (80%), Gaps = 67/1303 (5%)

5	NOV3d: 1	MGDPAPARSLEDDIDLSALRDPAGIFELVEVVGNQTYGQVYKGRHVKTGQLAAIKVMDVTX	60
		MGDPAPAPRSLEDDIDLSALRDPAGIFELVEVVGNQTYGQVYKGRHVKTGQLAAIKVMDVT	
	NIK : 1	MGDPAPAPRSLEDDIDLSALRDPAGIFELVEVVGNQTYGQVYKGRHVKTGQLAAIKVMDVTE	60
10	NOV3d: 61	XXXXXIKQEINMLKKYSHHRNIATYYGAFIKKSPPGNDDQLWLVMFCCAGSVTDLVKNT	120
		IKQEINMLKKYSHHRNIATYYGAFIKKSPPGNDDQLWLVMFCCAGSVTDLVKNT	
	NIK : 61	DEEEEIKQEINMLKKYSHHRNIATYYGAFIKKSPPGNDDQLWLVMFCCAGSVTDLVKNT	120
15	NOV3d: 121	KGNALKEDCIAYICREILRLAHLHAKVIHRDIKGQNVLLENAEVKLVDGFVSAQLDR	180
		KGNALKEDCIAYICREILRLAHLHAKVIHRDIKGQNVLLENAEVKLVDGFVSAQLDR	
	NIK : 121	KGNALKEDCIAYICREILRLAHLHAKVIHRDIKGQNVLLENAEVKLVDGFVSAQLDR	180
20	NOV3d: 181	TVGRRNTFIGTPYWMAPEVIACDENPDATYDYSRSDIWSL GITAIEMAEGAPPLCDMHPMR	240
		TVGRRNTFIGTPYWMAPEVIACDENPDATYDYSRSDIWSL GITAIEMAEGAPPLCDMHPMR	
	NIK : 181	TVGRRNTFIGTPYWMAPEVIACDENPDATYDYSRSDIWSL GITAIEMAEGAPPLCDMHPMR	240
25	NOV3d: 241	ALFLIPRNPPPRLKSKKWSKKFIDFIDTCLIKTYLSRPPTEQLLKFPFIRDQPTERQVRI	300
		ALFLIPRNPPPRLKSKKWSKKFIDFIDTCLIKTYLSRPPTEQLLKFPFIRDQPTERQVRI	
	NIK : 241	ALFLIPRNPPPRLKSKKWSKKFIDFIDTCLIKTYLSRPPTEQLLKFPFIRDQPTERQVRI	300
30	NOV3d: 301	QLKDHIXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXPSSIMNPVGESTLRREFLRLQQ	360
		QLKDHI PSSIMNPVGESTLRREFLRLQQ	
	NIK : 301	QLKDHDIDRSRKGEKEETEYEYSGSEEEDSHGEEGEPESSIMNPVGESTLRREFLRLQQ	360
35	NOV3d: 421	XXXXXXXXXXXXDMQALXXXXXXXXXXXXYIRHXXXXXXXXXXXXHAYLKSXX	480
		DMQAL Y R HAYLKS	
	NIK : 421	LQEKEQQRLEDMDQALRREEERRQAEREQEYKRQLEEQRQSERLQRQLQEHAYLKSQ	480
40	NOV3d: 481	XXXXXXXXXXXXPGDRKPLYHYGRGMNPADKPAWAREVVAH-----	526
		PGDRKPLYHYGRGMNPADKPAWAREVVAH-----	
	NIK : 481	QQQQQQQLQOQQQQQLPGDRKPLYHYGRGMNPADKPAWAREVEERTRMNKQONSPLAKS	540
45	NOV3d: 527	-----RVPLKPYAAP-----VPRSQ	541
		+ P++P P VPRSQ	
	NIK : 541	KPGSTGPEPIPQASPGPPGLSQTTPMQRVPQEGPHKSLVAHRVPLKPYAAPVPRSQ	600
50	NOV3d: 542	SLQDQPTRNLAAFPA SHXXXXXXXXXRGAVIRQNSDPTSEGPGSPNPPAWVRP	601
		SLQDQPTRNLAAFPA SH RGAVIRQNSDPTSEGPGSPNPPAWVRP	
	NIK : 601	SLQDQPTRNLAAFPA SHDPDAIPAPTATPSARGAVIRQNSDPTSEGPGSPNPPAWVRP	660
55	NOV3d: 602	DNEAPPKVPQRTSSIATALNTSGAGGSRPAQAVRASNPDLLRSDPGWERSDSVLPASHGH	661
		DNEAPPKVPQRTSSIATALNTSGAGGSRPAQAVRASNPDLLRSDPGWERSDSVLPASHGH	
	NIK : 661	DNEAPPKVPQRTSSIATALNTSGAGGSRPAQAVRASNPDLLRSDPGWERSDSVLPASHGH	720
60	NOV3d: 662	LPQAGSLERNRGGVSSKPDPSSPVLSPGNKAKPDDHRSRPGPASYKRAIGEDFVLLKERT	721
		LPQAGSLERNRGGVSSKPDPSSPVLSPGNKAKPDDHRSRPGPASYKRAIGEDFVLLKERT	
	NIK : 721	LPQAGSLERNRGGVSSKPDPSSPVLSPGNKAKPDDHRSRPGPASYKRAIGEDFVLLKERT	772
65	NOV3d: 722	LDEAPRPPKKAMDYXXXXXXXXXXXXXXXXXXXXXRDTPGGRSDGDTDSVSTMVVH	781
		RDTPGGRSDGDTDSVSTMVVH	
	NIK : 773	LDEAPRPPKKAMDYSSSSEEVESSEDDEEEGEGGPAEGSRDTPGGRSDGDTDSVSTMVVH	832
70	NOV3d: 782	DVEEITGTQPPYGGGTMVVQRTPEEERNLLHADSNGYTNLPDVVQPSHPTENSKQSPP	841

NIK : 833 DVEEITGTQPPYGGGTMVVQRTPEEERNLLHADSNGYTNLPDVVQPSHSPTENSKGQSPP
 NIK : 833 DVEEITGTQPPYGGGTMVVQRTPEEERNLLHADSNGYTNLPDVVQPSHSPTENSKGQSPP 892

5 NOV3d: 842 SKDGSQDYQSRGLVKAPGKSSFTMFVDLGIYQPGGSGDSIPITALVGGEGRLDQLQYDV 901
 NIK : 893 SKDGSQDYQSRGLVKAPGKSSFTMFVDLGIYQPGGSGDSIPITALVGGEGRLDQLQYDV 952

NOV3d: 902 RKGSVVNVNPNTNTRAHSETPEIRKYKKRFNSEILCAALWGVNLLVGTENGLMILLDRSGQG 961
 10 NIK : 953 RKGSVVNVNPNTNTRAHSETPEIRKYKKRFNSEILCAALWGVNLLVGTENGLMILLDRSGQG
 1012

NOV3d: 962 KVYGLIGRRRFQQMDVLEGNLNLLITISGKRNLRVYYLSWLRNKILHNDPEVEKKQGWTT
 15 1021 KVYGLIGRRRFQQMDVLEGNLNLLITISGKRNLRVYYLSWLRNKILHNDPEVEKKQGWTT
 NIK : 1013 KVYGLIGRRRFQQMDVLEGNLNLLITISGKRNLRVYYLSWLRNKILHNDPEVEKKQGWTT
 1072

NOV3d: 1022 VGDMECGHYRVVKYERIKFLVIALKSSVEVYAWAPKPYHKFMFKSFADLPHRPLLVDL
 20 1081 VGDMECGHYRVVKYERIKFLVIALKSSVEVYAWAPKPYHKFMFKSFADLPHRPLLVDL
 NIK : 1073 VGDMECGHYRVVKYERIKFLVIALKSSVEVYAWAPKPYHKFMFKSFADLPHRPLLVDL
 1132

25 NOV3d: 1082 TVEEGQRLKVIYGSSAGFHAVDVDSGNSYDIYIPVHIQSQITPHAIIFLPNTDGMEMLLC
 1141 TVEEGQRLKVIYGSSAGFHAVDVDSGNSYDIYIPVHIQSQITPHAIIFLPNTDGMEMLLC
 NIK : 1133 TVEEGQRLKVIYGSSAGFHAVDVDSGNSYDIYIPVHIQSQITPHAIIFLPNTDGMEMLLC
 1192

30 NOV3d: 1142 YEDEGVVNTYGRIIKDVVLQWGEMPTSVAIICSNQIMGWGEKAIEIRSvetGHLDGVFM
 1201 YEDEGVVNTYGRIIKDVVLQWGEMPTSVAIICSNQIMGWGEKAIEIRSvetGHLDGVFM
 NIK : 1193 YEDEGVVNTYGRIIKDVVLQWGEMPTSVAIICSNQIMGWGEKAIEIRSvetGHLDGVFM
 1252

NOV3d: 1202 HKRAQRQLKFLCERNDKVFFASVRSGGSSQVYFMTLNRNCIMNW 1244 (SEQ ID NO: 70)
 40 NIK : 1253 HKRAQRQLKFLCERNDKVFFASVRSGGSSQVYFMTLNRNCIMNW 1295 (SEQ ID NO: 37)

TABLE 23

Score = 2018 bits (5228), Expect = 0.0

Identities = 1054/1303 (80%), Positives = 1057/1303 (80%), Gaps = 59/1303
 45 (4%)

NOV3d: 1 MGDPAPARSLDDIDLSALRDPAGIFELVEVVGNGTYGQVYKGRHVKTGQAAIKVMDVTX 60
 MGDPAPARSLDDIDLSALRDPAGIFELVEVVGNGTYGQVYKGRHVKTGQAAIKVMDVT
 50 GCK : 1 MGDPAPARSLDDIDLSALRDPAGIFELVEVVGNGTYGQVYKGRHVKTGQAAIKVMDVTE 60

NOV3d: 61 XXXXXIKQEINMLKKYSHHRNIATYYGAFIKKSPPGNNDDQLWLVMFECGAGSVTDLVKNT 120
 IKQEINMLKKYSHHRNIATYYGAFIKKSPPGNNDDQLWLVMFECGAGSVTDLVKNT
 GCK : 61 DEEEEIKQEINMLKKYSHHRNIATYYGAFIKKSPPGNNDDQLWLVMFECGAGSVTDLVKNT 120

55 NOV3d: 121 KGNALKEDCTAYICREILRGLAHLHAHKVIHRDIKGQNVLLENAEVKLVDGFVSAQLDR 180
 KGNALKEDCTAYICREILRGLAHLHAHKVIHRDIKGQNVLLENAEVKLVDGFVSAQLDR
 GCK : 121 KGNALKEDCTAYICREILRGLAHLHAHKVIHRDIKGQNVLLENAEVKLVDGFVSAQLDR 180

NOV3d: 181 TVGRRNTFIGTPYWMAPEVIACDENPDATYDYRSIDIWSLGITAIEMAEGAPPLCDMHPMR 240
 60 TVGRRNTFIGTPYWMAPEVIACDENPDATYDYRSIDIWSLGITAIEMAEGAPPLCDMHPMR
 GCK : 181 TVGRRNTFIGTPYWMAPEVIACDENPDATYDYRSIDIWSLGITAIEMAEGAPPLCDMHPMR 240

NOV3d: 241 ALFLIPRNPPRPLSKWSKKFIDFIDTCLIKTYLSRPPTEQLLKFPFIRDQPTERQVRI 300
 GCK : 241 ALFLIPRNPPRPLSKWSKKFIDFIDTCLIKTYLSRPPTEQLLKFPFIRDQPTERQVRI 300

5 NOV3d: 301 QLKDHIXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXPSIMNPGESTLRLQQ 360
 GCK : 301 QLKDHIDRSRKRRGEKEETEYEYSGSEEEDSHGEEGEPSSIMNPGESTLRLQQ 360

10 NOV3d: 361 ENKSNSEALKXXXXXXXXXXRDPEAHIKHLLHXXXXXXXXXXXXXXXXXXXX 420
 GCK : 361 ENKSNSEALKQQQQLQQQQRDPEAHIKHLLHQQRRIEEQKEERRVEEQQRREQRK 420

15 NOV3d: 421 XXXXXXXXXXXXDMQALXXXXXXXXXXYIRXXXXXXXXXXXXHAYLKSXX 480
 GCK : 421 DMQAL Y R HAYLKS
 NOV3d: 481 XXXXXXXXXXXXXXXPGDRKPLYHYGRGMNPADKPAWAREVVAH----- 526
 GCK : 481 PGDRKPLYHYGRGMNPADKPAWAREV
 20 NOV3d: 527 -----RVPLKPYAAP-----VPRSQ 541
 GCK : 541 KPGSTGPEPPIPQASPGPPGPLSQTPPMQRVPVQECPHKSLVAHRVPLKPYAAPVPRSQ 600

25 NOV3d: 542 SLQDQPTRNLAAPFASHXXXXXXXXXXXXRGAVIRQNSDPTSEGPGPSPNPPAWVRP 601
 GCK : 601 SLQDQPTRNLAAPFASH RGAVIRQNSDPTSEGPGPSPNPPAWVRP
 NOV3d: 602 DNEAPPKVPQRTSSIATALNTSGAGGSRPAQAVRASNPDLRSDPGWERSDSVLPASHGH 661
 GCK : 661 DNEAPPKVPQRTSSIATALNTSGAGGSRPAQAVRASNPDLRSDPGWERSDSVLPASHGH 720

30 NOV3d: 662 LPQAGSLERNRGGVSSKPDSVPVSPGNKAKPDDHRSRPGRPASYKRAIGEDFVLLKERT 721
 GCK : 721 LPQAGSLERNRGGVSSKPDSVPVSPGNKAKPDDHRSRPGRPASYKRAIGEDFVLLKERT 780

35 NOV3d: 722 LDEAPRPPKKAMDYXXXXXXXXXXXXXXXXXXXXRDTPGGRSDGDTDSVSTMVVH 781
 GCK : 781 LDEAPRPPKKAMDY RDTPGGRSDGDTDSVSTMVVH
 NOV3d: 782 DVEITGTQPPYGGGTMVVQRTPEEERNLLHADSNGYTNLPDVVQPSHSPTENSKGQSPP 841
 GCK : 841 DVEITGTQPPYGGGTMVVQRTPEEERNLLHADSNGYTNLPDVVQPSHSPTENSKGQSPP 900

40 NOV3d: 842 SKDGSGDYQSRGLVKAPGKSSFTMFVDLGIYQPGGSGDSIPITALVGGEGRRLDQLQYDV 901
 GCK : 901 SKDGSGDYQSRGLVKAPGKSSFTMFVDLGIYQPGGSGDSIPITALVGGEGRRLDQLQYDV 960

45 NOV3d: 902 RKGSVVNVNPTNTRAHSETPEIRKYKKRFNSEILCAALWGVNLLVGTENGIMLLDRSGQG 961
 GCK : 961 RKGSVVNVNPTNTRAHSETPEIRKYKKRFNSEILCAALWGVNLLVGTENGIMLLDRSGQG
 1020

50 NOV3d: 962 KVYGLIGRRRFQQMDVLEGLNLLITISGKRNLRVYYLSWLRNKILHNDPEVEKKQGWTT
 1021
 GCK : 1021 KVYGLIGRRRFQQMDVLEGLNLLITISGKRNLRVYYLSWLRNKILHNDPEVEKKQGWTT
 1080

55 NOV3d: 1022 VGDMECGHRYVVKYERIKFLVIALKSSVEVYAWAPKPYHKFMFKSFADLPHRPLLVDL
 1081
 VGDMECGHRYVVKYERIKFLVIALKSSVEVYAWAPKPYHKFMFKSFADLPHRPLLVDL

GCK : 1081 VGDMECGGHYRVVKYERIKFLVIALKSSVEVYAWAPKPYHKFMAFKSFADLPHRPLLVDL
1140

5 NOV3d: 1082 TVEEGQRLKVIYGSSAGFHAVDVDSGNSYDIYIPVHIQSQITPHAIIFLPNTDGMEMLLC
1141

TVEEGQRLKVIYGSSAGFHAVDVDSGNSYDIYIPVHIQSQITPHAIIFLPNTDGMEMLLC

GCK : 1141 TVEEGQRLKVIYGSSAGFHAVDVDSGNSYDIYIPVHIQSQITPHAIIFLPNTDGMEMLLC
1200

10 NOV3d: 1142 YEDEGVVNTYGRIIKDVLQWGEMPTSVAYICSNQIMGWGEKAIEIRSVETGHLDGVFM
1201

YEDEGVVNTYGRIIKDVLQWGEMPTSVAYICSNQIMGWGEKAIEIRSVETGHLDGVFM

GCK : 1201 YEDEGVVNTYGRIIKDVLQWGEMPTSVAYICSNQIMGWGEKAIEIRSVETGHLDGVFM
1260

15 NOV3d: 1202 HKRAQRQLKFLCERNDKVFASVRSGGSSQVYFMTLNRCIMNW 1244 (SEQ ID NO: 71)
HKRAQRQLKFLCERNDKVFASVRSGGSSQVYFMTLNRCIMNW

GCK : 1261 HKRAQRQLKFLCERNDKVFASVRSGGSSQVYFMTLNRCIMNW 1303 (SEQ ID NO: 38)

20

Based on its relatedness to known members of the STE20 family of protein kinases, NOV3d provides new diagnostic and therapeutic compositions useful in the treatment of disorders associated with alterations in the expression of members of the STE20 family of protein kinases. Nucleic acids, polypeptides, antibodies, and other compositions of the present invention are useful in the treatment and diagnosis of a variety of diseases and pathologies, including, by way of nonlimiting example, those involving metabolic and endocrine disorders, cancer, bone disorders, and tissue/cell growth regulation disorders.

Table 24 shows a multiple sequence alignment of the disclosed NOV-3 polypeptides with a STE20 protein (GenBank Accession No: BAA90753), indicating the homology between the present invention and a known member of the protein family.

TABLE 24

STE20	MGDPAPARSLLLLDLSALRDPAGI FELVEVVNGTYGQVYKGRHVKTGQLAAIKVMDVTE
NOV3b	MGDPAPARSLLLLDLSALRDPAGI FELVEVVNGTYGQVYKGRHVKTGQLAAIKVMDVTE
35 NOV3a	MGDPAPARSLLLLDLSALRDPAGI FELVEVVNGTYGQVYKGRHVKTGQLAAIKVMDVTE
NOV3d	MGDPAPARSLLLLDLSALRDPAGI FELVEVVNGTYGQVYKGRHVKTGQLAAIKVMDVTE
NOV3c	MGDPAPARSLLLLDLSALRDPAGI FELVEVVNGTYGQVYKGRHVKTGQLAAIKVMDVTE *****
40 STE20	DEEEEIKQEINMLKKYSHHRNIATYYGAFIKKSPPGNDDQLWLVMFCGAGSVTDLVKNT
NOV3b	DEEEEIKQEINMLKKYSHHRNIATYYGAFIKKSPPGNDDQLWLVMFCGAGSVTDLVKNT
NOV3a	DEEEEIKQEINMLKKYSHHRNIATYYGAFIKKSPPGNDDQLWLVMFCGAGSVTDLVKNT
NOV3d	DEEEEIKQEINMLKKYSHHRNIATYYGAFIKKSPPGNDDQLWLVMFCGAGSVTDLVKNT
NOV3c	DEEEEIKQEINMLKKYSHHRNIATYYGAFIKKSPPGNDDQLWLVMFCGAGSVTDLVKNT *****
45 STE20	KGNALKEDCIAYICREILRGLAHLHAKVIIHRDIKGQNVLLTENAEVKLVDFGVSAQLDR
NOV3b	KGNALKEDCIAYICREILRGLAHLHAKVIIHRDIKGQNVLLTENAEVKLVDFGVSAQLDR
NOV3a	KGNALKEDCIAYICREILRGLAHLHAKVIIHRDIKGQNVLLTENAEVKLVDFGVSAQLDR
NOV3d	KGNALKEDCIAYICREILRGLAHLHAKVIIHRDIKGQNVLLTENAEVKLVDFGVSAQLDR
NOV3c	KGNALKEDCIAYICREILRGLAHLHAKVIIHRDIKGQNVLLTENAEVKLVDFGVSAQLDR *****

	STE20	TVGRRNTFIGTPYWMAPEVIACDENPDATYDYSRDIWSLGITAIEMAEGAPPLCDMHPMR
	NOV3b	TVGRRNTFIGTPYWMAPEVIACDENPDATYDYSRDIWSLGITAIEMAEGAPPLCDMHPMR
	NOV3a	TVGRRNTFIGTPYWMAPEVIACDENPDATYDYSRDIWSLGITAIEMAEGAPPLCDMHPMR
5	NOV3d	TVGRRNTFIGTPYWMAPEVIACDENPDATYDYSRDIWSLGITAIEMAEGAPPLCDMHPMR
	NOV3c	TVGRRNTFIGTPYWMAPEVIACDENPDATYDYSRDIWSLGITAIEMAEGAPPLCDMHPMR

10	STE20	ALFLIPRNPPPLKSKKWSKKFIDFIDTCLIKTYLSRPTEQLLKFPFIRDQPTERQVRI
	NOV3b	ALFLIPRNPPPLKSKKWSKKFIDFIDTCLIKTYLSRPTEQLLKFPFIRDQPTERQVRI
	NOV3a	ALFLIPRNPPPLKSKKWSKKFIDFIDTCLIKTYLSRPTEQLLKFPFIRDQPTERQVRI
	NOV3d	ALFLIPRNPPPLKSKKWSKKFIDFIDTCLIKTYLSRPTEQLLKFPFIRDQPTERQVRI
	NOV3c	ALFLIPRNPPPLKSKKWSKKFIDFIDTCLIKTYLSRPTEQLLKFPFIRDQPTERQVRI

15	STE20	QLKDHDIDRSRKKRGEKEETEYEYSGSEEEEDSHGEEGEPSSIMNVPGESTLRREFLRLQQ
	NOV3b	QLKDHDIDRSRKKRGEKEETEYEYSGSEEEEDSHGEEGEPSSIMNVPGESTLRREFLRLQQ
	NOV3a	QLKDHDIDRSRKKRGEKEETEYEYSGSEEEEDSHGEEGEPSSIMNVPGESTLRREFLRLQQ
	NOV3d	QLKDHDIDRSRKKRGEKEETEYEYSGSEEEEDSHGEEGEPSSIMNVPGESTLRREFLRLQQ
20	NOV3c	QLKDHDIDRSRKKRGEKEETEYEYSGSEEEEDSHGEEGEPSSIMNVPGESTLRREFLRLQQ

25	STE20	ENKSNSEALKQQQOLQQQOORDPEAHIKHLLHQQRRIEEQKEERRVEEQQREREQRK
	NOV3b	ENKSNSEALKQQQOLQQQOORDPEAHIKHLLHQQRRIEEQKEERRVEEQQREREQRK
	NOV3a	ENKSNSEALKQQQOLQQQOORDPEAHIKHLLHQQRRIEEQKEERRVEEQQREREQRK
	NOV3d	ENKSNSEALKQQQOLQQQOORDPEAHIKHLLHQQRRIEEQKEERRVEEQQREREQRK
	NOV3c	ENKSNSEALKQQQOLQQQOORDPEAHIKHLLHQQRRIEEQKEERRVEEQQREREQRK

30	STE20	LQEKEQQRLEDQALRREEERROAEREQEYKRQLEE-----
	NOV3b	LQEKEQQRLEDQALRREEERROAEREQEYIRHRLEE-----
	NOV3a	LQEKEQQRLEDQALRREEERROAEREQEYIRHRLEE-----
	NOV3d	LQEKEQQRLEDQALRREEERROAEREQEYIRHRLEE-----
35	NOV3c	LQEKEQQRLEDQALRREEERROAEREQEYIRHRLEE-----
		***** * : ***
40	STE20	-----QRQSERLQRQLQQEHAYLKSLOQQQQQQQLQKQQQQQLLPGDRKPLYHYGRGM
	NOV3b	-----QRQSERLQRQLQQEHAYLKSLOQQQQQQQLQKQQQQQLLPGDRKPLYHYGRGM
	NOV3a	KRKOLEEQRQSERLQRQLQQEHAYLKSLOQQQQQQQLQKQQQQQLLPGDRKPLYHYGRGM
	NOV3d	-----QRQSERLQRQLQQEHAYLKSLOQQQQQQQLQKQQQQQLLPGDRKPLYHYGRGM
	NOV3c	KRKOLEEQRQSERLQRQLQQEHAYLKSLOQQQQQQQLQKQQQQQLLPGDRKPLYHYGRGM

45	STE20	NPADKPAWAREVEERTRMNKQQNSPLAKSKPGSTGPEPPPIPQASPGPPGPLSQTPPMQRP
	NOV3b	NPADKPAWAREVEERTRMNKQQNSPLAKSKPGSTGPEPPPIPQASPGPPGPLSQTPPMQRP
	NOV3a	NPADKPAWAREVEERTRMNKQQNSPLAKSKPGSTGPEPPPIPQASPGPPGPLSQTPPMQRP
	NOV3d	NPADKPAWAREV-----
	NOV3c	NPADKPAWAREV-----

50	STE20	VEPQEGPHKSLVAHRVPLKYAAPVPRSQSLQDQPTRNLAAFPASHDPDAIPAPTATPS
	NOV3b	VEPQEGPHKSLVAHRVPLKYAAPVPRSQSLQDQPTRNLAAFPASHDPDAIPAPTATPS
	NOV3a	VEPQEGPHKSLVAHRVPLKYAAPVPRSQSLQDQPTRNLAAFPASHDPDAIPAPTATPS
	NOV3d	-----VAHRVPLKYAAPVPRSQSLQDQPTRNLAAFPASHDPDAIPAPTATPS
55	NOV3c	-----VAHRVPLKYAAPVPRSQSLQDQPTRNLAAFPASHDPDAIPAPTATPS

60	STE20	ARGAVIRQNSDPTSEGPGPSPNPPAWVRPDNEAPPKVPQRTSSIATALNTSGAGGSRPAQ
	NOV3b	ARGAVIRQNSDPTSEGPGPSPNPPAWVRPDNEAPPKVPQRTSSIATALNTSGAGGSRPAQ
	NOV3a	ARGAVIRQNSDPTSEGPGPSPNPPAWVRPDNEAPPKVPQRTSSIATALNTSGAGGSRPAQ
	NOV3d	ARGAVIRQNSDPTSEGPGPSPNPPAWVRPDNEAPPKVPQRTSSIATALNTSGAGGSRPAQ
	NOV3c	ARGAVIRQNSDPTSEGPGPSPNPPAWVRPDNEAPPKVPQRTSSIATALNTSGAGGSRPAQ

	STE20	AVRASNPDLRSDPGWERSDSVLPASHGHLHQAGSLERNR VGVSSKP DSSPV LSPGNKAK
	NOV3b	AVRASNPDLRSDPGWERSDSVLPASHGHLHQAGSLERNR VGVSSKP DSSPV LSPGNKAK
5	NOV3a	AVRASNPDLRSDPGWERSDSVLPASHGHLHQAGSLERNR VGVSSKP DSSPV LSPGNKAK
	NOV3d	AVRASNPDLRSDPGWERSDSVLPASHGHLHQAGSLERNR VGVSSKP DSSPV LSPGNKAK
	NOV3c	AVRASNPDLRSDPGWERSDSVLPASHGHLHQAGSLERNR VGVSSKP DSSPV LSPGNKAK

10	STE20	PDDHRSRPGRPA-----DFVLLKERTLDEAPRPPKKAMDYSSSSEEVESSEDDEEEG
	NOV3b	PDDHRSRPGRPASYKRAIGEDFVLLKERTLDEAPRPPKKAMDYSSSSEEVESSEDDEEEG
	NOV3a	PDDHRSRPGRPASYKRAIGEDFVLLKERTLDEAPRPPKKAMDYSSSSEEVESSEDDEEEG
	NOV3d	PDDHRSRPGRPASYKRAIGEDFVLLKERTLDEAPRPPKKAMDYSSSSEEVESSEDDEEEG
	NOV3c	PDDHRSRPGRPASYKRAIGEDFVLLKERTLDEAPRPPKKAMDYSSSSEEVESSEDDEEEG

15	STE20	EGGPAGE SRDTPGGRS DGD TDSV STMV VHD VEEITGTQPYGGGTMV QRT PEEERNLLH
	NOV3b	EGGPAGE SRDTPGGRS DGD TDSV STMV VHD VEEITGTQPYGGGTMV QRT PEEERNLLH
	NOV3a	EGGPAGE SRDTPGGRS DGD TDSV STMV VHD VEEITGTQPYGGGTMV QRT PEEERNLLH
	NOV3d	EGGPAGE SRDTPGGRS DGD TDSV STMV VHD VEEITGTQPYGGGTMV QRT PEEERNLLH
20	NOV3c	EGGPAGE SRDTPGGRS DGD TDSV STMV VHD VEEITGTQPYGGGTMV QRT PEEERNLLH

25	STE20	ADSN GYT NLPDV VQP SHS PTEN SKQ SPP SKDG SG DY QSR GLV KAPG KSS FT M FVD LGI Y
	NOV3b	ADSN GYT NLPDV VQP SHS PTEN SKQ SPP SKDG SG DY QSR GLV KAPG KSS FT M FVD LGI Y
	NOV3a	ADSN GYT NLPDV VQP SHS PTEN SKQ SPP SKDG SG DY QSR GLV KAPG KSS FT M FVD LGI Y
	NOV3d	ADSN GYT NLPDV VQP SHS PTEN SKQ SPP SKDG SG DY QSR GLV KAPG KSS FT M FVD LGI Y
	NOV3c	ADSN GYT NLPDV VQP SHS PTEN SKQ SPP SKDG SG DY QSR GLV KAPG KSS FT M FVD LGI Y

30	STE20	QP GGS GD SI PITAL VGG EGTR LDQ LQY D VRKG SVV NVN PNT NTRA HSET PEIR KYKK R FNS
	NOV3b	QP GGS GD SI PITAL VGG EGTR LDQ LQY D VRKG SVV NVN PNT NTRA HSET PEIR KYKK R FNS
	NOV3a	QP GGS GD SI PITAL VGG EGTR LDQ LQY D VRKG SVV NVN PNT NTRA HSET PEIR KYKK R FNS
	NOV3d	QP GGS GD SI PITAL VGG EGTR LDQ LQY D VRKG SVV NVN PNT NTRA HSET PEIR KYKK R FNS
35	NOV3c	QP GGS GD SI PITAL VGG EGTR LDQ LQY D VRKG SVV NVN PNT NTRA HSET PEIR KYKK R FNS

40	STE20	EILCAALWGVNLLVGTENGLMLLDRSGQGKVYGLIGRRRFQQMDVLEGLNLLITISGKR N
	NOV3b	EILCAALWGVNLLVGTENGLMLLDRSGQGKVYGLIGRRRFQQMDVLEGLNLLITISGKR N
	NOV3a	EILCAALWGVNLLVGTENGLMLLDRSGQGKVYGLIGRRRFQQMDVLEGLNLLITISGKR N
	NOV3d	EILCAALWGVNLLVGTENGLMLLDRSGQGKVYGLIGRRRFQQMDVLEGLNLLITISGKR N
	NOV3c	EILCAALWGVNLLVGTENGLMLLDRSGQGKVYGLIGRRRFQQMDVLEGLNLLITISGKR N

45	STE20	KLRVYYLSWLRN KILHNDPEVEKKQGWTTVGDMEGCGHYRVV KYERIKFLVIALKSSVEV
	NOV3b	KLRVYYLSWLRN KILHNDPEVEKKQGWTTVGDMEGCGHYRVV KYERIKFLVIALKSSVEV
	NOV3a	KLRVYYLSWLRN KILHNDPEVEKKQGWTTVGDMEGCGHYRVV KYERIKFLVIALKSSVEV
	NOV3d	KLRVYYLSWLRN KILHNDPEVEKKQGWTTVGDMEGCGHYRVV KYERIKFLVIALKSSVEV
	NOV3c	KLRVYYLSWLRN KILHNDPEVEKKQGWTTVGDMEGCGHYRVV KYERIKFLVIALKSSVEV

50	STE20	YAWAPKPYHKFM AFKS FADLPHRPLLVDLTVEEGQRLKVIYGSSAGFH A DV DSGNSYDI
	NOV3b	YAWAPKPYHKFM AFKS FADLPHRPLLVDLTVEEGQRLKVIYGSSAGFH A DV DSGNSYDI
	NOV3a	YAWAPKPYHKFM AFKS FADLPHRPLLVDLTVEEGQRLKVIYGSSAGFH A DV DSGNSYDI
	NOV3d	YAWAPKPYHKFM AFKS FADLPHRPLLVDLTVEEGQRLKVIYGSSAGFH A DV DSGNSYDI
55	NOV3c	YAWAPKPYHKFM AFKS FADLPHRPLLVDLTVEEGQRLKVIYGSSAGFH A DV DSGNSYDI

60	STE20	YIPVHIQS QIT PHAI I FLP NTDGM EMILL CYE DEG VY VNT YGRI IKD VV LQW GEMPT SVAY
	NOV3b	YIPVHIQS QIT PHAI I FLP NTDGM EMILL CYE DEG VY VNT YGRI IKD VV LQW GEMPT SVAY
	NOV3a	YIPVHIQS QIT PHAI I FLP NTDGM EMILL CYE DEG VY VNT YGRI IKD VV LQW GEMPT SVAY
	NOV3d	YIPVHIQS QIT PHAI I FLP NTDGM EMILL CYE DEG VY VNT YGRI IKD VV LQW GEMPT SVAY
	NOV3c	YIPVHIQS QIT PHAI I FLP NTDGM EMILL CYE DEG VY VNT YGRI IKD VV LQW GEMPT SVAY

STE20 NOV3b NOV3a 5 NOV3d NOV3c	ICSNQIMGWGEKAIEIRSVETGHLDGVFMHKRAQRLKFLCERNDKVFFASVRSGGSSQVY ICSNQIMGWGEKAIEIRSVETGHLDGVFMHKRAQRLKFLCERNDKVFFASVRSGGSSQVY ICSNQIMGWGEKAIEIRSVETGHLDGVFMHKRAQRLKFLCERNDKVFFASVRSGGSSQVY ICSNQIMGWGEKAIEIRSVETGHLDGVFMHKRAQRLKFLCERNDKVFFASVRSGGSSQVY *****
---	---

10 STE20 NOV3b NOV3a NOV3d NOV3c	FMTLNRNCIMNW (SEQ ID NO: 39) FMTLNRNCIMNW (SEQ ID NO: 9) FMTLNRNCIMNW (SEQ ID NO: 7) FMTLNRNCIMNW (SEQ ID NO: 13) FMTLNRNCIMNW (SEQ ID NO: 11) *****
--	---

15 **Consensus key**
 * - single, fully conserved residue
 : - conservation of strong groups
 . - conservation of weak groups
 - no consensus

20

Based on the relatedness between NOV-3 and STE20 kinases, the disclosed NOV3 proteins are novel members of the STE20 protein kinase family. Therefore, the nucleic acids and proteins of the inventions are useful in potential therapeutic applications implicated in various pathologies and disorders described and other pathologies and disorders related to 25 aberrant function or aberrant expression of these STE20-protein kinases.

Potential therapeutic uses for the nucleic acids and proteins of the invention include, by way of nonlimiting example, protein therapeutic, small molecule drug target, antibody target (including therapeutic, diagnostic, or drug targeting/cytotoxic antibodies), diagnostic and/or prognostic marker, gene therapy (gene delivery/gene ablation), research tools, and tissue 30 regeneration *in vitro* and *in vivo* (regeneration for all these tissues and cell types composing these tissues and cell types derived from these tissues).

The nucleic acids and proteins of the invention are useful in potential therapeutic applications implicated in various names of pathologies/disorders described above, as well as other pathologies or disorders. For example, a cDNA encoding the STE20 protein kinase-like 35 protein may be useful in gene therapy, and the STE20 protein kinase-like protein may be useful when administered to a subject in need thereof. By way of nonlimiting example, the compositions of the present invention will have efficacy for treatment of patients suffering from the pathologies described above. The novel nucleic acids encoding the STE20 protein kinase-like proteins, and the STE20 protein kinase-like proteins of the invention, or fragments 40 thereof, may further be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed. These materials are further useful in the generation of antibodies that bind immunospecifically to the novel substances of the invention for use in therapeutic or diagnostic methods.

NOV-4: A Novel Trypsin Inhibitor-like protein

The NOV-4 sequences (NOV-4a, NOV-4b, NOV-4c, NOV-4d, and NOV-4e) according to the invention are nucleotide sequences encoding respective polypeptides related 5 to trypsin inhibitor proteins.

The disclosed NOV-4 sequences are splice variants. Splice variants occur naturally. When a variant and the original sequence have the same or opposite activity, they may differ in various properties not directly connected to biological activity. A certain variant may be expressed mainly in one tissue, while the original sequence from which it has been varied, or 10 another variant derived from the same sequence, may be expressed mainly in another tissue. The presence or level of specific splice variants may be the cause, and/or indicative of, a disease, disorder, pathological or normal condition.

Because a drug may be effective against one variant but not another, or may cause side effects because it targets all splice variants, an effective drug needs to target the particular 15 splice variant. Because soluble variants with therapeutic or disease-related functions may be naturally occurring in specific tissues, they may be optimal candidates for drug targets or protein therapeutics. Variants may have no activity at all and may serve as dominant negative natural inhibitors. Thus, splice variants useful in generating new drug targets, protein therapeutics and markers for diagnostics.

20 NOV-4 sequences according to the invention encode polypeptides related to trypsin inhibitor proteins that are expressed in brain tumors, polypeptides related to sperm coat glycoproteins, and polypeptides related to glioma pathogenesis related proteins. See Yamakawa et al., 1998, Biochim Biophys Acta 1395(2):202-8; Murphy et al., 1995, Gene 159(1): 131-5. In addition, similarities were found between NOV-4 and insect allergens in 25 wasps, hornets, fire ants, and secreted/membrane proteins in nematode pathogens. See J Allergy Clin Immunol 1990, 85(6):988-96. Therefore, the nucleic acids and proteins of the NOV-4 splice variants described in this invention can have similar functions as these proteins.

NOV-4 proteins are expressed in the following tissues: pituitary gland, mammary gland, adrenal gland, thalamus, and fetal lung.

30 Functional roles attributed to trypsin inhibitor proteins include sperm coat maturation, immunological responses, glioma pathogenesis, and signal transduction pathways. Thus, NOV-4 nucleic acids and polypeptides, antibodies and related compounds according to the invention will be useful in therapeutic and diagnostic applications in disorders associated with, e.g., reproductive disorders, immunological disorders, cancer, and metabolic disorders.

Additional utilities for NOV-4 nucleic acids and polypeptides according to the invention are disclosed herein.

NOV-4a

5 A NOV-4a sequence according to the invention is a nucleic acid sequence that encodes a polypeptide related to trypsin inhibitor proteins. A disclosed NOV-4a nucleic acid and its encoded polypeptide is included in Table 25. The disclosed nucleic acid (SEQ ID NO: 14) is 2305 nucleotides in length and contains an open reading frame (ORF) that begins with an ATG initiation codon at nucleotide 453, and ends with a TGA stop codon at nucleotide 1602.

10 10 A disclosed, representative ORF encodes a 383 amino acid polypeptide (SEQ ID NO: 15). NOV-4a is missing one exon in the 5' nucleotide region compared to other splice variants (NOV-4b and NOV-4c), resulting in an alternative methionine start codon and a Kozak sequence.

15 **TABLE 25**

```

CTCTGACTGCTCCTATTGAGCTGTCTGCTCGCTGTGCCCGCTGTGCCTGCTGTGCCCGCG
CTGTCGCCGCTGCTACCGCGTCTACTGGACGCCGGAGACGCCAGCGAGCTGGTGATTGGA
GCCCTGCCGAGAGCTCAAGGCCAGCTCTGCCCGAGGAGGCCAGGCTGCCCGTGAGTC
CCATAGTTGCTACAGGAGTGGAGGCCATGAGCTGCGTCCTGGTGGTGTCACTCCCTTGGG
20 GCTGCTGTTCTGGTCCGCCGATCCAAAGGCTACCTCCTGCCAACGTCACTCTCTTAGA
GGAGCTGCTCAGCAAATACCAGCACAAACGAGTCTCACTCCGGTCCGCAGAGCCATCCC
CAGGGAGGACAAGGGAGATCCTCATGCTGACAACAAGCTTCGGGCCAGGTGCAGCC
TCAGGCCTCCAACATGGAGTACATGACCTGGGATGACGAACCTGGGCAGGTATCGCTCTC
CGGGGTTCCATGTGCAAGTCCCTGGTATGACGAGGTGAAGGACTACACCTACCCCTACCCGA
25 GCGAGTGCAACCCCTGGTGTCCAGAGAGGTGCTCGGGGCTATGTGCACGCACACACAC
AGATAGTTGGGCCACCACCAACAAGATCGGTTGTGCTGTGAACACCTGCCGGAAGATGA
CTGTCTGGGAGAAGTTGGGAGAACCGCGGTCTACTTTGTCTGCAATTATTCTCCAAAGG
GGAACCTGGATTGGAGAAGCCCCCTACAAGAATGGCCGGCCCTGCTCTGAGTGCCCAACCA
GCTATGGAGGCAGTGCAGGAACAACCTGTGTACCGAGAGAAACCTACACTCCAAAAC
30 CTGAAACGGACGAGATGAAATGAGGTGGAAACCGCTCCATTCTCTGAAGAAAACCATGTTT
GGCTCCAACCGAGGGTGATGAGACCCACCAAGCCCAAGAAAACCTCTGCCGTCAACTACA
TGACCCAAGTCGTAGATGTGACACCAAGATGAAGGGACAGGTGCAAAGGGTCCACGTGTA
ACAGGTACAGTGCCCAGCAGGCTGCCATGACACCAAGGCGAAGATCTTGAACTCTGT
TCTATGAAAGCTCGTCTAGCATATGCCGCCGCATCCACTACGGGATCTGGATGACA
35 AGGGAGGCCCTGGTGGATATCACCAGGAACGGGAAGGTCCCCCTCTCGTGAAGTCTGAGA
GACACGGCGTGCAGTCCCTCAGCAAATACAAACCTTCCAGCTCATTCTGGTGTCAAAG
TGAAAGTGCAGGATTGGACTGCTACACGACCGTTGCTCAGCTGTGCCGTTGAAAAGC
CAGCAACTCACTGCCAAGAATCCATTGTCCGGCACACTGCAAAGACGAACCTTCTACT
GGGCTCCGGTGGTGGAGCAACCAACATCTATGCAGATAACCTCAAGCATTGCAAGACAGCCG
40 TGCACGCCGGAGTCATCAGCAACGAGAGTGGGGGTGACGTGGACGTGATGCCGTGGATA
AAAAGAAGACCTACGTGGGTCGCTCAGGAATGGAGTTCACTGAAAGCCTGGGGACTC

```

CTCGGGATGGAAAGGCCCTCCGGATCTTGCTGTCAAGCAGTGAATTCCAGCACCAAGGG
 GAGAAGGGCGTCTCAGGAGGGCTCGGGGTTTGCTTTATTTTATTTGTCATTGC
 GGGGTATATGGAGACTCAGGAAACTTCCCTTGACTGATGTTCACTGTCATCAGTGTCA
 GCCTGTGGGTGAGGTGACATCTCATCCCCTCACTGAAGCAACAGCATCCAAAGGTGCTCA
 5 GCCGGACTCCCTGGTCCTGATCCTGCTGGGCCCGGGGCTCCATCTGGACGTCCCT
 CTCCTTAAAGAGATCTGAGCTGTCCTTAAAGGGACAGTTGCCAAAATGTTCCCTGCTA
 . TGTGTTCTCTGTTGGAGGAAGTTGATTCAACCTCCCTGCCAAAAGAACAAACCAT
 TTGAAGCTACAATTGTGAAGCATTACGGCGTCGGAAGAGGCCTTTGAGCAAGGCCA
 ATGAGTTTCAGGAATGAAGTAGAAGGTAGTTATTTAAAAATAAAAACACAGTCGTCCC
 10 TACCAATAGAGGAAATGGTTTAATGTTGCTGGTCAGACAGACAAATGGCTAGAGTA
 AGAGGGCTGCGGTATGAGAGACCCCGCTCCGCCCTGGCACGTGTCCTGCTGGCGCC
 CGCCACAGGCCCTCAATGGCGCATTCAAGATGGCTCTATACACAGCAGTGCTGGTT
 TATGTAAAGTTCAAGCAGTCACCTCA (SEQ ID NO: 14)

15 MTNWGRYRSPGFHVQSWYDEVKDYTYYPSECNPWCPERCSPGMCHYTQIVWATTN
 KIGCAVNTCRKMTVWGEVWENAVYFVCNYSPKGWNIGEAPYKNRPCSECPPSYGG
 CRNNLCYREETYTPKPETDEMNEVETAPIPEENHVLQPRVMRPTPKKTSAVNYMT
 QVVRCDTKMKDRCKGSTCNRYQCPAGCLNHKAKIFGTLFYESSSSICRAAIHYGILD
 DKGGLVDIRNGKVPFFVKSERHGVQSLSKYKPSSSFMVSKVKVQDLCYTTVAQLC
 20 PFEKPATHCPRIHCPAHCKDEPSYWAPVFGTNIYADTSSICKTAVHAGVISNESGGD
 VDVMPVDKKKYVGSLRNGVQSESLGTPRDGKAFRIFAVRQ (SEQ ID NO: 15)

The disclosed NOV-4a amino acid sequence has a high level of homology (99% identity, 99% similarity) to a human trypsin inhibitor-like protein (GenBank Accession No: CAB66795), shown in Table 26. Moreover, the NOV-4a amino acid sequence has homology (72% identity, 82% similarity) to a known human trypsin inhibitor (TREMBL ACC No: 043692), also shown in Table 26. As indicated by the "Expect" values, the probability of these alignments occurring by chance alone is 0.0 and 5.3e-51, respectively.

30 **TABLE 26**

- Score = 786 bits (2031), Expect = 0.0
Identities = 380/381 (99%), Positives = 381/381 (99%)

35	NOV4a: 3 NWGRYRSPGFHVQSWYDEVKDYTYYPSECNPWCPERCSPGMCHYTQIVWATTNKIGCA	62
	+WGGRYRSPGFHVQSWYDEVKDYTYYPSECNPWCPERCSPGMCHYTQIVWATTNKIGCA	
	TRYP : 117 HWGRYRSPGFHVQSWYDEVKDYTYYPSECNPWCPERCSPGMCHYTQIVWATTNKIGCA	176
40	NOV4a: 63 VNTCRKMTVWGEVWENAVYFVCNYSPKGWNIGEAPYKNRPCSECPPSYGGSCRNNLCYR	122
	VNTCRKMTVWGEVWENAVYFVCNYSPKGWNIGEAPYKNRPCSECPPSYGGSCRNNLCYR	
	TRYP : 177 VNTCRKMTVWGEVWENAVYFVCNYSPKGWNIGEAPYKNRPCSECPPSYGGSCRNNLCYR	236
45	NOV4a: 123 EETYTPKPETDEMNEVETAPIPEENHVLQPRVMRPTPKKTSAVNYMTQVVRCDTKMD	182
	EETYTPKPETDEMNEVETAPIPEENHVLQPRVMRPTPKKTSAVNYMTQVVRCDTKMD	
	TRYP : 237 EETYTPKPETDEMNEVETAPIPEENHVLQPRVMRPTPKKTSAVNYMTQVVRCDTKMD	296
	NOV4a: 183 RCKGSTCNRYQCPAGCLNHKAKIFGTLFYESSSSICRAAIHYGILDDKGGLVDITRNGKV	242
	RCKGSTCNRYQCPAGCLNHKAKIFGTLFYESSSSICRAAIHYGILDDKGGLVDITRNGKV	
	TRYP : 297 RCKGSTCNRYQCPAGCLNHKAKIFGTLFYESSSSICRAAIHYGILDDKGGLVDITRNGKV	356

NOV4a: 243 PFFVKSERHGVQSLSKYKPSSSFMVKVKVQDLDCTTVAQLCPFEKPATHCPRIHCPAH 302
 PFFVKSERHGVQSLSKYKPSSSFMVKVKVQDLDCTTVAQLCPFEKPATHCPRIHCPAH
 TRYP : 357 PFFVKSERHGVQSLSKYKPSSSFMVKVKVQDLDCTTVAQLCPFEKPATHCPRIHCPAH 416

5 NOV4a: 303 CKDEPSYWAPVFGTNIYADTSSICKTAVHAGVISNESGGDVDVMPVDKKKTYVGSLRNGV 362
 CKDEPSYWAPVFGTNIYADTSSICKTAVHAGVISNESGGDVDVMPVDKKKTYVGSLRNGV
 TRYP : 417 CKDEPSYWAPVFGTNIYADTSSICKTAVHAGVISNESGGDVDVMPVDKKKTYVGSLRNGV 476

10 NOV4a: 363 QSESLGTPRDGKAFRIFAVRQ 383 (SEQ ID NO: 72)
 QSESLGTPRDGKAFRIFAVRQ
 TRYP : 477 QSESLGTPRDGKAFRIFAVRQ 497 (SEQ ID NO: 40)

- 15 • Score = 530 (186.6 bits), Expect = 5.3e-51, P = 5.3e-51
 Identities = 85/117 (72%), Positives = 97/117 (82%)

NOV4a: 5 GRYRSPGPHVQSWYDEVKDYTYPYPSECNPWCPERCSPGMCTHYTQIVWATTNKIGCAVN 64
 GRYRS V+ WYDEVKDY +YPY +CNP CP RC GPMCTHYTQ+VWAT+N+IGCA++
 TRYP : 130 GRYRSILQLVLPWYDEVKDYAFPYQPDCNPRCPMRCFGPMCTHYTQMWWATSNRIGCAIH 189

20 NOV4a: 65 TCRKMTVWGEVWNENAVYFVCNYSPKGNWIGEAPYKNGRPCSECPPSYGGSCRNNLCY 121 (SEQ ID NO: 73)
 TC+ M VWG VW AVY VCNY+PKGNWIGEAPYK G PCS CPPSYGGSC +NLC+
 TRYP : 190 TCQNMMNVWSVWRRAVYLVCNYAPKGNWIGEAPYKVGVPCSSCPPSYGGSCTDNLCF 246 (SEQ ID NO: 41)

Furthermore, a PROSITE database search of protein families and domains confirmed that a NOV-4a polypeptide is a member of the trypsin inhibitor family. One of the conserved regions found in trypsin inhibitors is a SCP domain, located at the C-terminal half. The 30 pattern of this conserved domain is: [LIVMFYH]-[LIVMFY]-x-C-[NQRHS]-Y-x-[PARH]-x-[GL]-N-[LIVMFYWDN] (SEQ ID NO: 56). This pattern is found in amino acids 81-92 of SEQ ID NO: 15.

PSORT analyses indicate that that NOV-4a is likely located in the nucleus (certainty = 0.3000). The predicted molecular weight of NOV-4a is 43185.7 daltons.

35 Based on its relatedness to known members of the trypsin inhibitor family of proteins, NOV4a provides new diagnostic and therapeutic compositions useful in the treatment of disorders associated with alterations in the expression of members of the trypsin inhibitor protein family. Nucleic acids, polypeptides, antibodies, and other compositions of the present invention are useful in the treatment and diagnosis of a variety of diseases and pathologies, 40 including, by way of nonlimiting example, those involving reproductive disorders, immunological disorders, cancer, and metabolic disorders.

NOV-4b

A disclosed NOV-4b sequence according to the invention is a nucleic acid sequence 45 that encodes a polypeptide related to trypsin inhibitor proteins. A disclosed NOV-4b nucleic acid and its encoded polypeptide are included in Table 27. The disclosed nucleic acid (SEQ ID NO: 16) is 2400 nucleotides in length and contains an open reading frame (ORF) that

begins with an ATG initiation codon at nucleotide 205, and ends with a TGA stop codon at nucleotide 1697. A disclosed, representative ORF encodes a 497 amino acid polypeptide (SEQ ID NO: 17).

5

TABLE 27

CTCTGACTGCTCCTATTGAGCTGTCTGCTCGCTGTGCCCTGCTGTGCCCGCCTGTCGCCGCTGCTACCGCG
TCTACTGGACGGAGACGCCAGCAGCTGGTATTGGAGCCCTGCGGAGAGCTCAAGCGCCAGCTCTGCCCGAGGAG
CCCAGGCTGCCCGTGAATGCCCATAGTTGCTCAGGAGTGGAGCCATGAGCTGCCCTGGGTGGTGTATCCCCTGGG
GCTGCTGTTCCCTGGTCCCGGGATCCCAAGGCTACCTCCTGCCCAACGTCACTCTTAGAGGAGCTGCTCAGCAAATACC

10

AGCACAAACGAGTCACCTCCGGGTCGCAGGCCATCCCCAGGGAGGACAAGGAGGAGATCCTCATGCTGCACAACAAG
CTTCGGGGCCAGGTGCAGCCTCAGGCCCTCCAACATGGAGTACATGACCTGGGATGACGAACGGAGACTCTGCTGCAGC
GTGGGCCAGTCAGTGCATCTGGGAGCACGGGCCACCGGTCTGCTGGTGTCCATGGGCAGAACCTGGGCGCTCACTGGG
GCAGGTATCGCTCCGGGTTCCATGTGCAGTCCTGGTATGACGAGGTGAAGGAGTACACCTACCCCTACCGAGCGAG

15

TGCAACCCCTGGTGTCCAGAGAGGGTCTCGGGGCTATGTGCACGCACACTACACAGATAGTTGGGCCACCACCAAACAA
GATCGGTTGTGTGAACACCTGCCGAAGATGACTGTCTGGGAGAAGTTGGGAGAACGGGTCTACTTGTCTGCA
ATTATTCTCAAAGGGAACTGGATTGGAGAACGCCCTACAAGAATGGCCGCCCTGCTCTGAGTGCCAACCGAGCTAT

GGAGGCAGCTGCAGGAACAAACTTGTGTTACCGAGAACAAACCTACACTCCAAAACCTGAAACGGACAGGAGATGAATGAGGT
GGAAACGGCTCCCATTCTGAAGAAAACCATGTTGGCTCCAACCGAGGGTGTAGAGACCCACCAAGCCAAGAAAACCT

20

CTGCGGTCAACTACATGACCCAAGTCGTCAGATGTGACACCAAGATGAAGGACAGGTCAAAGGGTCCACGTGTAACAGG
TACCAAGTGGCCAGCAGGCTGCCCTGAACCACAAGGCGAAGATCTTGGAACTCTGTTCTATGAAAGCTCGTCTAGCATATG
CCGCGCCGCCATCCACTACGGGATCCTGGATGACAAGGGAGGCTGGATATCACCAGGAACGGGAAGGTCCCCTCT

TCGTGAAGTCTGAGAGACACGGCGTGCAGTCCTCAGCAAATACAACCTTCCAGCTCATTGTCAGGTTGCAAAAGTGAAA

GTGCAGGATTGGACTGCTACAGCACCGTTGCTCAGCTGTGCCCTGGTAAAGGCCAGCAACTCACTGCCCAAGAACATCCA

TTGTCCGGCACACTGCAAAGACGAACCTCTACTGGCTCCGGTGTGTTGAAACCAACATCTATGAGATAACCTCAAGCA

25

TCTGCAAGACAGCGTGCACGCCGGAGTCATCAGCAACGAGAGTGGGGTGAACGGTGTGATGCCGTGGATAAAAAG
AAGACCTACGTGGGCTCGCTCAGGAATGGAGGTTCACTGAAAGCCTGGGACTCCTGGGATGGAAAGGCCTTCCGGAT

CTTGCTGTCAGGCAGTGAATTCCAGCACCAAGGGAGAAGGGCGTCTCAGGAGGGCTTGGGTTTGCTTTTATTT

TTATTTGTCATTGGGGTATATGGAGAGTCAGGAAACTTCTTGTACTGATGTTCACTGTCAGGTTGCACTCATTGTCAGGTTG
TGGGTGAGGTGACATCTCATCCCTCACTGAAAGCAACAGCATTCCCAAGGTGCTCAGCCGGACTCCCTGGTGCCTGATCCT

30

GCTGGGGCCCGGGGGTCTCCATCTGGACGTCTCTCCTTAAGAGATCTGAGCTGTCTTAAAGGGGACAGTGCCT
AAATGTTCCCTGCTATGTTCTCTGGTGGAGGAAGTTGATTTCAACCTCCCTGCCAAAGAACAAACCAATTGAA

GCTCACAATTGTAAGCATTCA CGCGCTCGGAAGAGGCCTTGAGCAACAGCCTGGGATGGAAAGTGAAGTAGAAG

GTAGTTATTTAAAAAATAAAAACACAGTCCGTCCCTACCAATAGAGGAAATGGTTTATGTTGCTGGTCAGACAGAC

AAATGGGCTAGAGTAAGAGGGCTGGGGTATGAGAGACCCGGCTCCGCCCTGGCACGTGTCCTGGCAGACAGAC

35

CAGGCCCTTCATGGCCGATTCAAGGATGGCTCTATACACAGCAGTGTGGTTATGAAAGTTCAAGCAGTCACCTCA

(SEQ ID NO: 16)

40

MSCVLGGVIPLGLLFLVRGSQGYLLPNVTLEELLSKYQHNESHSRVRAIPREDKEEILMLHNKLRGVQPQASNM
EYMTWDDELEKSAAAASQCIWEHGPGLLVSIGQNLGAHWGRYRSPGFHVQSWSYDEVKDITYYPSECPNPWCPERC

SGPMCTHYTQIVWATTNKIGCAVNTRKMTVGEVWENAVYFCNVSPKGWIGEAPYKNRPCSECPPSYGGSCRN

NLCYREETYTPKPETDEMNEVETAPIPEENHVWLQPRVMRPTPKKTSAVNYMTQVVRCDTKMKDRCKSTCNRYQC

PAGCLNHKAIFGSLFYESSSSICRAAIHYGILDDKGGLVDITRNGKVFFVKSERHGVQSLSKYKPSSFMVSKVK

VQDLDCYTTVAQLCPFEKPATHCPRIHCPCAKDEPSYWAPVFGTNIYADTSSICKTAVHAGVISNESGGDVMPV

DKKKTYVGSLRNGVQSESLGTPRDKAFRIFAVRQ (SEQ ID NO: 17)

The disclosed NOV-4b amino acid sequence has 124 of 191 amino acid residues (64%) identical to, and 148 of 191 (77%) similar to, a known human trypsin inhibitor (TREMBL ACC No: 043692), as shown in Table 28. As indicated by the "Expect" value, the probability 5 of this alignment occurring by chance alone is 6.1e-73, which is a very low probability score.

TABLE 28

Score = 737 (259.4 bits), Expect = 6.1e-73, P = 6.1e-73
 Identities = 124/191 (64%), Positives = 148/191 (77%)

10	NOV4b:	45 SRVRAIPREDKEEILMLHNKLRGQVQPQASNMEYMTWDDLEKSAAAWASQCIWEHGPT 104 +R +R I + D IL HN++RG+V P A+NMEYMWD+ L KSA AWA+ CIW+HGP+
	TRYP :	56 ARRKRYISQNDMIAILDYHNQVRGKVFPAAANMEYMVWDENLAKSAEWAATCIWDHGPS 115
15	NOV4b:	105 GLLVSIGQNGLGAHWGRYRSPGFHVQSWSYDEVKDYTYPYPSECNPWCPERCSGPMCTHYTQ 164 LL +GQNL GRYRS V+ WYDEVKDY +PYP +CNP CP RC GPMCTHYTQ
	TRYP :	116 YLLRFLGQNLSVRTGRYRSILQLVKPWYDEVKDYAFPYQDCNPRCPMRCFGPMCTHYTQ 175
20	NOV4b:	165 IVWATTNKIGCAVNTRKMTTVWGEVWENAVYFVCNYSPKGNWIGEAPYKNGRPCSECPPS 224 +VWAT+N+IGCA++TC+ M VWG VW AVX VCNY+PKGWNWIGEAPYK G PCS CPPS
	TRYP :	176 MVWATSNRIGCAIHTCQNMNVWGSVWRRAVLYLCVNYAPKGWNWIGEAPYKVGVPCSSCPPS 235
	NOV4b:	225 YGGSCRNNLCY 235 (SEQ ID NO: 74) YGGSC +NLC+
25	TRYP :	236 YGGSCTDNLCF 246 (SEQ ID NO: 42)

Furthermore, a PROSITE database search of protein families and domains confirmed that NOV-4a is a member of the trypsin inhibitor family. One of the conserved regions found 30 in trypsin inhibitors is a SCP domain, located at the C-terminal half. The pattern of this conserved domain is: [LIVMFYH]-[LIVMFY]-x-C-[NQRHS]-Y-x-[PARH]-x-[GL]-N-[LIVMFYWDN] (SEQ ID NO: 56). This pattern is found in amino acids 195-206 of SEQ ID NO: 17.

SignalPep and PSORT analyses indicate that NOV-4b is likely located outside of 35 the cell (certainty = 0.6950), and is likely to have a cleavable N-terminal signal sequence with a cleavage site between positions 22 and 23: SQG-YL. The predicted molecular weight of NOV-4b is 55928.2 daltons.

Based on its relatedness to known members of the trypsin inhibitor family of proteins, NOV4b provides new diagnostic and therapeutic compositions useful in the treatment of 40 disorders associated with alterations in the expression of members of the trypsin inhibitor protein family. Nucleic acids, polypeptides, antibodies, and other compositions of the present invention are useful in the treatment and diagnosis of a variety of diseases and pathologies, including, by way of nonlimiting example, those involving reproductive disorders, immunological disorders, cancer, and metabolic disorders.

NOV-4c

A NOV-4c sequence according to the invention is a nucleic acid sequence that encodes a polypeptide related to trypsin inhibitor proteins. A disclosed NOV-4c nucleic acid and its encoded polypeptide are included in Table 29. The disclosed nucleic acid (SEQ ID NO: 18) is 1669 nucleotides in length and contains an open reading frame (ORF) that begins with an ATG initiation codon at nucleotide 205, and ends with a TAG stop codon at nucleotide 1636. The representative ORF encodes a 205 amino acid polypeptide (SEQ ID NO: 19).

10

TABLE 29

TCTGACTGCTCCTATTGAGCTGTCGCTCGCTGTGCCCTGTGCCTGCTGTGCCCGCG
 TGTCGCCGCTGCTACCGCGTCACTGGACGCCAGAGCCAGCGAGCTGGTGATTGGAG
 CCCTGCCGAGAGCTCAAGGCCAGCTCTGCCCGAGGAGCCAGGCTGCCCGTGAGTCC
 CATAGTTGCTGCAGGAGTGGAGCCATGAGCTGCCTGGGTGGTGTCACTCCCTTGGGG
 15 CTGCTGTTCTGGTCTCGGATCCAAAGGCTACCTCCTGCCAACGTCACTCTCTTAGAG
 GAGCTGCTCAGCAAATACCAGCACAAACGAGTCTCACTCCCGGGTCCGAGAGCCATCCCC
 AGGGAGGACAAGGAGGAGATCCTCATGCTGCACAAACAAGCTTCGGGGCAGGTGCAGCCT
 CAGGCCTCCAACATGGAGTACATGACCTGGGATGACGAACGGAGAAGTCTGCTGCAGCG
 TGGGCCAGTCAGTGCATCTGGGAGCACGGGCCACCGGTCTGCTGGTGTCCATGGGCAG
 20 AACCTGGGCGCTCACTGGGCAAGGTATCGCTCTCGGTTTCATGTGCAGTCCTGGTAT
 GACGAGGTGAAGGACTACACCTACCCCTACCCGAGCGAGTGCAACCCCTGGTGTCCAGAG
 AGGTGCTCGGGGCTATGTGCACGCACACACAGATAGTTGGGCCACCAACAAG
 ATCGGTTGTGCTGTGAACACCTGCCGGAAGATGACTGTCTGGGAGAAGTTGGAGAAC
 GCGGTCTACTTGTCTGCAATTATTCTCAAAGGGAACTGGATTGGAGAAGCCCCCTAC
 25 AAGAATGGCCGGCCCTGCTCTCAGTGCCAACCCAGCTATGGAGGCAGCTGCAGGAACAAC
 TTGTGTTACCGAGAAGAAAACCTACACTCCAAAACCTGAAACGGACGAGATGAATGAGGTG
 GAAACGGCTCCCATTCTGAAGAAAACCATGTTGGCTCCAACCGAGGGTGTGAGAACCC
 ACCAAGCCAAGAAAACCTCTCGGTCAACTACATGACCCAAGTCGTCTATGTGACACC
 AAGATGAAGGGACAGGTGCAAAGGGTCCACGTGAAACAGGTACCACTGCCAGCAGGCTGC
 30 CTGAACCACAAGCGAAGATCTTGAACTCTGTTCTATGAAAGCTCGTCTAGCATATGC
 CGCGCCGCCATCCACTACGGGATCCTGGATGACAAGGGAGGCCCTGGTGGATATCACCAGG
 AACGGGAAGGTCCCCCTTCTCGTGAAGTCTGAGAGACACGGCGTGCAGTCCTCAGCAA
 TACAAACCTTCCAGCTCATTGTTGTCAGGAAAGTGAAAGTGCAGGATTGACTGCTAC
 ACGACCGTTGCTCAGTGTGCCGTTGAAAGCCAGCAACTCACTGCCAACAAATCCAT
 35 TGTCCGGCACACTGCAAAGACGAACCTTCTACTGGCTCEGGTGTGAAACCAACATC
 TATGCAGATAACCTCAAGCATCTGCAAGACAGCCGTGCACGCCAGTCACTGACGAG
 AGTGGGGGTGACGTGGACGTGATGCCGTGGATAAAAGAAGACCTACACCTGCCGGCA
 GCCGCTCGAGCCCTATAGTGTAAACCGATTGCGACACTGGCGCCGT (SEQ ID
 NO: 18)

40

MSCVLGGVIPLGLLFLVCGSQGYLLPNVTLEELLSKYQHNESHSRVRAIP
 REDKEEILMLHNKLRGVQPQASNMEMTWDDELEKSAAAASQCIWEHGPT

GLLVSIGQNLGAHWGRYRSPGFHVQSWYDEVKDYTYPYPSECNPWCPCERCSG
 PMCTHYTQIVWATTNKIGCAVNTCRKMTVWGEVWENAVYFVCNYSPKGWNWIG
 EAPYKNGRPCSQCPPSYGGSCRNNLCYREETYTPKPETDEMNEVETAPIPEE
 NHVWLQPRVMRPTPKKTSSVNYSMTQVVLCDTKMKDRCKGSTCNRYQCPAGC
 5 LNHAKAKIFGTLFYESSSSICRAAIHYGILDDKGGLVDITRNGKVPPFKSER
 HGVQSLSKYKPSSSFMVSKVKVQDLDCTTVAQLCPFEKPATHCPRIHCPAH
 CKDEPSYWAPVFGTNIYADTSSICKTAVHAGVISNESGGDVDVMPVDKKTY
 TCPAAARAL (SEQ ID NO: 19)

10 The disclosed NOV-4c amino acid sequence has a high level of homology (97% identity, 97% similarity) to a human trypsin inhibitor-like protein (GenBank Accession No: CAB66795), shown in Table 30. As indicated by the "Expect" value, the probability of this alignment occurring by chance alone is 0.0, the lowest probability score.

15 **TABLE 30**

Score = 948 bits (2452), Expect = 0.0
 Identities = 458/468 (97%), Positives = 460/468 (97%)

20	NOV4c : 1	MSCVLGGVIPLGLLFLVCGSQGYLLPNVTXXXXXXSKYQHNESHSRVRAIPREDKEIL	60
		MSCVLGGVIPLGLLFLVCGSQGYLLPNVT	SKYQHNESHSRVRAIPREDKEIL
	TRYP : 1	MSCVLGGVIPLGLLFLVCGSQGYLLPNVTILLELLSKYQHNESHSRVRAIPREDKEIL	60
25	NOV4c : 61	MLHNKLRGQVQPQASNMEYMTWDDELEKSAAAASQCIWEHGPTGLLVSIGQNLGAHWGR	120
		MLHNKLRGQVQPQASNMEYMTWDDELEKSAAAASQCIWEHGPT	LLVSIGQNLGAHWGR
	TRYP : 61	MLHNKLRGQVQPQASNMEYMTWDDELEKSAAAASQCIWEHGPTSLLVSIGQNLGAHWGR	120
30	NOV4c : 121	YRSPGFHVQSWYDEVKDYTYPYPSECNPWCPCERCSGPMCTHYTQIVWATTNKIGCAVNTC	180
		YRSPGFHVQSWYDEVKDYTYPYPSECNPWCPCERCSGPMCTHYTQIVWATTNKIGCAVNTC	
	TRYP : 121	YRSPGFHVQSWYDEVKDYTYPYPSECNPWCPCERCSGPMCTHYTQIVWATTNKIGCAVNTC	180
35	NOV4c : 181	RKMTVWGEVWENAVYFVCNYSPKGWNWIGEAPYKNGRPCSQCPPSYGGSCRNNLCYREETY	240
		RKMTVWGEVWENAVYFVCNYSPKGWNWIGEAPYKNGRPCS+CPPSYGGSCRNNLCYREETY	
	TRYP : 181	RKMTVWGEVWENAVYFVCNYSPKGWNWIGEAPYKNGRPCSECPPSYGGSCRNNLCYREETY	240
40	NOV4c : 241	TPKPETDEMNEVETAPIPEENHVWLQPRVMRPTPKKTSSVNYSMTQVVLCDTKMKDRCKG	300
		TPKPETDEMNEVETAPIPEENHVWLQPRVMRPTPKKTTS+VNYSMTQVVLCDTKMKDRCKG	
	TRYP : 241	TPKPETDEMNEVETAPIPEENHVWLQPRVMRPTPKKTSAVNYSMTQVVRCDTKMKDRCKG	300
45	NOV4c : 301	STCNRYQCPAGCLNHAKIFGTLFYESSSSICRAAIHYGILDDKGGLVDITRNGKVPPFV	360
		STCNRYQCPAGCLNHAKIFGTLFYESSSSICRAAIHYGILDDKGGLVDITRNGKVPPFV	
	TRYP : 301	STCNRYQCPAGCLNHAKIFGTLFYESSSSICRAAIHYGILDDKGGLVDITRNGKVPPFV	360
50	NOV4c : 361	KSERHGVQSLSKYKPSSSFMVSKVKVQDLDCTTVAQLCPFEKPATHCPRIHCPAHCDE	420
		KSERHGVQSLSKYKPSSSFMVSKVKVQDLDCTTVAQLCPFEKPATHCPRIHCPAHCDE	
	TRYP : 361	KSERHGVQSLSKYKPSSSFMVSKVKVQDLDCTTVAQLCPFEKPATHCPRIHCPAHCDE	420
	NOV4c : 421	PSYWAPVFGTNIYADTSSICKTAVHAGVISNESGGDVDVMPVDKKTY	468 (SEQ ID NO: 75)
		PSYWAPVFGTNIYADTSSICKTAVHAGVISNESGGDVDVMPVDKKTY	
	TRYP : 421	PSYWAPVFGTNIYADTSSICKTAVHAGVISNESGGDVDVMPVDKKTY	468 (SEQ ID NO: 43)

Furthermore, a PROSITE database search of protein families and domains confirmed that NOV-4c is a member of the trypsin inhibitor family. One of the conserved regions found in trypsin inhibitors is a SCP domain, located at the C-terminal half. The pattern of this conserved domain is: [LIVMFYH]-[LIVMFY]-x-C-[NQRHS]-Y-x-[PARH]-x-[GL]-N-[LIVMFYWDN] (SEQ ID NO: 56). This pattern is found in amino acids 81-92 of SEQ ID NO: 19.

In addition, SignalPep and PSORT analyses indicate that NOV-4c is likely located outside of the cell (certainty = 0.8200), and is likely to have a cleavable N-terminal signal sequence with a cleavage site between positions 22 and 23: SQG-YL. The predicted molecular weight of NOV-4c is 53587.7 daltons.

Based on the relatedness between NOV-4c and the conserved trypsin inhibitor proteins, the NOV-4c protein is a novel member of the trypsin inhibitor family. NOV-4c provides new diagnostic and therapeutic compositions useful in the treatment of disorders associated with alterations in the expression of members of the trypsin inhibitor protein family. Nucleic acids, polypeptides, antibodies, and other compositions of the present invention are useful in the treatment and diagnosis of a variety of diseases and pathologies, including, by way of nonlimiting example, those involving reproductive disorders, immunological disorders, cancer, and metabolic disorders.

NOV-4d

A NOV-4d sequence according to the invention is a nucleic acid sequence that encodes a polypeptide related to trypsin inhibitor proteins. A disclosed NOV-4d nucleic acid and its encoded polypeptide are included in Table 31. The disclosed nucleic acid (SEQ ID NO: 20) is 2403 nucleotides in length and contains an open reading frame (ORF) that begins with an ATG initiation codon at nucleotide 206, and ends with a TGA stop codon at nucleotide 1700. A disclosed, representative ORF encodes a 498 amino acid polypeptide (SEQ ID NO: 21).

TABLE 31

CTCTGACTGCTCCATTGAGCTGCTGCTCGCTGTCCCCCTGTGCCCTCTGTGCCCGCGCTGCCCGCTGCTACCGCG
30 TCTACTGGACGCGGGAGACGCCAGCGAGCTGGTGAATTGGAGCCCTGCCAGAGAGCTCAAGCGCCAGCTCTGCCCGAGGAG
CCCAGGCTGCCCGTGAATCCCAGGCTACCTCCTGCCAACCTCACTCTTAGAGGAGCTGCTCAGCAAATACC
GCTGCTGTTCTGGTCCCGGATCCCAAGGCTACCTCCTGCCAACCTCACTCTTAGAGGAGCTGCTCAGCAAATACC
25 AGCACAAAGCTCTCACTCCGGTCCGCAGAGCCATCCCAGGGAGGACAAGGGAGGAGATCCTCATGCTGCACAAACAAG
CTTCGGGGCCAGGTGCAGCCTCAGGCCCTCCAACATGGAGTACATGACCTGGGATGACGAAGTGGAGAAGTCTGCTGCAGC
CTTGGGCCAGTCAGTCATCTGGGAGCACGGGCCACCGACTGCTGGTCCATGGCAGACCTGGGCGCTCACTGGG
35 GTGGGCCAGTCAGTCATCTGGGAGCACGGGCCACCGACTGCTGGTCCATGGCAGACCTGGGCGCTCACTGGG
GCAGGAGGTATCGCTCTCGGGGTTCCATGTGCAGTCCTGGTATGACGGAGGTGAAGGACTACACCTACCCCTACOCGAGC
GAGTGCAACCCCTGGTGTCCAGAGAGGTGCTGGGGCTATGTGCACGCACTACACACAGATAAGTTGGGCCACCAACCAA

CAAGATCGGGTGTGCTGTAAACACCTGCCGAAGATGACTGTCTGGGAGAAGTTGGGAGAACCGGGTCACTTTGTCT
 GCAATTATTCTCAAAGGGAACTGGATTGGAGAAGCCCCCTACAAGAATGGCCGCCCTGCTCTGAGTGCCCACCCAGC
 TATGGAGCAGCTGCAGGAACAACCTGTGTTACCGAGAAGAAACCTACAACCTGAAACCGACGAGATGAATGA
 GGTGAAAACGGCTCCCATTCTGAAGAAAACCATGTTGGCTCCAACCGAGGGTGTGAGACACCACCAAGCCAAAGAAAA
 5 CCTCTGCGGTCAACTACATGACCCAAGTCAGATGTGACACCAAGATGAAGGACAGGTGCAAAGGGTCCACGTGAAAC
 AGTACCACTGCCCAGCAGGCTGCCTGAACCAAGGCGAAGATCTTGGAGTCTGTCTATGAAAGCTCGTCTAGCAT
 ATGCCGCGCCGCATCCACTACGGGATCCTGGATGACAAGGGAGGCCTGGGATATCACAGGAACGGAAAGGTCCCCT
 TCTTCGTGAAGTCTGAGAGACACGGCGTGCAGTCAGCAAAATACAACCTTCAGCTCATTGATGGTCAAAAGTG
 AAAGTGCAGGATTGGACTGCTACACGACCGTGTGCTCAGCTGTGCCCTTGAAGAACCGACAACTCACTGCCAAGAAT
 10 CCATTGTCCGGCACACTGCAAAGACGAACCTCCTACTGGCTCCGGTGTGGAAACCAACATCTATGCAGATAACCTCAA
 GCATCTGCAAGACAGCGTGCACGCCGGAGTCATCAGCAACGAGAGTGGGGGTGACGTGGACGTGATGCCGTGGATAAA
 AAGAAGACCTACGGGGCTCGTCAGGAATGGAGTTCAGTCTGAAAGCCTGGGGACTCCTCGGGATGAAAAGGCCCTCCG
 GATCTTGCTGTCAGGAGTGAATTTCAGGACCCAGGGAGAAGGGCGTCTCAGGAGGGCTTCGGGTTTGCTTTA
 TTTTATTTGTCATTGCGGGGTATATGGAGAGTCAGGAAACTCCTTGACTGATGTTGACTGTCAGTGTCCATCACTTGTGGC
 15 CTGTTGGGTGAGGTGACATCTCATCCCTCACTGAAGCAACAGCATCCAAGGTGCTCAGCCGGACTCCCTGGTGCCTGAT
 CCTGCTGGGCCCCGGGGTCTCATCTGGACGTCCCTCTCCTTAGAGATCTGAGCTGTCCTAAAGGGGACAGTTGC
 CCAAAATGTTCTGCTATGTTCTCTGTTGGAGGAAGTGTGATTTCAACCTCCCTGCCAAAAGAACAAACCATTT
 GAAGCTCACAAATTGTGAAGCATTACGGCGTGGAGGCTTTGAGCAAGGCCAATGAGTTTCAGGAATGAAGTAG
 AAGGTAGTTATTTAAAAAATAAAAACACAGTCCGTCCTACCAATAGAGGAAATGGTTTAATGTTGCTGGTCAGACA
 20 GACAAATGGGCTAGAGTAAGAGGGCTGCCGGTATGAGAGACCCCGCTCCGCCCTGGCACGTGTCCTGCTGGCGGCCG
 CCACAGGCCCCCTCAATGGCCGATTAGGATGGCTCTACACAGCAGTGCTGGTTATGTAAGTTCAAGCAGTC
 TCA (SEQ ID NO: 20)

MSCVLGGVIPLGLLFLVRGSQGYLLPNVTLEELLSKYQHNESHSRVRAIPREDKEEILMLHNKLRGQV
 25 QPQASNMEYMTWDDELEKSAAWASQC1WEHGPSSLVSIGQNLGAHWGRYYRSPGFHVQSWYDEVKDYT
 YPYSECNPWC PERCSGP MCTHYTQIVWATTNK1GCAVNTRKMTVWGEVWENAVYFVCNYS PKGNWIGE
 APYKNRPCSECPPSYGGSCRNNLCYREETYTPKPETDEMNEVETAPIPEENHVWLQPRVMRPTPKKTS
 AVNYMTQVVRCDTKMKDRCKGSTCNRYQCPAGCLNHAKIFGSLFYESSSSICRAAIHYGILDGKGLVD
 ITRNGKVPFFVKSERHGVQSLSKYKPSMFMSVKVQDLDCYTTVAQLCPFEKPATHCPRIHCPCPAHCKD
 30 EPSYWAPVFGTNIYADTSSICKTAVHAGVISNESGGDVDVMPVDKKTYVGSLRNGVQSESLGTPRDGKA
 FRIFAVRQ (SEQ ID NO: 21)

The disclosed NOV-4d amino acid sequence has a high level of homology (98%
 identity, 98% similarity) to a human trypsin inhibitor-like protein (GenBank Accession No:
 35 CAB66795), as shown in Table 32. As indicated by the "Expect" value, the probability of this
 alignment occurring by chance alone is 0.0, the lowest probability score.

TABLE 32

Score = 1007 bits (2605), Expect = 0.0
 40 Identities = 489/498 (98%), Positives = 490/498 (98%), Gaps = 1/498 (0%)
 NOV4d: 1 MSCVLGGVIPLGLLFLVRGSQGYLLPNVTXXXXXXSKYQHNESHSRVRAIPREDKEEIL 60
 MSCVLGGVIPLGLLFLV GSQGYLLPNVT SKYQHNESHSRVRAIPREDKEEIL
 TRY : 1 MSCVLGGVIPLGLLFLVCGSQGYLLPNVTLEELLSKYQHNESHSRVRAIPREDKEEIL 60

NOV4d: 61 MLHNKLRGQVQPQASNMEYMTWDDELEKSAAAASQCIWEHGPTSLVSIGQNLGAHWGR 120
MLHNKLRGQVQPQASNMEYMTWDDELEKSAAAASQCIWEHGPTSLVSIGQNLGAHWG 5 TRYP : 61 MLHNKLRGQVQPQASNMEYMTWDDELEKSAAAASQCIWEHGPTSLVSIGQNLGAHWG- 119

NOV4d: 121 RYRSPGFHVQSWYDEVKDYTYPYPSECNPWCPERCSGPMCTHYTQIVWATTNKIGCAVNT 180
RYRSPGFHVQSWYDEVKDYTYPYPSECNPWCPERCSGPMCTHYTQIVWATTNKIGCAVNT TRYP : 120 RYRSPGFHVQSWYDEVKDYTYPYPSECNPWCPERCSGPMCTHYTQIVWATTNKIGCAVNT 179

NOV4d: 181 CRKMTVWGEVWENAVYFVCNYSPKGWNIGEAPYKNGRPCSECPPSYGGSCRNNLCYREET 240
CRKMTVWGEVWENAVYFVCNYSPKGWNIGEAPYKNGRPCSECPPSYGGSCRNNLCYREET TRYP : 180 CRKMTVWGEVWENAVYFVCNYSPKGWNIGEAPYKNGRPCSECPPSYGGSCRNNLCYREET 239

NOV4d: 241 YTPKPETDEMNEVETAPIPEENHVWLQPRVMRPTPKKTSAVNYMTQVVRCDTKMKDRCK 300
YTPKPETDEMNEVETAPIPEENHVWLQPRVMRPTPKKTSAVNYMTQVVRCDTKMKDRCK TRYP : 240 YTPKPETDEMNEVETAPIPEENHVWLQPRVMRPTPKKTSAVNYMTQVVRCDTKMKDRCK 299

NOV4d: 301 GSTCNRYQCPAGCLNHAKIFGSLFYESSSSICRAAIHYGILDDKGGLVDIRNGKVPFF 360
GSTCNRYQCPAGCLNHAKIFG+LFYESSSSICRAAIHYGILDDKGGLVDIRNGKVPFF 20 TRYP : 300 GSTCNRYQCPAGCLNHAKIFGTLFYESSSSICRAAIHYGILDDKGGLVDIRNGKVPFF 359

NOV4d: 361 VKSERHGVQSLSKYKPSSSFMSVKVKVQDLCYTTVAQLCPFEKPATHCPRIHCPAHC KD 420
VKSERHGVQSLSKYKPSSSFMSVKVKVQDLCYTTVAQLCPFEKPATHCPRIHCPAHC KD TRYP : 360 VKSERHGVQSLSKYKPSSSFMSVKVKVQDLCYTTVAQLCPFEKPATHCPRIHCPAHC KD 419

NOV4d: 421 EPSYWAPVFGTNIYADTSSICKTAVHAGVISNESGGDVDVMPVDKKTYVGSLRNGVQSE 480
EPSYWAPVFGTNIYADTSSICKTAVHAGVISNESGGDVDVMPVDKKTYVGSLRNGVQSE TRYP : 420 EPSYWAPVFGTNIYADTSSICKTAVHAGVISNESGGDVDVMPVDKKTYVGSLRNGVQSE 479

NOV4d: 481 SLGTPRDGKAFRIFAVRQ 498 (SEQ ID NO: 76)
SLGTPRDGKAFRIFAVRQ 30 TRYP : 480 SLGTPRDGKAFRIFAVRQ 497 (SEQ ID NO: 44)

A PROSITE database search of protein families and domains confirmed that a NOV-4c polypeptide is a member of the trypsin inhibitor family. One of the conserved regions found in trypsin inhibitors is a SCP domain, located at the C-terminal half. The pattern of this conserved domain is: [LIVMFYH]-[LIVMFY]-x-C-[NQRHS]-Y-x-[PARH]-x-[GL]-N-[LIVMFYWDN] (SEQ ID NO: 56). This pattern is found in amino acids 196-207 of SEQ ID NO: 21.

Based on the relatedness between NOV-4d and the conserved trypsin inhibitor proteins, NOV-4d is a novel member of the trypsin inhibitor family. NOV-4d provides new diagnostic and therapeutic compositions useful in the treatment of disorders associated with alterations in the expression of members of the trypsin inhibitor protein family. Nucleic acids, polypeptides, antibodies, and other compositions of the present invention are useful in the treatment and diagnosis of a variety of diseases and pathologies, including, by way of nonlimiting example, those involving reproductive disorders, immunological disorders, cancer, and metabolic disorders.

In addition, SignalPep and PSORT analyses indicate that NOV-4d is likely located outside of the cell (certainty = 0.6950), and is likely to have a cleavable N-terminal signal

sequence with a cleavage site between positions 22 and 23: SQG-YL. The predicted molecular weight of NOV-4b is 56114.4 daltons.

5 NOV-4e

A NOV-4e sequence according to the invention is a nucleic acid sequence that encodes a polypeptide related to trypsin inhibitor proteins. A disclosed NOV-4e nucleic acid and its encoded polypeptide are included in Table 33. The disclosed nucleic acid (SEQ ID NO: 22) is 2412 nucleotides in length and contains an open reading frame (ORF) that begins with an ATG initiation codon at nucleotide 206, and ends with a TGA stop codon at nucleotide 1709. A disclosed, representative ORF encodes a 501 amino acid polypeptide (SEQ ID NO: 23).

TABLE 33

	CTCTGACTGCTCCTATTGAGCTGCTGCTCGCTGTGCCCGCTGTGCCCTGCTGTGCCCG
15	CGCTGTCGCCGCTGCTACCGCGTCACTGGACGCCAGCAGCTGGTGA TGAGGCCCTGCGGAGAGCTCAAGGCCAGCTGCCAGGCCAGGCTGCCCG TGAGTCCCATAGTTGCTGCAGGAGTGGAGCCATGAGCTGCGTCCTGGGTGGTGTCA CCCTGGGGCTGCTGTCCTGGTCCGCCGATCCCCAAGGCTACCTCCTGCCAACGTCA CTCTCTAGAGGAGCTGCTCAGCAAATACCAGCACACGAGTCTCACTCCGGTCCG
20	CAGAGCCATCCCCAGGGAGGACAAGGGAGGAGATCCTCATGCTGCACAACAAGCTTCG GGCCAGGTGCAGCCTCAGGCCTCCAACATGGAGTACATGACCTGGGATGACGA AGAAGTCTGCTGCAGCGTGGGCCAGTCAGTGCATCTGGAGCACGGGCCACCGGTCT GCTGGTGTCCATCGGGCAGAACCTGGCGCTCACTGGGGCAGGTATCGCTCTCCGGGG TTCCATGTGCAGTCTGGTATGACGAGGTGAAGGACTACACCTACCCCTACCGAGCG
25	AGTGCAACCCCTGGTGTCCAGAGAGGTGCTGGGGCCATGTGCACGCAC GGTAACCTCAGATAGTTGGGCCACCAACAAGATCGGTGTGCTGTGAACACCTGC CGGAAGATGACTGTCTGGGAGAACGGCTACTTTGTCTGCAATT ATTCTCAAAGAGGGGAACTGGATTGGAGAACCCCCCTACAAGAATGGCGGCCCTG CTCTGAGTGCCACCCAGCTATGGAGGCAGCTGCAGGAACA GAAACCTACACTCCAAAACCTGAAACGGACGAGATGAATGAGGTGGAAACGGCTCCA TTCCCTGAAGAAAACCATGTTGGCTCCAACCGAGGGTGTGAGACCCACCAAGCCAA GAAAACCTCTGCCGTCAACTACATGACCCAAGTCGTCA GACAGGGTCAAAGGGTCCACGTGAAACAGGTACCGAGTGCAGGCCAGCAGGCTGCC ACAAGGCGAAGATCTTGAAGTCTGTTCTATGAAAGCTCGTCTAGCATATGCCCGCG 30
35	CGCCATCCACTACGGGATCCTGGATGACAAGGGAGGCCCTGGGATATCACCAGGAAC GGGAAGGTCCCCTCTCGTGAAGTCTGAGAGACACGGCGTGCAGTCCCTCAGCAA ACAAACCTTCCAGCTCATTGAGGCTCAAAAGTGAAGTGCAGGATTGGACTGCTA CACGACCGTTGCTCAGCTGTGCCGTTGAAAGCCAGCAACTCACTGCCAACGAA CATTGTCCGGCACACTGCAAAGACGAACCTCTACTGGCTCCGGTGTGTTGAAACCA

ACATCTATGCAGATAACCTCAAGCATCTGCAAGACAGCCGTGCACGCCGGGAGTCATCAG
 CAAACGAGAGTGGGGGTGACGTGGACGTGATGCCGTGGATAAAAAGAAGACCTACGTG
 GGCTCGCTCAGGAATGGAGTTCACTGCTGAAAGCCTGGGACTCCTCGGGATGGAAAGG
 CCTTCCGGATCTTGCTGTCAGGCAGTGAATTCCAGCACCAGGGGAGAAGGGCGTC
 5 TTCAGGAGGGCTCGGGGTTTGCTTTATTTTATTTGTATTGCTATTGCGGGGTATATGG
 AGAGTCAGGAAACTCCTTGACTGATGTTCACTGTCATCACTTTGTGGCTGTGGG
 TGAGGTGACATCTCATCCCTCACTGAAGCAACAGCATTCCAAGGTGCTCAGCCGGAC
 TCCCTGGTGCCTGATCCTGCTGGGGCCCGGGGCTCCATCTGGACGTCCCTCTCCT
 TTAGAGATCTGAGCTGTCTTAAAGGGGACAGTTGCCAAAATGTTCCCTGCTATGT
 10 GTTCTTCTGTTGGAGGAAGTTGATTCAACCTCCCTGCCAAAAGAACAAACCATT
 TGAAGCTACAATTGTGAAGCATTACGGCGTCGGAAGAGGCCCTTGAGCAAGGCC
 AATGAGTTCAAGGAATGAAGTAGAAGGTAGTTATTTAAAAAATAAAAACAGTCCGT
 CCCTACCAATAGAGGAAAATGGTTAATGTTGCTGGTCAGACAGACAAATGGGCTA
 GAGTAAGAGGGCTGCGGGTATGAGAGACCCGGCTCCGCCCTGGCACGTGTCCTTGCT
 15 GGCAGCCCCGCCACAGGCCCCCTCAATGGCCGCATTCAAGGATGGCTCTATACACAGCA
 GTGCTGGTTATGTAAGTTCAGCAGTCACTTCA (SEQ ID NO: 22)

MSCVLGGVIPLGLLFLVRGSQGYLLPNVTILLELLSKYQHNESHSRVRAIPREDKEE
 IILMLHNKLRGQVQPQASNMEMYTWDDELEKSAAAASQCIWEHGPTGLLVSIGQNLGA
 20 HWGRYRSPGFHVQSWSYDEVKDYPYPSECNPWC PERCSGP MCHYTQVTQIVWATTN
 KIGCAVNTRKMTVWGEVWENAVYFVCNYSPKRGNWIGEAPYKNRPCSECPPSYGGS
 CRNNLCYREETYTPKPETDEMNEVETAPIPEENHVWLQPRVMRPTPKKTSAVNYMTQ
 VVRCDTKMKDRCKGSTCNRYQCPAGCLNHAKIFGSLEYESSSSICRAAIHYGILDDK
 GGLVDITRNGKVPFFVKSERHGVQSLSKYKPSSSFMVSKVVKVQDLCYTTVAQLCPFE
 25 KPATHCPRIHCPAHCKDEPSYWAPVFGTNIYADTSSICKTAVHAGVISNESGGDVDVM
 PVDKKKYVGSLRNGVQSESLGTPRDGKA FRIFAVRQ (SEQ ID NO: 23)

The disclosed NOV-4e amino acid sequence has a high level of homology (97%
 identity, 97% similarity) to a human trypsin inhibitor-like protein (GenBank Accession No:
 30 CAB66795), shown in Table 34. As indicated by the "Expect" value, the probability of this
 alignment occurring by chance alone is 0.0, the lowest probability score.

TABLE 34

Score = 1001 bits (2588), Expect = 0.0
 35 Identities = 488/501 (97%), Positives = 489/501 (97%), Gaps = 4/501 (0%)
 NOV4e: 1 MSCVLGGVIPLGLLFLVRGSQGYLLPNVTXXXXXXSKYQHNESHSRVRAIPREDKEEIL 60
 MSCVLGGVIPLGLLFLV GSQGYLLPNVT SKYQHNESHSRVRAIPREDKEEIL
 TRYP : 1 MSCVLGGVIPLGLLFLVCGSQGYLLPNVTILLELLSKYQHNESHSRVRAIPREDKEEIL 60
 40 NOV4e: 61 MLHNKLRGQVQPQASNMEMYTWDDELEKSAAAASQCIWEHGPTGLLVSIGQNLGAHWGR 120
 MLHNKLRGQVQPQASNMEMYTWDDELEKSAAAASQCIWEHGPT LLVSIGQNLGAHWGR
 TRYP : 61 MLHNKLRGQVQPQASNMEMYTWDDELEKSAAAASQCIWEHGPTSLLVSIGQNLGAHWGR 120

NOV4e: 121 YRSPGFHVQSWYDEVKDYTYPYPSECNPWC PERCSGP MCTHY TQIVWATTNKIGCAV 180
 YRSPGFHVQSWYDEVKDYTYPYPSECNPWC PERCSGP MCTHY TQIVWATTNKIGCAV
 TRYP : 121 YRSPGFHVQSWYDEVKDYTYPYPSECNPWC PERCSGP MCTHY---TQIVWATTNKIGCAV 177

5 NOV4e: 181 NTCRKMTVWGEVWENAVYFVCNYS PKRGNWIGEAPYKNGRPC SECPPSYGGSCRNNLCYR 240
 NTCRKMTVWGEVWENAVYFVCNYS PK GNWIGEAPYKNGRPC SECPPSYGGSCRNNLCYR
 TRYP : 178 NTCRKMTVWGEVWENAVYFVCNYS PK-GNWIGEAPYKNGRPC SECPPSYGGSCRNNLCYR 236

10 NOV4e: 241 EETYTPKPETDEMNEVETAPIPEENHVLQPRVRM RPTKPKKTS AVNYMTQVVRCDTKMKD 300
 EETYTPKPETDEMNEVETAPIPEENHVLQPRVRM RPTKPKKTS AVNYMTQVVRCDTKMKD
 TRYP : 237 EETYTPKPETDEMNEVETAPIPEENHVLQPRVRM RPTKPKKTS AVNYMTQVVRCDTKMKD 296

15 NOV4e: 301 RCKGSTCNRYQCPAGCLNHKA KIFGSLFYESSSSICRAAIHYGILDDKGGLVDITRNGKV 360
 RCKGSTCNRYQCPAGCLNHKA KIFG+LFYESSSSICRAAIHYGILDDKGGLVDITRNGKV
 TRYP : 297 RCKGSTCNRYQCPAGCLNHKA KIFGTLFYESSSSICRAAIHYGILDDKGGLVDITRNGKV 356

20 NOV4e: 361 PFFVKSERHGVQSLSKYK PSSSF MVSKV QDLDCYTTVAQLCPFEK PATHCPRIHCPAH 420
 PFFVKSERHGVQSLSKYK PSSSF MVSKV QDLDCYTTVAQLCPFEK PATHCPRIHCPAH
 TRYP : 357 PFFVKSERHGVQSLSKYK PSSSF MVSKV QDLDCYTTVAQLCPFEK PATHCPRIHCPAH 416

25 NOV4e: 421 CKDEPSYWAPVFGTNIYADTSSICKTA VHAGVISNESGGD VDVM PVDKKK TYVGSLRNGV 480
 CKDEPSYWAPVFGTNIYADTSSICKTA VHAGVISNESGGD VDVM PVDKKK TYVGSLRNGV
 TRYP : 417 CKDEPSYWAPVFGTNIYADTSSICKTA VHAGVISNESGGD VDVM PVDKKK TYVGSLRNGV 476

NOV4e: 481 QSESLGTPRDGKA FRI FAVRQ 501 (SEQ ID NO: 77)
 QSESLGTPRDGKA FRI FAVRQ
 TRYP : 477 QSESLGTPRDGKA FRI FAVRQ 497 (SEQ ID NO: 45)

30 In addition, SignalPep and PSORT analyses indicate that that NOV-4e is likely located outside of the cell (certainty = 0.6950), and is likely to have a cleavable N-terminal signal sequence with a cleavage site between positions 22 and 23: SQG-YL. The predicted molecular weight of NOV-4b is 56412.8 daltons.

Based on the relatedness between NOV-4e and the conserved trypsin inhibitor 35 proteins, the NOV-4e protein is a novel member of the trypsin inhibitor family. NOV-4e provides new diagnostic and therapeutic compositions useful in the treatment of disorders associated with alterations in the expression of members of the trypsin inhibitor protein family. Nucleic acids, polypeptides, antibodies, and other compositions of the present invention are useful in the treatment and diagnosis of a variety of diseases and pathologies, 40 including, by way of nonlimiting example, those involving reproductive disorders, immunological disorders, cancer, and metabolic disorders.

Table 35 shows a sequence alignment between the NOV-4 polypeptides according to the invention and a human trypsin inhibitor-like protein (GenBank Accession No: CAB66795), indicating the homology between the present invention and the trypsin inhibitor 45 family. Moreover, the PROSITE conserved SCP region found in trypsin inhibitors is found in sequences 151-162 of the trypsin inhibitor-like protein shown (shown in bold font).

TABLE 35

	NOV4e	MSCVLGGVIPLGLLFLVRGSQGYLLPNVTLLLEELLSKYQHNESHSRVRAIPREDKEEIL
5	NOV4a	-----
	NOV4b	MSCVLGGVIPLGLLFLVRGSQGYLLPNVTLLLEELLSKYQHNESHSRVRAIPREDKEEIL
	NOV4d	MSCVLGGVIPLGLLFLVRGSQGYLLPNVTLLLEELLSKYQHNESHSRVRAIPREDKEEIL
	NOV4c	MSCVLGGVIPLGLLFLVCGSQGYLLPNVTLLLEELLSKYQHNESHSRVRAIPREDKEEIL
	TRYP	-----ARRKRYISQNDMIAIL
10	NOV4e	MLHNKLRGQVQPQASNMEMYMTWDDELEKSAAAWASQCIWEHGPTGLLVSIGQNLGAHWG-----MTNWG-----
	NOV4a	-----
	NOV4b	MLHNKLRGQVQPQASNMEMYMTWDDELEKSAAAWASQCIWEHGPTGLLVSIGQNLGAHWG-----
	NOV4d	MLHNKLRGQVQPQASNMEMYMTWDDELEKSAAAWASQCIWEHGPTSLLVSIGQNLGAHWGR-----
15	NOV4c	MLHNKLRGQVQPQASNMEMYMTWDDELEKSAAAWASQCIWEHGPTGLLVSIGQNLGAHWG-----
	TRYP	DYHNQVRGKVFPPAANMEYMWDENLAKSAAWAATCIWDHGPSYLLRFLGQNLSVRTG-----*
20	NOV4e	RYRSPGFHVQSWYDEVKDYTYPYPSECNPWCPERCSGPMCTHYTQVTQIVWATTNKIGCA
	NOV4a	RYRSPGFHVQSWYDEVKDYTYPYPSECNPWCPERCSGPMCTHY---TQIVWATTNKIGCA
	NOV4b	RYRSPGFHVQSWYDEVKDYTYPYPSECNPWCPERCSGPMCTHY---TQIVWATTNKIGCA
	NOV4d	RYRSPGFHVQSWYDEVKDYTYPYPSECNPWCPERCSGPMCTHY---TQIVWATTNKIGCA
	NOV4c	RYRSPGFHVQSWYDEVKDYTYPYPSECNPWCPERCSGPMCTHY---TQIVWATTNKIGCA
	TRYP	RYRSILQLVKPWYDEVKDYAFPYQPDCNPRCPMRCFGPMCTHY---TQM沃WATSNRIGCA
25	NOV4e	***** * :*****:*****:*****:***** * * * * ***** * :*****:*****:*****
	NOV4a	VNTCRKMTVWGEVWENAVYFVCNYSPKRGNWIGEAPYKNRPCSECPPSYGGSCRNNLCY
	NOV4b	VNTCRKMTVWGEVWENAVYFVCNYSPK-GNWIGEAPYKNRPCSECPPSYGGSCRNNLCY
30	NOV4d	VNTCRKMTVWGEVWENAVYFVCNYSPK-GNWIGEAPYKNRPCSECPPSYGGSCRNNLCY
	NOV4c	VNTCRKMTVWGEVWENAVYFVCNYSPK-GNWIGEAPYKNRPCSQCPPSYGGSCRNNLCY
	TRYP	IHTCQNMNVWGSVWRRAVLYVCNYAPK-GNWIGEAPYKVGVPCSSCPPSYGGSTDNLCF
35	NOV4e	REETYTPKPETDEMNEVETAPIPEENHVWLQPRVMRPTKPKKTSAVNYMTQVVRCDTKMK
	NOV4a	REETYTPKPETDEMNEVETAPIPEENHVWLQPRVMRPTKPKKTSAVNYMTQVVRCDTKMK
	NOV4b	REETYTPKPETDEMNEVETAPIPEENHVWLQPRVMRPTKPKKTSAVNYMTQVVRCDTKMK
	NOV4d	REETYTPKPETDEMNEVETAPIPEENHVWLQPRVMRPTKPKKTSAVNYMTQVVRCDTKMK
40	NOV4c	REETYTPKPETDEMNEVETAPIPEENHVWLQPRVMRPTKPKKTSVNYMTQVVLCDTKMK
	TRYP	-----
45	NOV4e	DRCKGSTCNRYQCPAGCLNHAKIFGSLFYESSSSICRAIHYGILDDKGGLVDITRNGK
	NOV4a	DRCKGSTCNRYQCPAGCLNHAKIFGTLFYESSSSICRAIHYGILDDKGGLVDITRNGK
	NOV4b	DRCKGSTCNRYQCPAGCLNHAKIFGSLFYESSSSICRAIHYGILDDKGGLVDITRNGK
	NOV4d	DRCKGSTCNRYQCPAGCLNHAKIFGSLFYESSSSICRAIHYGILDDKGGLVDITRNGK
	NOV4c	DRCKGSTCNRYQCPAGCLNHAKIFGTLFYESSSSICRAIHYGILDDKGGLVDITRNGK
	TRYP	-----
50	NOV4e	VPFFVKSERHGVQSLSKYKPSSSFMSVKVKVQDLDCYTTVAQLCPFEKPATHCPRIHCPA
	NOV4a	VPFFVKSERHGVQSLSKYKPSSSFMSVKVKVQDLDCYTTVAQLCPFEKPATHCPRIHCPA
	NOV4b	VPFFVKSERHGVQSLSKYKPSSSFMSVKVKVQDLDCYTTVAQLCPFEKPATHCPRIHCPA
55	NOV4d	VPFFVKSERHGVQSLSKYKPSSSFMSVKVKVQDLDCYTTVAQLCPFEKPATHCPRIHCPA
	NOV4c	VPFFVKSERHGVQSLSKYKPSSSFMSVKVKVQDLDCYTTVAQLCPFEKPATHCPRIHCPA
	TRYP	-----
60	NOV4e	HCKDEPSYWAPVFGTNIYADTSSICKTAVHAGVISNESGGDVDMVPDKKTYVGSLRNG
	NOV4a	HCKDEPSYWAPVFGTNIYADTSSICKTAVHAGVISNESGGDVDMVPDKKTYVGSLRNG
	NOV4b	HCKDEPSYWAPVFGTNIYADTSSICKTAVHAGVISNESGGDVDMVPDKKTYVGSLRNG
	NOV4d	HCKDEPSYWAPVFGTNIYADTSSICKTAVHAGVISNESGGDVDMVPDKKTYVGSLRNG

NOV4c	HCKDEPSYWAPVFGTNIYADTSSICKTAVHAGVISNESGGDVMPVDKKTYT-----
TRYP	-----

5	NOV4e	VQSESLGTPRDGKA F RIFAVRQ (SEQ ID NO: 23)
	NOV4a	VQSESLGTPRDGKA F RIFAVRQ (SEQ ID NO: 15)
	NOV4b	VQSESLGTPRDGKA F RIFAVRQ (SEQ ID NO: 17)
	NOV4d	VQSESLGTPRDGKA F RIFAVRQ (SEQ ID NO: 21)
10	NOV4c	-----CPAAARAL----- (SEQ ID NO: 19)
	TRYP	----- (SEQ ID NO: 46)

Consensus key

- * - single, fully conserved residue
- : - conservation of strong groups
- . - conservation of weak groups
- no consensus

The expression pattern, and protein similarity information for NOV-4 suggests that the human trypsin inhibitor-like proteins described in this invention may function as a trypsin inhibitor. Therefore, the nucleic acid and protein of the invention are useful in potential therapeutic applications implicated, for example but not limited to, in allergies and infectious diseases, in cancer, in metabolic disorders like obesity, hypertension and diabetes, and other diseases and disorders.

Homology to antigenic secreted and membrane proteins suggests that antibodies directed against the novel genes may be useful in treatment and prevention of allergic reactions and infectious diseases. Expression in pituitary and adrenal gland suggests therapeutic applications in metabolic disorders like obesity, hypertension and diabetes. Similarity to a brain tumor overexpressed trypsin inhibitor suggests that the splice variants of 10093872 may be involved in the pathogenesis of these cancers. Hence it could be useful as a cancer diagnostic marker or as a target for small molecule trypsin inhibitors in cancer treatment.

Potential therapeutic uses for the invention(s) include, for example, the following: (i) protein therapeutic, (ii) small molecule drug target, (iii) antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), (iv) diagnostic and/or prognostic marker, (v) gene therapy (gene delivery/gene ablation), (vi) research tools, and (vii) tissue regeneration *in vitro* and *in vivo* (regeneration for all these tissues and cell types composing these tissues and cell types derived from these tissues).

The nucleic acids and proteins of the invention are useful in potential therapeutic applications implicated in various diseases and disorders described below and/or other pathologies and disorders. For example, but not limited to, a cDNA encoding the human trypsin inhibitor-like protein may be useful in gene therapy, and the human trypsin inhibitor-like protein may be useful when administered to a subject in need thereof. By way of non-

limiting example, the compositions of the present invention will have efficacy for treatment of patients suffering from, for example, but not limited to, in allergies and infectious diseases, in cancer, in metabolic disorders like obesity, hypertension and diabetes, and other diseases and disorders. The novel nucleic acid encoding the human trypsin inhibitor-like protein, and the 5 human trypsin inhibitor-like protein of the invention, or fragments thereof, may further be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed. These materials are further useful in the generation of antibodies that bind immunospecifically to the novel substances of the invention for use in therapeutic or diagnostic methods.

10

NOV-X Nucleic acids

The nucleic acids of the invention include those that encode a NOV-X polypeptide or protein. As used herein, the terms polypeptide and protein are interchangeable.

In some embodiments, a NOV-X nucleic acid encodes a mature NOV-X polypeptide.

15 As used herein, a "mature" form of a polypeptide or protein described herein relates to the product of a naturally occurring polypeptide or precursor form or proprotein. The naturally occurring polypeptide, precursor or proprotein includes, by way of nonlimiting example, the full-length gene product, encoded by the corresponding gene. Alternatively, it may be defined as the polypeptide, precursor or proprotein encoded by an open reading frame described herein. The product "mature" form arises, again by way of nonlimiting example, as a result of one or more naturally occurring processing steps that may take place within the cell in which the gene product arises. Examples of such processing steps leading to a "mature" form of a polypeptide or protein include the cleavage of the N-terminal methionine residue encoded by the initiation codon of an open reading frame, or the proteolytic cleavage of a signal peptide or leader sequence. Thus a mature form arising from a precursor polypeptide or protein that has residues 1 to N, where residue 1 is the N-terminal methionine, would have residues 2 through N remaining after removal of the N-terminal methionine. Alternatively, a mature form arising from a precursor polypeptide or protein having residues 1 to N, in which an N-terminal signal sequence from residue 1 to residue M is cleaved, would have the residues from residue M+1 to residue N remaining. Further as used herein, a "mature" form of a polypeptide or protein may arise from a step of post-translational modification other than a proteolytic cleavage event. Such additional processes include, by way of non-limiting example, glycosylation, myristylation or phosphorylation. In general, a mature polypeptide or protein may result from the operation of only one of these processes, or a combination of any of them.

Among the NOV-X nucleic acids is the nucleic acid whose sequence is provided in SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57, or a fragment thereof. Additionally, the invention includes mutant or variant nucleic acids of SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57, or a fragment thereof, any of whose bases may be changed from the corresponding bases shown in SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57, while still encoding a protein that maintains at least one of its NOV-X-like activities and physiological functions (i.e., modulating angiogenesis, neuronal development). The invention further includes the complement of the nucleic acid sequence of SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57, including fragments, derivatives, analogs and homologs thereof.

10 The invention additionally includes nucleic acids or nucleic acid fragments, or complements thereto, whose structures include chemical modifications.

One aspect of the invention pertains to isolated nucleic acid molecules that encode NOV-X proteins or biologically active portions thereof. Also included are nucleic acid fragments sufficient for use as hybridization probes to identify NOV-X-encoding nucleic acids (e.g., NOV-X mRNA) and fragments for use as polymerase chain reaction (PCR) primers for the amplification or mutation of NOV-X nucleic acid molecules. As used herein, the term "nucleic acid molecule" is intended to include DNA molecules (e.g., cDNA or genomic DNA), RNA molecules (e.g., mRNA), analogs of the DNA or RNA generated using nucleotide analogs, and derivatives, fragments and homologs thereof. The nucleic acid molecule can be single-stranded or double-stranded, but preferably is double-stranded DNA.

"Probes" refer to nucleic acid sequences of variable length, preferably between at least about 10 nucleotides (nt), 100 nt, or as many as about, e.g., 6,000 nt, depending on use. Probes are used in the detection of identical, similar, or complementary nucleic acid sequences. Longer length probes are usually obtained from a natural or recombinant source, 25 are highly specific and much slower to hybridize than oligomers. Probes may be single- or double-stranded and designed to have specificity in PCR, membrane-based hybridization technologies, or ELISA-like technologies.

An "isolated" nucleic acid molecule is one that is separated from other nucleic acid molecules that are present in the natural source of the nucleic acid. Examples of isolated 30 nucleic acid molecules include, but are not limited to, recombinant DNA molecules contained in a vector, recombinant DNA molecules maintained in a heterologous host cell, partially or substantially purified nucleic acid molecules, and synthetic DNA or RNA molecules. Preferably, an "isolated" nucleic acid is free of sequences which naturally flank the nucleic acid (i.e., sequences located at the 5' and 3' ends of the nucleic acid) in the genomic DNA of

the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated NOV-X nucleic acid molecule can contain less than about 50 kb, 25 kb, 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb or 0.1 kb of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived. Moreover, 5 an "isolated" nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material or culture medium when produced by recombinant techniques, or of chemical precursors or other chemicals when chemically synthesized.

A nucleic acid molecule of the present invention, e.g., a nucleic acid molecule having the nucleotide sequence of SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57, or a 10 complement of any of this nucleotide sequence, can be isolated using standard molecular biology techniques and the sequence information provided herein. Using all or a portion of the nucleic acid sequence of SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57, as a hybridization probe, NOV-X nucleic acid sequences can be isolated using standard hybridization and cloning techniques (e.g., as described in Sambrook et al., eds., MOLECULAR 15 CLONING: A LABORATORY MANUAL 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989; and Ausubel, et al., eds., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, NY, 1993.)

A nucleic acid of the invention can be amplified using cDNA, mRNA or alternatively, genomic DNA, as a template and appropriate oligonucleotide primers according to standard 20 PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. Furthermore, oligonucleotides corresponding to NOV-X nucleotide sequences can be prepared by standard synthetic techniques, e.g., using an automated DNA synthesizer.

As used herein, the term "oligonucleotide" refers to a series of linked nucleotide 25 residues, which oligonucleotide has a sufficient number of nucleotide bases to be used in a PCR reaction. A short oligonucleotide sequence may be based on, or designed from, a genomic or cDNA sequence and is used to amplify, confirm, or reveal the presence of an identical, similar or complementary DNA or RNA in a particular cell or tissue.

Oligonucleotides comprise portions of a nucleic acid sequence having about 10 nt, 50 nt, or 30 100 nt in length, preferably about 15 nt to 30 nt in length. In one embodiment, an oligonucleotide comprising a nucleic acid molecule less than 100 nt in length would further comprise at least 6 contiguous nucleotides of SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57, or a complement thereof. Oligonucleotides may be chemically synthesized and may be used as probes.

In another embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule that is a complement of the nucleotide sequence shown in SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57, or a portion of this nucleotide sequence. A nucleic acid molecule that is complementary to the nucleotide sequence shown in SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57 is one that is sufficiently complementary to the nucleotide sequence shown in SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57 that it can hydrogen bond with little or no mismatches to the nucleotide sequence shown in SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57, thereby forming a stable duplex.

As used herein, the term "complementary" refers to Watson-Crick or Hoogsteen base pairing between nucleotide units of a nucleic acid molecule, and the term "binding" means the physical or chemical interaction between two polypeptides or compounds or associated polypeptides or compounds or combinations thereof. Binding includes ionic, non-ionic, Von der Waals, hydrophobic interactions, etc. A physical interaction can be either direct or indirect. Indirect interactions may be through or due to the effects of another polypeptide or compound. Direct binding refers to interactions that do not take place through, or due to, the effect of another polypeptide or compound, but instead are without other substantial chemical intermediates.

Moreover, the nucleic acid molecule of the invention can comprise only a portion of the nucleic acid sequence of SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57, e.g., a fragment that can be used as a probe or primer, or a fragment encoding a biologically active portion of NOV-X. Fragments provided herein are defined as sequences of at least 6 (contiguous) nucleic acids or at least 4 (contiguous) amino acids, a length sufficient to allow for specific hybridization in the case of nucleic acids or for specific recognition of an epitope in the case of amino acids, respectively, and are at most some portion less than a full length sequence. Fragments may be derived from any contiguous portion of a nucleic acid or amino acid sequence of choice. Derivatives are nucleic acid sequences or amino acid sequences formed from the native compounds either directly or by modification or partial substitution. Analogs are nucleic acid sequences or amino acid sequences that have a structure similar to, but not identical to, the native compound but differs from it in respect to certain components or side chains. Analogs may be synthetic or from a different evolutionary origin and may have a similar or opposite metabolic activity compared to wild type.

Derivatives and analogs may be full length or other than full length, if the derivative or analog contains a modified nucleic acid or amino acid, as described below. Derivatives or analogs of the nucleic acids or proteins of the invention include, but are not limited to,

molecules comprising regions that are substantially homologous to the nucleic acids or proteins of the invention, in various embodiments, by at least about 70%, 80%, 85%, 90%, 95%, 98%, or even 99% identity (with a preferred identity of 80-99%) over a nucleic acid or amino acid sequence of identical size or when compared to an aligned sequence in which the

5 alignment is done by a computer homology program known in the art, or whose encoding nucleic acid is capable of hybridizing to the complement of a sequence encoding the aforementioned proteins under stringent, moderately stringent, or low stringent conditions. See e.g. Ausubel, et al., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, NY, 1993, and below. An exemplary program is the Gap program (Wisconsin
10 Sequence Analysis Package, Version 8 for UNIX, Genetics Computer Group, University Research Park, Madison, WI) using the default settings, which uses the algorithm of Smith and Waterman (Adv. Appl. Math., 1981, 2: 482-489, which is incorporated herein by reference in its entirety).

A "homologous nucleic acid sequence" or "homologous amino acid sequence," or variations thereof, refer to sequences characterized by a homology at the nucleotide level or amino acid level as discussed above. Homologous nucleotide sequences encode those sequences coding for isoforms of a NOV-X polypeptide. Isoforms can be expressed in different tissues of the same organism as a result of, for example, alternative splicing of RNA. Alternatively, isoforms can be encoded by different genes. In the present invention,
20 homologous nucleotide sequences include nucleotide sequences encoding for a NOV-X polypeptide of species other than humans, including, but not limited to, mammals, and thus can include, e.g., mouse, rat, rabbit, dog, cat cow, horse, and other organisms. Homologous nucleotide sequences also include, but are not limited to, naturally occurring allelic variations and mutations of the nucleotide sequences set forth herein. A homologous nucleotide
25 sequence does not, however, include the nucleotide sequence encoding human NOV-X protein. Homologous nucleic acid sequences include those nucleic acid sequences that encode conservative amino acid substitutions (see below) in SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23, as well as a polypeptide having NOV-X activity. Biological activities of the NOV-X proteins are described below. A homologous amino acid sequence does not encode
30 the amino acid sequence of a human NOV-X polypeptide.

The nucleotide sequence determined from the cloning of the human NOV-X gene allows for the generation of probes and primers designed for use in identifying and/or cloning NOV-X homologues in other cell types, e.g., from other tissues, as well as NOV-X homologues from other mammals. The probe/primer typically comprises a substantially

purified oligonucleotide. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, 25, 50, 100, 150, 200, 250, 300, 350 or 400 or more consecutive sense strand nucleotide sequence of SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57; or an anti-sense strand nucleotide sequence of SEQ 5 ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57; or of a naturally occurring mutant of SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57.

Probes based on the human NOV-X nucleotide sequence can be used to detect transcripts or genomic sequences encoding the same or homologous proteins. In various embodiments, the probe further comprises a label group attached thereto, e.g., the label group 10 can be a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor. Such probes can be used as a part of a diagnostic test kit for identifying cells or tissue which misexpress a NOV-X protein, such as by measuring a level of a NOV-X-encoding nucleic acid in a sample of cells from a subject e.g., detecting NOV-X mRNA levels or determining whether a genomic NOV-X gene has been mutated or deleted.

15 A "polypeptide having a biologically active portion of NOV-X" refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the present invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. A nucleic acid fragment encoding a "biologically active portion of NOV-X" can be prepared by isolating a portion of SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 20 18, 20, 22, or 57 that encodes a polypeptide having a NOV-X biological activity (biological activities of the NOV-X proteins are described below), expressing the encoded portion of NOV-X protein (e.g., by recombinant expression *in vitro*) and assessing the activity of the encoded portion of NOV-X. For example, a nucleic acid fragment encoding a biologically active portion of NOV-X can optionally include an ATP-binding domain. In another 25 embodiment, a nucleic acid fragment encoding a biologically active portion of NOV-X includes one or more regions.

NOV-X Variants

The invention further encompasses nucleic acid molecules that differ from the 30 nucleotide sequences shown in SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57 due to the degeneracy of the genetic code. These nucleic acids thus encode the same NOV-X protein as that encoded by the nucleotide sequence shown in SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57 e.g., the polypeptide of SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23. In another embodiment, an isolated nucleic acid molecule of the invention has a nucleotide

sequence encoding a protein having an amino acid sequence shown in SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23.

In addition to the human NOV-X nucleotide sequence shown in SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57, it will be appreciated by those skilled in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequences of NOV-X may exist within a population (e.g., the human population). Such genetic polymorphism in the NOV-X gene may exist among individuals within a population due to natural allelic variation. As used herein, the terms "gene" and "recombinant gene" refer to nucleic acid molecules comprising an open reading frame encoding a NOV-X protein, preferably a mammalian NOV-X protein. Such natural allelic variations can typically result in 1-5% variance in the nucleotide sequence of the NOV-X gene. Any and all such nucleotide variations and resulting amino acid polymorphisms in NOV-X that are the result of natural allelic variation and that do not alter the functional activity of NOV-X are intended to be within the scope of the invention.

Moreover, nucleic acid molecules encoding NOV-X proteins from other species, and thus that have a nucleotide sequence that differs from the human sequence of SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57 are intended to be within the scope of the invention.

Nucleic acid molecules corresponding to natural allelic variants and homologues of the NOV-X cDNAs of the invention can be isolated based on their homology to the human NOV-X nucleic acids disclosed herein using the human cDNAs, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions. For example, a soluble human NOV-X cDNA can be isolated based on its homology to human membrane-bound NOV-X. Likewise, a membrane-bound human NOV-X cDNA can be isolated based on its homology to soluble human NOV-X.

Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 6 nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57. In another embodiment, the nucleic acid is at least 10, 25, 50, 100, 250, 500 or 750 nucleotides in length. In another embodiment, an isolated nucleic acid molecule of the invention hybridizes to the coding region. As used herein, the term "hybridizes under stringent conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences at least 60% homologous to each other typically remain hybridized to each other.

Homologs (i.e., nucleic acids encoding NOV-X proteins derived from species other than human) or other related sequences (e.g., paralogs) can be obtained by low, moderate or

high stringency hybridization with all or a portion of the particular human sequence as a probe using methods well known in the art for nucleic acid hybridization and cloning.

As used herein, the phrase "stringent hybridization conditions" refers to conditions under which a probe, primer or oligonucleotide will hybridize to its target sequence, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures than shorter sequences. Generally, stringent conditions are selected to be about 5°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength, pH and nucleic acid concentration) at which 50% of the probes complementary to the target sequence hybridize to the target sequence at equilibrium. Since the target sequences are generally present at excess, at T_m , 50% of the probes are occupied at equilibrium. Typically, stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes, primers or oligonucleotides (e.g., 10 nt to 50 nt) and at least about 60°C for longer probes, primers and oligonucleotides. Stringent conditions may also be achieved with the addition of destabilizing agents, such as formamide.

Stringent conditions are known to those skilled in the art and can be found in CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6.

Preferably, the conditions are such that sequences at least about 65%, 70%, 75%, 85%, 90%, 95%, 98%, or 99% homologous to each other typically remain hybridized to each other. A non-limiting example of stringent hybridization conditions is hybridization in a high salt buffer comprising 6X SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 mg/ml denatured salmon sperm DNA at 65°C. This hybridization is followed by one or more washes in 0.2X SSC, 0.01% BSA at 50°C. An isolated nucleic acid molecule of the invention that hybridizes under stringent conditions to the sequence of SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57 corresponds to a naturally occurring nucleic acid molecule. As used herein, a "naturally-occurring" nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (e.g., encodes a natural protein).

In a second embodiment, a nucleic acid sequence that is hybridizable to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57, or fragments, analogs or derivatives thereof, under conditions of moderate stringency is provided. A non-limiting example of moderate stringency hybridization

conditions are hybridization in 6X SSC, 5X Denhardt's solution, 0.5% SDS and 100 mg/ml denatured salmon sperm DNA at 55°C, followed by one or more washes in 1X SSC, 0.1% SDS at 37°C. Other conditions of moderate stringency that may be used are well known in the art. See, e.g., Ausubel et al. (eds.), 1993, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, NY, and Kriegler, 1990, GENE TRANSFER AND EXPRESSION, A LABORATORY MANUAL, Stockton Press, NY.

In a third embodiment, a nucleic acid that is hybridizable to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57, or fragments, analogs or derivatives thereof, under conditions of low stringency, is

provided. A non-limiting example of low stringency hybridization conditions are hybridization in 35% formamide, 5X SSC, 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 mg/ml denatured salmon sperm DNA, 10% (wt/vol) dextran sulfate at 40°C, followed by one or more washes in 2X SSC, 25 mM Tris-HCl (pH 7.4), 5 mM EDTA, and 0.1% SDS at 50°C. Other conditions of low stringency that may be used are well known in the art (e.g., as employed for cross-species hybridizations). See, e.g., Ausubel et al. (eds.), 1993, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, NY, and Kriegler, 1990, GENE TRANSFER AND EXPRESSION, A LABORATORY MANUAL, Stockton Press, NY; Shilo and Weinberg, 1981, Proc Natl Acad Sci USA 78: 6789-6792.

20 **Conservative mutations**

In addition to naturally-occurring allelic variants of the NOV-X sequence that may exist in the population, the skilled artisan will further appreciate that changes can be introduced by mutation into the nucleotide sequence of SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57, thereby leading to changes in the amino acid sequence of the encoded NOV-X protein, without altering the functional ability of the NOV-X protein. For example, nucleotide substitutions leading to amino acid substitutions at "non-essential" amino acid residues can be made in the sequence of SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57. A "non-essential" amino acid residue is a residue that can be altered from the wild-type sequence of NOV-X without altering the biological activity, whereas an "essential" amino acid residue is required for biological activity. For example, amino acid residues that are conserved among the NOV-X proteins of the present invention, are predicted to be particularly unamenable to alteration.

Another aspect of the invention pertains to nucleic acid molecules encoding NOV-X proteins that contain changes in amino acid residues that are not essential for activity. Such

NOV-X proteins differ in amino acid sequence from SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23, yet retain biological activity. In one embodiment, the isolated nucleic acid molecule comprises a nucleotide sequence encoding a protein, wherein the protein comprises an amino acid sequence at least about 75% homologous to the amino acid sequence of SEQ ID

5 NO: 2, 4, 6, or 8. Preferably, the protein encoded by the nucleic acid is at least about 80% homologous to SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23, more preferably at least about 90%, 95%, 98%, and most preferably at least about 99% homologous to SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23.

An isolated nucleic acid molecule encoding a NOV-X protein homologous to the 10 protein of can be created by introducing one or more nucleotide substitutions, additions or deletions into the nucleotide sequence of SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57, such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein.

Mutations can be introduced into the nucleotide sequence of SEQ ID NO: 1, 3, 6, 8, 15 10, 12, 14, 16, 18, 20, 22, or 57 by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Preferably, conservative amino acid substitutions are made at one or more predicted non-essential amino acid residues. A "conservative amino acid substitution" is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have 20 been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side 25 chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, a predicted nonessential amino acid residue in NOV-X is replaced with another amino acid residue from the same side chain family. Alternatively, in another embodiment, mutations can be introduced randomly along all or part of a NOV-X coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for NOV-X biological activity to identify mutants that retain 30 activity. Following mutagenesis of SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57 the encoded protein can be expressed by any recombinant technology known in the art and the activity of the protein can be determined.

In one embodiment, a mutant NOV-X protein can be assayed for (1) the ability to form protein:protein interactions with other NOV-X proteins, other cell-surface proteins, or

biologically active portions thereof, (2) complex formation between a mutant NOV-X protein and a NOV-X receptor; (3) the ability of a mutant NOV-X protein to bind to an intracellular target protein or biologically active portion thereof; (e.g., avidin proteins); (4) the ability to bind NOV-X protein; or (5) the ability to specifically bind an anti-NOV-X protein antibody.

5

Antisense NOV-X Nucleic acids

Another aspect of the invention pertains to isolated antisense nucleic acid molecules that are hybridizable to or complementary to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57, or fragments, 10 analogs or derivatives thereof. An "antisense" nucleic acid comprises a nucleotide sequence that is complementary to a "sense" nucleic acid encoding a protein, e.g., complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence. In specific aspects, antisense nucleic acid molecules are provided that comprise a sequence complementary to at least about 10, 25, 50, 100, 250 or 500 nucleotides or an entire NOV-X 15 coding strand, or to only a portion thereof. Nucleic acid molecules encoding fragments, homologs, derivatives and analogs of a NOV-X protein of SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23 or antisense nucleic acids complementary to a NOV-X nucleic acid sequence of SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57 are additionally provided.

In one embodiment, an antisense nucleic acid molecule is antisense to a "coding 20 region" of the coding strand of a nucleotide sequence encoding NOV-X. The term "coding region" refers to the region of the nucleotide sequence comprising codons which are translated into amino acid residues (e.g., the protein coding region of human NOV-X corresponds to SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23). In another embodiment, the antisense nucleic acid molecule is antisense to a "noncoding region" of the coding strand of a nucleotide 25 sequence encoding NOV-X. The term "noncoding region" refers to 5' and 3' sequences which flank the coding region that are not translated into amino acids (i.e., also referred to as 5' and 3' untranslated regions).

Given the coding strand sequences encoding NOV-X disclosed herein (e.g., SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57), antisense nucleic acids of the invention can be 30 designed according to the rules of Watson and Crick or Hoogsteen base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of NOV-X mRNA, but more preferably is an oligonucleotide that is antisense to only a portion of the coding or noncoding region of NOV-X mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of NOV-X mRNA. An

antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis or enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (e.g., an antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used.

Examples of modified nucleotides that can be used to generate the antisense nucleic acid include: 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 15 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 20 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).

The antisense nucleic acid molecules of the invention are typically administered to a subject or generated in situ such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding a NOV-X protein to thereby inhibit expression of the protein, e.g., by inhibiting transcription and/or translation. The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule that binds to DNA duplexes, through specific interactions in the major groove of the double helix. An example of a route of administration of antisense nucleic acid molecules of the invention includes direct injection at a tissue site. Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then administered systemically. For example, for systemic administration, antisense molecules can be modified

such that they specifically bind to receptors or antigens expressed on a selected cell surface, e.g., by linking the antisense nucleic acid molecules to peptides or antibodies that bind to cell surface receptors or antigens. The antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient intracellular concentrations of 5 antisense molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.

In yet another embodiment, the antisense nucleic acid molecule of the invention is an -anomeric nucleic acid molecule. An -anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual -units, the 10 strands run parallel to each other (Gaultier et al. (1987) Nucleic acids Res 15: 6625-6641). The antisense nucleic acid molecule can also comprise a 2'-o-methylribonucleotide (Inoue et al. (1987) Nucleic acids Res 15: 6131-6148) or a chimeric RNA -DNA analogue (Inoue et al. (1987) FEBS Lett 215: 327-330).

Such modifications include, by way of nonlimiting example, modified bases, and 15 nucleic acids whose sugar phosphate backbones are modified or derivatized. These modifications are carried out at least in part to enhance the chemical stability of the modified nucleic acid, such that they may be used, for example, as antisense binding nucleic acids in therapeutic applications in a subject.

20 NOV-X Ribozymes and PNA moieties

In still another embodiment, an antisense nucleic acid of the invention is a ribozyme. Ribozymes are catalytic RNA molecules with ribonuclease activity that are capable of cleaving a single-stranded nucleic acid, such as a mRNA, to which they have a complementary region. Thus, ribozymes (e.g., hammerhead ribozymes (described in Haselhoff and Gerlach 25 (1988) Nature 334:585-591)) can be used to catalytically cleave NOV-X mRNA transcripts to thereby inhibit translation of NOV-X mRNA. A ribozyme having specificity for a NOV-X-encoding nucleic acid can be designed based upon the nucleotide sequence of a NOV-X DNA disclosed herein (i.e., SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57). For example, a derivative of a Tetrahymena L-19 IVS RNA can be constructed in which the 30 nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in a NOV-X-encoding mRNA. See, e.g., Cech et al. U.S. Pat. No. 4,987,071; and Cech et al. U.S. Pat. No. 5,116,742. Alternatively, NOV-X mRNA can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, e.g., Bartel et al., (1993) Science 261:1411-1418.

Alternatively, NOV-X gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of the NOV-X (e.g., the NOV-X promoter and/or enhancers) to form triple helical structures that prevent transcription of the NOV-X gene in target cells. See generally, Helene. (1991) Anticancer Drug Des. 6: 569-84; Helene. et al. (1992) Ann. N.Y. Acad. Sci. 660:27-36; and Maher (1992) Bioassays 14: 807-15.

In various embodiments, the nucleic acids of NOV-X can be modified at the base moiety, sugar moiety or phosphate backbone to improve, e.g., the stability, hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of the nucleic acids can be modified to generate peptide nucleic acids (see Hyrup et al. (1996) Bioorg Med Chem 4: 5-23). As used herein, the terms "peptide nucleic acids" or "PNAs" refer to nucleic acid mimics, e.g., DNA mimics, in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained. The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under conditions of low ionic strength. The synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis protocols as described in Hyrup et al. (1996) above; Perry-O'Keefe et al. (1996) PNAS 93: 14670-675.

PNAs of NOV-X can be used in therapeutic and diagnostic applications. For example, PNAs can be used as antisense or antigene agents for sequence-specific modulation of gene expression by, e.g., inducing transcription or translation arrest or inhibiting replication. PNAs of NOV-X can also be used, e.g., in the analysis of single base pair mutations in a gene by, e.g., PNA directed PCR clamping; as artificial restriction enzymes when used in combination with other enzymes, e.g., S1 nucleases (Hyrup B. (1996) above); or as probes or primers for DNA sequence and hybridization (Hyrup et al. (1996), above; Perry-O'Keefe (1996), above).

In another embodiment, PNAs of NOV-X can be modified, e.g., to enhance their stability or cellular uptake, by attaching lipophilic or other helper groups to PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art. For example, PNA-DNA chimeras of NOV-X can be generated that may combine the advantageous properties of PNA and DNA. Such chimeras allow DNA recognition enzymes, e.g., RNase H and DNA polymerases, to interact with the DNA portion while the PNA portion would provide high binding affinity and specificity. PNA-DNA chimeras can be linked using linkers of appropriate lengths selected in terms of base stacking, number of bonds between the nucleobases, and orientation (Hyrup (1996) above). The synthesis of PNA-DNA chimeras can be performed as described in Hyrup (1996) above and Finn et al. (1996) Nucl Acids Res 24: 3357-63. For example, a DNA chain can be synthesized

on a solid support using standard phosphoramidite coupling chemistry, and modified nucleoside analogs, e.g., 5'- (4-methoxytrityl) amino-5'-deoxy-thymidine phosphoramidite, can be used between the PNA and the 5' end of DNA (Mag et al. (1989) Nucl Acid Res 17: 5973-88). PNA monomers are then coupled in a stepwise manner to produce a chimeric

5 molecule with a 5' PNA segment and a 3' DNA segment (Finn et al. (1996) above).

Alternatively, chimeric molecules can be synthesized with a 5' DNA segment and a 3' PNA segment. See, Petersen et al. (1975) Bioorg Med Chem Lett 5: 1119-1124.

In other embodiments, the oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors in vivo), or agents facilitating transport across

10 the cell membrane (see, e.g., Letsinger et al., 1989, Proc. Natl. Acad. Sci. U.S.A.

86:6553-6556; Lemaitre et al., 1987, Proc. Natl. Acad. Sci. 84:648-652; PCT Publication No.

W088/09810) or the blood-brain barrier (see, e.g., PCT Publication No. W089/10134). In

addition, oligonucleotides can be modified with hybridization triggered cleavage agents (See,

e.g., Krol et al., 1988, BioTechniques 6:958-976) or intercalating agents. (See, e.g., Zon, 1988,

15 Pharm. Res. 5: 539-549). To this end, the oligonucleotide may be conjugated to another

molecule, e.g., a peptide, a hybridization triggered cross-linking agent, a transport agent, a

hybridization-triggered cleavage agent, etc.

NOV-X Polypeptides

20 A NOV-X polypeptide of the invention includes the NOV-X-like protein whose sequence is provided in SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23. The invention also includes a mutant or variant protein any of whose residues may be changed from the corresponding residue shown in SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23 while still encoding a protein that maintains its NOV-X-like activities and physiological functions, 25 or a functional fragment thereof. In some embodiments, up to 20% or more of the residues may be so changed in the mutant or variant protein. In some embodiments, the NOV-X polypeptide according to the invention is a mature polypeptide.

In general, a NOV-X -like variant that preserves NOV-X-like function includes any variant in which residues at a particular position in the sequence have been substituted by other amino acids, and further include the possibility of inserting an additional residue or residues between two residues of the parent protein as well as the possibility of deleting one or more residues from the parent sequence. Any amino acid substitution, insertion, or deletion is encompassed by the invention. In favorable circumstances, the substitution is a conservative substitution as defined above.

One aspect of the invention pertains to isolated NOV-X proteins, and biologically active portions thereof, or derivatives, fragments, analogs or homologs thereof. Also provided are polypeptide fragments suitable for use as immunogens to raise anti-NOV-X antibodies. In one embodiment, native NOV-X proteins can be isolated from cells or tissue sources by an appropriate purification scheme using standard protein purification techniques. In another embodiment, NOV-X proteins are produced by recombinant DNA techniques. Alternative to recombinant expression, a NOV-X protein or polypeptide can be synthesized chemically using standard peptide synthesis techniques.

An "isolated" or "purified" protein or biologically active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the NOV-X protein is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized. The language "substantially free of cellular material" includes preparations of NOV-X protein in which the protein is separated from cellular components of the cells from which it is isolated or recombinantly produced.

In one embodiment, the language "substantially free of cellular material" includes preparations of NOV-X protein having less than about 30% (by dry weight) of non-NOV-X protein (also referred to herein as a "contaminating protein"), more preferably less than about 20% of non-NOV-X protein, still more preferably less than about 10% of non-NOV-X protein, and most preferably less than about 5% non-NOV-X protein. When the NOV-X protein or biologically active portion thereof is recombinantly produced, it is also preferably substantially free of culture medium, i.e., culture medium represents less than about 20%, more preferably less than about 10%, and most preferably less than about 5% of the volume of the protein preparation.

The language "substantially free of chemical precursors or other chemicals" includes preparations of NOV-X protein in which the protein is separated from chemical precursors or other chemicals that are involved in the synthesis of the protein. In one embodiment, the language "substantially free of chemical precursors or other chemicals" includes preparations of NOV-X protein having less than about 30% (by dry weight) of chemical precursors or non-NOV-X chemicals, more preferably less than about 20% chemical precursors or non-NOV-X chemicals, still more preferably less than about 10% chemical precursors or non-NOV-X chemicals, and most preferably less than about 5% chemical precursors or non-NOV-X chemicals.

Biologically active portions of a NOV-X protein include peptides comprising amino acid sequences sufficiently homologous to or derived from the amino acid sequence of the

NOV-X protein, e.g., the amino acid sequence shown in SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23 that include fewer amino acids than the full length NOV-X proteins, and exhibit at least one activity of a NOV-X protein. Typically, biologically active portions comprise a domain or motif with at least one activity of the NOV-X protein. A biologically active portion of a NOV-X protein can be a polypeptide which is, for example, 10, 25, 50, 100 or more amino acids in length.

A biologically active portion of a NOV-X protein of the present invention may contain at least one of the above-identified domains conserved between the NOV-X proteins, e.g. TSR modules. Moreover, other biologically active portions, in which other regions of the protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the functional activities of a native NOV-X protein.

In an embodiment, the NOV-X protein has an amino acid sequence shown in SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23. In other embodiments, the NOV-X protein is substantially homologous to SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23 and retains the functional activity of the protein of SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23 yet differs in amino acid sequence due to natural allelic variation or mutagenesis, as described in detail below. Accordingly, in another embodiment, the NOV-X protein is a protein that comprises an amino acid sequence at least about 45% homologous to the amino acid sequence of SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23 and retains the functional activity of the NOV-X proteins of SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23.

Determining homology between two or more sequence

To determine the percent homology of two amino acid sequences or of two nucleic acids, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in either of the sequences being compared for optimal alignment between the sequences). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are homologous at that position (i.e., as used herein amino acid or nucleic acid "homology" is equivalent to amino acid or nucleic acid "identity").

The nucleic acid sequence homology may be determined as the degree of identity between two sequences. The homology may be determined using computer programs known in the art, such as GAP software provided in the GCG program package. See, Needleman and Wunsch 1970 J Mol Biol 48: 443-453. Using GCG GAP software with the following settings

for nucleic acid sequence comparison: GAP creation penalty of 5.0 and GAP extension penalty of 0.3, the coding region of the analogous nucleic acid sequences referred to above exhibits a degree of identity preferably of at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99%, with the CDS (encoding) part of the DNA sequence shown in SEQ ID NO: 1, 3, 6, 8, 5 10, 12, 14, 16, 18, 20, 22, or 57.

The term "sequence identity" refers to the degree to which two polynucleotide or polypeptide sequences are identical on a residue-by-residue basis over a particular region of comparison. The term "percentage of sequence identity" is calculated by comparing two optimally aligned sequences over that region of comparison, determining the number of 10 positions at which the identical nucleic acid base (e.g., A, T, C, G, U, or I, in the case of nucleic acids) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the region of comparison (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity. The term "substantial identity" as used herein denotes a characteristic of a 15 polynucleotide sequence, wherein the polynucleotide comprises a sequence that has at least 80 percent sequence identity, preferably at least 85 percent identity and often 90 to 95 percent sequence identity, more usually at least 99 percent sequence identity as compared to a reference sequence over a comparison region. The term "percentage of positive residues" is calculated by comparing two optimally aligned sequences over that region of comparison, 20 determining the number of positions at which the identical and conservative amino acid substitutions, as defined above, occur in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the region of comparison (i.e., the window size), and multiplying the result by 100 to yield the percentage of positive residues.

25

Chimeric and fusion proteins

The invention also provides NOV-X chimeric or fusion proteins. As used herein, a NOV-X "chimeric protein" or "fusion protein" comprises a NOV-X polypeptide operatively linked to a non-NOV-X polypeptide. An "NOV-X polypeptide" refers to a polypeptide having 30 an amino acid sequence corresponding to NOV-X, whereas a "non-NOV-X polypeptide" refers to a polypeptide having an amino acid sequence corresponding to a protein that is not substantially homologous to the NOV-X protein, e.g., a protein that is different from the NOV-X protein and that is derived from the same or a different organism. Within a NOV-X fusion protein the NOV-X polypeptide can correspond to all or a portion of a NOV-X protein.

In one embodiment, a NOV-X fusion protein comprises at least one biologically active portion of a NOV-X protein. In another embodiment, a NOV-X fusion protein comprises at least two biologically active portions of a NOV-X protein. Within the fusion protein, the term "operatively linked" is intended to indicate that the NOV-X polypeptide and the non-NOV-X polypeptide are fused in-frame to each other. The non-NOV-X polypeptide can be fused to the N-terminus or C-terminus of the NOV-X polypeptide.

For example, in one embodiment a NOV-X fusion protein comprises a NOV-X polypeptide operably linked to the extracellular domain of a second protein. Such fusion proteins can be further utilized in screening assays for compounds that modulate NOV-X activity (such assays are described in detail below).

In another embodiment, the fusion protein is a GST-NOV-X fusion protein in which the NOV-X sequences are fused to the C-terminus of the GST (i.e., glutathione S-transferase) sequences. Such fusion proteins can facilitate the purification of recombinant NOV-X.

In another embodiment, the fusion protein is a NOV-X-immunoglobulin fusion protein in which the NOV-X sequences comprising one or more domains are fused to sequences derived from a member of the immunoglobulin protein family. The NOV-X-immunoglobulin fusion proteins of the invention can be incorporated into pharmaceutical compositions and administered to a subject to inhibit an interaction between a NOV-X ligand and a NOV-X protein on the surface of a cell, to thereby suppress NOV-X-mediated signal transduction *in vivo*. In one nonlimiting example, a contemplated NOV-X ligand of the invention is the NOV-X receptor. The NOV-X-immunoglobulin fusion proteins can be used to affect the bioavailability of a NOV-X cognate ligand. Inhibition of the NOV-X ligand/NOV-X interaction may be useful therapeutically for both the treatment of proliferative and differentiative disorders, e.g., cancer as well as modulating (e.g., promoting or inhibiting) cell survival, as well as acute and chronic inflammatory disorders and hyperplastic wound healing, e.g. hypertrophic scars and keloids. Moreover, the NOV-X-immunoglobulin fusion proteins of the invention can be used as immunogens to produce anti-NOV-X antibodies in a subject, to purify NOV-X ligands, and in screening assays to identify molecules that inhibit the interaction of NOV-X with a NOV-X ligand.

A NOV-X chimeric or fusion protein of the invention can be produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, e.g., by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate,

alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers that give rise to complementary overhangs between two consecutive gene fragments that can subsequently be annealed and reamplified to generate a chimeric gene sequence (see, for example, Ausubel et al. (eds.) CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST polypeptide). A NOV-X-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the NOV-X protein.

NOV-X agonists and antagonists

The present invention also pertains to variants of the NOV-X proteins that function as either NOV-X agonists (mimetics) or as NOV-X antagonists. Variants of the NOV-X protein can be generated by mutagenesis, e.g., discrete point mutation or truncation of the NOV-X protein. An agonist of the NOV-X protein can retain substantially the same, or a subset of, the biological activities of the naturally occurring form of the NOV-X protein. An antagonist of the NOV-X protein can inhibit one or more of the activities of the naturally occurring form of the NOV-X protein by, for example, competitively binding to a downstream or upstream member of a cellular signaling cascade which includes the NOV-X protein. Thus, specific biological effects can be elicited by treatment with a variant of limited function. In one embodiment, treatment of a subject with a variant having a subset of the biological activities of the naturally occurring form of the protein has fewer side effects in a subject relative to treatment with the naturally occurring form of the NOV-X proteins.

Variants of the NOV-X protein that function as either NOV-X agonists (mimetics) or as NOV-X antagonists can be identified by screening combinatorial libraries of mutants, e.g., truncation mutants, of the NOV-X protein for NOV-X protein agonist or antagonist activity. In one embodiment, a variegated library of NOV-X variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of NOV-X variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential NOV-X sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (e.g., for phage display) containing the set of NOV-X sequences therein. There are a variety of methods which can be used to produce libraries of potential

NOV-X variants from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be performed in an automatic DNA synthesizer, and the synthetic gene then ligated into an appropriate expression vector. Use of a degenerate set of genes allows for the provision, in one mixture, of all of the sequences encoding the desired set of potential NOV-X sequences. Methods for synthesizing degenerate oligonucleotides are known in the art (see, e.g., Narang (1983) *Tetrahedron* 39:3; Itakura et al. (1984) *Annu Rev Biochem* 53:323; Itakura et al. (1984) *Science* 198:1056; Ike et al. (1983) *Nucl Acid Res* 11:477.

10 **Polypeptide libraries**

In addition, libraries of fragments of the NOV-X protein coding sequence can be used to generate a variegated population of NOV-X fragments for screening and subsequent selection of variants of a NOV-X protein. In one embodiment, a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of a NOV-X coding sequence with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double stranded DNA that can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with S1 nuclease, and ligating the resulting fragment library into an expression vector. By this method, an expression library can be derived which encodes N-terminal and internal fragments of various sizes of the NOV-X protein.

Several techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA libraries for gene products having a selected property. Such techniques are adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of NOV-X proteins. The most widely used techniques, which are amenable to high throughput analysis, for screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates isolation of the vector encoding the gene whose product was detected. Recursive ensemble mutagenesis (REM), a new technique that enhances the frequency of functional mutants in the libraries, can be used in combination with the screening assays to identify NOV-X variants (Arkin and Yourvan (1992) *PNAS* 89:7811-7815; Delgrave et al. (1993) *Protein Engineering* 6:327-331).

NOV-X Antibodies

Also included in the invention are antibodies to NOV-X proteins, or fragments of NOV-X proteins. The term "antibody" as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin (Ig) molecules, i.e., molecules that contain an antigen binding site that specifically binds (immunoreacts with) an antigen. Such antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, F_{ab}, F_{ab'} and F_{(ab')2} fragments, and an F_{ab} expression library. In general, an antibody molecule obtained from humans relates to any of the classes IgG, IgM, IgA, IgE and IgD, which differ from one another by the nature of the heavy chain present in the molecule. Certain classes have subclasses as well, such as IgG₁, IgG₂, and others. Furthermore, in humans, the light chain may be a kappa chain or a lambda chain. Reference herein to antibodies includes a reference to all such classes, subclasses and types of human antibody species.

An isolated NOV-X-related protein of the invention may be intended to serve as an antigen, or a portion or fragment thereof, and additionally can be used as an immunogen to generate antibodies that immunospecifically bind the antigen, using standard techniques for polyclonal and monoclonal antibody preparation. The full-length protein can be used or, alternatively, the invention provides antigenic peptide fragments of the antigen for use as immunogens. An antigenic peptide fragment comprises at least 6 amino acid residues of the amino acid sequence of the full length protein, such as an amino acid sequence shown in SEQ ID NO: 2, 4, 6 , 8 ,10, 12, 14, 16, 18, or 20, and encompasses an epitope thereof such that an antibody raised against the peptide forms a specific immune complex with the full length protein or with any fragment that contains the epitope. Preferably, the antigenic peptide comprises at least 10 amino acid residues, or at least 15 amino acid residues, or at least 20 amino acid residues, or at least 30 amino acid residues. Preferred epitopes encompassed by the antigenic peptide are regions of the protein that are located on its surface; commonly these are hydrophilic regions.

In certain embodiments of the invention, at least one epitope encompassed by the antigenic peptide is a region of NOV-X-related protein that is located on the surface of the protein, e.g., a hydrophilic region. A hydrophobicity analysis of the human NOV-X-related protein sequence will indicate which regions of a NOV-X-related protein are particularly hydrophilic and, therefore, are likely to encode surface residues useful for targeting antibody production. As a means for targeting antibody production, hydropathy plots showing regions of hydrophilicity and hydrophobicity may be generated by any method well known in the art,

including, for example, the Kyte Doolittle or the Hopp Woods methods, either with or without Fourier transformation. See, e.g., Hopp and Woods, 1981, Proc. Nat. Acad. Sci. USA 78: 3824-3828; Kyte and Doolittle 1982, J. Mol. Biol. 157: 105-142, each of which is incorporated herein by reference in its entirety. Antibodies that are specific for one or more domains within an antigenic protein, or derivatives, fragments, analogs or homologs thereof, are also provided herein.

A protein of the invention, or a derivative, fragment, analog, homolog or ortholog thereof, may be utilized as an immunogen in the generation of antibodies that immunospecifically bind these protein components.

Various procedures known within the art may be used for the production of polyclonal or monoclonal antibodies directed against a protein of the invention, or against derivatives, fragments, analogs homologs or orthologs thereof (see, for example, Antibodies: A Laboratory Manual, Harlow E, and Lane D, 1988, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, incorporated herein by reference). Some of these antibodies are discussed below.

Polyclonal Antibodies

For the production of polyclonal antibodies, various suitable host animals (e.g., rabbit, goat, mouse or other mammal) may be immunized by one or more injections with the native protein, a synthetic variant thereof, or a derivative of the foregoing. An appropriate immunogenic preparation can contain, for example, the naturally occurring immunogenic protein, a chemically synthesized polypeptide representing the immunogenic protein, or a recombinantly expressed immunogenic protein. Furthermore, the protein may be conjugated to a second protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. The preparation can further include an adjuvant. Various adjuvants used to increase the immunological response include, but are not limited to, Freund's (complete and incomplete), mineral gels (e.g., aluminum hydroxide), surface active substances (e.g., lyssolecithin, pluronic polyols, polyanions, peptides, oil emulsions, dinitrophenol, etc.), adjuvants usable in humans such as Bacille Calmette-Guerin and Corynebacterium parvum, or similar immunostimulatory agents.

Additional examples of adjuvants which can be employed include MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate).

The polyclonal antibody molecules directed against the immunogenic protein can be isolated from the mammal (e.g., from the blood) and further purified by well known

techniques, such as affinity chromatography using protein A or protein G, which provide primarily the IgG fraction of immune serum. Subsequently, or alternatively, the specific antigen which is the target of the immunoglobulin sought, or an epitope thereof, may be immobilized on a column to purify the immune specific antibody by immunoaffinity chromatography. Purification of immunoglobulins is discussed, for example, by D. Wilkinson (The Scientist, published by The Scientist, Inc., Philadelphia PA, Vol. 14, No. 8 (April 17, 2000), pp. 25-28).

Monoclonal Antibodies

The term "monoclonal antibody" (MAb) or "monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one molecular species of antibody molecule consisting of a unique light chain gene product and a unique heavy chain gene product. In particular, the complementarity determining regions (CDRs) of the monoclonal antibody are identical in all the molecules of the population. MAbs thus contain an antigen binding site capable of immunoreacting with a particular epitope of the antigen characterized by a unique binding affinity for it.

Monoclonal antibodies can be prepared using hybridoma methods, such as those described by Kohler and Milstein, *Nature*, 256:495 (1975). In a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes can be immunized in vitro.

The immunizing agent will typically include the protein antigen, a fragment thereof or a fusion protein thereof. Generally, either peripheral blood lymphocytes are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, *Monoclonal Antibodies: Principles and Practice*, Academic Press, (1986) pp. 59-103). Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells can be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas

typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells.

Preferred immortalized cell lines are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, California and the American Type Culture Collection, Manassas, Virginia. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies (Kozbor, *J. Immunol.*, 133:3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, Marcel Dekker, Inc., New York, (1987) pp. 51-63).

The culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against the antigen. Preferably, the binding specificity of monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA). Such techniques and assays are known in the art. The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson and Pollard, *Anal. Biochem.*, 107:220 (1980). Preferably, antibodies having a high degree of specificity and a high binding affinity for the target antigen are isolated.

After the desired hybridoma cells are identified, the clones can be subcloned by limiting dilution procedures and grown by standard methods. Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium. Alternatively, the hybridoma cells can be grown *iv vivo* as ascites in a mammal.

The monoclonal antibodies secreted by the subclones can be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.

The monoclonal antibodies can also be made by recombinant DNA methods, such as those described in U.S. Patent No. 4,816,567. DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells of the invention serve as a preferred source of such DNA. Once isolated, the DNA can be placed into expression vectors,

which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also can be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences (U.S. Patent No. 4,816,567; Morrison, Nature 368, 812-13 (1994)) or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. Such a non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody.

Humanized Antibodies

The antibodies directed against the protein antigens of the invention can further comprise humanized antibodies or human antibodies. These antibodies are suitable for administration to humans without engendering an immune response by the human against the administered immunoglobulin. Humanized forms of antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')₂ or other antigen-binding subsequences of antibodies) that are principally comprised of the sequence of a human immunoglobulin, and contain minimal sequence derived from a non-human immunoglobulin.

Humanization can be performed following the method of Winter and co-workers (Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323-327 (1988); Verhoeyen et al., Science, 239:1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. (See also U.S. Patent No. 5,225,539.) In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies can also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the framework regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin (Jones et al., 1986; Riechmann et al., 1988; and Presta, Curr. Op. Struct. Biol., 2:593-596 (1992)).

Human Antibodies

Fully human antibodies relate to antibody molecules in which essentially the entire sequences of both the light chain and the heavy chain, including the CDRs, arise from human genes. Such antibodies are termed "human antibodies", or "fully human antibodies" herein.

5 Human monoclonal antibodies can be prepared by the trioma technique; the human B-cell hybridoma technique (see Kozbor, et al., 1983 *Immunol Today* 4: 72) and the EBV hybridoma technique to produce human monoclonal antibodies (see Cole, et al., 1985 In: *MONOCLONAL ANTIBODIES AND CANCER THERAPY*, Alan R. Liss, Inc., pp. 77-96). Human monoclonal antibodies may be utilized in the practice of the present invention and may be produced by

10 using human hybridomas (see Cote, et al., 1983. *Proc Natl Acad Sci USA* 80: 2026-2030) or by transforming human B-cells with Epstein Barr Virus in vitro (see Cole, et al., 1985 In: *MONOCLONAL ANTIBODIES AND CANCER THERAPY*, Alan R. Liss, Inc., pp. 77-96).

In addition, human antibodies can also be produced using additional techniques, including phage display libraries (Hoogenboom and Winter, *J. Mol. Biol.*, 227:381 (1991);
15 Marks et al., *J. Mol. Biol.*, 222:581 (1991)). Similarly, human antibodies can be made by introducing human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This
20 approach is described, for example, in U.S. Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in Marks et al. (*Bio/Technology* 10, 779-783 (1992)); Lonberg et al. (*Nature* 368 856-859 (1994)); Morrison (*Nature* 368, 812-13 (1994)); Fishwild et al., (*Nature Biotechnology* 14, 845-51 (1996)); Neuberger (*Nature Biotechnology* 14, 826 (1996)); and Lonberg and Huszar (*Intern. Rev. Immunol.* 13 65-93 (1995)).

25 Human antibodies may additionally be produced using transgenic nonhuman animals which are modified so as to produce fully human antibodies rather than the animal's endogenous antibodies in response to challenge by an antigen. (See PCT publication WO94/02602). The endogenous genes encoding the heavy and light immunoglobulin chains in the nonhuman host have been incapacitated, and active loci encoding human heavy and light
30 chain immunoglobulins are inserted into the host's genome. The human genes are incorporated, for example, using yeast artificial chromosomes containing the requisite human DNA segments. An animal which provides all the desired modifications is then obtained as progeny by crossbreeding intermediate transgenic animals containing fewer than the full complement of the modifications. The preferred embodiment of such a nonhuman animal is a

mouse, and is termed the Xenomouse™ as disclosed in PCT publications WO 96/33735 and WO 96/34096. This animal produces B cells which secrete fully human immunoglobulins. The antibodies can be obtained directly from the animal after immunization with an immunogen of interest, as, for example, a preparation of a polyclonal antibody, or alternatively from immortalized B cells derived from the animal, such as hybridomas producing monoclonal antibodies. Additionally, the genes encoding the immunoglobulins with human variable regions can be recovered and expressed to obtain the antibodies directly, or can be further modified to obtain analogs of antibodies such as, for example, single chain Fv molecules.

An example of a method of producing a nonhuman host, exemplified as a mouse, lacking expression of an endogenous immunoglobulin heavy chain is disclosed in U.S. Patent No. 5,939,598. It can be obtained by a method including deleting the J segment genes from at least one endogenous heavy chain locus in an embryonic stem cell to prevent rearrangement of the locus and to prevent formation of a transcript of a rearranged immunoglobulin heavy chain locus, the deletion being effected by a targeting vector containing a gene encoding a selectable marker; and producing from the embryonic stem cell a transgenic mouse whose somatic and germ cells contain the gene encoding the selectable marker.

A method for producing an antibody of interest, such as a human antibody, is disclosed in U.S. Patent No. 5,916,771. It includes introducing an expression vector that contains a nucleotide sequence encoding a heavy chain into one mammalian host cell in culture, introducing an expression vector containing a nucleotide sequence encoding a light chain into another mammalian host cell, and fusing the two cells to form a hybrid cell. The hybrid cell expresses an antibody containing the heavy chain and the light chain.

In a further improvement on this procedure, a method for identifying a clinically relevant epitope on an immunogen, and a correlative method for selecting an antibody that binds immunospecifically to the relevant epitope with high affinity, are disclosed in PCT publication WO 99/53049.

F_{ab} Fragments and Single Chain Antibodies

According to the invention, techniques can be adapted for the production of single-chain antibodies specific to an antigenic protein of the invention (see e.g., U.S. Patent No. 4,946,778). In addition, methods can be adapted for the construction of F_{ab} expression libraries (see e.g., Huse, et al., 1989 Science 246: 1275-1281) to allow rapid and effective identification of monoclonal F_{ab} fragments with the desired specificity for a protein or

derivatives, fragments, analogs or homologs thereof. Antibody fragments that contain the idiotypes to a protein antigen may be produced by techniques known in the art including, but not limited to: (i) an $F_{(ab)2}$ fragment produced by pepsin digestion of an antibody molecule; (ii) an F_{ab} fragment generated by reducing the disulfide bridges of an $F_{(ab)2}$ fragment; (iii) an F_{ab} fragment generated by the treatment of the antibody molecule with papain and a reducing agent and (iv) F_v fragments.

Bispecific Antibodies

Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. In the present case, one of the binding specificities is for an antigenic protein of the invention. The second binding target is any other antigen, and advantageously is a cell-surface protein or receptor or receptor subunit.

Methods for making bispecific antibodies are known in the art. Traditionally, the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chain/light-chain pairs, where the two heavy chains have different specificities (Milstein and Cuello, *Nature*, 305:537-539 (1983)). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of ten different antibody molecules, of which only one has the correct bispecific structure. The purification of the correct molecule is usually accomplished by affinity chromatography steps. Similar procedures are disclosed in WO 93/08829, published 13 May 1993, and in Traunecker et al., 1991 EMBO J., 10:3655-3659.

Antibody variable domains with the desired binding specificities (antibody-antigen combining sites) can be fused to immunoglobulin constant domain sequences. The fusion preferably is with an immunoglobulin heavy-chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have the first heavy-chain constant region (CH1) containing the site necessary for light-chain binding present in at least one of the fusions. DNAs encoding the immunoglobulin heavy-chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host organism. For further details of generating bispecific antibodies see, for example, Suresh et al., *Methods in Enzymology*, 121:210 (1986).

According to another approach described in WO 96/27011, the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers which are recovered from recombinant cell culture. The preferred interface comprises at least a part of the CH3 region of an antibody constant domain. In this method, one or more small amino

acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e.g. tyrosine or tryptophan). Compensatory "cavities" of identical or similar size to the large side chain(s) are created on the interface of the second antibody molecule by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine). This provides a mechanism for increasing the yield of the heterodimer over other unwanted end-products such as homodimers.

Bispecific antibodies can be prepared as full length antibodies or antibody fragments (e.g. F(ab')₂ bispecific antibodies). Techniques for generating bispecific antibodies from antibody fragments have been described in the literature. For example, bispecific antibodies can be

prepared using chemical linkage. Brennan et al., Science 229:81 (1985) describe a procedure wherein intact antibodies are proteolytically cleaved to generate F(ab')₂ fragments. These fragments are reduced in the presence of the dithiol complexing agent sodium arsenite to stabilize vicinal dithiols and prevent intermolecular disulfide formation. The Fab' fragments generated are then converted to thionitrobenzoate (TNB) derivatives. One of the Fab'-TNB derivatives is then reconverted to the Fab'-thiol by reduction with mercaptoethylamine and is mixed with an equimolar amount of the other Fab'-TNB derivative to form the bispecific antibody. The bispecific antibodies produced can be used as agents for the selective immobilization of enzymes.

Additionally, Fab' fragments can be directly recovered from E. coli and chemically coupled to form bispecific antibodies. Shalaby et al., J. Exp. Med. 175:217-225 (1992) describe the production of a fully humanized bispecific antibody F(ab')₂ molecule. Each Fab' fragment was separately secreted from E. coli and subjected to directed chemical coupling in vitro to form the bispecific antibody. The bispecific antibody thus formed was able to bind to cells overexpressing the ErbB2 receptor and normal human T cells, as well as trigger the lytic activity of human cytotoxic lymphocytes against human breast tumor targets.

Various techniques for making and isolating bispecific antibody fragments directly from recombinant cell culture have also been described. For example, bispecific antibodies have been produced using leucine zippers. Kostelny et al., J. Immunol. 148(5):1547-1553 (1992). The leucine zipper peptides from the Fos and Jun proteins were linked to the Fab' portions of two different antibodies by gene fusion. The antibody homodimers were reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for the production of antibody homodimers. The "diabody" technology described by Hollinger et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993) has provided an alternative mechanism for making bispecific antibody fragments. The fragments

comprise a heavy-chain variable domain (V_H) connected to a light-chain variable domain (V_L) by a linker which is too short to allow pairing between the two domains on the same chain. Accordingly, the V_H and V_L domains of one fragment are forced to pair with the complementary V_L and V_H domains of another fragment, thereby forming two antigen-binding sites. Another strategy for making bispecific antibody fragments by the use of single-chain Fv (sFv) dimers has also been reported. See, Gruber et al., *J. Immunol.* 152:5368 (1994). Antibodies with more than two valencies are contemplated. For example, trispecific antibodies can be prepared. Tutt et al., *J. Immunol.* 147:60 (1991).

Exemplary bispecific antibodies can bind to two different epitopes, at least one of which originates in the protein antigen of the invention. Alternatively, an anti-antigenic arm of an immunoglobulin molecule can be combined with an arm which binds to a triggering molecule on a leukocyte such as a T-cell receptor molecule (e.g. CD2, CD3, CD28, or B7), or Fc receptors for IgG (Fc R), such as Fc RI (CD64), Fc RII (CD32) and Fc RIII (CD16) so as to focus cellular defense mechanisms to the cell expressing the particular antigen. Bispecific antibodies can also be used to direct cytotoxic agents to cells which express a particular antigen. These antibodies possess an antigen-binding arm and an arm which binds a cytotoxic agent or a radionuclide chelator, such as EOTUBE, DPTA, DOTA, or TETA. Another bispecific antibody of interest binds the protein antigen described herein and further binds tissue factor (TF).

20

Heteroconjugate Antibodies

Heteroconjugate antibodies are also within the scope of the present invention. Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells (U.S. Patent No. 4,676,980), and for treatment of HIV infection (WO 91/00360; WO 92/200373; EP 03089). It is contemplated that the antibodies can be prepared in vitro using known methods in synthetic protein chemistry, including those involving crosslinking agents. For example, immunotoxins can be constructed using a disulfide exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptopbutyrimidate and those disclosed, for example, in U.S. Patent No. 4,676,980.

Effector Function Engineering

It can be desirable to modify the antibody of the invention with respect to effector

function, so as to enhance, e.g., the effectiveness of the antibody in treating cancer. For example, cysteine residue(s) can be introduced into the Fc region, thereby allowing interchain disulfide bond formation in this region. The homodimeric antibody thus generated can have improved internalization capability and/or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). See Caron et al., *J. Exp Med.*, 176: 1191-1195 (1992) and Shopes, *J. Immunol.*, 148: 2918-2922 (1992). Homodimeric antibodies with enhanced anti-tumor activity can also be prepared using heterobifunctional cross-linkers as described in Wolff et al. *Cancer Research*, 53: 2560-2565 (1993). Alternatively, an antibody can be engineered that has dual Fc regions and can thereby have enhanced complement lysis and ADCC capabilities. See Stevenson et al., *Anti-Cancer Drug Design*, 3: 219-230 (1989).

Immunoconjugates

The invention also pertains to immunoconjugates comprising an antibody conjugated to a cytotoxic agent such as a chemotherapeutic agent, toxin (e.g., an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or a radioactive isotope (i.e., a radioconjugate).

Chemotherapeutic agents useful in the generation of such immunoconjugates have been described above. Enzymatically active toxins and fragments thereof that can be used include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from *Pseudomonas aeruginosa*), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the trichothecenes. A variety of radionuclides are available for the production of radioconjugated antibodies. Examples include ²¹²Bi, ¹³¹I, ¹³¹In, ⁹⁰Y, and ¹⁸⁶Re.

Conjugates of the antibody and cytotoxic agent are made using a variety of bifunctional protein-coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in Vitetta et al., *Science*, 238: 1098 (1987). Carbon-14-labeled 1-isothiocyanatobenzyl-3-

methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. See WO94/11026.

In another embodiment, the antibody can be conjugated to a "receptor" (such as streptavidin) for utilization in tumor pretargeting wherein the antibody-receptor conjugate is administered to the patient, followed by removal of unbound conjugate from the circulation using a clearing agent and then administration of a "ligand" (e.g., avidin) that is in turn conjugated to a cytotoxic agent.

NOV-X Recombinant Expression Vectors and Host Cells

Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding a NOV-X protein, or derivatives, fragments, analogs or homologs thereof. As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively-linked. Such vectors are referred to herein as "expression vectors". In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, "plasmid" and "vector" can be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, that is operatively-linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, "operably-linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner that allows for expression of the nucleotide sequence (e.g., in an in

vitro transcription/translation system or in a host cell when the vector is introduced into the host cell).

The term "regulatory sequence" is intended to include promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Such regulatory sequences are

5 described, for example, in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990). Regulatory sequences include those that direct constitutive expression of a nucleotide sequence in many types of host cell and those that direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the
10 design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., NOV-X proteins, mutant forms of NOV-X proteins, fusion proteins, etc.).

15 The recombinant expression vectors of the invention can be designed for expression of NOV-X proteins in prokaryotic or eukaryotic cells. For example, NOV-X proteins can be expressed in bacterial cells such as Escherichia coli, insect cells (using baculovirus expression vectors) yeast cells or mammalian cells. Suitable host cells are discussed further in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San
20 Diego, Calif. (1990). Alternatively, the recombinant expression vector can be transcribed and translated in vitro, for example using T7 promoter regulatory sequences and T7 polymerase.

Expression of proteins in prokaryotes is most often carried out in Escherichia coli with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded
25 therein, usually to the amino terminus of the recombinant protein. Such fusion vectors typically serve three purposes: (i) to increase expression of recombinant protein; (ii) to increase the solubility of the recombinant protein; and (iii) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the
30 recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith and Johnson, 1988. Gene 67: 31-40), pMAL (New England Biolabs, Beverly, Mass.) and pRIT5 (Pharmacia, Piscataway, N.J.) that fuse

glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein.

Examples of suitable inducible non-fusion *E. coli* expression vectors include pTrc (Amrann et al., (1988) Gene 69:301-315) and pET 11d (Studier et al., GENE EXPRESSION TECHNOLOGY:

5 METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 60-89).

One strategy to maximize recombinant protein expression in *E. coli* is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein. See, e.g., Gottesman, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif. (1990) 119-128. Another strategy is to alter the 10 nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in *E. coli* (see, e.g., Wada, et al., 1992. Nucl. Acids Res. 20: 2111-2118). Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.

In another embodiment, the NOV-X expression vector is a yeast expression vector.

15 Examples of vectors for expression in yeast *Saccharomyces cerevisiae* include pYEpSec1 (Baldari, et al., 1987. EMBO J. 6: 229-234), pMFA (Kurjan and Herskowitz, 1982. Cell 30: 933-943), pJRY88 (Schultz et al., 1987. Gene 54: 113-123), pYES2 (Invitrogen Corporation, San Diego, Calif.), and picZ (InVitrogen Corp, San Diego, Calif.).

20 Alternatively, NOV-X can be expressed in insect cells using baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., SF9 cells) include the pAc series (Smith, et al., 1983. Mol. Cell. Biol. 3: 2156-2165) and the pVL series (Lucklow and Summers, 1989. Virology 170: 31-39).

25 In yet another embodiment, a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed, 1987. Nature 329: 840) and pMT2PC (Kaufman, et al., 1987. EMBO J. 6: 187-195). When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, adenovirus 2, cytomegalovirus, and simian virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells see, e.g., Chapters 16 and 17 of 30 Sambrook, et al., MOLECULAR CLONING: A LABORATORY MANUAL. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989.

In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific

regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert, et al., 1987. *Genes Dev.* 1: 268-277), lymphoid-specific promoters (Calame and Eaton, 1988. *Adv. Immunol.* 43: 235-275), in particular promoters of T cell receptors (Winoto and Baltimore, 1989. *EMBO J.* 8: 729-733) and immunoglobulins (Banerji, et al., 1983. *Cell* 33: 729-740; Queen and Baltimore, 1983. *Cell* 33: 741-748), neuron-specific promoters (e.g., the neurofilament promoter; Byrne and Ruddle, 1989. *Proc. Natl. Acad. Sci. USA* 86: 5473-5477), pancreas-specific promoters (Edlund, et al., 1985. *Science* 230: 912-916), and mammary gland-specific promoters (e.g., milk whey promoter; U.S. Pat. No. 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are also encompassed, e.g., the murine hox promoters (Kessel and Gruss, 1990. *Science* 249: 374-379) and the -fetoprotein promoter (Campes and Tilghman, 1989. *Genes Dev.* 3: 537-546).

The invention further provides a recombinant expression vector comprising a DNA molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operatively-linked to a regulatory sequence in a manner that allows for expression (by transcription of the DNA molecule) of an RNA molecule that is antisense to NOV-X mRNA. Regulatory sequences operatively linked to a nucleic acid cloned in the antisense orientation can be chosen that direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen that direct constitutive, tissue specific or cell type specific expression of antisense RNA. The antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced. For a discussion of the regulation of gene expression using antisense genes see, e.g., Weintraub, et al., "Antisense RNA as a molecular tool for genetic analysis," *Reviews-Trends in Genetics*, Vol. 1(1) 1986.

Another aspect of the invention pertains to host cells into which a recombinant expression vector of the invention has been introduced. The terms "host cell" and "recombinant host cell" are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but also to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.

A host cell can be any prokaryotic or eukaryotic cell. For example, NOV-X protein can be expressed in bacterial cells such as *E. coli*, insect cells, yeast or mammalian cells (such as human, Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to those skilled in the art.

5 Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection" are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (e.g., DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or
10 electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, et al. (*MOLECULAR CLONING: A LABORATORY MANUAL*. 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989), and other laboratory manuals.

15 For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (e.g., resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Various selectable markers include those that confer resistance to drugs, such as G418, hygromycin and methotrexate. Nucleic acid encoding a
20 selectable marker can be introduced into a host cell on the same vector as that encoding NOV-X or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (e.g., cells that have incorporated the selectable marker gene will survive, while the other cells die).

25 A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (i.e., express) NOV-X protein. Accordingly, the invention further provides methods for producing NOV-X protein using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding NOV-X protein has been introduced) in a suitable medium such that NOV-X protein is produced. In another embodiment, the method further
30 comprises isolating NOV-X protein from the medium or the host cell.

Transgenic NOV-X Animals

The host cells of the invention can also be used to produce non-human transgenic animals. For example, in one embodiment, a host cell of the invention is a fertilized oocyte or an embryonic stem cell into which NOV-X protein-coding sequences have been introduced.

Such host cells can then be used to create non-human transgenic animals in which exogenous NOV-X sequences have been introduced into their genome or homologous recombinant animals in which endogenous NOV-X sequences have been altered. Such animals are useful for studying the function and/or activity of NOV-X protein and for identifying and/or evaluating modulators of NOV-X protein activity. As used herein, a "transgenic animal" is a non-human animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal includes a transgene. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, amphibians, etc. A transgene is exogenous DNA that is integrated into the genome of a cell from which a transgenic animal develops and that remains in the genome of the mature animal, thereby directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal. As used herein, a "homologous recombinant animal" is a non-human animal, preferably a mammal, more preferably a mouse, in which an endogenous NOV-X gene has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, e.g., an embryonic cell of the animal, prior to development of the animal.

A transgenic animal of the invention can be created by introducing NOV-X-encoding nucleic acid into the male pronuclei of a fertilized oocyte (e.g., by microinjection, retroviral infection) and allowing the oocyte to develop in a pseudopregnant female foster animal. Sequences including SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57 can be introduced as a transgene into the genome of a non-human animal. Alternatively, a non-human homologue of the human NOV-X gene, such as a mouse NOV-X gene, can be isolated based on hybridization to the human NOV-X cDNA (described further *supra*) and used as a transgene. Intronic sequences and polyadenylation signals can also be included in the transgene to increase the efficiency of expression of the transgene. A tissue-specific regulatory sequence(s) can be operably-linked to the NOV-X transgene to direct expression of NOV-X protein to particular cells. Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866; 4,870,009; and 4,873,191; and Hogan, 1986. In: MANIPULATING THE MOUSE EMBRYO, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of the NOV-X transgene in its genome and/or expression of NOV-X mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed

additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene-encoding NOV-X protein can further be bred to other transgenic animals carrying other transgenes.

To create a homologous recombinant animal, a vector is prepared which contains at least a portion of a NOV-X gene into which a deletion, addition or substitution has been introduced to thereby alter, e.g., functionally disrupt, the NOV-X gene. The NOV-X gene can be a human gene (e.g., the DNA of SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57), but more preferably, is a non-human homologue of a human NOV-X gene. For example, a mouse homologue of human NOV-X gene of SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20,

22, or 57 can be used to construct a homologous recombination vector suitable for altering an endogenous NOV-X gene in the mouse genome. In one embodiment, the vector is designed such that, upon homologous recombination, the endogenous NOV-X gene is functionally disrupted (i.e., no longer encodes a functional protein; also referred to as a "knock out" vector).

15 Alternatively, the vector can be designed such that, upon homologous recombination, the endogenous NOV-X gene is mutated or otherwise altered but still encodes functional protein (e.g., the upstream regulatory region can be altered to thereby alter the expression of the endogenous NOV-X protein). In the homologous recombination vector, the altered portion of the NOV-X gene is flanked at its 5'- and 3'-termini by additional nucleic acid of the NOV-X gene to allow for homologous recombination to occur between the exogenous NOV-X gene carried by the vector and an endogenous NOV-X gene in an embryonic stem cell. The additional flanking NOV-X nucleic acid is of sufficient length for successful homologous recombination with the endogenous gene. Typically, several kilobases of flanking DNA (both at the 5'- and 3'-termini) are included in the vector. See, e.g., Thomas, et al., 1987. Cell 51: 20 503 for a description of homologous recombination vectors. The vector is then introduced into an embryonic stem cell line (e.g., by electroporation) and cells in which the introduced NOV-X gene has homologously-recombined with the endogenous NOV-X gene are selected. See, e.g., Li, et al., 1992. Cell 69: 915.

25 The selected cells are then injected into a blastocyst of an animal (e.g., a mouse) to form aggregation chimeras. See, e.g., Bradley, 1987. In: TERATOCARCINOMAS AND EMBRYONIC STEM CELLS: A PRACTICAL APPROACH, Robertson, ed. IRL, Oxford, pp. 113-152. A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term. Progeny harboring the homologously-recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the

homologously-recombined DNA by germline transmission of the transgene. Methods for constructing homologous recombination vectors and homologous recombinant animals are described further in Bradley, 1991. *Curr. Opin. Biotechnol.* 2: 823-829; PCT International Publication Nos.: WO 90/11354; WO 91/01140; WO 92/0968; and WO 93/04169.

5 In another embodiment, transgenic non-humans animals can be produced that contain selected systems that allow for regulated expression of the transgene. One example of such a system is the cre/loxP recombinase system of bacteriophage P1. For a description of the cre/loxP recombinase system, See, e.g., Lakso, et al., 1992. *Proc. Natl. Acad. Sci. USA* 89: 6232-6236. Another example of a recombinase system is the FLP recombinase system of
10 *Saccharomyces cerevisiae*. See, O'Gorman, et al., 1991. *Science* 251:1351-1355. If a cre/loxP recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein are required. Such animals can be provided through the construction of "double" transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the
15 other containing a transgene encoding a recombinase.

Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut, et al., 1997. *Nature* 385: 810-813. In brief, a cell (e.g., a somatic cell) from the transgenic animal can be isolated and induced to exit the growth cycle and enter G₀ phase. The quiescent cell can then be fused, e.g., through the use of
20 electrical pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated. The reconstructed oocyte is then cultured such that it develops to morula or blastocyst and then transferred to pseudopregnant female foster animal. The offspring borne of this female foster animal will be a clone of the animal from which the cell (e.g., the somatic cell) is isolated.

25

Pharmaceutical Compositions

The NOV-X nucleic acid molecules, NOV-X proteins, and anti-NOV-X antibodies (also referred to herein as "active compounds") of the invention, and derivatives, fragments, analogs and homologs thereof, can be incorporated into pharmaceutical compositions suitable
30 for administration. Such compositions typically comprise the nucleic acid molecule, protein, or antibody and a pharmaceutically acceptable carrier. As used herein, "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Suitable carriers are described in the most

recent edition of Remington's Pharmaceutical Sciences, a standard reference text in the field, which is incorporated herein by reference. Preferred examples of such carriers or diluents include, but are not limited to, water, saline, finger's solutions, dextrose solution, and 5% human serum albumin. Liposomes and non-aqueous vehicles such as fixed oils may also be used. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.

The antibodies disclosed herein can also be formulated as immunoliposomes.

Liposomes containing the antibody are prepared by methods known in the art, such as described in Epstein et al., Proc. Natl. Acad. Sci. USA, 82: 3688 (1985); Hwang et al., Proc. Natl. Acad. Sci. USA, 77: 4030 (1980); and U.S. Pat. Nos. 4,485,045 and 4,544,545. Liposomes with enhanced circulation time are disclosed in U.S. Patent No. 5,013,556.

Particularly useful liposomes can be generated by the reverse-phase evaporation method with a lipid composition comprising phosphatidylcholine, cholesterol, and PEG-derivatized phosphatidylethanolamine (PEG-PE). Liposomes are extruded through filters of defined pore size to yield liposomes with the desired diameter. Fab' fragments of the antibody of the present invention can be conjugated to the liposomes as described in Martin et al., J. Biol. Chem., 257: 286-288 (1982) via a disulfide-interchange reaction. A chemotherapeutic agent (such as Doxorubicin) is optionally contained within the liposome. See Gabizon et al., J. National Cancer Inst., 81(19): 1484 (1989).

A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (i.e., topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetates, citrates or phosphates, and agents for the adjustment of tonicity such as sodium chloride or dextrose. The pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringeability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating the active compound (e.g., a NOV-X protein or anti-NOV-X antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or

adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g.,

10 a gas such as carbon dioxide, or a nebulizer.

Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal

15 administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels,

or creams as generally known in the art.

The compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas

20 for rectal delivery.

In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides,

25 polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared

30 according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.

It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit

containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.

The nucleic acid molecules of the invention can be inserted into vectors and used as gene therapy vectors. Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (see, e.g., U.S. Patent No. 5,328,470) or by stereotactic injection (see, e.g., Chen, et al., 1994. Proc. Natl. Acad. Sci. USA 91: 3054-3057). The pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, e.g., retroviral vectors, the pharmaceutical preparation can include one or more cells that produce the gene delivery system.

Antibodies specifically binding a protein of the invention, as well as other molecules identified by the screening assays disclosed herein, can be administered for the treatment of various disorders in the form of pharmaceutical compositions. Principles and considerations involved in preparing such compositions, as well as guidance in the choice of components are provided, for example, in Remington : The Science And Practice Of Pharmacy 19th ed. (Alfonso R. Gennaro, et al., editors) Mack Pub. Co., Easton, Pa. : 1995; Drug Absorption Enhancement : Concepts, Possibilities, Limitations, And Trends, Harwood Academic Publishers, Langhorne, Pa., 1994; and Peptide And Protein Drug Delivery (Advances In Parenteral Sciences, Vol. 4), 1991, M. Dekker, New York. If the antigenic protein is intracellular and whole antibodies are used as inhibitors, internalizing antibodies are preferred. However, liposomes can also be used to deliver the antibody, or an antibody fragment, into cells. Where antibody fragments are used, the smallest inhibitory fragment that specifically binds to the binding domain of the target protein is preferred. For example, based upon the variable-region sequences of an antibody, peptide molecules can be designed that retain the ability to bind the target protein sequence. Such peptides can be synthesized chemically and/or produced by recombinant DNA technology. See, e.g., Marasco et al., 1993 Proc. Natl. Acad. Sci. USA, 90: 7889-7893. The formulation herein can also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. Alternatively, or in addition,

the composition can comprise an agent that enhances its function, such as, for example, a cytotoxic agent, cytokine, chemotherapeutic agent, or growth-inhibitory agent. Such molecules are suitably present in combination in amounts that are effective for the purpose intended. The active ingredients can also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacrylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles, and nanocapsules) or in macroemulsions.

10 The formulations to be used for *in vivo* administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes.

Sustained-release preparations can be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g., films, or microcapsules.

15 Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid and ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOT™ (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid. While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods.

20 The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

25

Screening and Detection Methods

The isolated nucleic acid molecules of the invention can be used to express NOV-X protein (e.g., via a recombinant expression vector in a host cell in gene therapy applications), to detect NOV-X mRNA (e.g., in a biological sample) or a genetic lesion in a NOV-X gene, 30 and to modulate NOV-X activity, as described further, below. In addition, the NOV-X proteins can be used to screen drugs or compounds that modulate the NOV-X protein activity or expression as well as to treat disorders characterized by insufficient or excessive production of NOV-X protein or production of NOV-X protein forms that have decreased or aberrant activity compared to NOV-X wild-type protein. In addition, the anti-NOV-X antibodies of the

invention can be used to detect and isolate NOV-X proteins and modulate NOV-X activity. For example, NOV-X activity includes growth and differentiation, antibody production, and tumor growth.

5 The invention further pertains to novel agents identified by the screening assays described herein and uses thereof for treatments as described, supra.

Screening Assays

The invention provides a method (also referred to herein as a "screening assay") for identifying modulators, i.e., candidate or test compounds or agents (e.g., peptides, peptidomimetics, small molecules or other drugs) that bind to NOV-X proteins or have a 10 stimulatory or inhibitory effect on, e.g., NOV-X protein expression or NOV-X protein activity. The invention also includes compounds identified in the screening assays described herein.

In one embodiment, the invention provides assays for screening candidate or test compounds which bind to or modulate the activity of the membrane-bound form of a NOV-X protein or polypeptide or biologically-active portion thereof. The test compounds of the 15 invention can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the "one-bead one-compound" library method; and synthetic library methods using affinity chromatography selection. The biological library approach is limited to peptide libraries, 20 while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds. See, e.g., Lam, 1997. Anticancer Drug Design 12: 145.

A "small molecule" as used herein, is meant to refer to a composition that has a molecular weight of less than about 5 kD and most preferably less than about 4 kD. Small molecules can be, e.g., nucleic acids, peptides, polypeptides, peptidomimetics, carbohydrates, 25 lipids or other organic or inorganic molecules. Libraries of chemical and/or biological mixtures, such as fungal, bacterial, or algal extracts, are known in the art and can be screened with any of the assays of the invention.

Examples of methods for the synthesis of molecular libraries can be found in the art, for example in: DeWitt, et al., 1993. Proc. Natl. Acad. Sci. U.S.A. 90: 6909; Erb, et al., 1994. 30 Proc. Natl. Acad. Sci. U.S.A. 91: 11422; Zuckermann, et al., 1994. J. Med. Chem. 37: 2678; Cho, et al., 1993. Science 261: 1303; Carell, et al., 1994. Angew. Chem. Int. Ed. Engl. 33: 2059; Carell, et al., 1994. Angew. Chem. Int. Ed. Engl. 33: 2061; and Gallop, et al., 1994. J. Med. Chem. 37: 1233.

Libraries of compounds may be presented in solution (e.g., Houghten, 1992. Biotechniques 13: 412-421), or on beads (Lam, 1991. Nature 354: 82-84), on chips (Fodor, 1993. Nature 364: 555-556), bacteria (Ladner, U.S. Patent No. 5,223,409), spores (Ladner, U.S. Patent 5,233,409), plasmids (Cull, et al., 1992. Proc. Natl. Acad. Sci. USA 89: 5 1865-1869) or on phage (Scott and Smith, 1990. Science 249: 386-390; Devlin, 1990. Science 249: 404-406; Cwirla, et al., 1990. Proc. Natl. Acad. Sci. U.S.A. 87: 6378-6382; Felici, 1991. J. Mol. Biol. 222: 301-310; Ladner, U.S. Patent No. 5,233,409.).

In one embodiment, an assay is a cell-based assay in which a cell which expresses a membrane-bound form of NOV-X protein, or a biologically-active portion thereof, on the cell surface is contacted with a test compound and the ability of the test compound to bind to a NOV-X protein determined. The cell, for example, can be of mammalian origin or a yeast cell. Determining the ability of the test compound to bind to the NOV-X protein can be accomplished, for example, by coupling the test compound with a radioisotope or enzymatic label such that binding of the test compound to the NOV-X protein or biologically-active portion thereof can be determined by detecting the labeled compound in a complex. For example, test compounds can be labeled with ^{125}I , ^{35}S , ^{14}C , or ^3H , either directly or indirectly, and the radioisotope detected by direct counting of radioemission or by scintillation counting. Alternatively, test compounds can be enzymatically-labeled with, for example, horseradish peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label detected by determination of conversion of an appropriate substrate to product. In one embodiment, the assay comprises contacting a cell which expresses a membrane-bound form of NOV-X protein, or a biologically-active portion thereof, on the cell surface with a known compound which binds NOV-X to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with a NOV-X protein, wherein determining the ability of the test compound to interact with a NOV-X protein comprises determining the ability of the test compound to preferentially bind to NOV-X protein or a biologically-active portion thereof as compared to the known compound.

In another embodiment, an assay is a cell-based assay comprising contacting a cell expressing a membrane-bound form of NOV-X protein, or a biologically-active portion thereof, on the cell surface with a test compound and determining the ability of the test compound to modulate (e.g., stimulate or inhibit) the activity of the NOV-X protein or biologically-active portion thereof. Determining the ability of the test compound to modulate the activity of NOV-X or a biologically-active portion thereof can be accomplished, for example, by determining the ability of the NOV-X protein to bind to or interact with a NOV-X

target molecule. As used herein, a "target molecule" is a molecule with which a NOV-X protein binds or interacts in nature, for example, a molecule on the surface of a cell which expresses a NOV-X interacting protein, a molecule on the surface of a second cell, a molecule in the extracellular milieu, a molecule associated with the internal surface of a cell membrane or a cytoplasmic molecule. A NOV-X target molecule can be a non-NOV-X molecule or a NOV-X protein or polypeptide of the invention. In one embodiment, a NOV-X target molecule is a component of a signal transduction pathway that facilitates transduction of an extracellular signal (e.g. a signal generated by binding of a compound to a membrane-bound NOV-X molecule) through the cell membrane and into the cell. The target, for example, can be a second intercellular protein that has catalytic activity or a protein that facilitates the association of downstream signaling molecules with NOV-X.

Determining the ability of the NOV-X protein to bind to or interact with a NOV-X target molecule can be accomplished by one of the methods described above for determining direct binding.

In one embodiment, determining the ability of the NOV-X protein to bind to or interact with a NOV-X target molecule can be accomplished by determining the activity of the target molecule. For example, the activity of the target molecule can be determined by detecting induction of a cellular second messenger of the target (i.e. intracellular Ca^{2+} , diacylglycerol, IP₃, etc.), detecting catalytic/enzymatic activity of the target an appropriate substrate, detecting the induction of a reporter gene (comprising a NOV-X-responsive regulatory element operatively linked to a nucleic acid encoding a detectable marker, e.g., luciferase), or detecting a cellular response, for example, cell survival, cellular differentiation, or cell proliferation.

In yet another embodiment, an assay of the invention is a cell-free assay comprising contacting a NOV-X protein or biologically-active portion thereof with a test compound and determining the ability of the test compound to bind to the NOV-X protein or biologically-active portion thereof. Binding of the test compound to the NOV-X protein can be determined either directly or indirectly as described above.

In one such embodiment, the assay comprises contacting the NOV-X protein or biologically-active portion thereof with a known compound which binds NOV-X to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with a NOV-X protein, wherein determining the ability of the test compound to interact with a NOV-X protein comprises determining the ability of the test

compound to preferentially bind to NOV-X or biologically-active portion thereof as compared to the known compound.

In still another embodiment, an assay is a cell-free assay comprising contacting NOV-X protein or biologically-active portion thereof with a test compound and determining the ability of the test compound to modulate (e.g. stimulate or inhibit) the activity of the NOV-X protein or biologically-active portion thereof. Determining the ability of the test compound to modulate the activity of NOV-X can be accomplished, for example, by determining the ability of the NOV-X protein to bind to a NOV-X target molecule by one of the methods described above for determining direct binding. In an alternative embodiment, determining the ability of the test compound to modulate the activity of NOV-X protein can be accomplished by determining the ability of the NOV-X protein further modulate a NOV-X target molecule. For example, the catalytic/enzymatic activity of the target molecule on an appropriate substrate can be determined as described above.

In yet another embodiment, the cell-free assay comprises contacting the NOV-X protein or biologically-active portion thereof with a known compound which binds NOV-X protein to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with a NOV-X protein, wherein determining the ability of the test compound to interact with a NOV-X protein comprises determining the ability of the NOV-X protein to preferentially bind to or modulate the activity of a NOV-X target molecule.

The cell-free assays of the invention are amenable to use of both the soluble form or the membrane-bound form of NOV-X protein. In the case of cell-free assays comprising the membrane-bound form of NOV-X protein, it may be desirable to utilize a solubilizing agent such that the membrane-bound form of NOV-X protein is maintained in solution. Examples of such solubilizing agents include non-ionic detergents such as n-octylglucoside, n-dodecylglucoside, n-dodecylmaltoside, octanoyl-N-methylglucamide, decanoyl-N-methylglucamide, Triton[®] X-100, Triton[®] X-114, Thesit[®], Isotridecypoly(ethylene glycol ether)_n, N-dodecyl-N,N-dimethyl-3-ammonio-1-propane sulfonate, 3-(3-cholamidopropyl) dimethylamminiol-1-propane sulfonate (CHAPS), or 3-(3-cholamidopropyl)dimethylamminiol-2-hydroxy-1-propane sulfonate (CHAPSO).

In more than one embodiment of the above assay methods of the invention, it may be desirable to immobilize either NOV-X protein or its target molecule to facilitate separation of complexed from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay. Binding of a test compound to NOV-X protein, or interaction of

NOV-X protein with a target molecule in the presence and absence of a candidate compound, can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtiter plates, test tubes, and micro-centrifuge tubes. In one embodiment, a fusion protein can be provided that adds a domain that allows one or both of the proteins to be

5 bound to a matrix. For example, GST-NOV-X fusion proteins or GST-target fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized microtiter plates, that are then combined with the test compound or the test compound and either the non-adsorbed target protein or NOV-X protein, and the mixture is incubated under conditions conducive to complex formation (e.g., at physiological
10 conditions for salt and pH). Following incubation, the beads or microtiter plate wells are washed to remove any unbound components, the matrix immobilized in the case of beads, complex determined either directly or indirectly, for example, as described, supra.

Alternatively, the complexes can be dissociated from the matrix, and the level of NOV-X protein binding or activity determined using standard techniques.

15 Other techniques for immobilizing proteins on matrices can also be used in the screening assays of the invention. For example, either the NOV-X protein or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated NOV-X protein or target molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques well-known within the art (e.g., biotinylation kit,
20 Pierce Chemicals, Rockford, Ill.), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). Alternatively, antibodies reactive with NOV-X protein or target molecules, but which do not interfere with binding of the NOV-X protein to its target molecule, can be derivatized to the wells of the plate, and unbound target or NOV-X protein trapped in the wells by antibody conjugation. Methods for detecting such complexes, in
25 addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the NOV-X protein or target molecule, as well as enzyme-linked assays that rely on detecting an enzymatic activity associated with the NOV-X protein or target molecule.

In another embodiment, modulators of NOV-X protein expression are identified in a
30 method wherein a cell is contacted with a candidate compound and the expression of NOV-X mRNA or protein in the cell is determined. The level of expression of NOV-X mRNA or protein in the presence of the candidate compound is compared to the level of expression of NOV-X mRNA or protein in the absence of the candidate compound. The candidate compound can then be identified as a modulator of NOV-X mRNA or protein expression

based upon this comparison. For example, when expression of NOV-X mRNA or protein is greater (i.e., statistically significantly greater) in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of NOV-X mRNA or protein expression. Alternatively, when expression of NOV-X mRNA or protein is less
5 (statistically significantly less) in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of NOV-X mRNA or protein expression. The level of NOV-X mRNA or protein expression in the cells can be determined by methods described herein for detecting NOV-X mRNA or protein.

In yet another aspect of the invention, the NOV-X proteins can be used as "bait
10 proteins" in a two-hybrid assay or three hybrid assay (see, e.g., U.S. Patent No. 5,283,317; Zervos, et al., 1993. Cell 72: 223-232; Madura, et al., 1993. J. Biol. Chem. 268: 12046-12054; Bartel, et al., 1993. Biotechniques 14: 920-924; Iwabuchi, et al., 1993. Oncogene 8: 1693-1696; and Brent WO 94/10300), to identify other proteins that bind to or interact with NOV-X ("NOV-X-binding proteins" or "NOV-X-bp") and modulate NOV-X activity. Such
15 NOV-X-binding proteins are also likely to be involved in the propagation of signals by the NOV-X proteins as, for example, upstream or downstream elements of the NOV-X pathway.

The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that codes for NOV-X is fused to a
20 gene encoding the DNA binding domain of a known transcription factor (e.g., GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein ("prey" or "sample") is fused to a gene that codes for the activation domain of the known transcription factor. If the "bait" and the "prey" proteins are able to interact, *in vivo*, forming a NOV-X-dependent complex, the DNA-binding and activation
25 domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g., LacZ) that is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene that encodes the protein which interacts with NOV-X.

30 The invention further pertains to novel agents identified by the aforementioned screening assays and uses thereof for treatments as described herein.

Detection Assays

Portions or fragments of the cDNA sequences identified herein (and the corresponding complete gene sequences) can be used in numerous ways as polynucleotide reagents. By way of example, and not of limitation, these sequences can be used to: (i) identify an individual from a minute biological sample (tissue typing); and (ii) aid in forensic identification of a biological sample. Some of these applications are described in the subsections, below.

Tissue Typing

The NOV-X sequences of the invention can be used to identify individuals from minute biological samples. In this technique, an individual's genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identification. The sequences of the invention are useful as additional DNA markers for RFLP ("restriction fragment length polymorphisms," described in U.S. Patent No. 5,272,057).

Furthermore, the sequences of the invention can be used to provide an alternative technique that determines the actual base-by-base DNA sequence of selected portions of an individual's genome. Thus, the NOV-X sequences described herein can be used to prepare two PCR primers from the 5'- and 3'-termini of the sequences. These primers can then be used to amplify an individual's DNA and subsequently sequence it.

Panels of corresponding DNA sequences from individuals, prepared in this manner, can provide unique individual identifications, as each individual will have a unique set of such DNA sequences due to allelic differences. The sequences of the invention can be used to obtain such identification sequences from individuals and from tissue. The NOV-X sequences of the invention uniquely represent portions of the human genome. Allelic variation occurs to some degree in the coding regions of these sequences, and to a greater degree in the noncoding regions. It is estimated that allelic variation between individual humans occurs with a frequency of about once per each 500 bases. Much of the allelic variation is due to single nucleotide polymorphisms (SNPs), which include restriction fragment length polymorphisms (RFLPs).

Each of the sequences described herein can, to some degree, be used as a standard against which DNA from an individual can be compared for identification purposes. Because greater numbers of polymorphisms occur in the noncoding regions, fewer sequences are necessary to differentiate individuals. The noncoding sequences can comfortably provide positive individual identification with a panel of perhaps 10 to 1,000 primers that each yield a noncoding amplified sequence of 100 bases. If predicted coding sequences, such as those in

SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57 are used, a more appropriate number of primers for positive individual identification would be 500-2,000.

Predictive Medicine

5 The invention also pertains to the field of predictive medicine in which diagnostic assays, prognostic assays, pharmacogenomics, and monitoring clinical trials are used for prognostic (predictive) purposes to thereby treat an individual prophylactically. Accordingly, one aspect of the invention relates to diagnostic assays for determining NOV-X protein and/or nucleic acid expression as well as NOV-X activity, in the context of a biological sample (e.g.,
10 blood, serum, cells, tissue) to thereby determine whether an individual is afflicted with a disease or disorder, or is at risk of developing a disorder, associated with aberrant NOV-X expression or activity. Disorders associated with aberrant NOV-X expression or activity include, for example, disorders of olfactory loss, e.g. trauma, HIV illness, neoplastic growth, and neurological disorders, e.g. Parkinson's disease and Alzheimer's disease.
15 The invention also provides for prognostic (or predictive) assays for determining whether an individual is at risk of developing a disorder associated with NOV-X protein, nucleic acid expression or activity. For example, mutations in a NOV-X gene can be assayed in a biological sample. Such assays can be used for prognostic or predictive purpose to thereby prophylactically treat an individual prior to the onset of a disorder characterized by or
20 associated with NOV-X protein, nucleic acid expression, or biological activity.

Another aspect of the invention provides methods for determining NOV-X protein, nucleic acid expression or activity in an individual to thereby select appropriate therapeutic or prophylactic agents for that individual (referred to herein as "pharmacogenomics").

25 Pharmacogenomics allows for the selection of agents (e.g., drugs) for therapeutic or prophylactic treatment of an individual based on the genotype of the individual (e.g., the genotype of the individual examined to determine the ability of the individual to respond to a particular agent.)

Yet another aspect of the invention pertains to monitoring the influence of agents (e.g., drugs, compounds) on the expression or activity of NOV-X in clinical trials.

30 These and other agents are described in further detail in the following sections.

Diagnostic Assays

An exemplary method for detecting the presence or absence of NOV-X in a biological sample involves obtaining a biological sample from a test subject and contacting the biological sample with a compound or an agent capable of detecting NOV-X protein or nucleic acid (e.g.,

mRNA, genomic DNA) that encodes NOV-X protein such that the presence of NOV-X is detected in the biological sample. An agent for detecting NOV-X mRNA or genomic DNA is a labeled nucleic acid probe capable of hybridizing to NOV-X mRNA or genomic DNA. The nucleic acid probe can be, for example, a full-length NOV-X nucleic acid, such as the nucleic acid of SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57, or a portion thereof, such as an oligonucleotide of at least 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to NOV-X mRNA or genomic DNA. Other suitable probes for use in the diagnostic assays of the invention are described herein.

One agent for detecting NOV-X protein is an antibody capable of binding to NOV-X protein, preferably an antibody with a detectable label. Antibodies directed against a protein of the invention may be used in methods known within the art relating to the localization and/or quantitation of the protein (e.g., for use in measuring levels of the protein within appropriate physiological samples, for use in diagnostic methods, for use in imaging the protein, and the like). In a given embodiment, antibodies against the proteins, or derivatives, fragments, analogs or homologs thereof, that contain the antigen binding domain, are utilized as pharmacologically-active compounds.

An antibody specific for a protein of the invention can be used to isolate the protein by standard techniques, such as immunoaffinity chromatography or immunoprecipitation. Such an antibody can facilitate the purification of the natural protein antigen from cells and of recombinantly produced antigen expressed in host cells. Moreover, such an antibody can be used to detect the antigenic protein (e.g., in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the antigenic protein. Antibodies directed against the protein can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, e.g., to, for example, determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling (i.e., physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β -galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include

luciferase, luciferin, and aequorin, and examples of suitable radioactive material include ^{125}I , ^{131}I , ^{35}S or ^3H .

Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g., Fab or F(ab')₂) can be used. The term "labeled", with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently-labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently-labeled streptavidin. The term "biological sample" is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. That is, the detection method of the invention can be used to detect NOV-X mRNA, protein, or genomic DNA in a biological sample *in vitro* as well as *in vivo*. For example, *in vitro* techniques for detection of NOV-X mRNA include Northern hybridizations and *in situ* hybridizations. *In vitro* techniques for detection of NOV-X protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations, and immunofluorescence. *In vitro* techniques for detection of NOV-X genomic DNA include Southern hybridizations. Furthermore, *in vivo* techniques for detection of NOV-X protein include introducing into a subject a labeled anti-NOV-X antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.

In one embodiment, the biological sample contains protein molecules from the test subject. Alternatively, the biological sample can contain mRNA molecules from the test subject or genomic DNA molecules from the test subject. A preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject.

In one embodiment, the methods further involve obtaining a control biological sample from a control subject, contacting the control sample with a compound or agent capable of detecting NOV-X protein, mRNA, or genomic DNA, such that the presence of NOV-X protein, mRNA or genomic DNA is detected in the biological sample, and comparing the presence of NOV-X protein, mRNA or genomic DNA in the control sample with the presence of NOV-X protein, mRNA or genomic DNA in the test sample.

The invention also encompasses kits for detecting the presence of NOV-X in a biological sample. For example, the kit can comprise: a labeled compound or agent capable of detecting NOV-X protein or mRNA in a biological sample; means for determining the amount

of NOV-X in the sample; and means for comparing the amount of NOV-X in the sample with a standard. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect NOV-X protein or nucleic acid.

Prognostic Assays

5 The diagnostic methods described herein can furthermore be utilized to identify subjects having or at risk of developing a disease or disorder associated with aberrant NOV-X expression or activity. For example, the assays described herein, such as the preceding diagnostic assays or the following assays, can be utilized to identify a subject having or at risk of developing a disorder associated with NOV-X protein, nucleic acid expression or activity.

10 Such disorders include for example, disorders of olfactory loss, e.g. trauma, HIV illness, neoplastic growth, and neurological disorders, e.g. Parkinson's disease and Alzheimer's disease.

Alternatively, the prognostic assays can be utilized to identify a subject having or at risk for developing a disease or disorder. Thus, the invention provides a method for

15 identifying a disease or disorder associated with aberrant NOV-X expression or activity in which a test sample is obtained from a subject and NOV-X protein or nucleic acid (e.g., mRNA, genomic DNA) is detected, wherein the presence of NOV-X protein or nucleic acid is diagnostic for a subject having or at risk of developing a disease or disorder associated with aberrant NOV-X expression or activity. As used herein, a "test sample" refers to a biological

20 sample obtained from a subject of interest. For example, a test sample can be a biological fluid (e.g., serum), cell sample, or tissue.

Furthermore, the prognostic assays described herein can be used to determine whether a subject can be administered an agent (e.g., an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate) to treat a disease or disorder

25 associated with aberrant NOV-X expression or activity. For example, such methods can be used to determine whether a subject can be effectively treated with an agent for a disorder. Thus, the invention provides methods for determining whether a subject can be effectively treated with an agent for a disorder associated with aberrant NOV-X expression or activity in which a test sample is obtained and NOV-X protein or nucleic acid is detected (e.g., wherein

30 the presence of NOV-X protein or nucleic acid is diagnostic for a subject that can be administered the agent to treat a disorder associated with aberrant NOV-X expression or activity).

The methods of the invention can also be used to detect genetic lesions in a NOV-X gene, thereby determining if a subject with the lesioned gene is at risk for a disorder

characterized by aberrant cell proliferation and/or differentiation. In various embodiments, the methods include detecting, in a sample of cells from the subject, the presence or absence of a genetic lesion characterized by at least one of an alteration affecting the integrity of a gene encoding a NOV-X-protein, or the misexpression of the NOV-X gene. For example, such

5 genetic lesions can be detected by ascertaining the existence of at least one of: (i) a deletion of one or more nucleotides from a NOV-X gene; (ii) an addition of one or more nucleotides to a NOV-X gene; (iii) a substitution of one or more nucleotides of a NOV-X gene, (iv) a chromosomal rearrangement of a NOV-X gene; (v) an alteration in the level of a messenger RNA transcript of a NOV-X gene, (vi) aberrant modification of a NOV-X gene, such as of the
10 methylation pattern of the genomic DNA, (vii) the presence of a non-wild-type splicing pattern of a messenger RNA transcript of a NOV-X gene, (viii) a non-wild-type level of a NOV-X protein, (ix) allelic loss of a NOV-X gene, and (x) inappropriate post-translational modification of a NOV-X protein. As described herein, there are a large number of assay techniques known in the art which can be used for detecting lesions in a NOV-X gene. A
15 preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject. However, any biological sample containing nucleated cells may be used, including, for example, buccal mucosal cells.

In certain embodiments, detection of the lesion involves the use of a probe/primer in a polymerase chain reaction (PCR) (see, e.g., U.S. Patent Nos. 4,683,195 and 4,683,202), such

20 as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, e.g., Landegran, et al., 1988. Science 241: 1077-1080; and Nakazawa, et al., 1994. Proc. Natl. Acad. Sci. USA 91: 360-364), the latter of which can be particularly useful for detecting point mutations in the NOV-X-gene (see, Abravaya, et al., 1995. Nucl. Acids Res. 23: 675-682). This method can include the steps of collecting a sample of cells from a patient, isolating
25 nucleic acid (e.g., genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or more primers that specifically hybridize to a NOV-X gene under conditions such that hybridization and amplification of the NOV-X gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. It is anticipated
30 that PCR and/or LCR may be desirable to use as a preliminary amplification step in conjunction with any of the techniques used for detecting mutations described herein.

Alternative amplification methods include: self sustained sequence replication (see, Guatelli, et al., 1990. Proc. Natl. Acad. Sci. USA 87: 1874-1878), transcriptional amplification system (see, Kwok, et al., 1989. Proc. Natl. Acad. Sci. USA 86: 1173-1177); Q β Replicase

(see, Lizardi, et al, 1988. BioTechnology 6: 1197), or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers.

5 In an alternative embodiment, mutations in a NOV-X gene from a sample cell can be identified by alterations in restriction enzyme cleavage patterns. For example, sample and control DNA is isolated, amplified (optionally), digested with one or more restriction endonucleases, and fragment length sizes are determined by gel electrophoresis and compared. Differences in fragment length sizes between sample and control DNA indicates mutations in
10 the sample DNA. Moreover, the use of sequence specific ribozymes (see, e.g., U.S. Patent No. 5,493,531) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site.

In other embodiments, genetic mutations in NOV-X can be identified by hybridizing a sample and control nucleic acids, e.g., DNA or RNA, to high-density arrays containing
15 hundreds or thousands of oligonucleotides probes. See, e.g., Cronin, et al., 1996. Human Mutation 7: 244-255; Kozal, et al., 1996. Nat. Med. 2: 753-759. For example, genetic mutations in NOV-X can be identified in two dimensional arrays containing light-generated DNA probes as described in Cronin, et al., supra. Briefly, a first hybridization array of probes can be used to scan through long stretches of DNA in a sample and control to identify base
20 changes between the sequences by making linear arrays of sequential overlapping probes. This step allows the identification of point mutations. This is followed by a second hybridization array that allows the characterization of specific mutations by using smaller, specialized probe arrays complementary to all variants or mutations detected. Each mutation array is composed of parallel probe sets, one complementary to the wild-type gene and the
25 other complementary to the mutant gene.

In yet another embodiment, any of a variety of sequencing reactions known in the art can be used to directly sequence the NOV-X gene and detect mutations by comparing the sequence of the sample NOV-X with the corresponding wild-type (control) sequence. Examples of sequencing reactions include those based on techniques developed by Maxim and Gilbert,
30 1977. Proc. Natl. Acad. Sci. USA 74: 560 or Sanger, 1977. Proc. Natl. Acad. Sci. USA 74: 5463. It is also contemplated that any of a variety of automated sequencing procedures can be utilized when performing the diagnostic assays (see, e.g., Naeve, et al., 1995. Biotechniques 19: 448), including sequencing by mass spectrometry (see, e.g., PCT International Publication

No. WO 94/16101; Cohen, et al., 1996. Adv. Chromatography 36: 127-162; and Griffin, et al., 1993. Appl. Biochem. Biotechnol. 38: 147-159).

Other methods for detecting mutations in the NOV-X gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or

5 RNA/DNA heteroduplexes. See, e.g., Myers, et al., 1985. Science 230: 1242. In general, the art technique of "mismatch cleavage" starts by providing heteroduplexes of formed by hybridizing (labeled) RNA or DNA containing the wild-type NOV-X sequence with potentially mutant RNA or DNA obtained from a tissue sample. The double-stranded duplexes are treated with an agent that cleaves single-stranded regions of the duplex such as

10 which will exist due to basepair mismatches between the control and sample strands. For instance, RNA/DNA duplexes can be treated with RNase and DNA/DNA hybrids treated with S₁ nuclease to enzymatically digesting the mismatched regions. In other embodiments, either DNA/DNA or RNA/DNA duplexes can be treated with hydroxylamine or osmium tetroxide and with piperidine in order to digest mismatched regions. After digestion of the mismatched
15 regions, the resulting material is then separated by size on denaturing polyacrylamide gels to determine the site of mutation. See, e.g., Cotton, et al., 1988. Proc. Natl. Acad. Sci. USA 85: 4397; Saleeba, et al., 1992. Methods Enzymol. 217: 286-295. In an embodiment, the control DNA or RNA can be labeled for detection.

In still another embodiment, the mismatch cleavage reaction employs one or more
20 proteins that recognize mismatched base pairs in double-stranded DNA (so called "DNA mismatch repair" enzymes) in defined systems for detecting and mapping point mutations in NOV-X cDNAs obtained from samples of cells. For example, the mutY enzyme of *E. coli* cleaves A at G/A mismatches and the thymidine DNA glycosylase from HeLa cells cleaves T at G/T mismatches. See, e.g., Hsu, et al., 1994. Carcinogenesis 15: 1657-1662. According to
25 an exemplary embodiment, a probe based on a NOV-X sequence, e.g., a wild-type NOV-X sequence, is hybridized to a cDNA or other DNA product from a test cell(s). The duplex is treated with a DNA mismatch repair enzyme, and the cleavage products, if any, can be detected from electrophoresis protocols or the like. See, e.g., U.S. Patent No. 5,459,039.

In other embodiments, alterations in electrophoretic mobility will be used to identify
30 mutations in NOV-X genes. For example, single strand conformation polymorphism (SSCP) may be used to detect differences in electrophoretic mobility between mutant and wild type nucleic acids. See, e.g., Orita, et al., 1989. Proc. Natl. Acad. Sci. USA: 86: 2766; Cotton, 1993. Mutat. Res. 285: 125-144; Hayashi, 1992. Genet. Anal. Tech. Appl. 9: 73-79.

Single-stranded DNA fragments of sample and control NOV-X nucleic acids will be denatured

and allowed to renature. The secondary structure of single-stranded nucleic acids varies according to sequence, the resulting alteration in electrophoretic mobility enables the detection of even a single base change. The DNA fragments may be labeled or detected with labeled probes. The sensitivity of the assay may be enhanced by using RNA (rather than DNA), in which the secondary structure is more sensitive to a change in sequence. In one embodiment, the subject method utilizes heteroduplex analysis to separate double stranded heteroduplex molecules on the basis of changes in electrophoretic mobility. See, e.g., Keen, et al., 1991. *Trends Genet.* 7: 5.

In yet another embodiment, the movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (DGGE). See, e.g., Myers, et al., 1985. *Nature* 313: 495. When DGGE is used as the method of analysis, DNA will be modified to insure that it does not completely denature, for example by adding a GC clamp of approximately 40 bp of high-melting GC-rich DNA by PCR. In a further embodiment, a temperature gradient is used in place of a denaturing gradient to identify differences in the mobility of control and sample DNA. See, e.g., Rosenbaum and Reissner, 1987. *Biophys. Chem.* 265: 12753.

Examples of other techniques for detecting point mutations include, but are not limited to, selective oligonucleotide hybridization, selective amplification, or selective primer extension. For example, oligonucleotide primers may be prepared in which the known mutation is placed centrally and then hybridized to target DNA under conditions that permit hybridization only if a perfect match is found. See, e.g., Saiki, et al., 1986. *Nature* 324: 163; Saiki, et al., 1989. *Proc. Natl. Acad. Sci. USA* 86: 6230. Such allele specific oligonucleotides are hybridized to PCR amplified target DNA or a number of different mutations when the oligonucleotides are attached to the hybridizing membrane and hybridized with labeled target DNA.

Alternatively, allele specific amplification technology that depends on selective PCR amplification may be used in conjunction with the instant invention. Oligonucleotides used as primers for specific amplification may carry the mutation of interest in the center of the molecule (so that amplification depends on differential hybridization; see, e.g., Gibbs, et al., 1989. *Nucl. Acids Res.* 17: 2437-2448) or at the extreme 3'-terminus of one primer where, under appropriate conditions, mismatch can prevent, or reduce polymerase extension (see, e.g., Prossner, 1993. *Tibtech.* 11: 238). In addition it may be desirable to introduce a novel restriction site in the region of the mutation to create cleavage-based detection. See, e.g., Gasparini, et al., 1992. *Mol. Cell Probes* 6: 1. It is anticipated that in certain embodiments

amplification may also be performed using Taq ligase for amplification. See, e.g., Barany, 1991. Proc. Natl. Acad. Sci. USA 88: 189. In such cases, ligation will occur only if there is a perfect match at the 3'-terminus of the 5' sequence, making it possible to detect the presence of a known mutation at a specific site by looking for the presence or absence of amplification.

5 The methods described herein may be performed, for example, by utilizing pre-packaged diagnostic kits comprising at least one probe nucleic acid or antibody reagent described herein, which may be conveniently used, e.g., in clinical settings to diagnose patients exhibiting symptoms or family history of a disease or illness involving a NOV-X gene.

10 Furthermore, any cell type or tissue, preferably peripheral blood leukocytes, in which NOV-X is expressed may be utilized in the prognostic assays described herein. However, any biological sample containing nucleated cells may be used, including, for example, buccal mucosal cells.

15 **Pharmacogenomics**

Agents, or modulators that have a stimulatory or inhibitory effect on NOV-X activity (e.g., NOV-X gene expression), as identified by a screening assay described herein can be administered to individuals to treat (prophylactically or therapeutically) disorders (e.g. disorders of olfactory loss, e.g. trauma, HIV illness, neoplastic growth, and neurological disorders, e.g. Parkinson's disease and Alzheimer's disease). In conjunction with such treatment, the pharmacogenomics (i.e., the study of the relationship between an individual's genotype and that individual's response to a foreign compound or drug) of the individual may be considered. Differences in metabolism of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug. Thus, the pharmacogenomics of the individual permits the selection of effective agents (e.g., drugs) for prophylactic or therapeutic treatments based on a consideration of the individual's genotype. Such pharmacogenomics can further be used to determine appropriate dosages and therapeutic regimens. Accordingly, the activity of NOV-X protein, expression of NOV-X nucleic acid, or mutation content of NOV-X genes in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual.

Pharmacogenomics deals with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. See e.g., Eichelbaum, 1996. Clin. Exp. Pharmacol. Physiol., 23: 983-985; Linder, 1997. Clin.

Chem., 43: 254-266. In general, two types of pharmacogenetic conditions can be differentiated. Genetic conditions transmitted as a single factor altering the way drugs act on the body (altered drug action) or genetic conditions transmitted as single factors altering the way the body acts on drugs (altered drug metabolism). These pharmacogenetic conditions can

5 occur either as rare defects or as polymorphisms. For example, glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common inherited enzymopathy in which the main clinical complication is hemolysis after ingestion of oxidant drugs (anti-malarials, sulfonamides, analgesics, nitrofurans) and consumption of fava beans.

As an illustrative embodiment, the activity of drug metabolizing enzymes is a major 10 determinant of both the intensity and duration of drug action. The discovery of genetic polymorphisms of drug metabolizing enzymes (e.g., N-acetyltransferase 2 (NAT 2) and cytochrome P450 enzymes CYP2D6 and CYP2C19) has provided an explanation as to why some patients do not obtain the expected drug effects or show exaggerated drug response and serious toxicity after taking the standard and safe dose of a drug. These polymorphisms are 15 expressed in two phenotypes in the population, the extensive metabolizer (EM) and poor metabolizer (PM). The prevalence of PM is different among different populations. For example, the gene coding for CYP2D6 is highly polymorphic and several mutations have been identified in PM, which all lead to the absence of functional CYP2D6. Poor metabolizers of CYP2D6 and CYP2C19 quite frequently experience exaggerated drug response and side 20 effects when they receive standard doses. If a metabolite is the active therapeutic moiety, PM show no therapeutic response, as demonstrated for the analgesic effect of codeine mediated by its CYP2D6-formed metabolite morphine. At the other extreme are the so called ultra-rapid metabolizers who do not respond to standard doses. Recently, the molecular basis of ultra-rapid metabolism has been identified to be due to CYP2D6 gene amplification.

25 Thus, the activity of NOV-X protein, expression of NOV-X nucleic acid, or mutation content of NOV-X genes in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual. In addition, pharmacogenetic studies can be used to apply genotyping of polymorphic alleles encoding drug-metabolizing enzymes to the identification of an individual's drug responsiveness 30 phenotype. This knowledge, when applied to dosing or drug selection, can avoid adverse reactions or therapeutic failure and thus enhance therapeutic or prophylactic efficiency when treating a subject with a NOV-X modulator, such as a modulator identified by one of the exemplary screening assays described herein.

Monitoring of Effects During Clinical Trials

Monitoring the influence of agents (e.g., drugs, compounds) on the expression or activity of NOV-X (e.g., the ability to modulate aberrant cell proliferation) can be applied not only in basic drug screening, but also in clinical trials. For example, the effectiveness of an

5 agent determined by a screening assay as described herein to increase NOV-X gene expression, protein levels, or upregulate NOV-X activity, can be monitored in clinical trials of subjects exhibiting decreased NOV-X gene expression, protein levels, or downregulated NOV-X activity. Alternatively, the effectiveness of an agent determined by a screening assay to decrease NOV-X gene expression, protein levels, or downregulate NOV-X activity, can be
10 monitored in clinical trials of subjects exhibiting increased NOV-X gene expression, protein levels, or upregulated NOV-X activity. In such clinical trials, the expression or activity of NOV-X and, preferably, other genes that have been implicated in, for example, a cellular proliferation or immune disorder can be used as a "read out" or markers of the immune responsiveness of a particular cell.

15 By way of example, and not of limitation, genes, including NOV-X, that are modulated in cells by treatment with an agent (e.g., compound, drug or small molecule) that modulates NOV-X activity (e.g., identified in a screening assay as described herein) can be identified. Thus, to study the effect of agents on cellular proliferation disorders, for example, in a clinical trial, cells can be isolated and RNA prepared and analyzed for the levels of expression of
20 NOV-X and other genes implicated in the disorder. The levels of gene expression (i.e., a gene expression pattern) can be quantified by Northern blot analysis or RT-PCR, as described herein, or alternatively by measuring the amount of protein produced, by one of the methods as described herein, or by measuring the levels of activity of NOV-X or other genes. In this manner, the gene expression pattern can serve as a marker, indicative of the physiological
25 response of the cells to the agent. Accordingly, this response state may be determined before, and at various points during, treatment of the individual with the agent.

In one embodiment, the invention provides a method for monitoring the effectiveness of treatment of a subject with an agent (e.g., an agonist, antagonist, protein, peptide, peptidomimetic, nucleic acid, small molecule, or other drug candidate identified by the
30 screening assays described herein) comprising the steps of (i) obtaining a pre-administration sample from a subject prior to administration of the agent; (ii) detecting the level of expression of a NOV-X protein, mRNA, or genomic DNA in the preadministration sample; (iii) obtaining one or more post-administration samples from the subject; (iv) detecting the level of expression or activity of the NOV-X protein, mRNA, or genomic DNA in the

post-administration samples; (v) comparing the level of expression or activity of the NOV-X protein, mRNA, or genomic DNA in the pre-administration sample with the NOV-X protein, mRNA, or genomic DNA in the post administration sample or samples; and (vi) altering the administration of the agent to the subject accordingly. For example, increased administration
5 of the agent may be desirable to increase the expression or activity of NOV-X to higher levels than detected, i.e., to increase the effectiveness of the agent. Alternatively, decreased administration of the agent may be desirable to decrease expression or activity of NOV-X to lower levels than detected, i.e., to decrease the effectiveness of the agent.

10 Methods of Treatment

The invention provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) a disorder or having a disorder associated with aberrant NOV-X expression or activity. Disorders associated with aberrant NOV-X expression include, for example, disorders of olfactory loss, e.g. trauma, HIV illness, neoplastic growth, and
15 neurological disorders, e.g. Parkinson's disease and Alzheimer's disease.

These methods of treatment will be discussed more fully, below.

Disease and Disorders

Diseases and disorders that are characterized by increased (relative to a subject not suffering from the disease or disorder) levels or biological activity may be treated with
20 Therapeutics that antagonize (i.e., reduce or inhibit) activity. Therapeutics that antagonize activity may be administered in a therapeutic or prophylactic manner. Therapeutics that may be utilized include, but are not limited to: (i) an aforementioned peptide, or analogs, derivatives, fragments or homologs thereof; (ii) antibodies to an aforementioned peptide; (iii) nucleic acids encoding an aforementioned peptide; (iv) administration of antisense nucleic
25 acid and nucleic acids that are "dysfunctional" (i.e., due to a heterologous insertion within the coding sequences of coding sequences to an aforementioned peptide) that are utilized to "knockout" endogenous function of an aforementioned peptide by homologous recombination (see, e.g., Capecchi, 1989. Science 244: 1288-1292); or (v) modulators (i.e., inhibitors, agonists and antagonists, including additional peptide mimetic of the invention or antibodies
30 specific to a peptide of the invention) that alter the interaction between an aforementioned peptide and its binding partner.

Diseases and disorders that are characterized by decreased (relative to a subject not suffering from the disease or disorder) levels or biological activity may be treated with Therapeutics that increase (i.e., are agonists to) activity. Therapeutics that upregulate activity

may be administered in a therapeutic or prophylactic manner. Therapeutics that may be utilized include, but are not limited to, an aforementioned peptide, or analogs, derivatives, fragments or homologs thereof; or an agonist that increases bioavailability.

Increased or decreased levels can be readily detected by quantifying peptide and/or RNA, by obtaining a patient tissue sample (e.g., from biopsy tissue) and assaying it in vitro for RNA or peptide levels, structure and/or activity of the expressed peptides (or mRNAs of an aforementioned peptide). Methods that are well-known within the art include, but are not limited to, immunoassays (e.g., by Western blot analysis, immunoprecipitation followed by sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis, immunocytochemistry, etc.) and/or hybridization assays to detect expression of mRNAs (e.g., Northern assays, dot blots, in situ hybridization, and the like).

Prophylactic Methods

In one aspect, the invention provides a method for preventing, in a subject, a disease or condition associated with an aberrant NOV-X expression or activity, by administering to the subject an agent that modulates NOV-X expression or at least one NOV-X activity. Subjects at risk for a disease that is caused or contributed to by aberrant NOV-X expression or activity can be identified by, for example, any or a combination of diagnostic or prognostic assays as described herein. Administration of a prophylactic agent can occur prior to the manifestation of symptoms characteristic of the NOV-X aberrancy, such that a disease or disorder is prevented or, alternatively, delayed in its progression. Depending upon the type of NOV-X aberrancy, for example, a NOV-X agonist or NOV-X antagonist agent can be used for treating the subject. The appropriate agent can be determined based on screening assays described herein. The prophylactic methods of the invention are further discussed in the following subsections.

25 Therapeutic Methods

Another aspect of the invention pertains to methods of modulating NOV-X expression or activity for therapeutic purposes. The modulatory method of the invention involves contacting a cell with an agent that modulates one or more of the activities of NOV-X protein activity associated with the cell. An agent that modulates NOV-X protein activity can be an agent as described herein, such as a nucleic acid or a protein, a naturally-occurring cognate ligand of a NOV-X protein, a peptide, a NOV-X peptidomimetic, or other small molecule. In one embodiment, the agent stimulates one or more NOV-X protein activity. Examples of such stimulatory agents include active NOV-X protein and a nucleic acid molecule encoding NOV-

X that has been introduced into the cell. In another embodiment, the agent inhibits one or more NOV-X protein activity. Examples of such inhibitory agents include antisense NOV-X nucleic acid molecules and anti-NOV-X antibodies. These modulatory methods can be performed in vitro (e.g., by culturing the cell with the agent) or, alternatively, in vivo (e.g., by 5 administering the agent to a subject). As such, the invention provides methods of treating an individual afflicted with a disease or disorder characterized by aberrant expression or activity of a NOV-X protein or nucleic acid molecule. In one embodiment, the method involves administering an agent (e.g., an agent identified by a screening assay described herein), or combination of agents that modulates (e.g., up-regulates or down-regulates) NOV-X 10 expression or activity. In another embodiment, the method involves administering a NOV-X protein or nucleic acid molecule as therapy to compensate for reduced or aberrant NOV-X expression or activity.

Stimulation of NOV-X activity is desirable in situations in which NOV-X is abnormally downregulated and/or in which increased NOV-X activity is likely to have a 15 beneficial effect. One example of such a situation is where a subject has a disorder characterized by aberrant cell proliferation and/or differentiation (e.g., cancer or immune associated). Another example of such a situation is where the subject has an immunodeficiency disease (e.g., AIDS).

Antibodies of the invention, including polyclonal, monoclonal, humanized and fully 20 human antibodies, may be used as therapeutic agents. Such agents will generally be employed to treat or prevent a disease or pathology in a subject. An antibody preparation, preferably one having high specificity and high affinity for its target antigen, is administered to the subject and will generally have an effect due to its binding with the target. Such an effect may be one of two kinds, depending on the specific nature of the interaction between the given antibody 25 molecule and the target antigen in question. In the first instance, administration of the antibody may abrogate or inhibit the binding of the target with an endogenous ligand to which it naturally binds. In this case, the antibody binds to the target and masks a binding site of the naturally occurring ligand, wherein the ligand serves as an effector molecule. Thus the receptor mediates a signal transduction pathway for which ligand is responsible.

30 Alternatively, the effect may be one in which the antibody elicits a physiological result by virtue of binding to an effector binding site on the target molecule. In this case the target, a receptor having an endogenous ligand which may be absent or defective in the disease or pathology, binds the antibody as a surrogate effector ligand, initiating a receptor-based signal transduction event by the receptor.

A therapeutically effective amount of an antibody of the invention relates generally to the amount needed to achieve a therapeutic objective. As noted above, this may be a binding interaction between the antibody and its target antigen that, in certain cases, interferes with the functioning of the target, and in other cases, promotes a physiological response. The amount required to be administered will furthermore depend on the binding affinity of the antibody for its specific antigen, and will also depend on the rate at which an administered antibody is depleted from the free volume other subject to which it is administered. Common ranges for therapeutically effective dosing of an antibody or antibody fragment of the invention may be, by way of nonlimiting example, from about 0.1 mg/kg body weight to about 50 mg/kg body weight. Common dosing frequencies may range, for example, from twice daily to once a week.

Determination of the Biological Effect of the Therapeutic

In various embodiments of the invention, suitable in vitro or in vivo assays are performed to determine the effect of a specific Therapeutic and whether its administration is indicated for treatment of the affected tissue.

In various specific embodiments, in vitro assays may be performed with representative cells of the type(s) involved in the patient's disorder, to determine if a given Therapeutic exerts the desired effect upon the cell type(s). Compounds for use in therapy may be tested in suitable animal model systems including, but not limited to rats, mice, chicken, cows, monkeys, rabbits, and the like, prior to testing in human subjects. Similarly, for in vivo testing, any of the animal model system known in the art may be used prior to administration to human subjects.

The invention will be further described in the following examples, which do not limit the scope of the invention described in the claims.

EXAMPLES

Example 1: Quantitative Expression Analysis of NOV-1, NOV-2, NOV-3, and NOV-4 in various cells and tissues.

RTQ-PCR Panel Descriptions:

Panel 1

As shown in the expression data in Tables 39, 40, and 41, Panel 1 of each table is composed of RNA or cDNA isolated from various human cells or cell lines from normal and

cancerous tissue. These cells and cell lines have been extensively characterized by investigators in both academia and the commercial sector regarding their tumorigenicity, metastatic potential, drug resistance, invasive potential, and other cancer-related properties. They serve as suitable tools for pre-clinical evaluation of anti-cancer agents and promising therapeutic strategies.

5

Panel 2:

In Tables 39, 40, and 41, Panel 2 of each table includes 2 control wells and 94 test samples composed of RNA or cDNA isolated from human tissue procured by surgeons working in close cooperation with the National Cancer Institute's Cooperative Human Tissue Network (CHTN) or the National Disease Research Initiative (NDRI). The tissues are derived from human malignancies and in cases where indicated, many malignant tissues have "matched margins", which is non-cancerous tissue adjacent to the tumor. These are termed normal adjacent tissues and are denoted "NAT" in Tables 39, 40, and 41. The tumor tissue and the matched margins are evaluated by two independent pathologists at NDRI or CHTN. This analysis provides a gross histopathological assessment of tumor differentiation grade. Moreover, most samples include the original surgical pathology report that provides information regarding the clinical stage of the patient. In addition, these RNA and cDNA samples were obtained from various human tissues derived from autopsies performed on elderly people or sudden death victims (accidents, etc.). These tissue were ascertained to be free of disease and were purchased from various commercial sources such as Clontech (Palo Alto, CA), Research Genetics, and Invitrogen.

20

15

20

25

RNA integrity from all samples is controlled for quality by visual assessment of agarose gel electropherograms using 28S and 18S ribosomal RNA staining intensity ratio as a guide (2:1 to 2.5:1 28s:18s) and the absence of low molecular weight RNAs that would be indicative of degradation products. Samples are controlled against genomic DNA contamination by RTQ PCR reactions run in the absence of reverse transcriptase using probe and primer sets designed to amplify across the span of a single exon.

30

Panel 3:

Panel 3 in Tables 39, 40, and 41, include samples on a 96 well plate (2 control wells, 94 test samples) composed of RNA or cDNA isolated from various human cell lines or tissues related to inflammatory conditions. Total RNA from control normal tissues such as colon and lung (Stratagene, La Jolla, CA) and thymus and kidney (Clontech) were employed. Total

RNA from liver tissue from cirrhosis patients and kidney from lupus patients was obtained from BioChain (Biochain Institute, Inc., Hayward, CA). Intestinal tissue for RNA preparation from patients diagnosed as having Crohn's disease and ulcerative colitis was obtained from the National Disease Research Interchange (NDRI) (Philadelphia, PA).

5 Astrocytes, lung fibroblasts, dermal fibroblasts, coronary artery smooth muscle cells, small airway epithelium, bronchial epithelium, microvascular dermal endothelial cells, microvascular lung endothelial cells, human pulmonary aortic endothelial cells, human umbilical vein endothelial cells were all purchased from Clonetics (Walkersville, MD) and grown in the media supplied for these cell types by Clonetics. These primary cell types were
10 activated with various cytokines or combinations of cytokines for 6 and/or 12-14 hours, as indicated. The following cytokines were used; IL-1 beta at approximately 1-5 ng/ml, TNF alpha at approximately 5-10 ng/ml, IFN gamma at approximately 20-50 ng/ml, IL-4 at approximately 5-10 ng/ml, IL-9 at approximately 5-10 ng/ml, IL-13 at approximately 5-10 ng/ml. Endothelial cells were sometimes starved for various times by culture in the basal
15 media from Clonetics with 0.1% serum.

Mononuclear cells were prepared from blood of employees at CuraGen Corporation, using Ficoll. LAK cells were prepared from these cells by culture in DMEM 5% FCS (Hyclone), 100 µM non essential amino acids (Gibco/Life Technologies, Rockville, MD), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), and 10 mM Hepes (Gibco) and Interleukin 2 for 4-6 days. Cells were then either activated with 10-20 ng/ml PMA and 1-2 µg/ml ionomycin, IL-12 at 5-10 ng/ml, IFN gamma at 20-50 ng/ml and IL-18 at 5-10 ng/ml for 6 hours. In some cases, mononuclear cells were cultured for 4-5 days in DMEM 5% FCS (Hyclone), 100 µM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), and 10 mM Hepes (Gibco) with
20 PHA (phytohemagglutinin) or PWM (pokeweed mitogen) at approximately 5 µg/ml. Samples were taken at 24, 48 and 72 hours for RNA preparation. MLR (mixed lymphocyte reaction) samples were obtained by taking blood from two donors, isolating the mononuclear cells using Ficoll and mixing the isolated mononuclear cells 1:1 at a final concentration of approximately
25 2×10^6 cells/ml in DMEM 5% FCS (Hyclone), 100 µM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol (5.5×10^{-5} M) (Gibco), and 10 mM Hepes (Gibco). The MLR was cultured and samples taken at various time points ranging from 1- 7 days for RNA preparation.

Monocytes were isolated from mononuclear cells using CD14 Miltenyi Beads, +ve VS selection columns and a Vario Magnet according to the manufacturer's instructions.

Monocytes were differentiated into dendritic cells by culture in DMEM 5% fetal calf serum (FCS) (Hyclone, Logan, UT), 100 µM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), and 10 mM Hepes (Gibco), 50 ng/ml GMCSF and 5 ng/ml IL-4 for 5-7 days. Macrophages were prepared by culture of monocytes

5 for 5-7 days in DMEM 5% FCS (Hyclone), 100 µM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), 10 mM Hepes (Gibco) and 10% AB Human Serum or MCSF at approximately 50 ng/ml. Monocytes, macrophages and dendritic cells were stimulated for 6 and 12-14 hours with lipopolysaccharide (LPS) at 100 ng/ml. Dendritic cells were also stimulated with anti-CD40 monoclonal antibody

10 (Pharmingen) at 10 µg/ml for 6 and 12-14 hours.

CD4 lymphocytes, CD8 lymphocytes and NK cells were also isolated from mononuclear cells using CD4, CD8 and CD56 Miltenyi beads, positive VS selection columns and a Vario Magnet according to the manufacturer's instructions. CD45RA and CD45RO CD4 lymphocytes were isolated by depleting mononuclear cells of CD8, CD56, CD14 and CD19

15 cells using CD8, CD56, CD14 and CD19 Miltenyi beads and +ve selection. Then CD45RO beads were used to isolate the CD45RO CD4 lymphocytes with the remaining cells being CD45RA CD4 lymphocytes. CD45RA CD4, CD45RO CD4 and CD8 lymphocytes were placed in DMEM 5% FCS (Hyclone), 100 µM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), and 10 mM Hepes (Gibco)

20 and plated at 10^6 cells/ml onto Falcon 6 well tissue culture plates that had been coated overnight with 0.5 µg/ml anti-CD28 (Pharmingen) and 3 µg/ml anti-CD3 (OKT3, ATCC) in PBS. After 6 and 24 hours, the cells were harvested for RNA preparation. To prepare chronically activated CD8 lymphocytes, we activated the isolated CD8 lymphocytes for 4 days on anti-CD28 and anti-CD3 coated plates and then harvested the cells and expanded them in

25 DMEM 5% FCS (Hyclone), 100 µM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), and 10 mM Hepes (Gibco) and IL-2. The expanded CD8 cells were then activated again with plate bound anti-CD3 and anti-CD28 for 4 days and expanded as before. RNA was isolated 6 and 24 hours after the second activation and after 4 days of the second expansion culture. The isolated NK cells were

30 cultured in DMEM 5% FCS (Hyclone), 100 µM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), and 10 mM Hepes (Gibco) and IL-2 for 4-6 days before RNA was prepared.

To obtain B cells, tonsils were procured from NDRI. The tonsil was cut up with sterile dissecting scissors and then passed through a sieve. Tonsil cells were then spun down and

resuspended at 10^6 cells/ml in DMEM 5% FCS (Hyclone), 100 μ M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), and 10 mM Hepes (Gibco). To activate the cells, we used PWM at 5 μ g/ml or anti-CD40 (Pharmingen) at approximately 10 μ g/ml and IL-4 at 5-10 ng/ml. Cells were harvested for RNA preparation at 5 24,48 and 72 hours.

To prepare the primary and secondary Th1/Th2 and Tr1 cells, six-well Falcon plates were coated overnight with 10 μ g/ml anti-CD28 (Pharmingen) and 2 μ g/ml OKT3 (ATCC), and then washed twice with PBS. Umbilical cord blood CD4 lymphocytes (Poietic Systems,

German Town, MD) were cultured at 10^{5-6} cells/ml in DMEM 5% FCS (Hyclone), 100 μ M

10 non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), 10 mM Hepes (Gibco) and IL-2 (4 ng/ml). IL-12 (5 ng/ml) and anti-IL4 (1

μ g/ml) were used to direct to Th1, while IL-4 (5 ng/ml) and anti-IFN gamma (1 μ g/ml) were used to direct to Th2 and IL-10 at 5 ng/ml was used to direct to Tr1. After 4-5 days, the activated Th1, Th2 and Tr1 lymphocytes were washed once in DMEM and expanded for 4-7

15 days in DMEM 5% FCS (Hyclone), 100 μ M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), 10 mM Hepes (Gibco) and IL-2 (1

ng/ml). Following this, the activated Th1, Th2 and Tr1 lymphocytes were re-stimulated for 5 days with anti-CD28/OKT3 and cytokines as described above, but with the addition of anti-CD95L (1 μ g/ml) to prevent apoptosis. After 4-5 days, the Th1, Th2 and Tr1 lymphocytes

20 were washed and then expanded again with IL-2 for 4-7 days. Activated Th1 and Th2 lymphocytes were maintained in this way for a maximum of three cycles. RNA was prepared from primary and secondary Th1, Th2 and Tr1 after 6 and 24 hours following the second and third activations with plate bound anti-CD3 and anti-CD28 mAbs and 4 days into the second and third expansion cultures in Interleukin 2.

25 The following leukocyte cell lines were obtained from the ATCC: Ramos, EOL-1, KU-812. EOL cells were further differentiated by culture in 0.1 mM dbcAMP at 5×10^5 cells/ml for 8 days, changing the media every 3 days and adjusting the cell concentration to 5×10^5 cells/ml. For the culture of these cells, we used DMEM or RPMI (as recommended by the ATCC), with the addition of 5% FCS (Hyclone), 100 μ M non essential amino acids

30 (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), 10 mM Hepes (Gibco). RNA was either prepared from resting cells or cells activated with PMA at 10 ng/ml and ionomycin at 1 μ g/ml for 6 and 14 hours. Keratinocyte line CCD106 and an airway epithelial tumor line NCI-H292 were also obtained from the ATCC. Both were cultured in

DMEM 5% FCS (Hyclone), 100 μ M non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10^{-5} M (Gibco), and 10 mM Hepes (Gibco).

CCD1106 cells were activated for 6 and 14 hours with approximately 5 ng/ml TNF alpha and 1 ng/ml IL-1 beta, while NCI-H292 cells were activated for 6 and 14 hours with the following cytokines: 5 ng/ml IL-4, 5 ng/ml IL-9, 5 ng/ml IL-13 and 25 ng/ml IFN gamma.

For these cell lines and blood cells, RNA was prepared by lysing approximately 10^7 cells/ml using Trizol (Gibco BRL). Briefly, 1/10 volume of bromochloropropene (Molecular Research Corporation) was added to the RNA sample, vortexed and after 10 minutes at room temperature, the tubes were spun at 14,000 rpm in a Sorvall SS34 rotor. The aqueous phase was removed and placed in a 15 ml Falcon Tube. An equal volume of isopropanol was added and left at -20 degrees C overnight. The precipitated RNA was spun down at 9,000 rpm for 15 min in a Sorvall SS34 rotor and washed in 70% ethanol. The pellet was redissolved in 300 μ l of RNase-free water and 35 μ l buffer (Promega) 5 μ l DTT, 7 μ l RNASin and 8 μ l DNase were added. The tube was incubated at 37 degrees C for 30 minutes to remove contaminating genomic DNA, extracted once with phenol chloroform and re-precipitated with 1/10 volume of 3 M sodium acetate and 2 volumes of 100% ethanol. The RNA was spun down and placed in RNase free water. RNA was stored at -80 degrees C.

Methods:

The quantitative expression of various clones was assessed using microtiter plates containing RNA samples from a variety of normal and pathology-derived cells, cell lines and tissues using real time quantitative PCR (RTQ PCR; TAQMAM[®]). RTQ PCR was performed on a Perkin-Elmer Biosystems ABI PRISM[®] 7700 Sequence Detection System. Various collections of samples are assembled on the plates, and referred to as Panel 1 (containing cells and cell lines from normal and cancer sources), Panel 2 (containing samples derived from tissues, in particular from surgical samples, from normal and cancer sources), Panel 3 (containing samples derived from a wide variety of cancer sources) and Panel 3 (containing cells and cell lines from normal cells and cells related to inflammatory conditions).

First, the RNA samples were normalized to constitutively expressed genes such as β -actin and GAPDH. RNA (~50 ng total or ~1 ng polyA+) was converted to cDNA using the TAQMAM[®] Reverse Transcription Reagents Kit (PE Biosystems, Foster City, CA; Catalog No. N808-0234) and random hexamers according to the manufacturer's protocol. Reactions were performed in 20 μ l and incubated for 30 min. at 48°C. cDNA (5 μ l) was then transferred to a separate plate for the TAQMAM[®] reaction using β -actin and GAPDH TAQMAM[®]

Assay Reagents (PE Biosystems; Catalog Nos. 4310881E and 4310884E, respectively) and TAQMAN® universal PCR Master Mix (PE Biosystems; Catalog No. 4304447) according to the manufacturer's protocol. Reactions were performed in 25 μ l using the following parameters: 2 min. at 50°C; 10 min. at 95°C; 15 sec. at 95°C/1 min. at 60°C (40 cycles).

5 Results were recorded as CT values (cycle at which a given sample crosses a threshold level of fluorescence) using a log scale, with the difference in RNA concentration between a given sample and the sample with the lowest CT value being represented as 2 to the power of delta CT. The percent relative expression is then obtained by taking the reciprocal of this RNA difference and multiplying by 100. The average CT values obtained for β -actin and GAPDH
 10 were used to normalize RNA samples. The RNA sample generating the highest CT value required no further diluting, while all other samples were diluted relative to this sample according to their β -actin /GAPDH average CT values.

Normalized RNA (5 μ l) was converted to cDNA and analyzed via TAQMAN® using One Step RT-PCR Master Mix Reagents (PE Biosystems; Catalog No. 4309169) and gene-specific primers according to the manufacturer's instructions. Probes and primers were designed for each assay according to Perkin Elmer Biosystem's *Primer Express* Software package (version I for Apple Computer's Macintosh Power PC) or a similar algorithm using the target sequence as input. Default settings were used for reaction conditions and the following parameters were set before selecting primers: primer concentration = 250 nM,
 20 primer melting temperature (T_m) range = 58°-60° C, primer optimal T_m = 59° C, maximum primer difference = 2° C, probe does not have 5' G, probe T_m must be 10° C greater than primer T_m , amplicon size 75 bp to 100 bp. The probes and primers selected (see below) were synthesized by Synthegen (Houston, TX, USA). Probes were double purified by HPLC to remove uncoupled dye and evaluated by mass spectroscopy to verify coupling of reporter and
 25 quencher dyes to the 5' and 3' ends of the probe, respectively. Their final concentrations were: forward and reverse primers, 900 nM each, and probe, 200nM.

The Taqman oligonucleotide set Ag756 for NOV-1, NOV-2, and NOV-2b (*i.e.*, 10132038) include the forward probe and reverse oligomers shown below:

30

TABLE 36

Primers	Sequences	TM	length	Start position
Forward	5'-GGAGCAGTTCCTCACTTATCG-3' (SEQ ID NO: 47)	59	21	248

Probe	TET-5'- TET-5'- TGATGACCAGACCTCAAGAAACACTCG-3'-TAMRA (SEQ ID NO: 48)	68.6	27	272
Reverse	5'-CAGTTGCCATCTTGTCTTCAT-3' (SEQ ID NO: 49)	59.2	22	304

The Taqman oligonucleotide set Ag756 for NOV-3a through NOV-3d (*i.e.*, 18552586) include the forward probe and reverse oligomers shown below:

TABLE 37

Primers	Sequences	TM	Length	Start Position
Forward	5'-AATGCTGAGGTCAAGCTAGGT-3' (SEQ ID NO: 50)	58.1	21	121
Probe	TET-5'-CTCCTCTGAGGCTGACGAGGACCT-3'- TAMRA (SEQ ID NO: 51)	69.3	25	149
Reverse	5'-CATTCTCTGTTCTGGAGGTGAA-3' (SEQ ID NO: 52)	59.3	22	174

5

The Taqman oligonucleotide set Ag756 for NOV-4a, NOV-4b, NOV-4c, NOV-4d, and NOV-4e (*i.e.*, 10093872) include the forward probe and reverse oligomers shown below:

TABLE 38

Primer	Sequences	Length
Forward	5'-GGACTCCTCGGGATGGAAAG-3' (SEQ ID NO: 53)	20
Probe	FAM-5'-CGGCCTTGGTCTCGGAGATCCC-3'- TAMRA (SEQ ID NO: 54)	23
Reverse	5'-CTCCCCCTGGTGCTGGAAATT-3' (SEQ ID NO: 55)	20

10 PCR conditions:

Normalized RNA from each tissue and each cell line was spotted in each well of a 96 well PCR plate (Perkin Elmer Biosystems). PCR cocktails including two probes (a probe specific for the target clone and another gene-specific probe multiplexed with the target probe) were set up using 1X TaqMan™ PCR Master Mix for the PE Biosystems 7700, with 5 mM MgCl₂, dNTPs (dA, G, C, U at 1:1:1:2 ratios), 0.25 U/ml AmpliTaq Gold™ (PE Biosystems), and 0.4 U/μl RNase inhibitor, and 0.25 U/μl reverse transcriptase. Reverse transcription was

15

performed at 48° C for 30 minutes followed by amplification/PCR cycles as follows: 95° C 10 min, then 40 cycles of 95° C for 15 seconds, 60° C for 1 minute.

TABLE 39: NOV-1, NOV-2, NOV-2b Taqman Results

5 • In panel 1 of the results, the following abbreviations are used:

	ca.	= carcinoma,
	*	= established from metastasis,
	met	= metastasis,
10	s cell var	= small cell variant,
	non-s	= non-sm =non-small,
	squam	= squamous,
	pl. eff	= pl effusion = pleural effusion,
	glio	= glioma,
15	astro	= astrocytoma, and
	neuro	= neuroblastoma.

- In panel 2 of the results, the following abbreviations are used:

Cca: Colon Cancer

PCa: Prostate Cancer

Lca: Lung Cancer

RCC: Renal Cell Carcinoma

UtCa: Uterine Cancer

ThyCa: Thyroid Cancer

BrCa: Breast Cancer

HCC: Hepatic Cell Carcinoma

TCC: Transitional Cell Carcinoma of the bladder

OvCa: Ovarian Cancer

GaCa: Gastric Cancer

—www.SantoshChaturvedi.com

[View all posts by admin](#)

Digitized by srujanika@gmail.com

10.000-10.000-10.000

	Panel 1					
	Run 1					
	Run 2		Panel 2		Panel 3	
Tissue_Name	ag756 % Rel. Expn.	g756 % Rel. Expn.	Tissue_Name	ag75 6 % Rel. Expn.	Tissue_Name	ag75 6 % Rel. Expn.
Endothelial cells	0.0	0.0	Normal Colon	78.5	93768_Secondary Th1_anti-CD28/anti-CD3	0
Endothelial cells (treated)	12.2	54.7	CCa 1	1.0	93769_Secondary Th2_anti-CD28/anti-CD3	0
Pancreas	27.6	5.4	CCa 1 Margin	7.9	93770_Secondary Tr1_anti-CD28/anti-CD3	0
Pancreatic ca.CAPAN 2	0.0	0.0	CCa 2	3.7	93573_Secondary Th1_resting day 4-6 in IL-2	0
Adrenal Gland (new lot*)	9.3	29.3	CCa 2 Margin	15.2	93572_Secondary Th2_resting day 4-6 in IL-2	0
Thyroid	8.0	6.5	CCa 3	0.4	93571_Secondary Tr1_resting day 4-6 in IL-2	0

Salavary gland	6.8	19.9	CCa 3 Margin	35.6	93568_primary Th1_anti-CD28/anti-CD3	0
Pituitary gland	3.2	7.8	CCa 4	10.1	93569_primary Th2_anti-CD28/anti-CD3	0
Brain (fetal)	3.4	18.4	CCa 4 Margin	11.6	93570_primary Tr1_anti-CD28/anti-CD3	0
Brain (whole)	6.9	27.4	CCa 5 Metastasis	7.2	93565_primary Th1_resting dy 4-6 in IL-2	0
Brain (amygdala)	2.5	13.8	CCa 5 Margin (Liver)	52.9	93566_primary Th2_resting dy 4-6 in IL-2	0
Brain (cerebellum)	2.0	28.7	CCa 6	2.5	93567_primary Tr1_resting dy 4-6 in IL-2	0
Brain (hippocampus)	3.8	20.9	CCa 6 Margin (Lung)	14.1	93351_CD45RA CD4 lymphocyte_anti-CD28/anti-CD3	0
Brain (thalamus)	3.0	11.0	Normal Prostate	10.0	93352_CD45RO CD4 lymphocyte_anti-CD28/anti-CD3	0
Cerebral Cortex	7.0	61.1	PCa 1	10.7	93251_CD8 Lymphocytes_anti-CD28/anti-CD3	0
Spinal cord	8.6	27.0	PCa 1 Margin	37.6	93353_chronic CD8 Lymphocytes 2ry_resting dy 4-6 in IL-2	0
CNS ca.(glio/astro) U87-MG	0.0	0.0	PCa 2	100.0	93574_chronic CD8 Lymphocytes 2ry_activated CD3/CD28	0
CNS ca.(glio/astro)U-118-MG	0.2	0.0	PCa 2 Margin	89.5	93354_CD4_none	0
CNS ca.(astro)SW1783	0.0	0.0	Normal Lung	51.1	93252_Secondary Th1/Th2/Tr1_anti-CD95 CH11	0
CNS ca.* (neuro; met)SK-N-AS	0.0	0.0	LCa 1 Metastasis	1.0	93103_LAK cells_resting	0
CNS ca. (astro)SF-539	0.1	0.0	LCa 1 Margin (Muscle)	11.3	93788_LAK cells_IL-2	0
CNS ca. (astro)SNB-75	0.3	0.3	LCa 2	8.5	93787_LAK cells_IL-2+IL-12	0
CNS ca. (glio)SNB-19	0.1	0.0	LCa 2 Margin	31.6	93789_LAK cells_IL-2+IFN gamma	0
CNS ca. (glio)U251	0.0	0.0	LCa 3	5.8	93790_LAK cells_IL-2+ IL-18	0
CNS ca. (glio)SF-295	0.0	0.0	LCa 3 Margin	28.3	93104_LAK cells_PMA/ionomycin and IL-18	0
Heart	28.5	77.9	LCa 4	1.6	93578_NK Cells IL-2_resting	0
Skeletal Muscle (new lot*)	16.3	15.7	LCa 5	4.2	93109_Mixed Lymphocyte Reaction_Two Way MLR	0
Bone marrow	0.7	0.9	LCa 5 Margin	29.5	93110_Mixed Lymphocyte Reaction_Two Way MLR	0
Thymus	1.1	2.7	Ocular Melanoma Metastasis	15.9	93111_Mixed Lymphocyte Reaction_Two Way MLR	0
Spleen	0.9	2.1	Ocular Melanoma Margin	38.7	93112_Mononuclear Cells (PBMCs)_resting	0

			(Liver)			
Lymph node	3.6	10.2	Melanoma Metastasis	0.0	93113_Mononuclear Cells (PBMCs)_PWM	0
Colorectal	2.2	11.4	Melanoma Margin (Lung)	32.3	93114_Mononuclear Cells (PBMCs)_PHA-L	0
Stomach	11.8	34.4	Normal Kidney	56.3	93249_Ramos (B cell)_none	0
Small intestine	11.7	18.7	RCC 1	71.2	93250_Ramos (B cell)_ionomycin	0
Colon ca.SW480	0.0	0.0	RCC 1 Margin	26.1	93349_B lymphocytes_PWM	0
Colon ca.* (SW480 met)SW620	0.0	0.0	RCC 2	63.7	93350_B lymphocytes_CD40L and IL-4	0
Colon ca.HT29	0.0	0.0	RCC 2 Margin	28.3	92665_EOL-1 (Eosinophil)_dbcAMP differentiated	0
Colon ca.HCT-116	0.0	0.0	RCC 3	37.1	93248_EOL-1 (Eosinophil)_dbcAMP/PmA ionomycin	0
Colon ca.CaCo-2	0.0	0.0	RCC 3 Margin	33.7	93356_Dendritic Cells_none	0
83219 CC Well to Mod Diff (ODO3866)	0.3	1.7	RCC 4	5.7	93355_Dendritic Cells_LPS 100 ng/ml	0
Colon ca.HCC-2998	0.0	0.0	RCC 4 Margin	18.2	93775_Dendritic Cells_anti-CD40	0
Gastric ca.* (liver met) NCI-N87	0.0	0.0	RCC 5	8.5	93774_Monocytes_resting	0
Bladder	16.4	29.3	RCC 5 Margin	5.5	93776_Monocytes_LPS 50 ng/ml	0
Trachea	4.2	12.7	RCC 6	1.0	93581_Macrophages_resting	0
Kidney	5.3	14.3	RCC 6 Margin	18.7	93582_Macrophages_LPS 100 ng/ml	0
Kidney (fetal)	7.8	24.3	RCC 7	6.0	93098_HUVEC (Endothelial)_none	0
Renal ca. 786-0	0.5	2.4	RCC 7 Margin	8.5	93099_HUVEC (Endothelial)_starved	0
Renal ca.A498	0.2	0.0	RCC 8	0.3	93100_HUVEC (Endothelial)_IL-1b	0
Renal ca.RXF 393	6.0	18.6	RCC 8 Margin	14.1	93779_HUVEC (Endothelial)_IFN gamma	0.1
Renal ca.ACHN	15.0	28.7	RCC 9	6.3	93102_HUVEC (Endothelial)_TNF alpha + IFN gamma	0.0
Renal ca.UO-31	1.2	4.2	RCC 9 Margin	19.6	93101_HUVEC (Endothelial)_TNF alpha + IL4	0.0
Renal ca.TK-10	10.3	21.2	Normal Uterus	7.0	93781_HUVEC (Endothelial)_IL-11	0.0
Liver	12.9	48.0	UtCa 1	46.0	93583_Lung Microvascular Endothelial Cells_none	37.1
Liver (fetal)	4.7	17.7	Normal Thyroid	6.1	93584_Lung Microvascular Endothelial Cells_TNF α (4 ng/ml) and IL1b (1 ng/ml)	12.9
Liver ca. (hepatoblast)	0.0	0.0	ThyCa 1	6.1	92662_Microvascular Dermal endothelium_none	81.2

HepG2						
Lung	7.4	25.4	ThyCa 2	0.8	92663_Microvascular Dermal endothelium_TNF α (4 ng/ml) and IL1b (1 ng/ml)	38.7
Lung (fetal)	9.6	19.0	ThyCa 2 Margin	22.5	93773_Bronchial epithelium_TNF α (4 ng/ml) and IL1b (1 ng/ml) **	0.0
Lung ca. (small cell) LX-1	0.0	0.0	Normal Breast	12.1	93347_Small Airway Epithelium_none	0.0
Lung ca. (small cell) NCI-H69	0.0	0.0	BrCa 1	7.5	93348_Small Airway Epithelium_TNF α (4 ng/ml) and IL1b (1 ng/ml)	0.5
Lung ca. (s.cell var.) SHP-77	0.0	0.0	BrCa 2	4.0	92668_Coronery Artery SMC_resting	0.6
Lung ca. (large cell)NCI-H460	0.1	0.0	BrCa 3 Metastasis	15.1	92669_Coronery Artery SMC_TNF α (4 ng/ml) and IL1b (1 ng/ml)	0.1
Lung ca. (non-sm. cell) A549	0.2	0.0	BrCa 4 Metastasis	18.4	93107_astrocytes_resting	20.0
Lung ca. (non-s.cell) NCI-H23	0.4	2.4	BrCa 5	11.7	93108_astrocytes_TNF α (4 ng/ml) and IL1b (1 ng/ml)	17.0
Lung ca (non-s.cell) HOP-62	1.3	0.8	BrCa 6	3.1	92666_KU-812 (Basophil)_resting	0.0
Lung ca. (non-s.cl) NCI-H522	100.0	100.0	BrCa 6 Margin	5.3	92667_KU-812 (Basophil)_PMA/ionoycin	0.0
Lung ca. (squam.) SW 900	0.7	0.8	BrCa 7	6.8	93579_CCD1106 (Keratinocytes)_none	0.0
Lung ca. (squam.) NCI-H596	0.0	0.0	BrCa 7 Margin	11.7	93580_CCD1106 (Keratinocytes)_TNF α and IFNg **	4.1
Mammary gland	5.0	7.5	Normal Liver	37.1	93791_Liver Cirrhosis	8.1
Breast ca.* (pl. effusion) MCF-7	2.7	12.0	HCC 1	47.0	93792_Lupus Kidney	18.1
Breast ca.* (pl.ef) MDA-MB-231	0.0	0.0	HCC 2	34.2	93577_NCI-H292	1.9
Breast ca.* (pl. effusion) T47D	0.2	0.0	HCC 3	5.2	93358_NCI-H292 IL-4	4.6
Breast ca.BT-549	0.0	0.0	HCC 4	27.6	93360_NCI-H292 IL-9	0.9
Breast ca. MDA-N	0.0	0.0	HCC 4 Margin	3.6	93359_NCI-H292 IL-13	1.7
Ovary	5.5	18.4	HCC 5	5.3	93357_NCI-H292 IFN gamma	4.6
Ovarian ca.OVCAR-3	11.8	21.2	HCC 5 Margin	15.9	93777_HPAEC -	0.0
Ovarian ca.OVCAR-4	4.6	12.5	Normal Bladder	27.0	93778_HPAEC IL-1 beta/TNA alpha	0.0
Ovarian ca.OVCAR-5	0.2	0.0	TCC 1	2.1	93254_Normal Human Lung Fibroblast_none	0.3
Ovarian ca.OVCAR-8	4.5	21.5	TCC 2	1.1	93253_Normal Human Lung Fibroblast_TNF α (4 ng/ml) and IL-1b (1 ng/ml)	0.8
Ovarian ca.IGROV-1	4.3	5.4	TCC 3	2.1	93257_Normal Human Lung Fibroblast IL-4	0.5
Ovarian ca.*	50.0	92.7	TCC 3	52.1	93256_Normal Human	0.3

(ascites) SK-OV-3			Margin		Lung Fibroblast_IL-9	
Uterus	7.6	24.2	Normal Ovary	7.7	93255_Normal Human Lung Fibroblast IL-13	1.7
Placenta	17.0	31.4	OvCa 1	89.5	93258_Normal Human Lung Fibroblast IFN gamma	10.2
Prostate	5.3	15.5	OvCa 2	45.1	93106_Dermal Fibroblasts CCD1070_resting	0.0
Prostate ca.* (bone met)PC-3	14.7	42.6	OvCa 2 Margin	8.7	93361_Dermal Fibroblasts CCD1070_TNF alpha 4 ng/ml	0.3
Testis	10.2	13.1	Normal Stomach	25.7	93105_Dermal Fibroblasts CCD1070_IL-1 beta 1 ng/ml	0.0
Melanoma Hs688(A).T	0.0	0.0	Normal Stomach	15.6	93772_dermal fibroblast IFN gamma	0.8
Melanoma* (met) Hs688(B).T	0.1	0.0	GaCa 1	26.6	93771_dermal fibroblast IL-4	0.5
MelanomaUAC C-62	0.2	0.0	GaCa 1 Margin	31.0	93259_IBD Colitis 1**	19.3
Melanoma M14	0.0	0.0	GaCa 2	15.4	93260_IBD Colitis 2	6.1
Melanoma LOX IMVI	0.0	0.0	GaCa 2 Margin	5.2	93261_IBD Crohns	3.7
Melanoma* (met)SK-MEL-5	0.1	0.0	GaCa 3	13.7	735010_Colon_normal	26.1
Adipose	2.5	29.9			735019_Lung_none	90.1
					64028-1_Thymus_none	100.0
					64030-1_Kidney_none	16.0

TABLE 40: NOV-3a, NOV-3b, NOV-3c Taqman Results

	Panel 1		Panel 2		Panel 3
Tissue_Name	Ag664 %Rel. Expn.	Tissue_Name	ag664 %Rel. Expn.	Tissue_Name	ag664 %Rel. Expn.
Liver adenocarcinoma	13.6	Normal Colon	70.2	93768_Secondary Th1_anti-CD28/anti-CD3	16.4
Heart (fetal)	6.5	CCa 1	22.7	93769_Secondary Th2_anti-CD28/anti-CD3	12.9
Pancreas	6.4	CCa 1 Margin	9.0	93770_Secondary Tr1_anti-CD28/anti-CD3	18.3
Pancreatic ca. CAPAN 2	1.6	CCa 2	14.0	93573_Secondary Th1_resting day 4-6 in IL-2	22.1
Adrenal gland	10.5	CCa 2 Margin	6.5	93572_Secondary Th2_resting day 4-6 in IL-2	13.1
Thyroid	5.6	CCa 3	42.6	93571_Secondary Tr1_resting day 4-6 in IL-2	23.0
Salivary gland	4.8	CCa 3 Margin	20.2	93568_primary Th1_anti-	11.5

				CD28/anti-CD3	
Pituitary gland	14.3	CCa 4	27.6	93569_primary Th2_anti-CD28/anti-CD3	15.9
Brain (fetal)	27.6	CCa 4 Margin	10.2	93570_primary Tr1_anti-CD28/anti-CD3	16.5
Brain (whole)	22.5	CCa 5 Metastasis	38.4	93565_primary Th1_resting dy 4-6 in IL-2	73.7
Brain (amygdala)	22.7	CCa 5 Margin (Liver)	7.3	93566_primary Th2_resting dy 4-6 in IL-2	47.0
Brain (cerebellum)	13.0	CCa 6	34.4	93567_primary Tr1_resting dy 4-6 in IL-2	26.4
Brain (hippocampus)	100.0	CCa 6 Margin (Lung)	5.9	93351_CD45RA CD4 lymphocyte anti-CD28/anti-CD3	8.5
Brain (thalamus)	22.4	Normal Prostate	20.7	93352_CD45RO CD4 lymphocyte anti-CD28/anti-CD3	19.3
Cerebral Cortex	24.3	PCa 1	26.6	93251_CD8 Lymphocytes_anti-CD28/anti-CD3	8.0
Spinal cord	22.7	PCa 1 Margin	32.8	93353_chronic CD8 Lymphocytes 2ry resting dy 4-6 in IL-2	9.9
glio/astro U87-MG	2.8	PCa 2	47.3	93574_chronic CD8 Lymphocytes 2ry activated CD3/CD28	6.7
glio/astro U-118-MG	22.7	PCa 2 Margin	36.9	93354_CD4 none	17.4
astro SW1783	5.4	Normal Lung	100.0	93252_Secondary Th1/Th2/Tr1_anti-CD95 CH11	20.7
neuro; met SK-N-AS	26.8	LCa 1 Metastasis	12.5	93103_LAK cells_resting	20.5
astro SF-539	12.8	LCa 1 Margin (Muscle)	3.8	93788_LAK cells IL-2	19.3
astro SNB-75	5.4	LCa 2	24.2	93787_LAK cells IL-2+IL-12	6.8
glio SNB-19	7.4	LCa 2 Margin	40.9	93789_LAK cells IL-2+IFN gamma	16.0
glio U251	4.0	LCa 3	13.6	93790_LAK cells IL-2+ IL-18	24.2
glio SF-295	4.5	LCa 3 Margin	7.8	93104_LAK cells_PMA/ionomycin and IL-18	1.5
Heart	2.4	LCa 4	10.4	93578_NK Cells IL-2_resting	18.7
Skeletal muscle	0.9	LCa 5	32.3	93109_Mixed Lymphocyte Reaction_Two Way MLR	23.7
Bone marrow	17.0	LCa 5 Margin	12.1	93110_Mixed Lymphocyte Reaction_Two Way MLR	5.8
Thymus	20.3	Ocular Melanoma Metastasis	6.8	93111_Mixed Lymphocyte Reaction_Two Way MLR	10.2
Spleen	25.4	Melanoma Margin (Liver)	8.0	93112_Mononuclear Cells (PBMCs)_resting	8.6
Lymph node	29.9	Melanoma Metastasis	18.2	93113_Mononuclear Cells (PBMCs)_PWM	24.5
Colorectal	15.9	Melanoma Margin (Lung)	16.4	93114_Mononuclear Cells (PBMCs)_PHA-L	18.6
Stomach	24.8	Normal Kidney	40.9	93249_Ramos (B cell)_none	5.2
Small intestine	14.4	RCC 1	32.8	93250_Ramos (B cell)_ionomycin	17.8
Colon SW480	4.9	RCC 1 Margin	30.6	93349_B lymphocytes_PWM	26.2
Colon SW620(SW480 met)	9.3	RCC 2	63.3	93350_B lymphocytes_CD40L and IL-4	30.6
Colon HT29	6.6	RCC 2 Margin	9.7	92665_EOL-1 (Eosinophil)_dbcAMP differentiated	9.7
Colon HCT-116	3.2	RCC 3	31.2	93248_EOL-1 (Eosinophil)_dbcAMP/PmAlonomycin in	22.2
Colon CaCo-2	3.7	RCC 3 Margin	18.6	93356_Dendritic Cells_none	12.1
Colon Ca tissue(ODO3866)	18.7	RCC 4	4.5	93355_Dendritic Cells_LPS 100 ng/ml	20.0

Colon HCC-2998	32.5	RCC 4 Margin	12.2	93775_Dendritic Cells_anti-CD40	17.7
Gastric(liver met) NCI-N87	11.0	RCC 5	11.6	93774_Monocytes_resting	22.4
Bladder	6.9	RCC 5 Margin	3.9	93776_Monocytes_LPS 50 ng/ml	2.0
Trachea	35.6	RCC 6	15.8	93581_Macrophages_resting	11.8
Kidney	6.4	RCC 6 Margin	14.6	93582_Macrophages_LPS 100 ng/ml	3.9
Kidney (fetal)	13.7	RCC 7	9.2	93098_HUVEC (Endothelial)_none	6.0
Renal 786-0	0.0	RCC 7 Margin	5.8	93099_HUVEC (Endothelial)_starved	15.0
Renal A498	20.7	RCC 8	20.9	93100_HUVEC (Endothelial)_IL-1b	5.3
Renal RXF 393	1.5	RCC 8 Margin	10.7	93779_HUVEC (Endothelial)_IFN gamma	13.2
Renal ACHN	1.8	RCC 9	23.0	93102_HUVEC (Endothelial)_TNF alpha + IFN gamma	9.0
Renal UO-31	1.6	RCC 9 Margin	21.0	93101_HUVEC (Endothelial)_TNF alpha + IL4	5.3
Renal TK-10	2.3	Normal Uterus	5.5	93781_HUVEC (Endothelial)_IL-11	5.5
Liver	10.5	UtCa 1	31.9	93583_Lung Microvascular Endothelial Cells_none	7.3
Liver (fetal)	21.8	Normal Thyroid	13.8	93584_Lung Microvascular Endothelial Cells_TNF α (4 ng/ml) and IL1b (1 ng/ml)	6.5
Liver (hepatoblast) HepG2	14.1	ThyCa 1	6.3	92662_Microvascular Dermal endothelium_none	8.0
Lung	48.6	ThyCa 2	7.9	92663_Microvascular Dermal endothelium_TNF α (4 ng/ml) and IL1b (1 ng/ml)	10.2
Lung (fetal)	24.3	ThyCa 2 Margin	7.0	93773_Bronchial epithelium_TNF α (4 ng/ml) and IL1b (1 ng/ml) **	12.2
Lung (small cell) LX-1	4.7	Normal Breast	36.9	93347_Small Airway Epithelium_none	4.9
Lung (small cell) NCI-H69	1.1	BrCa 1	10.7	93348_Small Airway Epithelium_TNF α (4 ng/ml) and IL1b (1 ng/ml)	32.5
Lung (s.cell var.) SHP-77	24.5	BrCa 2	11.2	92668_Coronary Artery SMC_resting	2.4
Lung (large cell) NCI-H460	1.6	BrCa 3 Metastasis	32.8	92669_Coronary Artery SMC_TNF α (4 ng/ml) and IL1b (1 ng/ml)	0.0
Lung (non-sm. cell) A549	1.4	BrCa 4 Metastasis	13.7	93107_astrocytes_resting	4.4
Lung (non-s.cell) NCI-H23	10.7	BrCa 5	19.8	93108_astrocytes_TNF α (4 ng/ml) and IL1b (1 ng/ml)	4.2
Lung (non-s.cell) HOP-62	32.3	BrCa 6	29.1	92666_KU-812 (Basophil)_resting	2.5
Lung (non-s.cl) NCI-H522	1.7	BrCa 6 Margin	17.2	92667_KU-812 (Basophil)_PMA/ionoycin	7.2
Lung (squam.) SW 900	3.6	BrCa 7	13.9	93579_CCD1106 (Keratinocytes)_none	6.6
Lung (squam.) NCI-H596	0.9	BrCa 7 Margin	25.5	93580_CCD1106 (Keratinocytes)_TNF α and IFNg **	3.0
Mammary gland	27.2	Normal Liver	8.3	93791_Liver Cirrhosis	5.4
Breast (pl.eff) MCF-7	12.4	HCC 1	14.1	93792_Lupus Kidney	2.2
Breast (pl.eff) MDA-MB-231	18.7	HCC 2	14.5	93577_NCI-H292	41.5
Breast (pl.eff) T47D	0.4	HCC 3	7.9	93358_NCI-H292 IL-4	62.4
Breast BT-549	28.9	HCC 4	16.0	93360_NCI-H292 IL-9	53.2
Breast MDA-N	20.6	HCC 4 Margin	19.3	93359_NCI-H292 IL-13	21.3
Ovary	12.2	HCC 5	4.0	93357_NCI-H292 IFN gamma	19.9

Ovarian OVCAR-3	2.1	HCC 5 Margin	2.0	93777_HPAEC -	6.5
Ovarian OVCAR-4	0.5	Normal Bladder	44.4	93778_HPAEC IL-1 beta/TNA alpha	9.7
Ovarian OVCAR-5	0.6	TCC 1	24.5	93254_Normal Human Lung Fibroblast none	2.2
Ovarian OVCAR-8	6.5	TCC 2	16.4	93253_Normal Human Lung Fibroblast TNFa (4 ng/ml) and IL-1b (1 ng/ml)	3.0
Ovarian IGROV-1	3.5	TCC 3	22.7	93257_Normal Human Lung Fibroblast IL-4	4.0
Ovarian (ascites) SK-OV-3	2.3	TCC 3 Margin	13.4	93256_Normal Human Lung Fibroblast IL-9	3.2
Uterus	17.2	Normal Ovary	12.7	93255_Normal Human Lung Fibroblast IL-13	4.8
Placenta	12.9	OvCa 1	23.3	93258_Normal Human Lung Fibroblast IFN gamma	4.0
Prostate	8.5	OvCa 2	72.2	93106_Dermal Fibroblasts CCD1070_resting	1.5
Prostate (bone met)PC-3	3.3	OvCa 2 Margin	4.1	93361_Dermal Fibroblasts CCD1070_TNF alpha 4 ng/ml	42.6
Testis	4.1	Normal Stomach	20.2	93105_Dermal Fibroblasts CCD1070 IL-1 beta 1 ng/ml	7.3
Melanoma Hs688(A).T	0.6	Normal Stomach	5.2	93772_dermal fibroblast IFN gamma	4.3
Melanoma (met) Hs688(B).T	0.5	GaCa 1	8.4	93771_dermal fibroblast IL-4	10.4
Melanoma UACC-62	1.6	GaCa 1 Margin	15.9	93259_IBD Colitis 1**	3.2
Melanoma M14	0.6	GaCa 2	38.4	93260_IBD Colitis 2	0.0
Melanoma LOX IMVI	1.7	GaCa 2 Margin	4.5	93261_IBD Crohns	0.0
Melanoma (met) SK-MEL-5	6.2	GaCa 3	55.5	735010_Colon_normal	23.0
Adipose	6.0			735019_Lung_none	6.4
				64028-1_Thymus_none	21.2
				64030-1_Kidney_none	100.0

TABLE 41: NOV-4a, NOV-4b, NOV-4c, NOV-4d, and NOV-4e Taqman results

Tissue_Name	Panel 1	Tissue_Name	Panel 2
	ag538 % Rel. expn.		ag538 % Rel. expn.
Adipose	12.6	Normal Colon GENPAK 061003	9.7
Adrenal gland	19.9	83219 CC Well to Mod Diff (ODO3866)	4.3
Bladder	100.0	83220 CC NAT (ODO3866)	3.3
Bone marrow	4.8	83221 CC Gr.2 rectosigmoid (ODO3868)	2.9
Endothelial cells	0.0	83222 CC NAT (ODO3868)	2.1
Endothelial cells (treated)	4.5	83235 CC Mod Diff (ODO3920)	8.0
Liver	9.3	83236 CC NAT (ODO3920)	4.6
Liver (fetal)	4.1	83237 CC Gr.2 ascend colon (ODO3921)	3.4
Spleen	4.4	83238 CC NAT (ODO3921)	2.4
Thymus	2.3	83241 CC from Partial Hepatectomy (ODO4309)	2.8

Thyroid	14.0	83242 Liver NAT (ODO4309)	4.5
Trachea	7.6	87472 Colon mets to lung (OD04451-01)	7.0
Testis	10.4	87473 Lung NAT (OD04451-02)	17.2
Spinal cord	8.7	Normal Prostate Clontech A+ 6546-1	6.2
Salavary gland	13.7	84140 Prostate Cancer (OD04410)	13.0
Brain (amygdala)	0.2	84141 Prostate NAT (OD04410)	100.0
Brain (cerebellum)	0.8	87073 Prostate Cancer (OD04720-01)	20.2
Brain (hippocampus)	1.2	87074 Prostate NAT (OD04720-02)	6.0
Brain (substantia nigra)	7.9	Normal Lung GENPAK 061010	2.7
Brain (thalamus)	1.2	83239 Lung Met to Muscle (ODO4286)	0.5
Cerebral Cortex	1.0	83240 Muscle NAT (ODO4286)	9.8
Brain (whole)	0.4	84136 Lung Malignant Cancer (OD03126)	2.0
Brain (fetal)	0.1	84137 Lung NAT (OD03126)	3.1
CNS ca. (glio/astro) U-118-MG	1.3	84871 Lung Cancer (OD04404)	2.0
CNS ca. (astro)SF-539	0.4	84872 Lung NAT (OD04404)	13.2
CNS ca. (astro) SNB-75	1.0	84875 Lung Cancer (OD04565)	9.8
CNS ca. (astro) SW1783	4.7	85950 Lung Cancer (OD04237-01)	4.2
CNS ca. (glio) U251	0.0	85970 Lung NAT (OD04237-02)	13.3
CNS ca. (glio) SF-295	2.1	83255 Ocular Mel Met to Liver (ODO4310)	0.7
CNS ca. (glio)SNB-19	0.0	83256 Liver NAT (ODO4310)	8.7
CNS ca. (glio/astro)U87-MG	0.0	84139 Melanoma Mets to Lung (OD04321)	1.2
CNS ca.* (neuro; met) SK-N-AS	0.1	84138 Lung NAT (OD04321)	6.0
Small intestine	31.4	Normal Kidney GENPAK 061008	7.5
Colorectal	29.7	83786 Kidney Ca, Nuclear grade 2 (OD04338)	8.8
Colon ca. HT29	0.2	83787 Kidney NAT (OD04338)	16.5
Colon ca.CaCo-2	0.0	83788 Kidney Ca Nuclear grade 1/2 (OD04339)	3.9
Colon ca.HCT-15	0.4	83789 Kidney NAT (OD04339)	6.9
Colon ca.HCT-116	0.0	83790 Kidney Ca, Clear cell type (OD04340)	8.0
Colon ca. HCC-2998	0.8	83791 Kidney NAT (OD04340)	8.8
Colon ca. SW480	0.3	83792 Kidney Ca, Nuclear grade 3 (OD04348)	3.9
Colon ca.* (SW480 met)SW620	0.0	83793 Kidney NAT (OD04348)	13.3
Fetal Skeletal	16.5	87474 Kidney Cancer (OD04622-01)	5.2

Skeletal muscle	20.9	87475 Kidney NAT (OD04622-03)	9.1
Heart	33.9	85973 Kidney Cancer (OD04450-01)	4.4
Stomach	19.8	85974 Kidney NAT (OD04450-03)	11.3
Gastric ca.* (liver met) NCI-N87	2.2	Kidney Cancer Clontech 8120607	2.1
Kidney	15.8	Kidney NAT Clontech 8120608	5.0
Kidney (fetal)	8.1	Kidney Cancer Clontech 8120613	0.1
Renal ca. 786-0	3.0	Kidney NAT Clontech 8120614	3.6
Renal ca. A498	3.9	Kidney Cancer Clontech 9010320	6.5
Renal ca.ACHN	97.3	Kidney NAT Clontech 9010321	5.6
Renal ca.TK-10	0.4	Normal Uterus GENPAK 061018	8.9
Renal ca.UO-31	10.4	Uterus Cancer GENPAK 064011	6.1
Renal ca. RXF 393	6.4	Normal Thyroid Clontech A+ 6570-1**	2.3
Pancreas	13.1	Thyroid Cancer GENPAK 064010	1.0
Pancreatic ca. CAPAN 2	0.1	Thyroid Cancer INVITROGEN A302152	10.2
Ovary	23.8	Thyroid NAT INVITROGEN A302153	6.5
Ovarian ca.IGROV-1	0.0	Normal Breast GENPAK 061019	8.1
Ovarian ca.OVCAR-3	26.6	84877 Breast Cancer (OD04566)	6.0
Ovarian ca.OVCAR-4	1.4	85975 Breast Cancer (OD04590-01)	8.0
Ovarian ca.OVCAR-5	3.4	85976 Breast Cancer Mets (OD04590-03)	7.2
Ovarian ca.OVCAR-8	0.0	87070 Breast Cancer Metastasis (OD04655-05)	2.2
Ovarian ca.* (ascites) SK-OV-3	0.0	GENPAK Breast Cancer 064006	19.2
Prostate	56.3	Breast Cancer Clontech 9100266	4.0
Prostate ca.* (bone met)PC-3	0.0	Breast NAT Clontech 9100265	6.6
Placenta	66.0	Breast Cancer INVITROGEN A209073	4.7
Pituitary gland	4.5	Breast NAT INVITROGEN A2090734	9.0
Uterus	22.4	Normal Liver GENPAK 061009	4.6
		Liver Cancer GENPAK 064003	1.1
		Liver Cancer Research Genetics RNA 1025	4.5
		Liver Cancer Research Genetics RNA 1026	4.6

		Paired Liver Cancer Tissue Research Genetics RNA 6004-T	3.9
		Paired Liver Tissue Research Genetics RNA 6004-N	3.6
		Paired Liver Cancer Tissue Research Genetics RNA 6005-T	5.4
		Paired Liver Tissue Research Genetics RNA 6005-N	5.1
		Normal Bladder GENPAK 061001	10.4
		Bladder Cancer Research Genetics RNA 1023	5.7
		Bladder Cancer INVITROGEN A302173	2.5
		87071 Bladder Cancer (OD04718-01)	4.9
		87072 Bladder Normal Adjacent (OD04718-03)	11.4
		Normal Ovary Res. Gen.	3.8
		Ovarian Cancer GENPAK 064008	19.1
		87492 Ovary Cancer (OD04768-07)	2.1
		87493 Ovary NAT (OD04768-08)	23.8
		Normal Stomach GENPAK 061017	12.3
		NAT Stomach Clontech 9060359	12.2
		Gastric Cancer Clontech 9060395	8.1
		NAT Stomach Clontech 9060394	18.3
		Gastric Cancer Clontech 9060397	7.7
		NAT Stomach Clontech 9060396	8.5
		Gastric Cancer GENPAK 064005	15.4

The Taqman results are summarized in Table 42.

TABLE 42

NOVX	Internal Accession Number	Results
NOV-1	10132038.0.67	Normal adjacent tissue to colon cancer tissue
NOV-2a	10132038.0.139	showed a higher expression of the gene as compared to colon cancer tissue itself. The results also demonstrate a similar profile for lung and ocular melanoma.
NOV-2b	10132038.0.136	
NOV-3a	18552586_EXT1	High level of expression in brain and moderate expression in lung and trachea, suggesting its potential role in diseases involving these tissues.
NOV-3b	18552586_EXT2	
NOV-3c	18552586_EXT3	Increased expression in normal colon as compared to colon cancer tissue. Cancerous uterus and ovary tissues exhibited significantly higher expression than their normal counterparts.
NOV-3d	18552586_EXT4	
NOV-4a	10093872.0.107	Increased expression in normal bladder and moderate expression in prostate, heart, placenta, small intestine, and colorectal cells. Normal adjacent tissue (NAT) of prostate showed maximum expression.
NOV-4b	10093872.1	
NOV-4c	10093872.0.38	
NOV-4d	10093872.2	
NOV-4e	10093872.3	

5

OTHER EMBODIMENTS

While the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

What is claimed is:

1. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
 - a) a mature form of the amino acid sequence selected from the group consisting of SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23;
 - b) a variant of a mature form of the amino acid sequence selected from the group consisting of SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23, wherein any amino acid in the mature form is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed;
 - c) the amino acid sequence selected from the group consisting of SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23;
 - d) a variant of the amino acid sequence selected from the group consisting of SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23 wherein any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence are so changed; and
 - e) a fragment of any of a) through d).
2. The polypeptide of claim 1 that is a naturally occurring allelic variant of the sequence selected from the group consisting of SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23.
3. The polypeptide of claim 2, wherein the variant is the translation of a single nucleotide polymorphism.
4. The polypeptide of claim 1 that is a variant polypeptide described therein, wherein any amino acid specified in the chosen sequence is changed to provide a conservative substitution.
5. An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence selected from the group consisting of:
 - a) a mature form of the amino acid sequence given SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23;

- b) a variant of a mature form of the amino acid sequence selected from the group consisting of SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23 wherein any amino acid in the mature form of the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed;
- c) the amino acid sequence selected from the group consisting of SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23;
- d) a variant of the amino acid sequence selected from the group consisting of SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23, in which any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence are so changed;
- e) a nucleic acid fragment encoding at least a portion of a polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23 or any variant of said polypeptide wherein any amino acid of the chosen sequence is changed to a different amino acid, provided that no more than 10% of the amino acid residues in the sequence are so changed; and
- f) the complement of any of said nucleic acid molecules.

6. The nucleic acid molecule of claim 5, wherein the nucleic acid molecule comprises the nucleotide sequence of a naturally occurring allelic nucleic acid variant.

7. The nucleic acid molecule of claim 5 that encodes a variant polypeptide, wherein the variant polypeptide has the polypeptide sequence of a naturally occurring polypeptide variant.

8. The nucleic acid molecule of claim 5, wherein the nucleic acid molecule comprises a single nucleotide polymorphism encoding said variant polypeptide.

9. The nucleic acid molecule of claim 5, wherein said nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of

- a) the nucleotide sequence selected from the group consisting of SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57;

- b) a nucleotide sequence wherein one or more nucleotides in the nucleotide sequence selected from the group consisting of SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57 is changed from that selected from the group consisting of the chosen sequence to a different nucleotide provided that no more than 15% of the nucleotides are so changed;
- c) a nucleic acid fragment of the sequence selected from the group consisting of SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57; and
- d) a nucleic acid fragment wherein one or more nucleotides in the nucleotide sequence selected from the group consisting of SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57 is changed from that selected from the group consisting of the chosen sequence to a different nucleotide provided that no more than 15% of the nucleotides are so changed.

10. The nucleic acid molecule of claim 5, wherein said nucleic acid molecule hybridizes under stringent conditions to the nucleotide sequence selected from the group consisting of SEQ ID NO: 1, 3, 6, 8, 10, 12, 14, 16, 18, 20, 22, or 57, or a complement of said nucleotide sequence.

11. The nucleic acid molecule of claim 5, wherein the nucleic acid molecule comprises a nucleotide sequence in which any nucleotide specified in the coding sequence of the chosen nucleotide sequence is changed from that selected from the group consisting of the chosen sequence to a different nucleotide provided that no more than 15% of the nucleotides in the chosen coding sequence are so changed, an isolated second polynucleotide that is a complement of the first polynucleotide, or a fragment of any of them.

12. A vector comprising the nucleic acid molecule of claim 11.

13. The vector of claim 12, further comprising a promoter operably linked to said nucleic acid molecule.

14. A cell comprising the vector of claim 12.

15. An antibody that binds immunospecifically to the polypeptide of claim 1.

16. The antibody of claim 15, wherein said antibody is a monoclonal antibody.
17. The antibody of claim 15, wherein the antibody is a humanized antibody.
18. A method for determining the presence or amount of the polypeptide of claim 1 in a sample, the method comprising:
 - (a) providing said sample;
 - (b) introducing said sample to an antibody that binds immunospecifically to the polypeptide; and
 - (c) determining the presence or amount of antibody bound to said polypeptide, thereby determining the presence or amount of polypeptide in said sample.
19. A method for determining the presence or amount of the nucleic acid molecule of claim 5 in a sample, the method comprising:
 - (a) providing said sample;
 - (b) introducing said sample to a probe that binds to said nucleic acid molecule; and
 - (c) determining the presence or amount of said probe bound to said nucleic acid molecule, thereby determining the presence or amount of the nucleic acid molecule in said sample.
20. A method of identifying an agent that binds to the polypeptide of claim 1, the method comprising:
 - (a) introducing said polypeptide to said agent; and
 - (b) determining whether said agent binds to said polypeptide.
21. A method for identifying a potential therapeutic agent for use in treatment of a pathology, wherein the pathology is related to aberrant expression or aberrant physiological interactions of the polypeptide of claim 1, the method comprising:
 - (a) providing a cell expressing the polypeptide of claim 1 and having a property or function ascribable to the polypeptide;
 - (b) contacting the cell with a composition comprising a candidate substance; and
 - (c) determining whether the substance alters the property or function ascribable to the polypeptide;

whereby, if an alteration observed in the presence of the substance is not observed when the cell is contacted with a composition devoid of the substance, the substance is identified as a potential therapeutic agent.

22. A method for modulating the activity of the polypeptide of claim 1, the method comprising introducing a cell sample expressing the polypeptide of said claim with a compound that binds to said polypeptide in an amount sufficient to modulate the activity of the polypeptide.
23. A method of treating or preventing a pathology associated with the polypeptide of claim 1, said method comprising administering the polypeptide of claim 1 to a subject in which such treatment or prevention is desired in an amount sufficient to treat or prevent said pathology in said subject.
24. The method of claim 23, wherein said subject is a human.
25. A method of treating or preventing a pathology associated with the polypeptide of claim 1, said method comprising administering to a subject in which such treatment or prevention is desired a NOVX nucleic acid in an amount sufficient to treat or prevent said pathology in said subject.
26. The method of claim 25, wherein said subject is a human.
27. A method of treating or preventing a pathology associated with the polypeptide of claim 1, said method comprising administering to a subject in which such treatment or prevention is desired a NOVX antibody in an amount sufficient to treat or prevent said pathology in said subject.
28. The method of claim 27, wherein the subject is a human.
29. A pharmaceutical composition comprising the polypeptide of claim 1 and a pharmaceutically acceptable carrier.
30. A pharmaceutical composition comprising the nucleic acid molecule of claim 5 and a

pharmaceutically acceptable carrier.

31. A pharmaceutical composition comprising the antibody of claim 15 and a pharmaceutically acceptable carrier.
32. A kit comprising in one or more containers, the pharmaceutical composition of claim 29.
33. A kit comprising in one or more containers, the pharmaceutical composition of claim 30.
34. A kit comprising in one or more containers, the pharmaceutical composition of claim 31.
35. The use of a therapeutic in the manufacture of a medicament for treating a syndrome associated with a human disease, the disease selected from a pathology associated with the polypeptide of claim 1, wherein said therapeutic is the polypeptide of claim 1.
36. The use of a therapeutic in the manufacture of a medicament for treating a syndrome associated with a human disease, the disease selected from a pathology associated with the polypeptide of claim 1, wherein said therapeutic is a NOVX nucleic acid.
37. The use of a therapeutic in the manufacture of a medicament for treating a syndrome associated with a human disease, the disease selected from a pathology associated with the polypeptide of claim 1, wherein said therapeutic is a NOVX antibody.
38. A method for screening for a modulator of activity or of latency or predisposition to a pathology associated with the polypeptide of claim 1, said method comprising:
 - a) administering a test compound to a test animal at increased risk for a pathology associated with the polypeptide of claim 1, wherein said test animal recombinantly expresses the polypeptide of claim 1;
 - b) measuring the activity of said polypeptide in said test animal after administering the compound of step (a); and
 - c) comparing the activity of said protein in said test animal with the activity of

said polypeptide in a control animal not administered said polypeptide, wherein a change in the activity of said polypeptide in said test animal relative to said control animal indicates the test compound is a modulator of latency of, or predisposition to, a pathology associated with the polypeptide of claim 1.

39. The method of claim 38, wherein said test animal is a recombinant test animal that expresses a test protein transgene or expresses said transgene under the control of a promoter at an increased level relative to a wild-type test animal, and wherein said promoter is not the native gene promoter of said transgene.
40. A method for determining the presence of or predisposition to a disease associated with altered levels of the polypeptide of claim 1 in a first mammalian subject, the method comprising:
 - a) measuring the level of expression of the polypeptide in a sample from the first mammalian subject; and
 - b) comparing the amount of said polypeptide in the sample of step (a) to the amount of the polypeptide present in a control sample from a second mammalian subject known not to have, or not to be predisposed to, said disease, wherein an alteration in the expression level of the polypeptide in the first subject as compared to the control sample indicates the presence of or predisposition to said disease.
41. A method for determining the presence of or predisposition to a disease associated with altered levels of the nucleic acid molecule of claim 5 in a first mammalian subject, the method comprising:
 - a) measuring the amount of the nucleic acid in a sample from the first mammalian subject; and
 - b) comparing the amount of said nucleic acid in the sample of step (a) to the amount of the nucleic acid present in a control sample from a second mammalian subject known not to have or not be predisposed to, the disease; wherein an alteration in the level of the nucleic acid in the first subject as compared to the control sample indicates the presence of or predisposition to the disease.

42. A method of treating a pathological state in a mammal, the method comprising administering to the mammal a polypeptide in an amount that is sufficient to alleviate the pathological state, wherein the polypeptide is a polypeptide having an amino acid sequence at least 95% identical to a polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 2, 4, 5, 7, 9, 11, 13, 15, 17, 19, 21, or 23 or a biologically active fragment thereof.
43. A method of treating a pathological state in a mammal, the method comprising administering to the mammal the antibody of claim 15 in an amount sufficient to alleviate the pathological state.